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If it were not for the great variability 
among individuals, Medicine might be a 
Science, not an Art  
Sir William Osler, 1892 
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Abstract 
Background: Individual patient variability may explain why despite a growing 
number of therapeutic options in the treatment of inflammatory bowel disease 
(IBD) many patients still suffer from disabling disease. Precision medicine aims 
to address this dilemma by improving the timing and delivery of healthcare for 
each patient by targeting treatment according to the application of biomarkers. I 
therefore sought biomarkers that could help deliver two key aspects of precision 
IBD medicine: accelerating time to diagnosis from the first onset of symptoms 
and predicting the risk of adverse drug reactions.   
Methods: I used prospective observational cohort studies firstly to explore the 
diagnostic accuracy of faecal calprotectin in distinguishing IBD from functional 
gut disorder in the primary care setting, and secondly, the factors associated 
with a delayed IBD diagnosis. Agnostic genome- and exome-wide association  
methodologies were used to investigate the association between genetic 
variants and thiopurine-induced myelosuppression in patients of European 
ancestry. 
Results: Faecal calprotectin is a clinically useful biomarker that helps General 
Practitioners (GPs) distinguish IBD from functional gut disorder in young adults 
and children. Use of calprotectin was not associated with time to IBD diagnosis, 
although its uptake in primary care was poor. The greatest component of the 
total time to diagnosis was the time it took patients to first present to their GP. In 
the adverse drug reaction study, I discovered a novel association between a 
variant in NUDT15 and thiopurine-induced myelosuppression. 
Conclusions and Impact: The actionable findings reported in this thesis have 
led to changes in clinical practice locally and nationally. Our primary care study 
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of calprotectin has demonstrated how a faecal biomarker can help prioritise 
outpatient referrals and deliver cost-savings, leading to the adoption of our 
clinical pathway across several UK sites. The identification of NUDT15 variants 
as determinants of thiopurine-induced myelosuppression in European 
individuals has led to the rapid development of an NHS clinical service from the 
Exeter molecular genetics laboratory and in due course adoption of the test to 
the National Genomic Test Directory.  
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The aims and objectives of this thesis 
Despite the arrival of a number of new IBD therapies no one treatment leads to 
sustained remission for even half of treated patients. Precision medicine in the 
field of IBD has been proposed as a potential solution for this clinical conundrum, 
and although studies over the last decade have begun to address this goal, 
knowledge gaps remain.1  
 
The four central precepts of precision IBD medicine are:  
1. making an early diagnosis  
2. disease prognostication  
3. predicting drug response and avoiding toxicity  
4. treat-to-target with tight control 
 
The aim of this thesis is to investigate how biomarkers may be used to help 
deliver two of the four key aspects of this precision medicine approach for the 
treatment of IBD patients: making an early diagnosis of IBD, as soon after the 
onset of symptoms as possible to maximise the effectiveness of modern 
therapies and ultimately to modify the natural history of these lifelong disabling 
diseases; and, predicting adverse drug reactions and minimising drug toxicity. 
 
I will explore these aims through the 10 objectives that I set out below in Table 
1.1-2 below.
AIMS AND OBJECTIVES OF THESIS 
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Table 1.2-2. Research questions and objectives 
Chapter Research question(s) Objectives Methodology 
3 
 
What is the diagnostic accuracy of a new 
calprotectin based-referral pathway in 
distinguishing functional gut disorder from 
IBD in the adult primary care setting? 
 
What is the diagnostic accuracy of faecal 
calprotectin in distinguishing non-IBD from 
IBD in the paediatric primary care 
setting? 
 
Do the presence of gastrointestinal alarm 
symptoms in adults alter the diagnostic 
accuracy of the test? 
 
Does faecal calprotectin alter referral 
behaviour in paediatric and adult patients? 
 
To ascertain:  
1) the diagnostic accuracy of faecal calprotectin 
in distinguishing functional gut disorder from 
IBD in adult and paediatric patients in the 
primary care setting 
2) whether faecal calprotectin testing altered 
primary care referral behaviour 
3) whether the presence of gastrointestinal alarm 
symptoms altered the performance of the test 
in adults 
 
Prospective observational cohort 
study to describe the diagnostic 
accuracy of calprotectin testing to 
exclude IBD in primary care 
 
Table 1.1-2 continued… 
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Table 1.1-2 continued… 
Chapter Research question(s) Objectives Methodology 
3 
What is/are the factor/s which influence 
time to diagnosis in IBD? 
Does the use of faecal calprotectin reduce 
time to IBD diagnosis? 
 
To identify:  
4) where delays occur in the referral pathway 
between onset of symptoms through primary 
and secondary care to diagnosis of IBD  
5) the clinical and laboratory factors which 
influence time to diagnosis in IBD patients  
6) if a delayed diagnosis is associated with more 
hospitalisations, surgeries and a greater 
requirement for immunosuppressive and biologic 
therapies  in the first year after diagnosis than 
patients with a timely diagnosis  
Retrospective review of all new IBD 
diagnoses between 2014-2018 at 
the Royal Devon and Exeter 
Hospital  
Table 1.1-2 continued… 
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Table 1.1-2 continued… 
Chapter Research question(s) Objectives Methodology 
4 
What genetic factors are associated 
with thiopurine-induced 
myelosuppression (TIM) in patients 
with IBD? 
 
 
To investigate  
7) the association between genetic variants and TIM 
in European patients with IBD 
8) if genetic variants are present, to explore if the 
frequency of these variants is enriched in those 
patients with early drug reactions (≤ 8 weeks from 
start of maximum dose) 
To define: 
9) the clinical phenotype and morbidity related to 
carriage of a TIM associated genetic variant(s) 
10) the clinical usefulness (e.g. sensitivity, specificity, 
negative and positive predictive values) of genetic 
testing to identify patients at risk of TIM 
Case-control disease matched 
genetic study of patients who 
suffered either thiopurine-induced 
myelosuppression versus 
thiopurine-tolerant patients utilising 
genome wide- and exome-wide 
association methodologies 
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The structure of this thesis 
I present this thesis as five chapters. The first two chapters introduce IBD and 
precision medicine in IBD. 
 
Chapter 1: Introduction to IBD. Presents a literature review of the latest research on 
the aetiology, pathophysiology, diagnosis, treatment and complications of IBD. 
Specifically, it details how seminal genetic and observational studies have informed 
current thinking in the field. This chapter includes a summary of current treatment 
paradigms and their limitations, serving as a backdrop for the precision medicine 
approach described in Chapter 2. 
 
Chapter 2: Introduction to Precision Medicine. Details the evidence supporting the 
use of a precision medicine approach in the field of IBD with a focus on four specific 
areas: the importance of making an early diagnosis of IBD; prognostication of disease 
course; predicting response to drug therapy and avoiding toxicity; and, treating to 
target with tight control.  
 
In Chapters 3 and 4, I present four papers (RESEARCH PAPERS I-IV), each relating 
to a different component of precision medicine. All of the papers are self-contained i.e. 
all tables, references and figures are separate to the rest of the thesis and are located 
either within the manuscript itself or in the manuscript supplement that immediately 
follows. 
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In each of the two data chapters (chapters 3 and 4) I set out: 
• the background to the chapter; 
• the objective(s) of the chapter; 
• the publication or work of the chapter; 
• how the chapter contributes to addressing the aims of the thesis; and 
• the implications for practice of the work that I present 
 
Chapter 3: The role of faecal calprotectin in the delivery of precision medicine: 
making an early diagnosis of IBD. In this chapter I first present two prospective 
observational cohort studies which describe the real-world experience of introducing 
faecal calprotectin into primary care to help GPs differentiate patients with functional 
gut disorder and IBD. These separate papers relate to the use of a National Institute 
for Health and Care Excellence (NICE) approved faecal biomarker in paediatric and 
adult patients, respectively.  
 
RESEARCH PAPER I: ‘Faecal calprotectin effectively excludes inflammatory bowel 
disease in 789 symptomatic young adults with/without alarm symptoms: a prospective 
UK primary care cohort study’ Walker, G. J., Moore, L., Heerasing, N., Hendy, P., 
Perry, M. H., McDonald, T. J., Debenham, T., Bethune, R., Bewshea, C., Hyde, C., 
Heap, G. A., Singh, A., Calvert, C., Kennedy, N. A., Goodhand, J. R. and Ahmad, T. 
 
RESEARCH PAPER II: ‘The diagnostic accuracy of primary care faecal calprotectin 
testing in children with suspected inflammatory bowel disease.’ Walker, G. J., Thomas 
A., Chanchlani, N., Lin, S., Moore, L.N. Heerasing, N., Hendy, P., Perry, M. H., 
McDonald, T., Abdulrahim, M., Mole, S., Bewshea, C., Hyde, C., Heap, G. A., Singh, 
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A., Calvert, C., Russell, R.K., Hart, J., Goodhand, J. R., Ahmad, T., and Kennedy, N. 
A. 
 
I then present a retrospective cohort study of the factors associated with a delayed 
diagnosis in IBD. The overall time to diagnosis is sub-divided into 3 sections: patient 
delay (i.e. the time from onset of symptoms to first GP presentation); primary care 
delay (i.e. the time from first GP presentation to GP referral) and secondary care delay 
(i.e. the time from GP referral to IBD diagnosis). Specifically, I evaluate whether use 
of primary care faecal calprotectin was associated with a reduction in the time to 
diagnosis. I then explore whether complications, such as surgery and hospitalisations 
and, drug use in the first year after diagnosis, were associated with diagnostic delay. 
Finally, I sought the demographic and clinical factors associated with an emergent 
presentation prior to IBD diagnosis. 
 
RESEARCH PAPER III: ‘A prospective cohort study to identify factors associated with 
a delay in IBD diagnosis.’ Walker, G. J., Thomas A., Chanchlani, N., Lin, S., Moore, 
L.N. Heerasing, N., Hendy, P., Perry, M. H., McDonald, T., Abdulrahim, M., Mole, S., 
Bewshea, C., Singh, A., Kennedy, N. A, Ahmad, T. and Goodhand, J. R. 
 
Chapter 4: The role of pharmacogenetics in the delivery of precision medicine: 
avoiding adverse drug reactions. This chapter starts with a literature review that has 
been published as a book chapter relating to the use of biomarkers in the reduction of 
adverse drug reactions in IBD. 
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BOOK CHAPTER: ‘The utility of genetic biomarkers to reduce adverse drug reactions 
in IBD.’ Walker, G. J and Ahmad, T. Chapter in ‘Biomarkers in Inflammatory Bowel 
Diseases’ N. S. Ding, P. De Cruz. (eds.)   Publisher, Springer Nature (2019). 
 
I then present a retrospective case-control study that aimed to identify novel clinical 
and genetic biomarkers associated with thiopurine-induced myelosuppression (TIM). 
 
RESEARCH PAPER IV: ‘Association of Genetic Variants in NUDT15 With Thiopurine-
Induced Myelosuppression in Patients with Inflammatory Bowel Disease.’ Walker, G. 
J., Harrison, J. W., Heap, G. A et al.  
 
Finally, in Chapter 5 I summarise the findings and discuss the issues and challenges 
arising from the thesis and look ahead to the future.  
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Definitions; abbreviations 
ADA  Adalimumab 
ADAb  Anti-drug antibody 
ADR  Adverse drug reaction 
ASG  American society gastroenterology 
AZA  Azathioprine 
BMI  Body mass index 
BSG  British society gastroenterology 
CD  Crohn’s disease 
CEUS  Contrast enhanced ultrasound   
CPIC  Clinical pharmacogenetics implementation consortium 
CRP   C-reactive protein 
CV  Co-efficient of variation 
DNA  Deoxyribonucleic acid 
DRESS Drug reaction with hypereosinophilia and systemic symptoms 
ECCO  European Crohn’s Colitis Organisation   
EWAS  Exome-Wide Association Study 
ELISA  Enzyme-linked immunosorbent assay 
EU  European union 
GI  Gastrointestinal  
GP  General practitioner 
GWAS  Genome-wide association study 
IBD  Inflammatory bowel disease 
IBD-U  Inflammatory bowel disease-unclassified 
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IBS  Irritable bowel syndrome 
IFX  Infliximab 
LOR  Loss of response 
MP  Mercaptopurine 
MRE  Magnetic resonance enterography  
NICE   National Institute Health and Care Excellence 
NK  Natural killer  
NPV  Negative predictive value 
OGD   Organic gastrointestinal disease 
PNR  Primary non-response 
PPV  Positive predictive value 
RNA  Ribonucleic acid 
SBCE  Small bowel capsule endoscopy  
SCAR  Severe cutaneous adverse reaction 
SCFA  Short chain fatty acids 
SJS  Stephens-Johnson syndrome 
TDM  Therapeutic drug monitoring 
TEN  Toxic epidermal necrolysis 
TIM   Thiopurine-induced myelosuppression 
TILI   Thiopurine-induced liver injury 
TNF  Tumour necrosis factor 
TRFIA  Time-resolved fluorescent immunoassay 
UC   Ulcerative colitis
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Chapter 1 
1 Introduction to IBD 
Inflammatory bowel disease (IBD) is the collective term given to describe chronic 
relapsing-remitting inflammation of the gastrointestinal (GI) tract. The two commonest 
forms of IBD are Crohn’s disease (CD) and ulcerative colitis (UC); the former can affect 
any part of the gastrointestinal tract whilst UC only affects the large bowel/colon. In 
approximately 9% of patients the clinical, histological or radiological features do not 
permit a definitive diagnosis of either CD or UC and such patients are deemed to have 
‘IBD-unclassified’ (IBD-U).2  
 
IBD can present at any age although typically a bimodal distribution is described in 
Western populations, with a younger peak between 15-40 years and a second peak 
in older adults aged 60-70 years old.3 Disease prevalence varies with ethnicity and 
geography and to a lesser extent by social-class and sex.4 The incidence of IBD is 
highest in Northern and Western Europe with annual rates as high as 24.3 per 100,000 
and 12.7 per 100,000 persons for UC and CD respectively.5 Although the incidence of 
IBD is reportedly static in Northern and Western Europe6, globally the incidence of IBD 
is increasing.5 Work from Devon, UK (unpublished) and Lothian, Scotland report a 
growing prevalence of IBD (0.80% and 0.78%, respectively), despite a static 
incidence, reflecting the compounding effects of an ageing population and falling rates 
of disease related mortality (see Figure 1.1-1).7,8 
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Figure 1.2-1. Incidence per 100,000 of background population against time for 
ulcerative colitis (green) and Crohn’s disease (red) in Exeter, UK from 2008-2016 
The mean incidence of UC was 13.1 (95% 
CI 12.4 – 13.6) per 100,000 background 
population per year, and the mean 
incidence of Crohn’s disease was 10.2 
(95%CI 8.6 – 11.7) per 100,000 background 
population per year.  No statistically 
significant change was demonstrated for 
the period 2008-2016. Incident cases were 
defined as patients who lived within the 
Exeter, UK catchment at date of diagnosis. 
Image used with permission from Dr Ben 
Hamilton, Exeter IBD Pharmacogenetics 
Team 
 
Sex differences differ by age group and IBD subtype in Western countries (Figure 1.1-
2).9 Recent evidence suggests that female sex hormones may play a role in IBD 
pathogenesis: in a recent meta-analysis authors concluded that the use of the oral 
contraceptive pill was associated with an increased risk of IBD10. Furthermore, data 
from a large cohort study found that women with IBD reported changes in symptom 
severity during times of hormone fluctuation (e.g., menstruation, pregnancy, 
postpartum, post-menopause).11  
Figure 1.2-2. Sex-differences in the incidence of Crohn’s disease and ulcerative 
colitis, based on a pooled analysis from Western countries 
Sex-Based Differences in Incidence of Inflammatory Bowel Diseases—Pooled Analysis of 
Population-Based Studies from Western Countries. Figure taken from S. C. Shah et al. in 
Gastroenterology Volume 155, Issue 4, Pages 1079-1089.e3, October 2018.  
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1.1.1.1 Disease presentation 
CD typically presents with symptoms of abdominal pain, diarrhoea, fatigue and weight 
loss, although presentation can vary with disease site and severity.4,12 UC is 
characterised by symptoms of bloody diarrhoea, faecal urgency and abdominal pain. 
Although some patients may experience only mild gut inflammation, symptoms can be 
severe with significant disruption to education, employment and family life.13–15 For 
some patients a debilitating disease course ensues, requiring the initialisation of long-
term drug therapies and surgery in order to quell inflammation and treat complications. 
In CD, up to 38% of patients may require surgery in the first 5-10 years after 
diagnosis.16,17 Whereas approximately 6-10% of UC patients undergo  colectomy 
within the first 10 years of diagnosis for refractory symptoms.18,19 After 15 years, the 
number of surgeries for refractory UC starts to decrease, although the incidence of 
colorectal cancer in UC rises, with one meta-analysis citing a cumulative probability of 
cancer of 2% by 10 years, 8% by 20 years, and 18% by 30 years.19,20 Colorectal cancer 
in IBD is discussed further later in this introduction.  
1.2 Aetiology of IBD 
The exact pathogenesis of IBD is yet to be fully elucidated, however, current 
knowledge of this complex disorder may suggest an inappropriate immune response 
to antigenic stimulation by the gut microbiota on a background of genetic susceptibility. 
1.2.1 Genetic factors 
A genetic component to the aetiology of IBD is suggested by observations such as the 
high concordance rates of first-degree relatives with IBD in family studies21,  the higher 
heritability of IBD found in monozygotic rather than dizygotic twins22,23, as well as the 
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high prevalence of the disease in certain populations such as the Ashkenazi Jews.24 
The risk of IBD is higher in first-degree relatives of a CD proband (overall risk between 
2 and 14%) than in UC (overall risk between 7 and 11%), although more distant 
relatives of patients with CD and UC are also at increased risk.25 In large European 
twin studies the concordance rate among monozygotic twins is estimated to be 
between 20-50%, whilst for dizygotic twins it is lower at approximately 10%.22,23 These 
data support a role for genetics in the aetiology of IBD, although shared environmental 
factors may also contribute to this clustering of disease in families.  The importance of 
environmental factors is highlighted by the fact that only a minority of patients carrying 
a particular variant will develop IBD, the exception being the development of very early 
onset IBD in children who carry highly penetrant monogenic variants.26   
 
Over the last 20 years a number of different genetic approaches have been employed 
to unravel IBD genetic loci which now total more than 240.27 These discoveries have 
provided novel insights into the pathogenesis of IBD and targets for new therapies.28 
The first IBD susceptibility locus, termed ‘IBD1’, was identified using linkage 
analysis.29 Such agnostic linkage studies investigate how genetic markers along a 
chromosome co-segregate among members of a single large family with multiple 
affected individuals. A score is used to quantify the likelihood that a genetic marker is 
inherited together with the true disease-causing gene; markers in close proximity to 
such a gene are more likely to be inherited together following meiosis (chromosomal 
recombination during gamete production) and have a higher score than more distant 
markers.  IBD1 was subsequently mapped to variants within the NOD2 gene (a.k.a. 
CARD15).30 NOD2 plays a crucial role in the innate immune response by recognising 
the muramyl dipeptide (MDP) component of bacterial cell walls and triggering immune 
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activation and autophagy of dendritic cells through a series of nuclear transcription 
factors (most notably NF-κB).31 Further loci, termed IBD2 were identified by linkage 
studies but mapping studies failed to identify the causal genes reflecting the limited 
power of such analyses.32   
1.2.1.1 The GWAS era 
In the 21st Century a combination of World-wide collaboration, with successful 
endeavours such as the Human Genome and HapMap projects, and technological 
advances, heralded a new tool in the exploration of IBD genetic susceptibility: the 
hypothesis-free genome-wide association study (GWAS). 
 
The GWAS approach compares the allele frequencies of thousands of single 
nucleotide polymorphisms between affected cases and unaffected controls in a bid to 
uncover the association between genetic regions (loci) and phenotypic traits, such as 
IBD (see Figure 1.2-1). 
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Figure 1.2-1: Diagram to show basic principles of GWAS 
 
 
Figure illustrates how GWAS utilises the haplotype structure of the human genome: each 
chromosome consists of multiple haplotypes–regions that are inherited together during 
meiosis. Within each haplotype, there are typically many SNPs, which are co-inherited within 
the larger genetic region, and thus, their alleles are inherited non-randomly (i.e. they are in 
linkage disequilibrium with one and other). This means that it is possible to infer the genotypes 
at multiple SNPs within the haplotype (shown as grey vertical lines) if the genotype at one or 
more SNPs is known. GWAS SNPs (shown in black vertical lines) are selected so as to tag each 
haplotype, but where association is observed, they are unlikely to be the causal variant at the 
locus (shown as red vertical line). By genotyping SNPs from each haplotype in the genome in 
disease cases and healthy controls, it is possible to identify SNPs where the allele frequency is 
significantly different between the cases and controls, and which are associated with the 
disease. Taken from Verstockt, B., Smith, K.G.C. and Lee, JC.  Genome-wide association studies 
in Crohn’s disease: Past, present and future. Clinical & Translational Immunology 2018 33 
 
At first, GWAS findings were modest, typically only uncovering up to 10 new genetic 
associations as a consequence of small sample sizes and thus limited study power. 
However, in time, a combination of World-wide collaboration (ultimately with sample 
sizes ~ 50,000 cases and controls) and more affordable genotyping uncovered several 
crucial insights into the pathophysiology of IBD:  
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i) autophagy related genes (ATG16L134, IRGM35): autophagy is a process 
which recycles cell organelles and cytosolic macromolecules by presentation 
to lysosomes. This process is important for anti-bacterial host defence against 
intracellular invading micro-organisms (also known as xenophagy) and 
resolving endoplasmic reticular stress, a key component of intestinal 
inflammation and the pathogenesis of CD.  
ii) defective colonic mucosal barrier in UC: the diminished mucosal barrier 
permits increased microbial adhesion and invasion which is thought to trigger 
mucosal immune reactions that result in chronic intestinal inflammation.36,37 
iii) a failure to suppress an aberrant immune response: disruption of the 
normal mechanisms by which the body prevents aberrant responses to non-
pathogenic commensal gut organisms leads to colitis in animal models.38 Focus 
has been on the role of the anti-inflammatory IL-10 cytokine with several other 
genes implicated in this pathway (IL10, IL10RB, STAT3 and TYK2).39,40  
iv) the IL-23/IL-17 axis: IL-23 is a cytokine which promotes expansion and 
maintenance of mucosal effector Th17 cells, which in turn produce pro-
inflammatory IL-17. Numerous genetic studies identified variants within or near 
to genes implicated in Th17 biology (e.g. RORC, IL23R, IL12B, TYK2, JAK2, 
STAT3, CCR6 and ICOSLG).41,42 Although the functional consequences of 
these risk alleles still need further elucidation, this   discovery was crucial in the 
development of CD drugs targeting this system (anti-IL12/23: Ustekinumab, 
[Janssen Biotech] and anti-IL12: Risankizumab [AbbVie]).  
 
Subsequent genetic meta-analyses increased statistical power even further and 
enabled the detection of 240 susceptibility loci, each exerting a low effect size.28 For 
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the majority of these loci the causal gene and/or causal variants have not been 
mapped.  In some cases, this may be possible using statistical fine mapping and in 
others it will require a functional characterisation of the downstream effects of each 
SNP locus.33 Currently, the CD and UC loci identified to date only account for ~23% 
and ~16% of disease heritability, respectively, and yet observations of concordance in 
twin studies informs us that the genetic contribution to IBD aetiology should be much 
greater;  this phenomenon is termed ‘missing heritability’. Explanations for this 
paradox include the presence of gene-gene interactions (epistasis), gene-
environmental interactions, as well as deficiencies inherent in the GWAS 
methodologies and technologies upon which these estimates of missing heritability 
have been made.43 With regards this latter explanation, further progress may be made 
with the advent of widespread whole-exome and whole genome- sequencing. 
1.2.1.2 Whole-exome (WES) and whole-genome sequencing (WGS) 
The advent of next generation sequencing, which permits the rapid sequencing of 
large amounts of DNA, has moved genetic studies into a new era once more and 
enables the detection of rare variants across thousands of individuals. Whole-exome 
sequencing (WES) characterises nucleotide sequences in the protein coding exomes 
which make up approximately 1% of our genome. Whereas whole-genome 
sequencing (WGS) will also detect rare variants in the remaining non-coding intronic 
regions. Although in reality, due to the difficulty in sequencing technically challenging 
regions of the genome with current sequencing platforms (i.e. high guanine-cytosine 
content, large repeat regions, centromeres, telomeres, etc.), whole-genome 
sequencing still only covers 95% to 98% of the genome.44 Conceivably these rare 
variants may have much larger effect sizes than the common variants detected by 
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GWAS. However, in common with first GWAS studies, the initial forays into the use of 
WES and WGS in the field of IBD and autoimmune disease pathogenesis have been 
a little disappointing and yielded few interesting hits.45,46 Further gains may require 
collaboration across centres, new methods for combining sequence data-sets and 
greater computational power. 
1.2.2 Environmental factors 
That IBD has a higher incidence in developed Western countries when compared with 
undeveloped and developing nations may be explained by both environmental and 
genetic factors.5,47 However, two important epidemiological observations highlight the 
importance of environmental factors as distinct from genetics in the pathogenesis of 
IBD:  first, the rapid rise in disease incidence in both developed and developing nations 
cannot be easily explained by genetics; second, the incidence of IBD increases in 
migrant populations moving from developing countries with a low incidence of IBD to 
Western counties with higher IBD incidence.48–50 Environmental changes such 
urbanisation, diet, lifestyle (smoking and alcohol) and hygiene may underpin these 
observations.47 In particular Western diets,  characterised by processed foods high in 
animal fats, protein, carbohydrate and emulsifiers and low in fibre, may be responsible. 
Changing to a predominantly animal-based diet in humans (composed of meats, eggs, 
and cheeses) has been shown to rapidly alter host microbiota composition, 
specifically, increasing the abundance of bile-tolerant microorganisms (Alistipes, 
Bilophila, and Bacteroides) and decreasing the levels of Firmicutes that metabolise 
dietary plant polysaccharides (Roseburia, Eubacterium rectale, and Ruminococcus 
bromii).51 In contrast, predominantly plant-based diets (rich in grains, legumes, fruits, 
and vegetables) did not alter either the microbial diversity within each subject at a 
given time-point (α-diversity) or the difference between each subjects' baseline and 
CHAPTER 1: INTRODUCTON TO IBD 
 
 
44 
diet-associated gut microbiota (β-diversity).51 Such changes in the microbiota, in 
particular Faecalibacterium prausnitzii and Roseburia intestinalis, may alter the 
production of metabolites such as Short Chain Fatty Acids (SCFA’s) and bacterial 
metabolites that are formed as result of anaerobic fermentation of dietary fibre.51,52 
SCFA’s such as acetate, propionate and butyrate, are reduced in IBD patients, and 
are important as a primary energy source for colonic epithelial cells, maintain intestinal 
homeostasis, strengthen gut barrier function, and may also have immunomodulatory 
functions.52,53  
 
Established IBD treatment options such as faecal diversion54 and exclusive enteral 
nutrition55 have both been shown to alter microbiota composition.  In the future, further 
therapeutic manipulation of the gut microbiome may be achieved by through whole-
food exclusion diets56, pro- and pre-biotics57 as well as faecal transplantation.58 
However, it remains unclear whether dysbiosis is a cause or a consequence of IBD; 
future, inception cohorts, such as the RISK59 and GEM60 studies, that describe real-
time genetic, environmental, and microbial interactions may help address this 
conundrum.   
1.2.3 Epigenetics: Linking genetic and environmental factors 
Epigenetics is possibly the missing key that links the effects of the environment, 
genetic predisposition and intestinal microbiota with IBD pathogenesis. This term was 
first proposed by Waddington in 2012 to describe how an organism’s phenotype may 
result from an interaction between its genes and environment.61 Epigenetics is more 
commonly used now to refer to alterations in gene expression events that occur 
independently of the primary sequence of Deoxyribonucleic acid (DNA).62 A few 
studies have found these events to be inheritable, although this is a somewhat 
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contentious issue.63 Such epigenetic mechanisms include DNA methylation, histone 
modification and micro RNA interference - which may be influenced through lifestyle 
factors such as diet and smoking.64–66  
 
Evidence supporting the importance of epigenetics in the pathogenesis of IBD can be 
found from both genome- and epigenome-wide methylation association studies. The 
International IBD Genetics Consortium reported an association between a SNP linked 
to DNMT3a, a gene encoding an enzyme responsible for establishment of DNA 
methylation, and IBD pathogenesis.41 Whereas Nimmo et al reported 50 differentially 
methylated sites, including several in important immune response genes (IL21R, 
S100A13, FASLG, MAPK13, RIPK3 or PRF1) which differed in patients with CD as 
compared with healthy controls.67 Such epigenetic studies are limited by the 
heterogeneity of the cell types and tissue investigated (e.g. peripheral blood 
mononuclear cells [PBMCs] vs. epithelial cells vs. tissue biopsies) as well as the 
controls which are used (i.e. healthy controls vs. unaffected tissue from the same 
patient). Each methylome signature is specific for a given cell type, therefore changes 
in cell proportions in conditions of inflammation may mimic true epigenetic changes 
and lead to misleading results. Although machine learning algorithms are commonly 
used to help differentiate signatures from different cell lines, methylome profiles should 
ideally be studied in sorted cell populations to allow definitive conclusions about 
epigenetic changes to be made.68 
1.2.4 Clinical presentation 
The clinical manifestations of IBD are dependent on the area of the gut involved. UC 
commonly presents with bloody diarrhoea, urgency and tenesmus, sometimes 
associated with abdominal pain. In contrast, CD commonly presents with recurrent 
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abdominal pain, weight loss and diarrhoea. Children may additionally present with 
growth retardation and delayed or failed sexual maturation.  
 
Systemic symptoms are commonly reported by IBD patients and include weight loss, 
fever, sweats, malaise, arthralgia and fatigue.  In 10%-20% of cases, patients present 
with extra-intestinal manifestations including, arthritis, dermatoses, uveitis, or liver 
disease.69  
1.3 Diagnosis of IBD 
1.3.1 Serological and faecal biomarkers 
At diagnosis, current European IBD guidelines recommend that every patient should 
have a biochemical assessment with full blood count, inflammatory markers (C-
reactive protein [CRP]), electrolytes, liver enzymes, and a stool sample for 
microbiological analysis, including C. difficile.69  
 
CRP broadly correlates with clinical severity in CD but less so in UC, except in the 
case of acute severe colitis.69 However, it is not uncommon for CRP to be normal, 
even in the context of active disease.70 Faecal calprotectin, a neutrophil-derived 
protein, appears to be the most sensitive marker of intestinal inflammation in IBD and 
its role is described in more detail later in Chapter 3.  
 
Approximately 30% of UC patients and 66% of CD patient receive immunosuppressive 
therapies in the first 5 years after diagnosis.17,18 Therefore, it is recommended that 
patients are screened and vaccinated at diagnosis to prevent severe infections: 
hepatitis B surface antibody, hepatitis B antigen, hepatitis B core antibody, hepatitis A 
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IgG, measles serology, varicella serology hepatitis C serology, Epstein Barr serology 
and HIV serology.69  
1.3.2 Endoscopy 
Ileocolonoscopy with a minimum of two biopsies from the inflamed regions69 remains 
the gold-standard diagnostic test in IBD and allows classification of disease based on 
endoscopic extent, severity of mucosal disease and histological features. Whilst 
complete colonoscopy, and the use of purgatives may be best avoided in severely 
active UC, flexible sigmoidoscopy with a phosphate enema is considered safe.  
 
CD is characterised by patchy transmural inflammation anywhere in the 
gastrointestinal tract and may be defined by age of onset, location, and behaviour. UC 
is characterised by diffuse mucosal inflammation which is limited to the colon and is 
classified according to the maximal extent of inflammation observed at colonoscopy. 
It is more broadly categorised into the following three subgroups: pan-ulcerative colitis; 
left-sided disease and distal disease/proctitis.71 The implication of microscopic 
(histological) disease activity in the absence of macroscopic inflammation in UC has 
long been debated. Indeed, Wright and Truelove reported that microscopic 
inflammation was associated with disease relapse disease back in 1966.72 More 
recently, microscopic inflammation in UC was associated with higher corticosteroid 
use and hospitalisation over a median of 6 years follow up.73,74 Unsurprisingly, 
histology is increasingly being used as an endpoint in modern clinical UC trials, 
although there remains considerable debate about the most appropriate scoring 
system to use and how to deal with intra-observer variability. 
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1.3.3 Imaging 
Imaging modalities used in the diagnosis of IBD include magnetic resonance 
enterography (MRE), small bowel capsule endoscopy (SBCE) and small intestinal 
contrast enhanced ultrasound (CEUS).  Imaging is particularly required to detect 
disease in the small bowel, especially in patients with a clinical suspicion of CD and 
normal ileocolonoscopy. MRE is now routinely available throughout the UK and uses 
magnetic resonance imaging (MRI) following distension with an oral contrast agent.  It 
offers several advantages including no radiation exposure, high-contrast resolution, 
multiplanar ability and dynamic (cine) imaging. Importantly, it can help distinguish 
between inflammatory, stricturing and penetrating disease as well as both mural and 
extramural complications; these are key questions for clinicians when deliberating 
treatment choices.69 MRI is also the modality of choice to delineate the extent and 
severity of peri-anal CD.  
 
Small intestinal contrast enhanced ultrasound is not yet widely practiced in the UK, 
although advocates of this technology cite a lack of radiation, low cost in comparison 
to MRI and CT, and real-time dynamic assessment, which make it an attractive option 
for the detection of strictures.69   
 
SBCE uses a camera within a small pill which is either swallowed or placed 
endoscopically into the stomach. It then wirelessly records real-time images from 
within the small bowel which are viewed by the reporting clinician at a later date.  SBCE 
is a sensitive tool to detect mucosal abnormalities and is comparable to other 
modalities including CEUS and MRE.69 Patients with normal MRE and/or CEUS and 
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an elevated calprotectin should be considered for SBCE, as cross sectional imaging 
modalities may miss proximal small bowel CD.75   
1.3.4 Pathology of IBD 
The typical histological hallmarks of CD are of granulomas with focal crypt architectural 
abnormalities, in conjunction with focal or patchy chronic inflammation in untreated 
adults.69 The inflammatory changes are defined by the presence of lymphocytes and 
plasma cells.  
 
In contrast, UC is typified by focal or diffuse basal plasmacytosis which may be present 
as early as two weeks after symptom onset in nearly a third of patients.76 Later 
changes include widespread mucosal and crypt architectural distortion, mucosal 
atrophy, an irregular or villous mucosal surface and mucin depletion.76   
 
IBD-U is used to describe approximately 12% of paediatric and 6% of adult patients 
where endoscopic appearances and biopsies are inconclusive for making a firm 
diagnosis of either CD or UC.77 The histopathology of childhood-onset IBD is distinctly 
different from adult-onset IBD and in UC may lack the architectural distortion seen with 
chronic disease.78 The distinction of infectious colitis from IBD is usually characterised 
by preserved crypt architecture and acute inflammation, although as eluded to above, 
these changes are often absent in early IBD.  
1.4 Modern treatment paradigms 
Treatment paradigms in IBD are changing with the realisation that IBD, particularly 
Crohn’s disease is a progressive disease for a substantial proportion of patients. 
Treatment plans are increasingly tailored to individual patients according to severity 
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and prognosis rather than using an empirical one-approach-fits-all strategy. Clinicians 
are also adopting more ambitious treatment goals for their patients.  Clinical remission 
and clinical response have been replaced by more objective end-points that have 
prognostic significance such as mucosal healing; a so-called ‘treat-to-target’ 
approach.  Therapeutic drug monitoring (TDM) is widely used to help guide the 
management of treatment failure and increasingly is being used proactively in patients 
in remission to optimise drug levels and reduce the risk of treatment failure.  
 
Currently, in the UK, the most common IBD treatment strategy is based on an 
accelerated stepwise escalation of pharmacotherapy from corticosteroid to 
immunosuppressive and then biologic therapies in response to repeated flares or 
persistently active disease: this is termed the ‘accelerated step-up’ approach.  This 
‘accelerated step-up’ strategy aims to avoid over-treating patients but conceivably 
exposes some patients to the complications of persistently active disease if progress 
up the steps is too slow. 
 
In 2013 the AZTEC79 and RAPID80 studies cast doubt on the effectiveness of such an 
accelerated step-up approach. These studies failed to demonstrate that the early 
initiation of thiopurines improved effectiveness over standard care. However, both 
studies had a number of limitations including an open label rather than blinded design 
(RAPID); use of an unselected cohort of newly diagnosed patients with CD, a 
proportion of which were destined to  experience an uncomplicated and mild disease 
course in any case16; and, neither study optimised thiopurine dosing according to drug 
metabolite levels. There were, however, some positive secondary end-points. The 
AZTEC study demonstrated that early treatment reduced the occurrence of active 
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perianal lesions with less need for perianal surgery, and the RAPID study reported 
that early thiopurine therapy reduced the rate of more severe disease flares.   
 
The seminal TOP-DOWN vs. STEP-UP study demonstrated that early combined 
immunosuppression with an immunomodulator and an anti-TNF drug (‘top-down’) was 
superior to the step-up approach for the treatment of CD patients.81 The top-down 
group received standard induction with infliximab [0, 2, and 6 weeks] and then 
continued with azathioprine monotherapy (as was standard practice at the time 
additional infliximab infusions were only provided if patients deteriorated clinically). In 
contrast, the step-up group received two tapering courses of corticosteroids, followed 
by treatment with azathioprine and then infliximab as required. Steroid-free and 
surgery-free clinical remission was found to be higher in the top-down group at 14, 26, 
and 52 weeks, but did not persist beyond a year. The rates of serious adverse events 
among the two cohorts were reported as no different, although the study was 
underpowered for this analysis. A follow-up study of 37% (49/133) of participants found 
that mucosal healing was superior in the top-down group at 2-years [71% vs 30%, P 
= 0.036].82  
 
Furthermore, the SONIC study by Colombel et al demonstrated that treatment with 
both a thiopurine and anti-TNF drug (‘combination therapy’) in CD patients naïve to 
both drugs, resulted in higher rates of steroid-free clinical remission and mucosal 
healing at 26 weeks as compared with azathioprine or infliximab monotherapy.83 
However, given our modern understanding of pharmacokinetics, it is unclear to what 
extent the addition of a thiopurine offers a therapeutic advantage in and of itself, 
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beyond a reduction in antibody formation against anti-TNF (so-called 
‘immunogenicity’) which often precipitates a loss of response.79,80,84   
 
Despite the findings of SONIC and the TOP-DOWN studies, concerns over both cost 
and the risks inherent in exposing up to one half of patients who might only ever have 
suffered a benign disease course to potentially life threatening side effects, have 
prevented widespread adoption of a top-down approach.85–89 One possible solution is 
suggested by the contemporary open-label randomised REACT study90: Khana et al 
report that the initiation of combination therapy earlier in the treatment algorithm (within 
12 weeks if the disease remained active after corticosteroid treatment) was more 
effective at reducing major adverse events (IBD-related surgery, hospital admissions, 
and serious disease-related complications) than a conventional step-wise approach. 
However, the surprising omission of mucosal healing as a primary end-point led to 
much criticism and has prompted the follow-up REACT II study.  
 
Other therapeutic options in the modern management of IBD patients include the use 
of exclusive enteral nutrition (EEN), not only in paediatric cohorts55 but increasingly in 
adults as well.91 The role of surgery should also not be dismissed. Often seen as a 
consequence of a failure of medical management, timely surgery can in fact be a 
valuable tool in the treatment of IBD, allowing long-term drug free remission in some 
patients.92,93 As discussed further in Chapter 2, the dilemma for clinicians is selecting 
the right strategy for the right patient at the right time. The solution to this problem may 
lie in the application of a combination of biomarkers; a central tenet of precision 
medicine.  
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1.5 Complications and comorbidities 
1.5.1 Strictures 
Strictures occur as a consequence of intestinal fibrosis, an exaggerated accumulation 
of collagen-rich extracellular matrix deposited by myofibroblasts which are themselves 
activated by inflammatory conditions.94 In CD, fibrosis appears to take place in two 
layers: first, in the submucosa there is smooth muscle fibrosis and hyperplasia; and,  
second, in the muscularis propria there is thickening and hyperplasia.95 
 
Strictures are present in approximately 13-21% of CD patients at diagnosis, and 
approximately 15-25% of patients 5 years after diagnosis.17,96 However, given that 
many patients with stricturing CD are asymptomatic, the true number of patients with 
strictures and fistulae at diagnosis may be as high as 40%.97 Although classically 
associated with CD, strictures also complicate UC in approximately 3-6% of 
patients.98,99   
 
Inflammation may persist in the absence of symptoms and in some patients this leads 
to a destructive progressive evolution from fibrostenotic stricturing to penetrating 
lesions, such as fistulae and abscesses (see Figure 1.4-1).100 
  
CHAPTER 1: INTRODUCTON TO IBD 
 
 
54 
Figure 1.5-1. Progression of digestive damage and inflammatory activity in a 
theoretical patient with CD. 
Progression of digestive damage and 
inflammatory activity in a theoretical 
patient with CD. Figure taken from 
Pariente B et al. Development of the 
Crohn's disease digestive damage 
score, the Lémann score. Inflamm 
Bowel Dis. 2011;17(6):1415–1422.100 
 
 
 
 
 
 
The degree to which medical therapies can reverse a stricture has previously been 
thought to be dependent on the extent to which the lesion is comprised of active 
inflammation versus the amount of established, and therefore assumed irreversible, 
fibrosis.  However, this paradigm has recently been questioned by the findings of two 
studies in mice that demonstrated reversal of established fibrosis through systematic 
administration of IL-36 antibodies101 and a topically administered Rho kinase 
inhibitor.102 For the time being, the mainstay of treatment for established fibrotic 
strictures is with endoscopic balloon dilation, surgical stricturoplasty and surgical 
resection. Endoscopic balloon dilatation is immediately successful in 97% of patients 
and over a median follow up of 5.8 yrs (IQR 3.0-8.4 yrs). Van Assche et al reported 
that no further dilatations were required in over half (54%) of patients.103 Ding et al 
found that the likelihood of requiring a further dilatation could be reduced by use of 
combination therapy (thiopurine and anti-TNF), independent of the length of stricture, 
duration of CD and Rutgeerts score.104 
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Colonic strictures should raise concerns about the risk of colorectal cancer: the 
GETAID group published a nationwide retrospective study of 12,000 French patients 
who underwent surgery for colonic strictures between 1992-2014 and reported that 
3.5% (248 patients with CD and 39 patients with UC) were found to have dysplasia or 
cancer.105 
1.5.2 Fistulae and abscesses 
A fistula is an abnormal opening between organs or other structures in the body. 
Symptoms of peri-anal discomfort and faecal leakage may be indicative of peri-anal 
abscesses and fistulae formation in perianal CD. The reported incidence of perianal 
CD varies widely depending on whether the definition includes the commonplace 
findings of skin tags and haemorrhoids.71 The incidence of perianal CD, when defined 
by the presence of fistulae and abscesses, increases with more distal involvement and 
is present in approximately 12% of isolated ileal CD, 15% of ileocolonic CD and 41% 
of colonic CD.106  
1.5.3 Dysmotility and anorectal dysfunction 
It has long been recognised that colonic dysmotility and anorectal dysfunction can 
complicate long-term UC. These sequelae result from a loss of colonic elasticity and 
consequently a narrow and stiff colon which may lead to diarrhoea, urgency, tenesmus 
and incontinence even in the absence of active inflammation.107 In the bygone era of 
barium enema investigation, it was not uncommon to see the so-called ‘lead-pipe’ 
colon, characterised by a loss of haustral folds, shortened length and reduced caliber 
in patients with long-term disabling UC. 
 
Colonic inflammation may damage and alter the number and function of the nerves, 
glial cells (which support and insulate neurons) and the interstitial cells of Cajal (which 
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act as pacemakers and regulators of smooth muscle contraction).108,109 This suggests 
that in UC it isn’t just the mucosal layer which is targeted by the disease. Furthermore, 
smooth muscle cells have been shown to be permanently altered in UC, even after 
the inflammation has subsided.110 
1.5.4 Colorectal cancer 
Patients with UC and colonic CD are at increased risk of colorectal cancer and hence 
national and international guidelines suggest frequent surveillance in all patients apart 
from those with proctitis.69,111,112 In a 2001, a meta-analysis based on 116 studies 
reported a cumulative probability of colorectal cancer in UC of 2% after 10 years, 8% 
after 20 years, and 18% after 30 years of disease duration.20 However, this study may 
have overestimated the risk of colorectal cancer, as many of the studies included were 
from the pre-surveillance era. In a more recent study of a large cohort of 1356 patients 
undergoing surveillance at a tertiary Canadian IBD centre, the incidence of colorectal 
cancer/high grade dysplasia in UC and colonic CD was 19.5/58.5 and 25.1/37.6 per 
100,000 patient-years, respectively.95 The incidence of dysplasia was low prior to 8 
years disease duration, both in UC and CD (19.5 and 12.5/100,000 patient-years, 
respectively). Reassuringly, and in keeping with current European surveillance 
guidelines, no colorectal cancer was detected prior to 8 years of disease duration.111 
 
There are several phenotypic and genetic differences between sporadic and IBD-
related colorectal cancer. IBD-related colorectal cancer affects younger individuals, 
more frequently progresses to adenocarcinoma from flat and non-polypoid dysplasia, 
has a higher proportion of mucinous and signet ring cell histology and is more likely to 
occur in one or more sites of the colon at the same time (a.k.a. ‘synchronous’) as 
compared with sporadic colorectal carcinoma.113 The higher incidence of synchronous 
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cancer is thought to reflect the broader ‘field-effect’ of widespread inflammation on the 
colonic mucosa of IBD patients. Whilst the same broad molecular pathogenic 
mechanisms are seen in both types of colorectal cancer; namely, chromosomal 
instability and microsatellite instability, the order of the mutations appear to be different 
in IBD-related and sporadic colon cancer (see Figure 1.4-2) 114  
Figure 1.5-2. Comparison of molecular alterations in sporadic colon cancer and 
colitis-associated colon cancer. 
 
Mut, mutation. Diagnosis and management of dysplasia in patients with inflammatory bowel 
diseases. Gastroenterology. 2004; 126:1634–1648. Modified from Itzkowitz SH., Harpaz N. by Xie 
J. and Itkowitz AH. Cancer in inflammatory bowel disease. World J Gastroenterol. 2008; 14(3): 
378–389.   
 
Dysplastic lesions in IBD are categorised either as endoscopically ‘visible’ or 
‘invisible’.  With respect to colorectal cancer surveillance, multiple (≥ 33 biopsies) 
throughout the colon used to be advocated in order to detect about 90% of invisible 
lesions. However, both international115 and national guidelines111,116 now strongly 
recommend utilising chromoendoscopy (dye spray) with targeted biopsies as the 
standard surveillance practice. With the advent of high-definition white-light 
endoscopy and chromoendoscopy, ‘invisible’ lesions now only account for about 10% 
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of dysplastic lesions.115 Endoscopically visible lesions are described as either polypoid 
or non-polypoid-like with management determined by the size, morphology, ulceration 
and border. Often the fibrosis associated with inflammation makes removal of the 
lesions difficult and requires endoscopic mucosal resection, endoscopic submucosal 
dissection or hybrid techniques. Colectomy is not necessary if a dysplastic polyp can 
be entirely removed endoscopically in the absence of dysplasia in the surrounding 
tissues. Traditionally colectomy was advocated for invisible lesions, however, now 
with the advent of chromoendoscopy for both low- and high-grade invisible dysplasia 
repeat surveillance by an experienced endoscopist is recommended and the relative 
risks of continued intense surveillance versus colectomy are discussed with the 
patient.117  While proctocolectomy abolishes the risk of CRC, it does not remove the 
low risk of anal cancer or cancer of the rectal cuff or ileo-anal pouch. 
  59 
Chapter 2 
2 Introduction to precision medicine in IBD 
Precision medicine is a “move away from a one size fits all approach to the treatment 
and care of patients with a particular condition, to one which uses new approaches to 
better manage patients health and target therapies to achieve the best outcomes in 
the management of a patient’s disease or predisposition to disease”. This concept is 
far from new, and some 2500 years ago the Greek physician Hippocrates wrote of the 
individuality of disease and the necessity of giving ‘different [drugs] to different 
patients; for the sweet ones do not benefit everyone, nor do the astringent ones, nor 
are all the patients able to drink the same things’.118  
 
Over the next couple millennia little progress was made or indeed possible beyond 
characterising responses in patients based on the most rudimental of phenotypic 
differences, and in 1892, Sir William Osler commented that, ‘If it were not for the great 
variability among individuals, Medicine might be a Science, not an Art’.119 However, 
just over 100 years after Osler made this statement, scientific advances in the field of 
genetics meant that clinicians could observe inherited differences between individuals 
which were associated with response to therapies. A new era of precision medicine 
had arrived in which clinicians sought to exploit new biomarkers, serological, and 
genetic data to improve patient response and possibly in the future, even prevent 
disease.   
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2.1 Precepts of precision IBD medicine 
The need for a new approach in the field of IBD is obviously apparent: current 
treatment paradigms mean that many patients still suffer a complicated disease 
course with multiple drug side-effects, hospital admissions and IBD-related 
surgeries.120,121 The key to harnessing the potential of precision medicine in IBD is to 
improve the timing and delivery of healthcare by targeting both pharmacological and 
non-pharmacological treatment according to specific clinical and biological 
characteristics of individual patients.122,123 The central precepts of precision IBD 
medicine that will be summarised in the following introduction are (see Figure 2.1-1):  
1. making an early diagnosis 
2. prognostication of disease course and complications  
3. predicting drug response and adverse drug reactions 
4. monitoring response to treatment with stringent targets and iterative 
adjustments 
Figure 2.1-1. Schematic showing the components precision medicine in IBD 
Early 
diagnosis
Disease 
prognostication
Predicting 
response
Monitoring 
response
Iterative 
adjustment
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This precision medicine approach aims to identify IBD patients early in their disease 
course, when therapies appear most effective and prior to the development of 
complications.124 Physicians will be able to identify those patients who are likely to 
suffer a complicated disease course and target them with early more aggressive 
pharmacotherapies. Conversely, patients destined to follow a benign disease course 
could be spared the risks of such therapies. Clinicians will select the right treatment or 
combination of treatments based on the pathophysiological mechanisms driving a 
particular individual’s disease. The right treatment will not only vary between patients 
who have the same disease but also within an individual patient as they get older and 
their body changes. Additionally, this will not only facilitate escalation of treatment, but 
safe and appropriate de-escalation in order to minimise the risk of disease relapse and 
reduce long-term drug side-effects. Deeper pharmacokinetic and pharmacodynamic 
understanding will enable personalised therapeutic drug monitoring and the fine 
adjustment of drug dosing and intervals in order to meet stringent treatment targets. 
Arguably, in an era defined by financial constraints, such an approach within the NHS 
should also have the equalitarian ambition to make the best use of available 
resources. 
2.2 Precept #1: The importance of making an early diagnosis  
The concept of disease modification through early treatment has revolutionised 
rheumatology and dermatology practice. In IBD, evidence is now accumulating that 
early diagnosis allows early intervention in a window of opportunity, prior to irreversible 
bowel damage, when therapies are more effective. 
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Post hoc analyses of several individual and pooled IBD studies stratified by disease 
duration at time of enrolment suggest a therapeutic treatment window in which 
treatment responses were better in CD patients treated early in their disease 
course.125–129  For example in a sub-analysis of the SONIC data, the benefit of 
combination therapy in achieving a stringent composite outcome of clinical remission, 
mucosal healing and CRP normalisation, was most apparent in patients whose 
treatment was instigated within 18 months of diagnosis (early disease cohort: IFX 
combination therapy = 65%; IFX monotherapy= 25%; AZA monotherapy = 10%, [P = 
0.010]; late disease cohort: IFX combination therapy = 44%; IFX monotherapy = 26%; 
AZA monotherapy = 14% [P = 0.069]).  
 
Unfortunately, there are a paucity of prospective data supporting the early initiation of 
IBD therapies. As afore mentioned in Chapter 1, the RAPID80 and AZTEC79 studies 
failed to demonstrate an advantage to the early initiation of thiopurine monotherapy, 
however, to date no study has done the same for anti-TNF mono- or combination-
therapy in adults. In contrast in a paediatric CD cohort, the RISK study reported higher 
rates of one-year steroid-free remission, and reduced progression to year-three 
internal fistulating complications in patients who received anti-TNF within three 
months of diagnosis.59  
 
The immunological mechanisms underlying the benefits of aggressive early treatment 
are largely unknown, although differences in the peripheral but not mucosal IL-17/Th1 
response130 as well as a diminished T-cell response to Th1 cytokines in human cell 
studies131, and a blunted response to CCR9/CCL25 blockade in treating murine 
colitis132 have all been described as differing in late and early disease.  
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Whilst early combination therapy may offer patients the best chance of long-term 
disease modification133,134, such an approach remains expensive, even with the 
advent of biosimilars, and risks exposing patients who might only ever have suffered 
a benign disease course to potentially life threatening side effects.85–89 For other 
patients, an early surgical intervention is a better option than medical therapy and 
offers long-term drug free clinical remission.92,93 Central to these decisions is the 
concept of disease prognostication; allowing clinicians to predict which patients are 
likely to suffer disabling sequelae in order that they may apply the correct therapeutic 
strategy to each individual. 
2.3 Precept #2: Prognostication of disease course and complications 
Despite extensive work investigating clinical, genetic and serological markers of IBD 
susceptibility there are no routinely used tools that reliably predict disease course at 
the point of diagnosis in IBD. Such an advance would not only allow precision 
treatment strategies but would also revolutionise clinical study design which may have 
been flawed by disease outcome confounders in the past. Terms such as ‘complicated’ 
and ‘disabling’ disease are used interchangeably, but invariably refer to patients that 
require hospitalisation, surgery, prolonged steroid exposure and cancer. It is not only 
necessary to identify those patients at high risk of disabling disease, but also those 
patients at low risk of disease progression, to inform discussion of the risks and 
benefits of treatment options.1 In future, a combination of genetic clinical and 
serological markers nay be used to predict disease course and response to treatment. 
Furthermore, clinicians may come to revise the current sub-phenotypes of IBD (CD, 
UC, IBD-U) in favour of new descriptors that better reflect the heterogeneity of the 
disease and the diverse outcomes that are seen in everyday practice. In the following 
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section I will summarise progress in the field of predicting disease course and 
behaviour.  
2.3.1 Clinical criteria 
Simple clinical features have long been used to predict the likelihood of a complicated 
disease course. In CD, this phenotype has been associated with clinical factors such 
as an initial need for steroids, age below 40 years old at time of diagnosis and the 
presence of perianal disease at diagnosis.135 Although scoring systems using these 
clinical biomarkers have been replicated and found to be sensitive predictors of 
disabling disease in IBD patients Worldwide136, they lack specificity and are present 
in many patients with benign disease who are therefore at risk of being overtreated. 
Other predictors include extensive small bowel involvement, severe upper GI disease, 
early stricturing or penetrating disease and smoking.137  In contrast, patients with 
colonic CD rarely require resective surgery, remaining free of complications for many 
years.121 Patients with childhood-onset CD are more likely to have severe disease that 
requires immunosuppressant treatment, although stricturing, penetrating 
complications and surgery don’t appear more common.138 Whilst many genetic factors 
have been implicated in the pathogenesis of IBD, patients with a strong family history 
of CD seem to have no worse a prognosis or disease course when compared with 
sporadic cases.139  
 
Environmental factors may also predict disease course. Following Crohn’s disease-
related surgery, smoking is associated with a doubling of the risk of disease recurrence 
and need for further surgery: indeed this can be used to stratify patients who are most 
appropriately started on prophylactic immunosuppressive treatment following ileal 
resection.140  
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In UC, approximately 80-90% of patients suffer a relapsing disease course, with 
disease activity and extent in the first couple years predicting subsequent disease 
activity over the next few years.141,142 Patients with more extensive and aggressive 
disease have a higher risk of relapse, need for surgery and risk of developing colon 
cancer.137 Extensive colitis, with disease proximal to the splenic flexure, at 
presentation is the most reliable independent predictor of colectomy within 10 
years.141,143,144,145 Smoking cessation increases the severity of UC and the risk of being 
admitted into hospital admission for rescue medical therapy.146 Unlike CD, UC is a 
fairly dynamic disease with 27%–54% of patients with initial  proctitis or left-sided 
disease showing proximal extension during the course of their disease.110 Indeed, 
studies from the UK147 and Denmark141 both suggest that this cohort of patients with 
proximal extension of disease have a higher rate of colectomy as compared with 
patients with extensive disease from the outset. Young age at diagnosis141,148 and the 
presence extra-intestinal manifestations141 have both been associated with higher risk 
of proximal extension.  
 
Following colectomy and ileal pouch-anal anastomosis, some UC patients develop 
complications such as chronic pouchitis and a Crohn’s Disease-like phenotype. These 
complications are increased in the presence of enteropathic arthropathy, primary 
sclerosing cholangitis (PSC) and a longer duration of time to ileostomy closure.149 
CHAPTER 2: INTRODUCTION TO PRECISION MEDICINE 
 
 
66 
2.3.2 Faecal biomarkers  
2.3.2.1 Predicting relapse after drug withdrawal in IBD 
Two studies exploring the clinical and biochemical factors associated with disease 
relapse following infliximab withdrawal in patients in long-term corticosteroid-free 
remission have reported the value of the biomarker faecal calprotectin. Both STORI150 
and Kennedy et al151 found that that a calprotectin of ≥ 300 µg/g and > 50 µg/g, 
respectively, increased the odds of relapse 3-fold, independent of factors such as age 
of disease onset, white blood cell count and CRP. Kennedy et al reported that re-
treatment with infliximab was effective and well tolerated in 88% of patients who 
experienced a relapse. These studies suggest that faecal calprotectin can be used 
with other readily available biomarkers to help clinicians decide whom they might 
safely de-escalate treatment. Whether patients in long-term remission on combination 
therapy should have their thiopurine or anti-TNF, or both withdrawn, is unknown and 
the subject of the SPARE study (a prospective randomised controlled trial comparing 
infliximab and immunomodulatory combination therapy vs. immunomodulator 
monotherapy and infliximab monotherapy in CD).152  
2.3.2.2 Predicting relapse in IBD  
Costa et al153 report that the median calprotectin in CD patients who relapsed and 
those who maintained remission was no different among 28 patients in clinical 
remission and followed-up with serial biochemical and faecal tests over a year: 
220 µg/g [95%CI 22 - 419 µg/g] vs. 221 µg/g [95%CI 53 - 388 µg/g], respectively; P = 
0.395. In contrast, the same study in 41 UC patients, found that the median 
calprotectin was higher in those who suffered a relapse than those who didn’t: 221 
CHAPTER 2: INTRODUCTION TO PRECISION MEDICINE 
 
 
67 
µg/g [95%CI 86 - 355.2 µg/g] vs. 67 µg/g [95%CI 15 - 119 µg/g], respectively 
P < 0.001. The proportional multivariate Cox hazard regression model showed a 2-
fold and 14-fold increase in the relapse risk in those patients with CD and UC, 
respectively, who had a faecal calprotectin concentration > 150 µg/g, independent of 
other confounding variables. Interestingly in UC, De Vos et al report a rise in 
calprotectin above 300 µg/g may precede a flare by up to 3 months, and that two such 
consecutive calprotectin measurements with a 1-month interval was the best predictor 
for this with a 62% sensitivity and 100% specificity.154 
2.3.2.3 Predicting relapse after ileocaecal resection in CD 
The current gold-standard of post-ileocaecal resection evaluation is to review the pre-
anastomotic, anastomotic and neo-terminal ileal mucosa at 6 months after surgery 
and to escalate treatment according to the severity of inflammation as defined by the 
Rutgeerts score.155,156 Faecal calprotectin is a good surrogate marker of endoscopic 
disease recurrence as defined by the Rutgeerts score.157 In a recent systematic review 
and meta-analysis of 9 studies by Tham et al the authors report that the optimal 
diagnostic accuracy for determining endoscopic recurrence was obtained using a 
calprotectin threshold of 150 µg/g. This resulted in a pooled sensitivity of 70% [95%CI 
59 – 81%] and specificity 69% [95% CI 61 – 77%] with an area under the receiver 
operating curve of 0.73.158 However, given the clinical repercussions of re-instigating 
long-term immunosuppressive medications, it is unlikely that a 30% false negative rate 
will mean that calprotectin will replace endoscopic evaluation for this purpose.  
2.3.3 Serological Antibodies 
Subsets of IBD patients may have an abnormal immune responses to various 
microbial antigens, which can be used not only to diagnose IBD, and distinguish CD 
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from UC159, but also help predict the course of disease.160–162 Anti-Saccharomyces 
cerevisiae antibodies (ASCA), Escherichia coli outer-membrane porin C (OmpC), anti-
CD related bacterial sequence 12 (anti-I2) and CBir1 flagellin (anti-CBir1) have been 
associated with early CD onset, a fibrostenosing and penetrating disease course and 
the need for early small bowel surgery.163–166 Combining these serological antibodies 
with age of IBD onset, as well as environmental factors such as smoking can be used 
to ascertain useful predictions for risk of future surgery in CD.167 In the population-
based IBSEN cohort, ASCA-positive patients aged less than 20 years old who had 
been diagnosed with penetrating disease and had been initially treated with systemic 
steroids had a probability of CD-related surgery of 97%.167  
2.3.4 Genetic factors 
2.3.4.1 Genetic factors for disease prognostication 
Compared to clinical parameters or serologic markers, genetic markers are more 
appealing for risk stratification as they are present long before the onset of disease, 
stable over time and unaffected by disease flares.168 However, in contrast to the 240 
loci found to be associated with susceptibility to IBD, only a few genetic markers have 
been shown to predict its course.169,170 Patients carrying a NOD2 genetic variant were 
previously thought to be more likely to require earlier resection surgery and experience 
a higher rate of post-operative recurrence than patients who don’t share this allele.171–
175 However, contemporary studies subsequently showed that this association was 
entirely driven by the association between NOD2 and ileal  disease, which is more 
commonly treated with surgery.27  
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In the first study to explore prognostic as distinct from disease susceptibility genes, 
Lee et al reported a candidate gene study that identified a non-coding SNP in FOXO3 
which was associated with a milder course of CD.176 In subsequent functional 
experiments the authors found that the FOXO3-driven pathway abrogated 
inflammatory responses in monocytes via TGFβ1 and led to reduced TNF-α and IL-6 
production in carriers  of  the  mild  CD-associated  allele.176 
 
Gene expression profiling studies illustrate the dynamic function of genes in vivo by 
simultaneously measuring the activity of thousands of genes to create a global picture 
of cellular function. This design was used by Lee et al to further define an expression 
signature within peripheral blood CD8 T-cells isolated from patients with active 
untreated UC and CD which stratified all patients into two clinically indistinguishable 
subgroups, called ‘IBD1’ and ‘IBD2’.177 Prospective follow-up demonstrated that those 
in the IBD1 subgroup had a high incidence of treatment-refractory, relapsing disease, 
while those in the IBD2 subgroup typically achieved stable remission on minimal 
immunosuppression. These markers were independent of biomarkers for inflammation 
and superior to clinical and serological factors. To aid translation of this work Lee et al 
have detected a similar gene signature detectable in whole blood samples. This work 
has formed the basis for PROFILE, a prospective UKCRN study to stratify patients 
based on this prognostic biomarker to either step-up or top-down therapies; the results 
are eagerly awaited and may transform practice.  In children, similar gene expression 
signatures that predict disease course have also been discovered.59  
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2.3.4.2 Genetic factors for cancer prediction  
Many of the genetic alterations responsible for sporadic colorectal cancer such 
chromosomal instability, microsatellite instability and CpG island hypermethylation 
also occur in IBD-related colorectal cancer.178 Genetic biomarkers may help assess 
the future risk of colorectal cancer in UC patients; a microarray study found 40 genes 
that were differently expressed between 10 UC patients diagnosed with cancer and 
43 UC patients without cancer.179 Included in this list of genes was LRP5 and LRP6 
(low-density lipoprotein receptor–related protein), which promote cancer cell 
proliferation, tumorigenesis and are considered candidate oncogenes.179 Studies 
reporting differential methylation of genes associated with carcinogenesis (e.g. 
CDKN2a/p16INK4A, CDKN2a/p14ARF, CDH1, MLH1, HPP1 and MYOD1) in the 
colonic mucosa of UC patients with dysplasia and/or carcinoma as compared with the 
quiescent mucosa from the same patients may provide an insight into the role of 
unchecked inflammation in the pathway to IBD-related colorectal cancer.68,180,181 
Interestingly, changes in gene expression182 as well as abnormal number of 
chromosomes in a cell (aneuploidy)183 and loss of p53 heterozygosity184 occur in the 
normal looking rectal mucosa of patients with IBD-related colorectal cancer elsewhere 
in the colon; these changes may act as a biomarker in patients at high risk of 
dysplasia/cancer and thus could be incorporated into future personalised surveillance 
algorithms. 
2.3.5 Combining genetic, serological and clinical factors 
The paediatric RISK CD inception cohort enrolled over 1000 children at diagnosis from 
28 sites and sought to define factors associated with a complicated disabling disease 
course within the first 5 years after diagnosis.59,185 A validated model was developed 
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which integrated clinical and serological biomarkers. Those patients of older age-of-
onset, African American ethnicity, and ASCA IgA and CBir1 seropositivity were shown 
to be at higher risk of stricturing and fistulating disease. 
2.4 Precept #3: Predicting drug response and adverse drug reactions 
Rather than arriving at the best therapy by chance or following multiple failed trials of 
alternative therapies, one of the cornerstones of precision medicine is to select the 
drug or combinations of drugs with the greatest effectiveness and the least toxicity. 
Therapeutic options are rapidly expanding and represent the major cost of IBD 
healthcare. As a consequence, optimal selection/use of therapies is now an urgent 
priority. In the following sections exploring prediction of response to drugs used in the 
treatment of IBD, I will primarily focus on biologic drugs and in particular anti-tumour 
necrosis factor (anti-TNF) therapies, as arguably these are the most effective 
therapies for IBD.  
2.4.1.1 Predicting response to anti-TNF 
TNF-α is potent pro-inflammatory acute phase response cytokine produced mainly by 
macrophages but also by lymphocytes, natural killer (NK) cells and neutrophils. Anti-
TNF treatment has been one of the mainstays of the treatment of IBD for more than 
two decades, although treatment failure is common: 40% of patients fail to respond to 
induction therapy (primary non-response, PNR), 46% of patients suffer secondary 
loss-of-response in the first year of treatment (LOR), and approximately 10% suffer an 
adverse drug reaction that curtails treatment.84 Variability in response to anti-TNF 
therapies, may be a consequence of pharmacokinetic and pharmacodynamic factors, 
both of which may be influenced by genetics.  
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A number of clinical factors have been reported to be associated with primary non-
response to anti-TNF therapy including body mass index (BMI), longer disease 
duration, older age at diagnosis, previous surgery, and absence of mucosal 
lesions.186–189 However, these factors are neither sensitive nor specific enough to be 
clinically useful. 
 
Multiple small case control studies have investigated the genetic determinants of 
response and non-response to anti-TNF drugs, both in IBD and in a range of other 
inflammatory conditions.190–192 To date, results have been inconsistent with no 
clinically useful marker identified. In the largest hypothesis free study to date, GWAS 
methodologies were used to explore PNR among 474 patients with IBD [359 CD, 99 
UC, 16 IBD-U] of European ancestry.193 A genetic risk score was constructed using 
11 IBD susceptibility loci associated with PNR with a P value < 0.05 and 4 novel 
variants associated with PNR with a more stringent P value of < 1x10-4. Like many 
previous reports in this field this study was limited by a retrospective design and lack 
of therapeutic drug monitoring (TDM) data (to distinguish pharmacokinetic from 
pharmacodynamic treatment failure). 
 
Pre-treatment gene expression from mucosal biopsies may help to determine future 
response to anti-TNF and could attractively be performed at the time of diagnosis. In 
a study of UC patients by Arijs et al expression profiles of 5 genes separated non-
responders from responders with a sensitivity of 95% and 85% specificity.194 However, 
like many similar studies responders and non-responders were stratified by 
expression levels after drug administration. Therefore, it is likely that these biomarkers 
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simply represent another proxy measure of inflammation, when what is really needed 
is a biomarker that separates patients before drug exposure which predicts response 
to anti-TNF prior to induction.  In addition, gene expression profiling is challenged by 
its inherently unstable nature and sensitivity to external factors such as environmental 
factors and drugs.  
 
Measuring tissue cytokine levels targeted by drugs may seem like a more obvious 
correlate of future treatment success. Atreya et al used FITC labelled adalimumab, 
which was applied directly to the mucosa at the time of pre-treatment colonoscopy 
using a spray catheter, and real-time confocal laser endomicroscopy to yield specific 
signals for cells expressing mucosal-TNF (mTNF).195 After in vivo imaging the patients 
were then treated with adalimumab and clinical response evaluated at week 12. The 
authors found a significant correlation in the mean number of mTNF+ cells per 
confocal image and clinical response. Importantly the high and low mTNF groups did 
not differ in terms of histological activity or serum CRP. Translation of this promising 
study has partly been delayed by the legislation surrounding the manufacture of 
monoclonal antibodies which must meet the same level of European Medicine Agency 
(EMA) quality control as any other drug. 
 
There are many causes of secondary loss of response, and not all are due to active 
disease (e.g. fibrostenotic strictures, bile salt malabsorption, functional gut disorder 
overlap etc.). Immunogenicity and anti-drug antibody (ADAb) formation is the most 
studied underlying mechanism and leads not only to treatment failure but also infusion 
reactions. In a recent meta-analysis of 13 studies that evaluated 1378 patients with 
IBD treated with IFX, the pooled relative risk of secondary loss of response in patients 
CHAPTER 2: INTRODUCTION TO PRECISION MEDICINE 
 
 
74 
with ADAb was 3.2 (95%CI 2.0-4.9; P < 0.001), when compared to patients without 
ADAb.196 The ability to identify patients at risk of immunogenicity prior to treatment 
might allow targeted use of immunomodulatory therapies or alternative treatments to 
be used. It is possible that some patients are primed to develop immunogenicity 
through environmental exposures: in a small exploratory single centre retrospective 
study from Denmark the presence of high titres of pre-treatment cross reacting murine 
antibodies targeting the Fab portion of IFX, were associated with treatment failure at 
12 months.197   
 
The Exeter PANTS study198 found that among 955 biologic naïve CD patients treated 
with infliximab and 655 treated with adalimumab the only factor independently 
associated with primary non-response was low anti-TNF drug levels at week 14; the 
optimal week 14 drug concentrations associated with remission at both week 14 and 
week 54 were 7 mg/L for infliximab and 12 mg/L for adalimumab. The proportion of 
patients who developed immunogenicity (anti-drug antibodies-ADAb) was 63% 
(95%CI 59 - 63%) for infliximab and 29% (95%CI 24-33%) for adalimumab. In 
unpublished work, we also report that the Human Leukocyte Antigen (HLA) allele, 
HLA-DQA1*05, carried by approximately 40% of Europeans, significantly increased 
the rate of immunogenicity (hazard ratio [HR] 1.90 [95%CI 1.60-2.25]; P = 5.9 x10-13). 
This finding was confirmed in a replication cohort (HR 2.00 [95%CI 1.35 to 2.98]; P = 
6.60 x10-4) and was consistent for patients treated with adalimumab (HR 1.89 [95% 
CI, 1.32-2.70] and infliximab (HR 1.92 [95%CI, 1.57-2.33], and for patients treated with 
anti-TNF therapy alone (HR 1.75 [95% CI, 1.37-2.22] or in combination with an 
immunomodulator (HR 2.01 [95%CI, 1.57-2.58]. 
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2.4.1.2 Predicting response to anti-integrin therapy 
Etrolizumab is a humanised monoclonal antibody that selectively binds the β7 subunit 
of the heterodimeric integrins α4β7 and αEβ7. In a post-hoc analysis, high as 
compared with low αE (ITGAE) gene expression at baseline colonic biopsy predicted 
clinical remission at 10 weeks. 
2.5 Precept #4: Monitoring response to treatment  
The ‘treat-to-target’ strategy is based on the frequent assessment of disease activity, 
using objective markers of inflammation and subsequently adjusting therapy 
accordingly to reach the pre-established target.200 The 2015 STRIDE guidelines 
suggest that the ideal target in both UC and CD should be a composite of clinical and 
endoscopic remission with faecal calprotectin and blood CRP only used as 
adjuncts.201 It is possible that histological remission, that is, healing at the 
cellular/microscopic level, may be added in the future, although evidence is still being 
gathered for this endpoint.202  
 
‘Tight-control’ is the use of regular (suggested at least every 3 months) monitoring of 
patient symptoms and biomarkers to direct treatment escalation. Data from the 
multicenter open-label CALM study showed that escalation of treatment based on both 
clinical symptoms and biomarkers (faecal calprotectin and CRP) was superior to a 
conventional symptom-based approach.203 Crucially, the study protocol meant that 
patients in the tight-control arm who were in symptomatic remission but had either a 
raised CRP and/or faecal calprotectin had their treatment escalated. Escalation in both 
arms consisted in the sequential use of adalimumab every other week, adalimumab 
weekly, and finally adalimumab weekly plus azathioprine. At week 48, patients in the 
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tight control arm had better clinical and endoscopic outcomes than in the conventional 
treatment arm. These data suggest that tight-control may prevent, or at least delay, 
disease progression. In the long-term follow up of CALM patients,  when patients were 
stratified by outcomes at 1 year into (1) clinical remission (Crohn’s disease activity 
index, CDAI <150), (2) endoscopic remission (Crohn’s disease endoscopic index of 
severity, CDEIS <4 with no deep ulcerations); and, (3) deep remission (CDAI <150, 
CDEIS <4 with no deep ulcerations, and no steroids for ≥ 8 weeks) both endoscopic 
remission and deep remission, but not clinical remission were significantly associated 
with lower risk of major adverse outcomes (new internal fistula/abscesses, strictures, 
perianal fistula/abscesses, CD hospitalisations, or CD surgeries). Thus, the authors 
concluded that the early CD patients who achieve endoscopic or deep remission after 
1 year of intensive treatment are less likely to have disease progression over a median 
of 3 years’ follow-up.204 
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Chapter 3 
3  The role of faecal calprotectin in the delivery of 
precision IBD medicine: making an early 
diagnosis 
3.1 Background to the chapter 
Calprotectin is an abundant calcium and zinc binding protein with antimicrobial and 
anti-proliferative activity found in the cytosol of neutrophils and to a lesser extent 
monocytes and reactive macrophages.205 It can be measured in numerous fluids 
including serum and faeces, although for discriminating IBD from healthy controls, 
faecal is superior to serum calprotectin.206 Raised calprotectin levels detected in stool 
reflect cellular damage and apoptosis and therefore correlate with levels of 
gastrointestinal inflammation.207 This enables its use as a biomarker for a number of 
purposes in gastroenterology including: differentiation of inflammatory and functional 
disease in patients presenting with lower GI symptoms; evaluation of disease activity; 
and, assessment of treatment response in patients with a prior IBD diagnosis. In this 
regard, faecal calprotectin has been shown to outperform older inflammatory 
biomarkers such as FBC, ESR and CRP, both in distinguishing IBD from functional 
gut disorder, and as an adjunct in the assessment of disease activity in patients with 
known IBD.208–210 
CHAPTER 3: CALPROTECTIN IN PRIMARY CARE 
 
 
78 
3.1.1 Measurement of faecal calprotectin 
Calprotectin levels are higher when time between bowel movements is longer; hence 
morning stool samples are recommended in order to measure it at its nadir. 
Calprotectin is stable in faeces stored at room temperature for up to 3 days, thereafter, 
levels fall by approximately 28% between days 3-7 days, which may be of clinical 
relevance at lower calprotectin thresholds in the 100-200µg/g range that is most 
commonly used to influence investigation and treatment decisions.211 Further sample 
variability may be introduced by the method of faecal extraction; in comparison to 
manual weighing, commercial extraction devices may under-recover calprotectin by 
8-28%.212 Once extracted into buffer, calprotectin levels are stable for ~2.5 months at 
−20°C.213  
 
Several faecal calprotectin tests are available to the NHS in England, including214:  
i. fully quantitative laboratory-based tests (mostly ELISA based platforms) 
ii. fully quantitative rapid tests (Immunoassays) 
iii. semi-quantitative pointofcare tests (POCTS) (Immunochromatographic 
rapid test) 
For each type of test there are several methods of performing the assay and multiple 
manufacturers.  The most commonly used methods of calprotectin testing include:  
3.1.1.1 Enzyme Linked Immunosorbent Assay (ELISA) 
An antibody against calprotectin is attached to a microtiter plate by the manufacturer. 
When the patient faecal sample is added to the plate, calprotectin within the sample 
is bound by the antibody. The plate is washed to remove remaining sample and a 
detection antibody to calprotectin which is linked to an enzyme is then added. When 
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an enzyme substrate is then added the product of this reaction is proportional to the 
amount of calprotectin present and can be detected by colorimetry or fluorimetry (see 
Figure 3.1-1).214 Whitehead et al demonstrated that different manufacturers of 
calprotectin ELISA assays differ in their performance and precision profiles.212 In this 
study of three commonly used two-step ELISA assays (EK-CAL, by Bühlmann 
Laboratories AG; PhiCal by Immunodiagnostik AG and Calprest by Eurospital) the 
authors found that mean intra-assay imprecision (as measured by percentage 
coefficient variation [%CV]) was 6.4%, 10.0% and 10.1%, respectively. The inter-
assay %CV  ranges were 5.3–8.2%, 7.0–8.9% and 7.1–8.2%, respectively.212 A 
general laboratory rule of thumb is that the intra-and inter-assay %CV should be <10% 
and <15%, respectively, and therefore all three assays tested met this criteria. 
Figure 3.1-1. Examples of different enzyme-linked immunosorbent 
immunoassays (ELISA's)  
Direct, enzyme labelled primary antibody ‘directly’ binds to the antigen (Ag) that is immobilised 
to the plate surface. The enzyme then reacts with substrate to produce measured visible signal 
proportional to concentration of Ag. Indirect, both primary and secondary antibody used with 
enzyme bound to second antibody. Sandwich, instead of binding the Ag to the plate, it is the 
capture antibody which is bound to the plate. The Ag binds to this antibody, which is then bound 
by the primary antibody. Thirdly, the secondary antibody bound to enzyme binds the primary 
antibody. Image taken from https://www.bosterbio.com/protocol-and-troubleshooting/elisa-
principle 
3.1.1.2 Time-resolved fluorescent immunoassay (TRFIA)  
The TRFIA is similar to an ELISA, with a capture antibody which has been adsorbed 
onto the surface of a microtiter plate, and steps involving adding sample, washing and 
using a detection antibody. During standard fluorometric detection, excitation and 
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emission both occur at the same time, which can lead to self-quenching when the two 
overlap. In contrast, TRFIA relies on the use of very specific fluorescent molecules, 
called lanthanide chelate labels, which allow detection of the emitted light to take place 
after excitation has occurred with fluorescence measured during a defined time 
window. The most commonly used lanthanide chelate label is the Europium ion 
(Eu3+). A further advantage to a TRFIA is that biological samples, which often have 
their own autofluorescence, are washed away, thus reducing background noise. 
These technical differences mean that TFRIA’s are more sensitive, have a greater 
measurement range – as there is no need to further dilute samples, and are ~25% 
cheaper, as compared with ELISA’s.215,216 
3.1.1.3 Point-of-care semi-quantitative/ quantitative tests  
Most semi-quantitative and quantitative methods are based on a chromatographic 
immunoassay involving lateral flow of sample and reagents along a membrane strip 
encased within a plastic palette which contains a sample well and an elongated 
window for result viewing (see Figure 3.1-2). The expected position of the lines 
developed during the test are usually imprinted on the plastic at the side of the window. 
The test lines contain anti-calprotectin antibodies and the control line contains anti-
immunoglobulin antibodies, both of which have been dried onto the membrane strip. 
When the liquid sample is added to the sample well the labelled antibodies bind to 
calprotectin in the sample and the complex migrates along the membrane by capillary 
action. The calprotectin/labelled antibody complexes are bound to the test line by the 
immobilised antibodies to a different part of the calprotectin molecule. The unbound 
labelled antibody moves on to be bound by the immobilised immunoglobulin 
antibodies in the control line. A visible developed control line is essential to show that 
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the test has run properly. Where there is more than one test-line they indicate different 
concentrations of calprotectin present. The results are available after 10-15 minutes 
and can be quantitative or semi-quantitative; the latter show the results as ranges or 
as a traffic light rating scale. Lateral flow technology is ideal for home use and may, if 
proven reliable and robust, herald a new era in disease monitoring in IBD with 
electronic patient smart phone links to clinician databases. 157,217  
Figure 3.1-2. Schematic of lateral flow assay  
 
 
 
 
 
 
 
 
 
 
 
 
 
Labelled antibody-calprotectin complexes migrate along the membrane by capillary action and 
are bound by the primary antibody to a different part of the calprotectin molecule. Taken from 
https://www.cd-diatest.com/218  
 
3.1.2 Applications of calprotectin in gastroenterology 
The clinical validity of calprotectin is specific to the stated clinical application, which is 
principally related to the test setting and thereby disease prevalence and pre-test 
probability.219 Calprotectin testing is used in primary, secondary and tertiary care 
centres, both in paediatric and adult patients, and for a range of purposes; namely, 
differentiating IBS from IBD, IBD treatment monitoring, predicting relapse following 
drug withdrawal and stratifying therapy.  
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3.1.3 Distinguishing IBS and IBD in primary care 
The following is a summary of the use of faecal calprotectin in primary care which is 
the focus of the two papers presented later in this chapter.  
3.1.3.1 The clinical need for calprotectin  
Gastrointestinal symptoms are reported in 8-10% of all presenting complaints reported 
in new primary care appointments: whilst the majority of these patients will be 
diagnosed with functional gut disorder a few will have IBD.220–223 Distinguishing 
between functional and organic diagnoses based on symptoms alone can be 
notoriously difficult for GPs and secondary care specialists alike.214  Whilst blood tests 
such as haemoglobin, albumin and CRP are specific for the presence of organic 
intestinal disease they lack sensitivity, and therefore risk missing IBD.70,224,225  
 
Several studies have shown prior to the introduction of faecal calprotectin in the 
primary care setting, that the conventional GP assessment strategy which included 
history taking, physical examination and serological biomarkers had a high sensitivity, 
but low specificity for the diagnosis of IBD.214,226,227 This resulted in a low number of 
missed IBD cases at the expense of referring many disease-free patients to secondary 
care.  
 
Endoscopic examination and histological analysis of biopsies remain the ‘gold-
standard’ investigation for the diagnosis and quantification of inflammatory and other 
organic pathology of the lower gastrointestinal tract, however, this test can be 
uncomfortable and has notable risks including bleeding (1 in 400) and bowel 
perforation (1 in 2500).228,229 Therefore, calprotectin is an attractive non-invasive cost-
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effective alternative to endoscopy, especially in children, where a general anaesthetic 
in usually performed to facilitate the test. Furthermore, it is an attractive option for GPs 
when venesection in children might be difficult or distressing.  
 
It is estimated that up to one in four CD patients wait more than two years from the 
onset of symptoms to a definitive IBD diagnosis being made.230 Delays in the order of 
this magnitude are associated with an increase in bowel stenosis and intestinal 
surgery, even when immunosuppressive and anti-TNF therapy use are taken into 
account.231 In childhood IBD, diagnostic delay has additionally been associated with 
malnutrition and growth failure.232  In UC, data suggest that preventing the proximal 
extension of disease and reducing exposure of the colon to unchecked inflammation 
reduces the risk of colonic dysfunction, colectomy233, dysplasia and cancer234, as well 
as reducing sick leave235 and improving quality of life.236  
 
Diagnostic delay is more often reported in CD than UC, most likely as CD may present 
exclusively with abdominal pain which might mimic and be incorrectly attributed to a 
functional gut disorder.231 Amongst CD patients, ileal disease location230, age less 
than 40 years old230, smoking231, use of  NSAIDs231 and female sex231 have all 
previously been independently associated with diagnostic delay. Whereas in UC, male 
gender and recent NSAID use were associated with a delayed diagnosis.230 In 
paediatric and adolescent CD cohorts, male sex was associated with diagnostic 
delay.232  
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3.1.3.2 Introduction of NICE guidance in the UK 
Calprotectin has been NICE (DG11; 2013) approved since 2013 to help clinicians 
distinguish IBD from irritable bowel syndrome (IBS) in patients in whom cancer is not 
suspected (Figures 3-3).214 Although this guidance extended the use of calprotectin to 
the primary care setting, by the authors own admission, all of the literature they 
reviewed related to studies in patients who had already been referred by their GP to 
secondary care.  In such ‘referred’ cohorts there is a higher pre-test probability 
(prevalence) of organic disease such as IBD, colorectal cancer and diverticulitis, than 
in an ‘unreferred’ cohort. Increasing the prevalence of disease results in higher positive 
predictive values and lower negative predictive values, and therefore, it might not be 
appropriate to extrapolate performance from one setting to the other. This clearly 
demonstrated the urgent need for primary care specific calprotectin studies. Given the 
importance of pre-test probability of disease on the performance of the calprotectin in 
the primary care setting, herein I will preferentially cite positive (PPV) and negative 
predictive values (NPV) in preference to sensitivity and specificity which are less 
effected by disease prevalence.  
Figure 3.1-3. NICE DG11 (2013) Section 1.1: Use of faecal calprotectin in adults 
Faecal calprotectin testing is recommended as an option to support clinicians with the 
differential diagnosis of inflammatory bowel disease (IBD) or irritable bowel syndrome 
(IBS) in adults with recent onset lower gastrointestinal symptoms for whom specialist 
assessment is being considered, if:  
- cancer is not suspected, having considered the risk factors (for example, age) described 
in the NICE guideline on suspected cancer, and; 
- appropriate quality assurance processes and locally agreed care pathways are in place 
for the testing. 
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3.1.3.3 The importance of cut-off thresholds 
The clinical validity of faecal calprotectin is dependent on the cut-off threshold used to 
distinguish positive and negative tests. Most enzyme-linked immunosorbent assay 
(ELISA) manufacturers and NICE guidance (DG11; 2013) recommend using a cut-off 
of 50 µg/g to distinguish a positive result suitable for onward referral and 
investigation.237,238 However, there is no nationally accepted cut-off value, partly due 
to the paucity of primary care specific calprotectin literature, but also the large number 
of different assays used throughout the UK. The aim of the test, and consequently the 
threshold employed in these settings is quite different: in primary care, the prevalence 
of IBD is lower and the objective of the test is to ‘rule out’ disease; a negative result 
from a test with a high NPV therefore either rules out disease and provides 
reassurance, or prompts a ‘watchful waiting strategy’.239 In contrast, in secondary care 
the role of calprotectin is to ‘rule in’ IBD: increasing the probability of disease in order 
to justify invasive and expensive tests such as endoscopy and/or cross-sectional 
imaging; therefore, a high positive likelihood ratio is preferred.239 Increasing the 
calprotectin cut-off threshold increases the specificity of the test and therefore reduces 
unnecessary secondary care referrals, but this is at the expense of sensitivity, and 
false negative tests, thus delaying diagnosis of IBD. 
3.1.3.4 Primary care specific faecal calprotectin studies 
To date, aside from the initial NICE endorsed pilot projects, only two large scale 
primary care calprotectin studies from Brighton240 and York241 have been reported. 
 
Turvill et al demonstrated that doubling the calprotectin cut-off threshold from 50 µg/g 
to 100 µg/g (EK-CAL ELISA, Bühlmann) increased the PPV for identifying IBD from 
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0.20 to 0.40 with a negligible reduction in NPV from 0.98 to 0.97.241 This study noted 
that referral of patients with indeterminate results (first samples in the range 50-
100 µg/g) results and ongoing symptoms may be avoided by repeating the test, rather 
than immediate referral. The probability of IBD in patients with such an indeterminate 
and then negative test was less than 3%.  
 
In the Brighton cohort of 962 patients who underwent faecal calprotectin testing in the 
primary care setting, 71% had a negative test (< 50μg/g).240 28% (77/276) of the 
patients testing positive and 3% (17/686) of those patients testing negative were later 
diagnosed with an organic lower GI disorder such as, colorectal cancer, diverticulitis 
and IBD. Using a 50μg/g cut-off, the NPV and PPV were 98% and 28%, respectively. 
Increasing the calprotectin threshold to 150 μg/g reduced the NPV by 1% whilst 
increasing the PPV to 71%. The authors estimated that by doubling the recommended 
threshold to 100µg/g they would reduce colonoscopy and flexible sigmoidoscopy 
bookings by 10% at the cost of four missed cases of inflammatory bowel disease. 
Interestingly, 38% of the patients tested were outside the age criteria specified in the 
pathway (18-45 yrs old), suggesting that GPs 'gate-keep' a significant proportion of 
older patients with lower gastrointestinal symptoms from secondary care referral. 
3.1.3.5 Financial Savings 
NICE endorsed pilot projects of faecal calprotectin in primary care were completed in 
Stafford & Surrounds CCG; Yorkshire and Humber ASHN; Northumberland CCG and 
Durham Dales CCG.242 Although the projects used a mix point of care tests and 
different cut-off thresholds the estimated reduction in secondary care referrals ranged 
from 56-86%, which led to an average cost saving of £134,000 (range £29,000 - 
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£280,000) over a year. Specifically, the Yorkshire and Humber pilot project rolled out 
a new calprotectin-based referral pathway across 7 CCGs and 198 GP practices in 
the North of England.243 Using a threshold of 50 µg/g to determine a positive result, 
the authors reported has a 40-57% reduction in new hospital outpatients’ 
appointments and a 21-50% reduction in colonoscopies.  
3.1.3.6 Use of calprotectin in paediatric patients  
Approximately 10% of IBD presents before adulthood, with a median age at diagnosis 
of 11.5 years old. As in adults, clinical symptoms are a poor discriminant of IBD and 
non-IBD pathology. Typically, only 25% of children diagnosed with CD present with 
the usual triad of diarrhoea, weight loss and abdominal pain, and nearly half report no 
diarrhoea.244 Calprotectin varies with age and is typically higher in children aged 1-4 
yrs old than in adults, although levels in older children and adults are approximately 
the same.245 This observation may reflect increased migration of neutrophil 
granulocytes into the gut lumen in early life along with development of the gut immune 
system and establishment of a normal bacterial flora.246  
 
NICE guidance for use of calprotectin in paediatric primary care patients differs to that 
in adults (Figure 3.1-4): specifically, it should be used as an option to help clinicians 
distinguish IBD from non-IBD, but importantly, only in referred patients. In this regard, 
it is really a tool to help secondary care clinicians stratify referrals and increase the 
productiveness of the first clinical encounter, given that a result should already be 
present at the time of the appointment.  
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Figure 3.1-4. NICE DG11 (2013) section 1.2: Use of faecal calprotectin in children 
Faecal calprotectin testing is recommended as an option to support clinicians with the 
differential diagnosis of IBD or non-IBD (including IBS) in children with suspected IBD who 
have been referred for specialist assessment, if: appropriate quality assurance processes 
and locally agreed care pathways are in place for the testing. 
 
To my knowledge, no primary care faecal calprotectin studies in children have been 
published, and all data relates to secondary care.  
 
3.1.3.7 The importance of not missing other organic disease 
It is important for primary care practitioners that calprotectin not only detects IBD, but 
also identifies all treatable organic disease, including high risk adenomas and 
colorectal cancer. It is reassuring that this biomarker performs well in this regard as 
well. In an urgently referred cohort (median age 64 yrs [IQR 52-73 yrs]) with new 
gastrointestinal symptoms Mowat et al reported that a threshold of 50 µg/g (EK-CAL 
ELISA, Bühlmann) had a PPV = 0.51 and NPV = 0.98 for detecting colorectal cancer, 
high risk adenoma and IBD.247 Likewise, Turvill et al found calprotectin performed well 
in patients referred with suspected colorectal cancer via the two week wait pathway 
with a NPV of 98.6% for colorectal cancer and 97.2% when including polyps greater 
than 10mm in diameter.248   
3.1.3.8 Limitations of current guidance for clinicians 
In addition to the setting in which the test is applied, age, symptoms, family history, 
and comorbidities also all alter the pre-test probability of disease. The NICE 
implementation document ‘Faecal Calprotectin in Primary Care as a Decision 
Diagnostic for Inflammatory Bowel Disease and Irritable Bowel Syndrome’ 
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recommended calprotectin is only used in patients aged less than 50-60 years old249; 
older patients with new lower gastrointestinal symptoms have a higher likelihood of 
underlying colorectal cancer and should be urgently referred without requiring a 
calprotectin. Likewise, patients with symptoms meeting the relevant criteria in the 
latest NICE lower gastro-intestinal cancer referral guidelines (NG12; 2017) should also 
be referred urgently. NG12 no longer refers to ‘red-flag’ symptoms, unlike the NICE 
IBS guidelines (NICE; CG61), and instead advises either ‘urgent suspected cancer 
referral’, ‘routine referral’ or ‘consideration of referral’ based on symptoms and age. 
However, patients under 50 years old will often report symptoms which NG12 advises 
GPs to consider referral (Figure 3.1-5).  
Figure 3.1-5. NICE NG12 (2017) Section 1.3.3 
Consider a suspected cancer pathway referral (for an appointment within 2 weeks) for 
colorectal cancer in adults aged under 50 with rectal bleeding and any of the following 
unexplained symptoms or findings: abdominal pain; change in bowel habit; weight loss; and, 
iron-deficiency anaemia. [new 2015] 
 
Rectal bleeding is common, and reported by 10% of the general population250 and up 
to 30% of patients with IBS per year.251 It is likely therefore to occur concomitantly in 
patients with symptoms of IBS, which has an estimated UK prevalence of 
approximately 10%.221 GPs might look to faecal calprotectin to aid them when deciding 
if onward referral is appropriate, but its use in patients with rectal bleeding is 
discouraged.249 The Brighton study, similarly discouraged use of the test in patients 
with alarm symptoms, but even so symptoms meeting these criteria were present in 
14% (136/962) of cases reviewed retrospectively, illustrating the real-world dilemma 
facing GPs.240
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3.2 The objective(s) of the chapter 
Early diagnosis is an essential element of IBD precision medicine. It has been 
proposed that primary care use of faecal calprotectin may help distinguish functional 
gut disorder from IBD and allow earlier diagnosis, but knowledge of how this test 
performs in this setting is limited. Implementation requires knowledge of the clinical 
validity of the test in the real-World primary care setting, both in adults and children. 
This includes exploration of the calprotectin cut-off threshold in order to deliver on the 
purpose of the test: to distinguish functional gut disorder from IBD.  
 
• Objective 1: Assess the diagnostic accuracy of faecal calprotectin in 
distinguishing functional gut disorder from IBD in adult and non-IBD from IBD in 
paediatric patients in the primary care setting 
 
• Objective 2: Assess the optimal calprotectin cut-off threshold for the purpose of 
minimising referrals of patients later diagnosed with IBS whilst also not missing 
IBD 
 
• Objective 3: Assess whether faecal calprotectin testing altered primary care 
referral behaviour 
 
The NICE cancer (NG12) and calprotectin (DG11) guidelines do not reconcile whether 
clinicians should use calprotectin to guide referral in patients that report GI-alarm 
symptoms in whom cancer is not suspected by their GP. 
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• Objective 4: Assess whether the presence of GI-alarm symptoms altered the 
performance of the test in adults 
 
There are a paucity of data relating to factors that influence time to diagnosis in UK 
patients with IBD. In particular, it is unknown if calprotectin helps triage patients to 
urgent review or straight-to-test endoscopy. 
 
• Objective 5: Ascertain where delays occur in the referral pathway between onset 
of symptoms through primary and secondary care to diagnosis of IBD  
 
• Objective 6 Explore the clinical and laboratory factors which influence time to 
diagnosis in IBD patients, and specifically whether faecal calprotectin reduces 
time to diagnosis 
 
• Objective 7: Assess if a delayed diagnosis is associated with a more 
complicated disease course in the first year after diagnosis
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3.3 Research Paper I 
 
RESEARCH PAPER I 
 
‘Faecal calprotectin effectively excludes inflammatory bowel disease in 
789 symptomatic young adults with/without alarm symptoms: a 
prospective UK primary care cohort study’  
 
PUBLISHED: Alimentary Pharmacology & Therapeutics, 47(8), pp. 
1103–1116. (2018) doi: 10.1111/apt.14563 
 
Walker, G. J., Moore, L., Heerasing, N., Hendy, P., Perry, M. H., 
McDonald, T. J., Debenham, T., Bethune, R., Bewshea, C., Hyde, C., 
Heap, G. A., Singh, A., Calvert, C., Kennedy, N. A., Goodhand, J. R. and 
Ahmad, T. 
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3.3.1 Summary  
Background: Primary care faecal calprotectin testing distinguishes inflammatory 
bowel disease (IBD) from functional gut disorder in young patients presenting with 
abdominal symptoms: however, previous evaluations have excluded patients with 
alarm symptoms.    
Aims: We sought to evaluate the diagnostic accuracy of calprotectin to distinguish 
IBD from functional gut disorder in young adults in whom general practitioners (GPs) 
suspected IBD; including, patients reporting gastrointestinal alarm symptoms. We 
hypothesised that calprotectin would reduce secondary care referrals and healthcare 
costs. 
Methods: We undertook a prospective cohort study of 789 young adults (18-46 years 
old) presenting with gastrointestinal symptoms to 49 local general practices that had 
undergone calprotectin testing (1053 tests: between Jan 2014 and May 2016) 
because of suspected IBD. We considered calprotectin levels of ≥100μg/g positive. 
Primary and secondary care records over 12 months’ from the point of calprotectin 
testing were used as the reference standard.  
Results: Overall, 39% (308/789) patients reported gastrointestinal alarm symptoms 
and 6% (50/789) tested patients were diagnosed with IBD. The positive and negative 
predictive values of calprotectin testing for distinguishing IBD from functional gut 
disorder in patients with gastrointestinal alarm symptoms were 50% [95% confidence 
interval 36-64%] and 98% [96-100%]: and in patients without gastrointestinal alarm 
symptoms were 27% [16-41%] and 99% [98-100%], respectively. We estimate savings 
of 279 referrals and £160 per patient.  
Conclusions: Calprotectin testing of young adults with suspected IBD in primary care 
accurately distinguishes IBD from functional gut disorder, even in patients with 
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gastrointestinal alarm symptoms and reduces secondary care referrals and diagnostic 
healthcare costs. 
CHAPTER 3: RESEARCH PAPER I-CALPROTECTIN IN ADULTS 
 
 
97 
3.3.2 Background  
Gastrointestinal symptoms constitute 8 to 10% of all presenting complaints reported 
in new primary care appointments220,221: the majority of young adults will be diagnosed 
with a functional gut disorder; a minority, however, will have inflammatory bowel 
disease (IBD) and even fewer colorectal cancer.222,223,252 
 
Faecal calprotectin (calprotectin) is a stool biomarker that reliably distinguishes IBD 
and other organic intestinal diseases from functional gut disorder, but its use is only 
recommended in patients in whom colorectal cancer is not suspected.214 Many young 
patients with functional gut disorder will report incidental symptoms, including 
anorectal bleeding, that together satisfy referral guidelines for suspected colorectal 
cancer.251,253 Without the application of clinical acumen a significant proportion of 
young patients risk being prioritised inappropriately along suspected cancer 
pathways253 obviating the potential benefits of calprotectin assessment.  
 
The National Institute for Clinical Excellence (NICE) has endorsed calprotectin based-
referral pathways for use in primary care because they estimate that calprotectin 
increases diagnostic yields of IBD and reduces unnecessary secondary care costs for 
the investigation and management of functional gut disorder.214,243 Previous 
calprotectin studies in primary care setting have largely excluded patients with 
gastrointestinal alarm symptoms and therefore it is unknown what effect inclusion of 
these patients would have had on the diagnostic accuracy of the test and subsequent 
secondary care referrals.240,241 
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3.3.2.1 Objectives 
We aimed to assess: 
1. the diagnostic accuracy of a new calprotectin based-referral pathway in 
distinguishing functional gut disorder from IBD in young adults including those 
with gastrointestinal alarm symptoms.  
2. whether calprotectin testing altered referral behaviour in young patients, both 
with and without gastrointestinal alarm symptoms.  
 
We hypothesised that a primary care calprotectin referral pathway would: 
• distinguish IBD and organic intestinal disease from functional gut disorder 
regardless of gastrointestinal alarm symptoms with clinically useful positive and 
negative predictive values. 
• reduce referrals to secondary care services and subsequent healthcare costs. 
3.3.3 Methods 
3.3.3.1 Study design  
We designed a prospective observational cohort study to describe the diagnostic 
accuracy of calprotectin testing to exclude IBD in primary care.   
3.3.3.2 Clinical setting 
The Royal Devon & Exeter (RD&E) NHS Trust is a tertiary referral centre for IBD in 
the South West of England. We serve the Eastern locality of the Northern, Eastern 
and Western Devon Clinical Commissioning group comprising 49 primary care 
practices that serve 378,000 people.254 Patients with gastrointestinal symptoms are 
CHAPTER 3: RESEARCH PAPER I-CALPROTECTIN IN ADULTS 
 
 
99 
referred to either gastroenterology or surgical services at the RD&E. A working group 
comprising representation from primary and secondary care devised a new 
calprotectin referral pathway in January 2014 based on the 2013 NICE guidance.214 
Patients tested between January 2014 and May 2016 were followed-up for at least 12 
months and diagnoses were captured from both primary and secondary care records. 
3.3.3.3 Participants 
All adult patients aged between 18-46 years old referred on the calprotectin pathway 
for investigation of gastrointestinal symptoms were included. Exclusion criteria were a 
previous diagnosis of IBD, suspicion of colorectal cancer, and use of NSAIDS/aspirin 
within the previous six weeks. The cohort represents a convenience series as 
calprotectin was not mandated in all patients meeting eligibility criteria and use of the 
test was at the discretion of General Practitioners (GPs). 
3.3.3.4 New East Devon faecal calprotectin referral pathway  
We disseminated information about the new calprotectin pathway to GPs through a 
series of educational meetings. In accordance with NICE guidelines214, GPs were 
asked to use calprotectin in patients presenting with lower gastrointestinal symptoms 
whom they suspected but were uncertain had IBD. Purpose-designed request forms 
were embedded within routine electronic primary care pathology requesting systems 
(Supplementary Appendix 3.3-2). Incomplete request forms were rejected by the 
blood sciences laboratory and prompts sent to aid completion.  Test results, including 
defined thresholds, and recommended actions were returned to GPs within 10 days.  
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3.3.3.5 Variables and data acquisition 
Our purpose-designed request forms to captured patient demographic data, 
presenting symptoms, family history of IBD and colorectal or ovarian cancer. These 
data were used to determine whether patients met NICE lower gastrointestinal cancer 
referral guidelines (‘Suspected cancer: recognition and referral’; NG12)253 
(Supplementary Appendix 3.3-1). Patients satisfying these criteria were deemed to 
have ‘gastrointestinal alarm symptoms’. 
 
GPs were asked the following hypothetical referral question to assess expected 
referral behaviour: “If calprotectin was not available would you have referred this 
patient to secondary care?” [“Yes”; “No”; “Unsure”]. GPs were also prompted to send 
blood tests for full blood count (FBC), ferritin, C-reactive protein (CRP) and coeliac 
serology (Tissue TransGlutaminase [TTG]). Pathology databases were accessed to 
capture the above data. Where a laboratory test was reported as greater or less than 
a threshold, for statistical purposes it was assigned to one more or less than the 
threshold respectively.   
 
Health-care utilisation data in the year after calprotectin testing including: outpatient 
clinic referrals (gastroenterology, colorectal and upper gastrointestinal surgeons, 
dieticians and private clinics); diagnostic imaging (ultrasound [USS], computerised 
tomography [CT] and magnetic resonance imaging [MRI]) and endoscopy 
(colonoscopy, flexible sigmoidoscopy and gastroscopy) were recorded from electronic 
secondary care databases.  
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3.3.3.6 Faecal calprotectin (index test) 
Samples were analysed using a quantitative monoclonal enzyme-linked 
immunosorbent assay (ELISA, K6927, Immundiagnostik, Bensheim, Germany) on a 
Dynex DS2 analyser (Werfen, Cheshire, UK). Inter-run coefficient of variation (CV) for 
the patient pool was 10.1% at 60µg/g. Calprotectin levels were reported in the range 
6 to 2100µg/g, with results lower than this reported as <6µg/g and results above the 
upper analytical limits not diluted and re-assayed but reported as >2100µg/g.  
 
Based on calprotectin manufacturers and NICE recommendations the pre-specified 
calprotectin cut-offs were: calprotectin ≥100µg/g = positive, calprotectin 50-99µg/g = 
intermediate and calprotectin <50µg/g = negative. GPs were asked to send repeat 
stool samples from patients with intermediate results and second samples considered 
positive if calprotectin ≥50μg/g. We advised referral of patients with a positive 
calprotectin and GP management for negative tests; although GPs were also able to 
refer patients whom they felt required specialist review based on their clinical 
assessment. Regrettably, repeat tests were rarely undertaken for intermediate 
calprotectin results (50-99µg/g) and excluding these “valid inconclusive” data255 as per 
our a priori analysis plan, would have removed critical data in the calprotectin cut-off 
zone, where the test is likely to perform worst and consequently over-estimate its 
performance. In view of this, we adjusted our analysis and calprotectin test result 
status was determined by the first calprotectin test only, with values <100µg/g deemed 
negative, and those ≥100µg/g, positive.  
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3.3.3.7 Reference standard 
The diagnosis of IBD and other organic intestinal disease usually requires 
ileocolonoscopy with or without gastroscopy and small bowel imaging. This burden of 
investigation is impractical and inappropriate for the diagnosis of functional gut 
disorder; therefore, and in common with previous published literature240, we recorded 
diagnoses after a 12-month period of follow-up to allow sufficient time for organic 
pathology to evolve and any missed cases of IBD and organic intestinal disease to be 
correctly diagnosed.  
3.3.3.8 Definition of diagnostic outcomes 
Diagnoses were recorded firstly as per the responsible clinician, and then assigned to 
one of three groups for the final analysis: functional gut disorder; organic intestinal 
disease and inflammatory bowel disease (Supplementary Figure 3.3-1). Clinicians 
were not blinded to the index test results. The diagnosis of IBD was based on clinical, 
radiological and histopathological findings.256 A diagnosis of functional gut disorder 
was assigned to patients based on a composite of normal lower gastrointestinal 
endoscopy and cross-sectional imaging with CT or MRI if available, and an absence 
of organic intestinal disease after at least 12 months’ follow-up from the time of the 
index test, if not. Patients not referred to secondary care were followed-up by a primary 
care researcher who visited every practice to record the GP diagnosis using the 
patient’s electronic and paper-based Lloyd George notes. Patients with inflammatory 
lower gastrointestinal lesions insufficient to record a diagnosis of IBD were recorded 
as having non-specific inflammation, and were grouped as having organic intestinal 
disease, but not IBD.  
 
CHAPTER 3: RESEARCH PAPER I-CALPROTECTIN IN ADULTS 
 
 
103 
Where a definitive diagnosis was not recorded by either a GP or secondary care 
consultant, relevant data were reviewed independently by two consultant 
gastroenterologists and a consensus reached (NH, PH). Where data were deemed 
insufficient to reach a diagnosis an outcome of “lost to follow-up” was recorded and 
excluded. Patients who were diagnosed with non-enteric diseases (e.g. 
gynaecological diagnoses, respiratory tract infections, thyroid disease) are reported 
but not included in the final analyses.  
3.3.3.9 Sample size calculation  
Because this study was designed as a service evaluation a priori power calculations 
were not undertaken. Rather we decided to allow our new pathway to bed-in and then 
assessed its utility over two years.  
3.3.3.10 Statistical Methods 
All analyses were two tailed and P-values <0.05 were considered significant. 
Summary statistics are reported based on normality: descriptive statistics are reported 
as mean (SEM) and median [IQR]. We included patients with missing clinical data in 
analyses for which they had data, and specified the denominator for each variable.  
 
Chi-squared analyses were used to compare expected and observed referrals to 
determine whether calprotectin and alarm symptoms influenced referral behaviour. 
We calculated observed healthcare utilisation costs based on the 2017 National 
Tariff257 in patients referred to gastrointestinal outpatients and/or endoscopy and/or 
diagnostic imaging. We used the observed proportions of patients investigated to 
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estimate the expected secondary care healthcare utilisation costs saved by 
calprotectin testing in patients subsequently not referred to secondary care.  
 
We performed univariable analyses using chi-squared analyses for categorical data, 
Student’s t-test for continuous normally distributed variables and Mann-Whitney U 
tests for nonparametric data to identify baseline clinical variables and biomarkers 
predictive of a diagnosis of IBD and organic intestinal disease. Factors that predicted 
these diagnoses were entered into a stepwise forward multivariable logistic regression 
model.  
 
Receiver operator characteristic curves and area under the curve (AUC) analyses 
were undertaken to determine clinical validity of calprotectin as a continuous variable 
to diagnose IBD and organic intestinal disease: Youden’s formula was used to 
determine the optimal cut-off.258 Sensitivity and specificity analyses were undertaken 
to calculate positive (PPV) and negative (NPV) predictive values at our pre-specified 
cut-off and then at various calprotectin cut-off thresholds to optimise its use in 
diagnosing IBD and organic intestinal disease. These analyses were performed in 
patients with and without gastrointestinal alarm symptoms. All statistical analyses 
were undertaken in Stata (v14.2. StataCorp. College Station, TX USA). 
3.3.3.11 Ethical consideration and patient involvement 
This project was endorsed by the Local Medical Council, Devon Clinical 
Commissioning Group, primary and secondary care Caldicott guardians and the 
Southwest Academic Health Sciences Network (SWAHSN). Patients were not 
involved in the conception or design of this study and in accordance with UK Health 
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Research Authority guidelines we did not require formal ethical approval.259 Results 
will be disseminated to patients through posters, educational sessions at GP practices 
and lay summaries. 
3.3.4 Results 
3.3.4.1 Study overview  
We report data in the order displayed in Figure 3.3-1; 1053 calprotectin samples were 
received from 980 primary care patients aged 18 to 46 yrs between January 2014 and 
May 2016. 149 patients were excluded from the final analysis: age ≥46 years (n=84), 
inadequate faecal sample (n=23), known IBD (n=22), inadequate GP request form 
data (n=20). Of the remaining 831 adult patients with valid samples, 23 patients were 
lost to follow-up (calprotectin <100µg/g [n=16], calprotectin ≥100µg/g [n=7]), and a 
further 19 patients were diagnosed with non-enteric diseases. 789 patients were 
included in the final analysis. A family history of IBD was reported in 15% (112/757) 
and of colorectal cancer or ovarian cancer in 11% (84/754). Gastro-intestinal alarm 
symptoms were reported by 39% (311/789) of all patients: 38% (302/789) rectal 
bleeding and one or more of abdominal pain/ change in bowel habit/ weight loss/ iron-
deficiency anaemia in patients under 50 years old; 2% (16/789) abdominal pain and 
weight loss in patients over 40 years old. Positive calprotectin tests (≥100µg/g) were 
returned in 17% (132/789) patients.  
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Figure 3.3-1: Flow diagram showing derivation of the cohort, faecal calprotectin 
result and diagnosis of functional gut disorder, inflammatory bowel disease and 
organic intestinal disease 
CT, computerised tomography; MRI, magnetic resonance imaging; NPV, negative predictive 
value, PPV, positive predictive values; GI, gastrointestinal 
3.3.4.2 Primary care management 
GPs were asked to report their referral intentions before the calprotectin result was 
available to them: "Would you have referred this patient if no calprotectin test were 
available?” Over half (55%, 409/739) of GP responses stated that they intended to 
refer their patient had calprotectin testing not been available, a further 39% (287/739) 
were unsure if they would have referred, and 6% (43/739) stated that they would not 
Di
ag
no
st
ic
ac
cu
ra
cy
DIAGNOSTIC
ACCURACY
100µg/g
THRESHOLD
functional gut disorder              
vs. inflammatory bowel disease
Sensitivity = 86% 
Specificity= 90% 
PPV= 38%   NPV= 99%
Calprotectin saved referral
Not referred: not 
influenced by calprotectin
Referred: not influenced 
by calprotectin
Key for observed referrals
Calprotectin added referral
Referred patients
functional gut disorder                  
vs. organic intestinal disease
Sensitivity = 64%   
Specificity= 90%
PPV= 49%   NPV= 95%
89% (98/110) 
attend GI outpatient 
service
75% (220/295) 
attend GI outpatient 
service
GENERAL 
PRACTITIONER 
EXPECTED 
REFERRALS
39%
“Unsure”
55%
”Yes”
6%
“No”
WOULD YOU HAVE 
REFERRED THIS 
PATIENT IF NO 
CALPROTECTIN 
WERE AVAILABLE?
257  patients 
primary care 
calprotectin 
tests
Excluded: 
• Age > 46 years old = 84
• Inadequate sample = 23
• Known IBD =22
• Inadequate GP data = 20
Excluded:
Lost to follow-up = 23
GENERAL 
PRACTITIONER 
OBSERVED  
REFERRALS
ENDOSCOPY
P < 0.001  
IMAGING
P = 0.024 
OUTPATIENTS
P = 0.002
831 patients 
valid 
calprotectin 
tests
18% (53/295) 
patients undergo CT 
and/or MRI
91% (100/110) 
patients undergo 
endoscopy
28% (31/110) 
patients undergo CT 
and/or MRI
16%31%53%
Pr
im
ar
y 
ca
re
 
m
an
ag
em
en
t
Se
co
nd
ar
y 
ca
re
 
m
an
ag
em
en
t
Excluded: 
Non-enteric other diagnoses = 19
• Gynaecological = 12 
• Respiratory infection = 2 
• Thyroid disease = 2 
• Immune deficiency = 1 
• Rheumatological = 1 
• Adverse drug reaction= 1
SECONDARY 
CARE 
HEALTHCARE 
UTILISATION
45%51%
67% (199/295) 
patients undergo 
endoscopy
17% (132) patients 
calprotectin ≥100µg/g
83% (657) patients 
calprotectin <100µg/g
4%
789 patients 
final analysis 
cohort
CHAPTER 3: RESEARCH PAPER I-CALPROTECTIN IN ADULTS 
 
 
107 
have referred. Regardless of initial referral intentions, calprotectin testing significantly 
altered referral behaviour (Table 3.3-1). Overall, a negative calprotectin saved 317 
referrals; whereas, a positive calprotectin added 38 referrals, and thus 279 referrals 
were saved overall. Patients without gastrointestinal alarm symptoms were less likely 
to be referred to secondary care gastrointestinal services than patients with such 
symptoms (48% [230/478] vs. 56% [175/311], respectively, P = 0.025). Likewise, 
patients with a calprotectin <100µg/g were also less likely to be referred by their GP 
than calprotectin positive patients (45% [295/657] vs. 83% [110/132], respectively, P 
< 0.001). 
Table 3.3-1: Table comparing expected and observed general practitioner 
referral behaviour by calprotectin result 
* P Value represents chi-squared or Fisher’s exact test as appropriate.  
Total saved referrals using 100µg/g calprotectin threshold = (170 + 147) – (32 + 6) = 279; 
Additional saved referrals if referral pathway strictly enforced = (11 + 74 + 189) – (1 + 11 + 8) = 
254; Total saved referrals if referral pathway strictly enforced = 254 + 279 = 533 
 
Expected referral 
behaviour (pre-
calprotectin test 
result)a 
Calprotectin 
test result 
(µg/g) 
Observed referral behaviour                                                    
(post-calprotectin test result) P value 
No referral made Referral made 
GP not intending to 
refer the patient if 
calprotectin testing 
were unavailable = 6% 
(43/739) 
< 100 
 
69% (25/36) 
 
 
31% (11/36) 
0.011 
≥ 100 
 
14% (1/7) 
 
 
86% (6/7) 
 
 GP unsure whether to 
refer the patient if 
calprotectin testing 
were unavailable = 
39% (287/739) 
 
< 100 
 
70% (170/244) 
 
 
30% (74/244) 
  
<0.001 
≥ 100 
 
26% (11/43) 
 
 
74% (32/43) 
 
GP did intend to refer 
the patient if 
calprotectin testing 
were unavailable = 
55% (409/739) 
< 100 
 
44% (147/336) 
 
 
56% (189/336) 
 
<0.001 
≥ 100 
 
11% (8/73) 
 
 
89% (65/73) 
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3.3.4.3  Diagnostic accuracy 
Primary outcome diagnoses: The incidence of IBD, organic intestinal disease 
(including IBD) and functional gut disorder was 6% (50/789), 13% (100/789), 87% 
(689/789) respectively (Table 3.3-2). 
Table 3.3-2: Frequency of diagnoses contained within each of three primary 
analysis groups 
Inflammatory 
bowel disease % (n) 
Functional gut 
disorder % (n)  
Organic intestinal 
disease % (n) 
Ulcerative colitis 52 (26/50) 
Functional gut 
disorder/Irritable 
bowel syndrome 
91 
(625/689) 
Inflammatory bowel 
disease 
50 
(50/100) 
Crohn’s disease 38 (19/50) Haemorrhoids 4 (25/689) 
Upper 
gastrointestinal 
disorders 
16 
(16/100) 
IBD-unclassified 10 (5/50) Symptoms resolved 2 (12/689) 
Infective 
gastrointestinal 
condition 
14 
(14/100) 
  
Eating disorder 
or chronic pain 
disorder 
1 (9/689) Microscopic colitis 5 (5/100) 
  Polyp/s: adenoma <1cm 1 (7/689) 
Non-specific 
inflammation 4 (4/100) 
  Anal fissure 1 (6/689) Appendicitis 3 (3/100) 
  Diverticular disease 1 (5/689) 
Bile acid 
malabsorption 2 (2/100) 
    Coeliac disease 2 (2/100) 
    Polyp/s: adenoma ≥ 1cm 2 (2/100) 
    Rectocoele  1 (1/100) 
    Intermittent small bowel obstruction  1 (1/100) 
Total 50  689  100 
 
  Calprotectin saved referral 
 Referred: not influenced by calprotectin 
 Calprotectin added referral 
 Not referred: not influenced by calprotectin 
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3.3.4.4 Clinical variables and biomarkers to distinguish IBD from functional gut 
disorder 
Symptoms: Patients subsequently diagnosed with IBD reported significantly more 
stools per day, less abdominal pain and had a shorter duration of symptoms prior to 
calprotectin testing than patients with functional gut disorder (Table 3.3-3). There was 
no difference in the proportion of patients later diagnosed with either IBD or functional 
gut disorder who initially reported diarrhoea (defined as Bristol stool score >4 and/or 
>3 stools per day) (88% [44/50] vs. 81% [560/689]) respectively, P = 0.235). 
Gastrointestinal alarm symptoms were frequently observed in both groups but more 
commonly in patients diagnosed with IBD than functional gut disorder, (64% [32/50] 
vs. 38% [260/689], P <0.001 respectively).
CHAPTER 3: RESEARCH PAPER I-CALPROTECTIN IN ADULTS 
 
 
110 
Table 3.3-3:Comparison of clinical variables and biomarkers in patients diagnosed with FGD, IBD and OID 
 Functional gut 
disorder (n=689) 
Inflammatory bowel 
disease (n=50) 
IBD vs. Functional gut 
disorder P value † 
Organic intestinal 
disease ‡ (n=100) 
Organic intestinal disease vs 
Functional gut disorder P † 
Demographics       
Female  60% (416/689) 52% (26/50) 0.243 54% (54/100) 0.225 
Age (years)  30.0 [23.2-36.5] 29.1 [23.2-33.9] 0.514 30.6 [24.8-38.0] 0.156 
Family history colorectal/ovarian cancer  11% (71/658) 8% (4/48) 0.594 14% (13/96) 0.423 
Family history IBD  14% (95/660) 24% (12/49) 0.057 18% (17/97) 0.417 
Symptoms       
Abdominal pain  85% (580/680) 74% (37/50) 0.033 79% (78/99) 0.095 
Change in frequency  82% (547/667) 86% (43/50) 0.476 81% (79/98) 0.738 
Change in appearance  80% (509/636) 83% (40/48) 0.579 85% (81/95) 0.228 
Defaecation improves pain  42% (270/636) 54% (25/46) 0.116 52% (48/92) 0.079 
Rectal bleeding  38% (259/677) 65% (32/49) <0.001 51% (50/98) 0.016 
Gastrointestinal alarm symptoms*  38% (260/689) 64% (32/50) <0.001 51% (51/100) 0.011 
Nocturnal symptoms  25% (167/664) 35% (17/49) 0.141 32% (31/96) 0.136 
Unintentional weight loss  17% (115/674) 18% (9/49) 0.815 24% (23/97) 0.110 
Symptom duration (months) n=765  6 [3-12] 4 [2-8] 0.001 4 [2-10] <0.001 
Number of stools per day n=756 3 [2-5] 4 [3-6] 0.048 3 [2-5] 0.582 
Blood/Stool Markers       
CRP (mg/L) n=673 1 [<1-4] 2 [1-10] 0.001 2 [1-7] <0.001 
B12 (ng/L) n=216 334 [260-481] 346.5 [252-423] 0.811 394 [256-490] 0.590 
Albumin (g/L) n=566 48 [45-49] 46 [43-48] 0.002 46 [44-48] 0.001 
Ferritin (µg/L) n=486 65.5 [34-126] 69 [28-100] 0.233 61 [30-114.5] 0.373 
Folate (µg/L) n=216 8.5 [6.4-12.5] 5.8 [4.9-8.0] 0.004 6.3 [5.4-9.9] 0.018 
Haemoglobin (g/L) n=705 139 [131-149] 139 [129-150] 0.437 139.5 [132-149] 0.756 
Platelet count (x109/L) n=705 225 [189-266] 246 [209-295] 0.008 239 [204-293] 0.011 
White cell count (x109/L) n=705 6.5 [5.4-8] 7.3 [5.9-8.5] 0.030 7.2 [5.6-8.6] 0.050 
Calprotectin (µg/g) n=789 22 [9-48] 320 [175-936] <0.001 159 [44-423] <0.001 
*See Supplementary Appendix S6 for gastrointestinal alarm criteria (NICE; NG12); † P value represents Mann-Whitney U, chi-squared or Fisher’s 
exact test as appropriate; ‡ Organic intestinal disease category 
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Faecal calprotectin: Calprotectin was higher in patients diagnosed with IBD than 
functional gut disorder (Figure 3.3-2). 86% of patients subsequently diagnosed 
with IBD had a calprotectin ≥100µg/g compared to 10% of patients with functional 
gut disorder. Amongst patients with a normal CRP (≤5mg/L), median calprotectin 
was higher in patients with IBD than functional gut disorder (241µg/g [IQR 116-
453] vs. 21µg/g [IQR 9-46], P <0.001, respectively). 
Figure 3.3-2: Box plot showing difference in faecal calprotectin between 
patients with a) functional gut disorder and inflammatory bowel disease b) 
functional gut disorder and organic intestinal disease * P < 0.001 
FGD, functional gut disorder; IBD, inflammatory bowel disease; OID, organic intestinal 
disease 
Blood markers: Patients diagnosed with IBD had significantly higher CRP levels, 
total white cell and platelet counts, but lower albumin and folate levels than 
patients diagnosed with functional gut disorder (Table 3.3-3). CRP was abnormal 
(>5mg/L) in 33% patients with IBD (15% [4/26] ulcerative colitis; 65% [11/17] 
Crohn’s disease; 20% [1/5] IBD-unclassified) compared to 16% of patients with 
functional gut disorder (P = 0.002).  
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Multivariable logistic regression: The above significant clinical biomarkers 
were included in our multivariable logistic regression model. Co-linearity was 
demonstrated between rectal bleeding and gastrointestinal alarm symptoms and 
we used the latter more inclusive term. In our model, calprotectin ≥100µg/g 
increased the odds of IBD 54-fold (OR 53.9, 95%CI 23.2-125.2, P <0.001), 
independent of the presence of gastrointestinal alarm symptoms, which 
increased the odds 3-fold (OR 2.6, 95%CI 1.3-5.2, P = 0.008). 
3.3.4.5 Diagnostic accuracy of calprotectin in distinguishing IBD from functional 
gut disorder 
Sensitivity and specificity analyses: Using our calprotectin threshold of 
100µg/g, the sensitivity for distinguishing IBD vs. functional gut disorder was 
86.0%, the specificity was 90.1%, the positive predictive value (PPV) was 38.7%, 
the negative predictive value (NPV) 98.9%, with an overall accuracy of 89.9%.  
 
Receiver operator characteristic (ROC) analyses: Using calprotectin as a 
continuous variable in ROC analyses revealed an area under curve (AUC) for 
distinguishing IBD from functional gut disorder of 0.93 [95%CI 0.88-0.98] (Figure 
3.3-3). We estimated the optimum calprotectin threshold as 107 µg/g using 
Youden’s formula.  
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Figure 3.3-3: Receiver operating characteristic curves for faecal 
calprotectin as predictors of inflammatory bowel disease or organic 
intestinal disease vs. functional gut disorder. 2x2 tables for diagnosis of 
inflammatory bowel disease or organic intestinal disease vs. functional gut 
disorder.  
AUC, area under the curve; CI, confidence interval  
False negative IBD cases: Seven (14%) patients diagnosed with IBD had a false 
negative calprotectin test (median calprotectin 65µg/g [IQR 14-75]). Four of the 
seven patients had an intermediate first calprotectin but were not re-tested. These 
seven patients had a longer time to diagnosis (149 [IQR 133-240] days vs. 55 
[IQR 29-69] days; P = 0.043) and lower serum CRP levels (<1mg/L [IQR <1-2] 
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Disease	Status 
Total 
IBD FGD 
FC
	(µ
g/
g)
 <100 7 621 628 
≥100 43 68 111 
Total 50 689 739 
 
Disease	Status 
Total 
OID FGD 
FC
	(µ
g/
g)
 <100 36 621 657 
≥100 64 68 132 
Total 100 689 789 
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vs. 2mg/L [IQR 1-11]; P = 0.050) than true positive cases (Supplementary Table 
3.3-1).  
3.3.4.6 Diagnostic accuracy of calprotectin in distinguishing organic intestinal 
disease from functional gut disorder 
The sensitivity for distinguishing organic intestinal disease vs. functional gut 
disorder using a threshold of 100µg/g was 64.0%, the specificity was 90.1%, the 
PPV was 48.5%, the NPV 94.5%, with an overall accuracy of 86.8%. The ROC 
AUC for organic intestinal disease vs. functional gut disorder was 0.82 [95%CI 
0.77-0.87] with an estimated optimal cut-off of 62µg/g. 
3.3.4.7 Optimisation of calprotectin thresholds for diagnosis of IBD and organic 
intestinal disease 
Raising the calprotectin threshold increases the PPV for both IBD and organic 
intestinal disease with a negligible reduction in NPV for IBD and a modest 
reduction for organic intestinal disease. Raising the calprotectin threshold from 
the manufacturers recommended limit (50µg/g) to the level used in our analysis 
(100µg/g) approximately doubles the post-test probability of IBD (Table 3.3-4).   
3.3.4.8 Effect of gastrointestinal alarm symptoms on distinguishing IBD and 
organic intestinal disease from functional gut disorder 
Comparing the performance of calprotectin to distinguish IBD from functional gut 
disorder in patients with and without gastrointestinal alarm symptoms, 
demonstrated that the presence of such symptoms nearly doubled the PPV at 
lower calprotectin thresholds (50µg/g & 100µg/g), with a more modest effect at 
higher thresholds (150µg/g, 200µg/g and 150µg/g). The converse was seen with 
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NPV; at lower calprotectin thresholds the performance of the test was very similar 
in patients with and without alarm symptoms. However, at higher thresholds, a 
more modest reduction in NPV was seen in patients with alarm symptoms 
compared to those patients not reporting such symptoms. Similar trends, albeit 
with a more modest increase PPV, were seen in the performance of calprotectin 
to distinguish functional gut disorder from organic intestinal disease in patients 
with and without alarm symptoms (Table 3.3-4). 
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Table 3.3-4: Effect of gastrointestinal alarm symptoms on diagnostic 
accuracy of faecal calprotectin at different thresholds for the diagnosis of 
inflammatory bowel disease and organic intestinal disease 
 PPV, positive predictive value; NPV negative predictive value; CI, confidence interval 
Values in black represent diagnostic accuracy of faecal calprotectin in patients without 
gastrointestinal alarm symptoms (n=447 inflammatory bowel disease vs. functional gut 
disorder; n=478 organic intestinal disease vs. functional gut disorder); values in red 
represent the diagnostic accuracy of calprotectin in patients with gastrointestinal alarm 
symptoms (n=292 inflammatory bowel disease vs. functional gut disorder; n=311 organic 
intestinal disease vs. functional gut disorder). Black boxes represent data at 
100µg/g threshold 
3.3.4.9 Secondary care diagnostics utilisation 
In referred patients, significantly fewer patients with a negative calprotectin 
underwent outpatient review (75% [220/295] vs. 89% [98/110], P = 0.002), 
endoscopic evaluation (67% [199/295] vs. 91% [100/110], P <0.001) and 
  Calprotectin 
threshold 
Sensitivity               
%(95% CI)  
Specificity             
%(95% CI)  
PPV                        
%(95% CI)  
NPV                          
%(95% CI)  
  inflammatory bowel disease vs. functional gut disorder 
  ≥ 50 µg/g 100 (82-100) 75 (71-79) 14 (0-22) 100 (99-100) 
  ≥ 50 µg/g 91 (75-98) 77 (71-82) 32 (23-43) 99 (96-100) 
  ≥ 100 µg/g 83 (59-96) 91 (88-93) 27 (16-41) 99 (98-100) 
  ≥ 100 µg/g 88 (71-97) 89 (85-93) 50 (36-64) 98 (96-100) 
  ≥ 150 µg/g 78 (52-94) 95 (93-97) 40 (24-58) 99 (98-100) 
  ≥ 150 µg/g 78 (60-91) 93 (89-96) 58 (42-73) 97 (94-99) 
  ≥ 200 µg/g 72 (47-90) 98 (96-99) 57 (35-77) 99 (97-100) 
  ≥ 200 µg/g 63 (44-79) 95 (91-97) 59 (41-75) 95 (92-98) 
  ≥ 250 µg/g 67 (41-87) 99 (97-100) 71 (44-90) 99 (97-100) 
  ≥ 250 µg/g 56 (38-74) 97 (94-98) 67(46-84) 95(91-97) 
 organic intestinal disease vs. functional gut disorder 
  ≥ 50 µg/g 69 (55-82) 75 (71-79) 24 (17-32) 96 (93-97) 
  ≥ 50 µg/g 78 (65-89) 77 (71-82) 40 (30-50) 95 (91-97) 
  ≥ 100 µg/g 55 (40-69) 91 (88-93) 40 (28-53) 95 (92-97) 
  ≥ 100 µg/g 73 (58-84) 89 (85-93) 57 (44-69) 94 (91-97) 
  ≥ 150 µg/g 43 (29-58) 95 (93-97) 50 (34-66) 94 (91-96) 
  ≥ 150 µg/g 59 (44-72) 93 (89-96) 63 (47-76) 92 (88-95) 
  ≥ 200 µg/g 39 (25-54) 98 (96-99) 66 (46-82) 93 (91-95) 
  ≥ 200 µg/g 49 (35-63) 95 (91-97) 64 (47-79) 90 (86-94) 
  ≥ 250 µg/g 33 (20-48) 99 (97-100) 76 (53-92) 93 (90-95) 
  ≥ 250 µg/g 43 (29-58) 97 (94-98) 71 (52-86) 90 (85-93) 
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diagnostic imaging (18% [53/295] vs. 28% [31/110], P = 0.024) than did positive 
calprotectin patients (Table 3.3-5). 
Table 3.3-5: Influence of faecal calprotectin on primary care referrals to 
gastrointestinal services and secondary care investigation of referred 
patients 
 
  Calprotectin <100µg/g  
Calprotectin   
≥100µg/g  Total P Value
†  
Primary care referral of patients to secondary care gastrointestinal services  
Referred to GI services  45% (295/657)  83% (110/132)  51% (405/789)  <0.001
  
Secondary care investigation of patients referred to secondary care gastrointestinal services   
Reviewed in outpatient clinic* 75% (220/295)  89% (98/110)  79% (318/405)  0.002  
Gastroenterology     56% (124/220)     89% (87/98)  66% (211/318)  <0.001
  
Colorectal surgeons     28% (61/220)     5% (5/98)  21% (66/318)  <0.001
  
Dieticians     8% (18/220)     1% (1/98)  6% (19/318)  0.010  
Private clinic     4% (8/220)     2% (2/98)  3% (10/318)  0.729  
  
Did Not Attend (DNA)     2% (5/220)     3% (3/98)  3% (8/318)  0.706  
Advice and guidance      2% (4/220)     0% (0/98)  1% (4/318)  0.316  
Endoscopic assessment   67% (199/295)  91% (100/110)  74% (299/405)  <0.001
  
Colonoscopy     50% (100/199)     57% (57/100)  53% (157/299)  0.270  
Flexible sigmoidoscopy     16% (32/199)     10% (10/100)  14% (42/299)  0.153  
Gastroscopy (OGD)     13% (25/199)     4% (4/100)  10% (29/299)  0.021  
OGD + lower GI endoscopy     21% (42/199)     29% (29/100)  23% (71/299)  0.130  
  
Endoscopy referral pathway        
Straight-to-test  53% (105/199)  56% (56/100)  54% (161/299)  0.596  
Outpatient clinic prior-to-test  47% (94/199)  44% (44/100)  46% (138/299)  0.596  
     
Radiological assessment 18% (53/295)  28% (31/110)  21% (84/405)  0.024  
CT abdomen and pelvis      47% (25/53)  16% (5/31)  36% (30/84)  0.005  
MRI abdomen and pelvis     53% (28/53)  84% (26/31)  64% (54/84)  0.005  
CT, computerised tomography; MRI, magnetic resonance imaging; GI, gastrointestinal 
* represents first service seen 
† P value represents chi-squared or Fisher’s exact test as appropriate 
 
Costings analysis: Using the aforementioned assumptions pertaining to GP 
intended (expected) and actual (observed) referral behaviour (Table 3.3-1), we 
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estimate that 279 referrals were saved by the primary care calprotectin pathway. 
This equated to 212 saved outpatient appointments and 228 endoscopies (32 
flexible sigmoidoscopies, 120 colonoscopies, 22 gastroscopies and 54 combined 
upper and lower gastrointestinal endoscopies) and 64 cross-sectional diagnostic 
imaging tests. To the point of diagnosis, we estimated that the pathway delivered 
savings of £52,355 per year (£160 per patient). Additionally, had we enforced the 
referral pathway such that only patients with a calprotectin ≥100µg/g were 
referred to secondary care services, this would have saved a further 254 referrals; 
doubling the total savings to £106,469 per year (£326 per patient) 
(Supplementary Appendices 3.3-3 to 3.3-5).  
3.3.5 Discussion 
3.3.5.1 Key Results  
In this real-world primary care cohort of young patients, including for the first-time 
a large subset of patients with gastrointestinal alarm symptoms, we have shown 
that a calprotectin ≥100µg/g distinguishes functional gut disorder from IBD (PPV 
39%; NPV 99%) and other organic intestinal diseases (PPV 49%; NPV 95%) with 
clinically useful positive and negative predictive values. For both diagnostic 
categories at the 100µg/g threshold, the negative predictive value remained high, 
and was nearly identical for patients reporting and not reporting gastrointestinal 
alarm symptoms, supporting the extension of calprotectin testing to this group. 
Both calprotectin and the presence of gastrointestinal alarm symptoms influenced 
referral behaviour and subsequent onward investigations: patients with a 
negative calprotectin and those without alarm symptoms were less likely to be 
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referred to gastrointestinal services, although in those who were, fewer 
underwent lower gastrointestinal endoscopy.  
3.3.5.2 Interpretation 
Based on the results of our multivariable model, faecal calprotectin and 
gastrointestinal alarm symptoms independently predicted the diagnosis of IBD. 
Therefore, one might consider two strategies combining the two: (i) investigating 
patients with either gastrointestinal alarm symptoms or calprotectin ≥100µg/g; or 
(ii) only investigating patients with both features (Supplementary Table 3.3-2). 
The first strategy would reduce the number of missed cases of IBD (sensitivity 
increased from 86% to 94%), but the PPV (14%) is poor. However, the high NPV 
(99%) means that this strategy could be used to rule out IBD in patients who met 
neither of these criteria. The second strategy could potentially reduce the number 
of referrals with functional gut disorder (specificity increases to 96%) but the 
sensitivity falls (56%) and consequently many cases of IBD may be missed. By 
using a calprotectin ≥100µg/g, regardless of gastrointestinal alarm symptoms, we 
missed 7 false negative cases of IBD who perhaps as a result incurred a 
diagnostic delay. Four had an intermediate calprotectin result and in accordance 
with our pathway should have undergone a repeat test but did not. These patients 
had a less severe phenotype than cases with calprotectin ≥100µg/g. All of the 
Crohn’s disease patients (4/4) with a false negative calprotectin had ileocaecal 
disease (L1): a location previously associated with a diminished diagnostic 
calprotectin performance.260,261 Additionally, all of the missed ulcerative colitis 
cases (3/3) had proctitis (E1), which is likely to return lower calprotectin results 
than more extensive disease. These findings are similar to those reported in the 
Brighton study (14% mis-rate at 100µg/g)240 and taken together demonstrate the 
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need to closely monitor adherence to the pathway and clinical review of patients 
with refractory lower gastrointestinal symptoms.  
 
Reassuringly for GPs, using our a priori threshold calprotectin also adequately 
distinguishes functional gut disorder from other treatable organic intestinal 
diseases, and even in patients with gastrointestinal alarm symptoms there were 
no missed cases of colorectal cancer and only 1 missed case of a large (13mm) 
adenoma. Further improvements in PPV by raising the cut-off above 100µg/g are 
offset by increased missed cases of organic intestinal disease. Overall, based on 
this data and work from others we advocate a threshold for referral of 
100µg/g.240,241,248  
3.3.5.3 Strengths and Limitations  
The strengths of our study lie in the prospective design, meticulous follow-up of 
all the primary care records of non-referred patients and the cohort size with a 
large subset with gastrointestinal alarm symptoms. We acknowledge, however, 
some important limitations.  
 
Firstly, there is selection bias due to inter-user variability whereby patients with 
gastrointestinal alarm symptoms suspected of having cancer were excluded; 
therefore, the clinical judgment of GPs is fundamental to the successful 
application of calprotectin in this setting and our data are only representative of 
patients deemed unsuitable for urgent cancer referral by their GP. 
 
Secondly, the uptake of calprotectin testing in primary care was relatively poor 
with only 26% (50/192) of patients aged 18 to 46 diagnosed with IBD during the 
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time-period of the study referred by participating practices via the pathway. 
Therefore, patients diagnosed with IBD in our cohort may have a milder 
phenotype than patients diagnosed outside of the pathway and a spectrum bias 
may exist. Despite our larger catchment population, we received only 36 
calprotectin samples/month compared with 57 and 43/month in the Brighton and 
York studies, respectively.240,241 Explanations may include the cessation of GP 
educational sessions soon after study commencement and that we did not prompt 
calprotectin assessment before accepting referrals in eligible patients. In line with 
this, there was poor adherence to our pre-specified pathway for intermediate test 
results, and we are therefore unable to comment on the value of retesting in this 
group. Because of our convenience sampling, we also acknowledge that we 
cannot report to what extent our data reflect the total eligible population 
presenting to their GP with lower gastrointestinal symptoms.  
 
Thirdly, about three quarters of patients with a negative calprotectin, and one third 
of patients with a positive calprotectin later diagnosed with functional gut disorder 
did not undergo a gold standard lower gastrointestinal endoscopy, leading to an 
inevitable partial verification bias that may have overestimated the accuracy of 
calprotectin. We took various measures, however, to limit the effect of this bias. 
Like others we used a 12-month follow-up period to allow for IBD to evolve240, but 
for the first-time we captured all data across both primary and secondary care. 
Furthermore, the capture of primary care data in un-referred patients, should 
have avoided an erroneous diagnosis of functional gut disorder being assigned 
to patients who may have been diagnosed with IBD and organic intestinal disease 
in private clinics or in other hospitals.  
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3.3.5.4 Generalisability 
We acknowledge that our data may have limited external validity to healthcare 
systems where referrals are made direct to specialists and not regulated by GP 
‘gatekeepers’.  However, based on data with two other primary care calprotectin 
studies in patients of a similar age range in Brighton240 and York241 (albeit noting 
that patients with gastrointestinal alarm symptoms were discouraged from these 
other two cohorts), it is reassuring that there was just one reported case of 
colorectal cancer in 2055 (0.05%) patients who underwent the test in this setting. 
This is not only due to the low prevalence of colorectal cancer in this age 
group222,252, but also the clinical acumen of primary care physicians, meaning that 
calprotectin can safely be applied in young patients with gastrointestinal alarm 
symptoms deemed unsuitable for urgent referral using current national cancer 
guidelines by their GP (NICE, NG12)253. Existing studies of the performance of 
calprotectin for distinguishing organic from non-organic intestinal diseases, that 
mostly excluded patients with gastrointestinal alarm symptoms, report negative 
predictive values of 98 to 99%, and positive predictive values 14 to 40%; the wide 
variation in the latter reflecting the impact that age and presenting symptoms 
have on the prevalence of disease.240,241,262  
 
Despite a much higher number of patients with gastrointestinal alarm symptoms 
in our cohort and a different manufacturer of our ELISA assay, we report a similar 
prevalence of IBD (6.3%) and organic intestinal disease (excluding upper 
gastrointestinal disease; 11%), as well as similar diagnostic accuracy to both the 
Brighton and York cohorts. Given these similarities, it is possible that either GPs 
under reported gastrointestinal alarm symptoms in the previous two cohorts or 
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that a marginal increase in disease prevalence results but that the effect size is 
too small to be detected with the given sample sizes. In contrast to the original 
2008 version of the NICE IBS guidelines (CG61), the latest 2017 version, in 
keeping with the 2015 NICE cancer guidelines (NG12), no longer refer to “red 
flag” symptoms.253,263 The presence of some symptoms, such as weight loss and 
abdominal pain in patients over 40 years old (NG12; Section 1.3.1)253, are 
advised to lead to an urgent referral, whilst other symptom combinations should 
prompt consideration of an urgent referral. However, if all patients under 50 years 
old with rectal bleeding and abdominal pain or change in bowel habit (NG12; 
section 1.3.3)253, are excluded from using calprotectin pathways (DG11, 2013; 
section 1.1)214, then rectal bleed pathways may be overwhelmed, more urgent 
cases delayed and calprotectin will be withheld from a large number of patients 
who may benefit from it.  
3.3.5.5 Implications for future practice 
In the light of our findings, we will continue to allow GPs to use the test in patients 
with gastrointestinal alarm symptoms and will make the following revisions to our 
calprotectin pathway: a single 100µg/g calprotectin cut-off; eight-week safety-net 
review of patients in non-referred calprotectin negative patients; closer oversight 
by a lead clinician; and sending patients with a calprotectin ≥250µg/g straight-to-
test, as over two thirds (68% [30/44]) will have IBD once infective conditions have 
been excluded. Indeed, the presence of alarm symptoms, which raise the pre-
test probability of IBD, may be crucial to the successful application of calprotectin 
diagnostic pathways in primary care; without which the PPV of calprotectin may 
too low to be clinically useful in identifying IBD.262 Further research is required to 
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establish how calprotectin will integrate with faecal immunochemical testing (FIT), 
in particular in older age-groups than included here.247,248,264,265   
 
Our service evaluation demonstrates that faecal calprotectin is a clinically useful 
primary care test to distinguish IBD and organic intestinal disease as a whole 
from functional gut disorder in patients aged less than 46. However, simply 
introducing the pathway is not sufficient to either maximise gains, or guarantee 
its success. To do so requires consistent interpretation of calprotectin results, 
both in primary and secondary care, with buy-in from all relevant stakeholders, 
oversight by a responsible consultant, on-going GP educational and feedback 
sessions as well as careful adjustment of pathways and thresholds based on 
audit data. 
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3.3.10 Supplement 
 
 
RESEARCH PAPER I 
SUPPLEMENT 
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Supplementary Table 3.3-1: Disease severity in false negative and true 
positive IBD cases  
* values represent % (n) or median [IQR] ‡ P value represents chi-squared, Fisher’s 
exact, Mann-Whitney U test as appropriate. CD, Crohn’s disease; UC, ulcerative colitis; 
IBD-U, IBD-unclassified; GI, gastrointestinal; FC, faecal calprotectin; CRP, C-reactive 
protein. 
Characteristic 
False 
Negatives/Missed IBD 
cases 
 (n=7)* 
 
True 
Positives/Correctly 
identified IBD cases 
(n=43)* 
P 
Value‡ 
 
Age Age (years) median [IQR] 29.6 [IQR 23.6-32.9] 29.0 [IQR 22.9-34.9] 0.900 
Sex  Female  43 (3/7)  
51 (22/43) 
 
1.000 
 
Smoking 
Current 
Ex 
Never 
Unknown 
29 (2/7) 12 (5/43) 
0.036  
  
29 (2/7) 30 (13/43) 
14(1/7) 54(23/43) 
29 (2/7) 5 (2/43) 
IBD 
CD 
IBD-U  
UC 
57 (4/7) 35 (15/43) 
0.488  
  
0 (0/7) 12 (5/43) 
43 (3/7) 54 (23/43) 
Montreal 
Classification CD  
A2: 17-40 years 
A3: >40 years 
100 (4/4) 100 (15/15) 1.000 
0 (0/4) 0(0) 
L1: Ileal 
L2: Colonic 
L3: Ileocolonic  
100 (4/4) 53 (8/15) 0.398  
 0 (0/4) 27 (4/15) 0 (0/4) 20 (3/15) 
+ L4: Upper GI  0 (0/4) 0 (0/15) 1.000 
B1: Inflammatory 
B2: Stricturing 
B3: Penetrating 
100 (4/4) 87 (13/15) 1.000 
 0 (0/4) 13.3(2/15) 0 (0/4) 0 (0/15) 
+ p: Perianal 
 0 (0/4) 0 (0/4) 1.000 
Montreal 
Classification UC 
E1: proctitis  
E2: left-sided 
E3: pan-colitis 
100 (3/3) 36 (10/28) 0.200  
 0 (0/3) 43 (12/28) 0 (0/3) 21 (6/28) 
Blood markers at 
diagnosis 
 
 
CRP (mg/L) <1 [<1-2] 2 [1-11] 0.050 
B12 (ng/L) 328 [230-425] 347 [254-421] 0.874 
Albumin (g/L) 48 [47-49] 46 [42.5-47] 0.078 
Ferritin (µg/L) 46 [41-73] 69 [27-107] 0.732 
Folate (µg/L) 5.3 [4.9-5.7] 6.1 [4.8-8.2] 0.525 
Haemoglobin (g/L) 150 [141-154] 138 [127-149] 0.073 
Platelet count 
(x109/L) 227 [208-245] 251 [210-305] 0.458 
White cell count 
(x109/L)  7.2 [5.4-8.2] 7.3 [5.9-8.6] 0.685 
Faecal calprotectin Faecal calprotectin (µg/g) 65 [14-75] 364 [234-997] <0.001 
Time to diagnosis  
(FC to diagnostic 
test) 
Time (days) 133 [149-240] 55 [29-71] 0.043 
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Supplementary Table 3.3-2: Referral strategies for IBD using model from 
multiple logistic regression  
Strategy Sensitivity %(95%CI) 
Specificity 
%(95%CI) 
PPV 
%(95%CI) 
NPV  
%(95%CI) 
Interpretation 
of strategy 
GI alarm 
symptoms only 64 (49-77) 62 (59-66) 11 (8-15) 96 (94-98) 
Too many 
referrals with 
functional gut 
disorder  
FC ≥ 100µg/g only 86 (73-94) 90(88-92) 39 (30-49) 99 (98-100) 
Optimal 
combination 
of PPV and 
NPV 
GI alarm 
symptoms or FC ≥ 
100µg/g   
94 (84-99) 56 (53-60) 14 (10-18) 99 (98-100) 
Too many 
referrals with 
functional gut 
disorder 
GI alarm 
symptoms and FC 
≥ 100µg/g   
56 (41-70) 96 (94-97) 50 (36-64) 97 (95-98) 
Too many 
missed cases 
of IBD 
PPV, positive predictive value; NPV negative predictive value; CI, confidence interval; GI, 
gastrointestinal; FC, faecal calprotectin  
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Supplementary Table 3.3-3: Image depicting how each diagnosis was 
collapsed into one of the three primary diagnostic outcome groups, or 
excluded 
GI, gastrointestinal; FGD, functional gut disorder; IBD, inflammatory bowel disease; OID, 
organic intestinal disease (includes IBD) 
  
Ulcerative	colitis
Crohn’s	disease
IBD-unclassified
Diverticulitis
Colorectal	cancer
≥1cm	polyps
Non-specific	inflammation
Coeliac	disease
Infective	gastroenteritis
Bile	Acid	Malabsorption
Functional	Gut	Disorder
(FGD)
Inflammatory	Bowel	Disease
(IBD)
Irritable	Bowel	Syndrome
Functional	Gut	Disorder
Eating	disorders
Somatisation disorder
Haemorrhoids
<	1cm	polyps
Anal	fissures
Diverticular	disease
Organic	Intestinal	Disease
(OID)
Upper	GI	Disorders
Barrett’s	oesophagus
Oesophagitis
Peptic	ulcer	disease
FGD	vs.	IBD
FGD	vs.	OID
Incidental	GI	Disease
Thyroid	disease
Haematological disorder	
(non	cancer)
Drug	side	effects
Gynaecological diagnoses
Respiratory	tract	infection
Non-enteric	other
Lost	to	follow-up
Excluded	from	final	analysis	
groups
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Supplementary Table 3.3-4: Proposed guidelines for the use of faecal 
calprotectin (FC) in the management of patients presenting with lower 
gastrointestinal symptoms. 
 
IBS, Irritable Bowel Syndrome; IBD, Inflammatory Bowel Disease; NICE, National Institute 
for Health and Care Excellence; PS, World Health Organisation (WHO) performance 
status; NSAIDs, Non-steroidal anti-inflammatory drugs; GP, general practitioner; FBC, 
full blood count; U&E, urea and electrolytes; CRP, C-reactive protein. 
New	lower	GI	symptoms
Cancer	not	suspected
Request	
faecal
calprotectin	(FC)	*
IBS	or	functional	
gut	disorder	likely	
FC	<100µg/g
Refer	STT	for	
urgent	
colonoscopy
FC	≥250µg/g
Treat	as	IBS
(NICE	guidance)
Symptoms	
persist
GP	review	8	weeks
FC	100-250µg/g
Routine	
gastroenterology	
OPD	review
Symptoms	
resolved
Nurse	led	
assessment
PS	≤2	urgent	
endoscopy
PS	>2	urgent	OPD	
review
Continue	GP	
management
Refer	routinely	to	
gastroenterology
Exclusion	criteria
1. Cancer	suspected
2. NSAIDs	within	last	6	weeks
Inclusion	criteria
• Aged	18	to	46	years	old
• New	lower	GI	symptoms	and	IBD	
suspected
• Normal	or	negative	preliminary	
investigations	(FBC,	U&E,	CRP,	coeliac	
screen,	stool	culture	as	appropriate)
• Patients	with	GI	alarm	symptoms	
such	as	rectal	bleeding	and	change	in	
bowel	habit	may	be	included	in	the	
pathway	as	long	as	cancer	is	not	
suspected
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Supplementary Appendix 3.3-1: NICE referral guidelines for lower 
gastrointestinal tract cancers: NG12, 2015253 
Section 1.3.1 Refer adults using a suspected cancer pathway referral (for an 
appointment within 2 weeks) for colorectal cancer if:  
• they are aged 40 and over with unexplained weight loss and abdominal 
pain or 
• they are aged 50 and over with unexplained rectal bleeding or  
• they are aged 60 and over with:  
• iron-deficiency anaemia or  
• changes in their bowel habit, or  
• tests show occult blood in their faeces. [new 2015]  
Section 1.3.2 Consider a suspected cancer pathway referral (for an appointment 
within 2 weeks) for colorectal cancer in adults with a rectal or abdominal mass. 
[new 2015]  
Section 1.3.3 Consider a suspected cancer pathway referral (for an appointment 
within 2 weeks) for colorectal cancer in adults aged under 50 with rectal bleeding 
and any of the following unexplained symptoms or findings:  
• abdominal pain  
• change in bowel habit  
• weight loss  
• iron-deficiency anaemia. [new 2015]   
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Supplementary Appendix 3.3-2: Faecal calprotectin request form for 
primary care 
  
Impact of FC in Primary Care:
If FC was not available would you have
referred this patient to secondary care?
Yes No Unsure
Are you planning to refer this patient to
secondary care even if FC is normal?
Yes No Unsure
Version 1.1
                                  When to use Faecal Calprotectin in Primary Care:
Suspected Inflammatory Bowel disease (IBD) in patient aged 45 or below
If you suspect a patient age !45 might have IBD then perform FC as part of your usual work up/investigations.
• Positive: FC"100 µg/g faeces, referral to Gastroenterology recommended.
• Negative: FC<50 µg/g faeces, IBD unlikely- consider primary care IBS management.
• Indeterminate: FC 50-99 µg/g faeces, if symptoms persist re-test FC. If on re-test FC "50 µg/g faeces referral to
Gastroenterology is recommended.
If FC is normal, but CRP raised without another obvious explanation, then consider referral for suspected IBD
If you remain clinically concerned about a patient despite a negative FC then there is no need to repeat the test. You may refer in the
normal way but please state in your referral letter what features are concerning you and prompting the referral.
Secondary care referral:
• Please title your referral letter “SUSPECTED IBD” and send to RD&E gastroenterology only. All patients will be seen in
gastroenterology outpatients within 3 weeks.
• For more urgent opinions please Fax 01392 402810 or call one of the gastroenterologists
    IMPORTANT  - STOOL SAMPLES MUST ARRIVE IN THE LABORATORY WITHIN 24 HOURS OF COLLECTION
Please also request:
a) FBC, Ferritin, CRP if not done in the past 6 weeks
b) TTG if not previously done
Faecal Calprotectin (FC) Request Form for Primary Care
NHS Number
/ /
Surname                                                (Block CAPITALS please) First name(s)                                     (Block CAPITALS please)
Doctor's Laboratory Code Practice Laboratory Code
Date of Birth
Sample date
Affix Label Here
M F
Gender
For EXTRA copy reports, state doctor & location
Criteria for Sample Analysis:
** Please note, samples will only be processed
when the following questions are marked "Yes" **
Yes No
Yes No
Yes No
Yes No
Do you confirm it has been >6 weeks
since any NSAID, including aspirin?
Is there a low suspicion of colorectal
cancer?
Is IBD suspected or possible?
Is patient age !45 years?
EXETER PATHOLOGY SERVICES
DEPARTMENT OF BLOOD SCIENCES
REQUESTS ENQUIRIES (01392 40)2934
Clinical Information
Duration of Symptoms (months):
24 hour stool frequency (number of times):
Stool consistency (see Bristol Stool Chart on reverse):
Alcohol (units per week):
Abdominal Pain:
Pain improves with defecation:
Change in stool frequency:
Change in stool appearance/consistency:
Rectal bleeding:
Unintentional weight loss:
Nocturnal symptoms:
Family history of IBD:
Family history of bowel or ovarian cancer:
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
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Supplementary Appendix 3.3-3: Estimated current savings  
Estimated current savings using 100µg/g threshold (279 referrals saved) 
Resource saved (% 
based on secondary 
care healthcare 
utilisation in 
referred patients) 
Number of 
referrals 
saved to 
each 
resource 
(assuming 
279 fewer 
referrals) 
Secondary Care Service (% based 
on secondary care healthcare 
utilisation in referred patients)  
Resources saved if 
279 referrals 
(n/£*)  
Total savings (£) 
Outpatient clinic 
only                                              
(18.1% ) 
50.5
Surgical outpatient clinic (25.8%) 13  
£8,815  £1,859.00 Gastroenterology outpatient clinic 
(74.2%) 
37 
£6,956.00 
Endoscopy only                                             
(24.1%) 67.2 
Flexible sigmoidoscopy (12.5%)  8  
£29,553  
£2,728.00 
Colonoscopy (48.9%) 33 £14,322.00 
Gastroscopy (13.6%) 9 £3,280.50 
Combined upper and lower 
endoscopy (25.0%) 
17 
£9,222.50 
Endoscopy and 
outpatient clinic                                             
(57.8% ) 
161.3 
Flexible sigmoidoscopy (14.7%) 24  
£99,319  
£8,184.00 
Colonoscopy (54.0%) 87 £37,758.00 
Gastroscopy (8.1%) 13 £4,738.50 
Combined upper and lower 
endoscopy (23.2%) 
37 
£20,072.50 
Surgical outpatient clinic (25.8%) 42 £6,006.00 
Gastroenterology outpatient clinic 
(74.2%) 
120 
£22,560.00 
Ultrasound (12.0%) 33.5 £6,195  £1,591.25  
£6,195  
Computerised 
Tomography (4.2%) 11.7 _ £1,269.45 
Magnetic 
Resonance Imaging 
(6.8%) 
19.0 _ £3,334.50 
 TOTAL £143,882  
  
  
  
  
Cost FC testing in 
789 adult patients 
(£22/test)  
£17,358  
TOTAL SAVING (29 
months) £126,524 
TOTAL SAVING 
(per year) £52,355  
Per patient £160  
*using 2017-18 National Tariff257    
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Supplementary Appendix 3.3-4: Estimated potential savings  
Estimated additional savings if pathway strictly enforced at 100µg/g threshold (additional 
254 referrals saved; total 533) 
Resource saved (% 
based on secondary 
care healthcare 
utilisation in 
referred patients) 
Number of 
referrals 
saved to 
each 
resource 
(assuming 
533 fewer 
referrals) 
Secondary Care Service (% based 
on secondary care healthcare 
utilisation in referred patients)  
Resources saved if 
533 referrals 
(n*/£)  
Total savings 
(£) 
Outpatient clinic 
only                                              
(18.1% ) 
96.5
Surgical outpatient clinic (25.8%) 25  
£17,111  
£3,575.00 
Gastroenterology outpatient clinic 
(74.2%) 
72 
£13,536.00 
Endoscopy only                                             
(24.1%) 128.5 
Flexible sigmoidoscopy (12.5%)  16  £5,456.00 
£56,355 
Colonoscopy (48.9%) 63 £27,342.00 
Gastroscopy (13.6%) 17 £6,196.50 
Combined upper and lower 
endoscopy (25.0%) 
32 
£17,360.00 
Endoscopy and OPD                                             
(57.8% ) 308.1 
Flexible sigmoidoscopy (14.7%) 45  
£189,368  
£15,345.00 
Colonoscopy (54.0%) 166 £72,044.00 
Gastroscopy (8.1%) 25 £9,112.50 
Combined upper and lower 
endoscopy (23.2%) 
71 
£38,517.50 
Surgical outpatient clinic (25.8%) 79 £11,297.00 
Gastroenterology outpatient clinic 
(74.2%) 
229 
£43,052.00 
Ultrasound (12.0%) 64.0 £11,824  £3,040.00  
£11,824  
Computerised 
Tomography (4.2%) 22.4 _ £2,430.40 
Magnetic Resonance 
Imaging (6.8%) 36.2 _ £6,353.10 
 TOTAL £274,657  
  
  
  
  
  
  
  
  
  
  
Cost calprotectin 
testing in 789 adult 
patients (£22/test)  
£17,358  
TOTAL SAVINGS 
(29 months) £257,299  
TOTAL SAVINGS  
per year £106,469  
TOTAL SAVINGS  
per patient 
£326 
*using 2017-18 National Tariff257    
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Supplementary Appendix 3.3-5: 2017-18 National tariffs used for costings 
analysis257 
Item Cost (£) Average Cost (£) 
Diagnostic Colonoscopy with Biopsy, ≥ 19 years 465 434.0 Diagnostic Colonoscopy, ≥ 19 years 403 
Diagnostic Flexible Sigmoidoscopy, ≥ 19 years 310 
341.0 Diagnostic Flexible Sigmoidoscopy with Biopsy, ≥ 19 
years 372 
Combined Upper and Lower GI Tract Diagnostic 
Endoscopic Procedures 496  
542.5 Combined Upper and Lower Gastrointestinal Tract Diagnostic Endoscopic Procedures with Biopsy, 19 
years and over 
589 
Diagnostic Endoscopic Upper GI Tract Procedures, ≥ 
19 years and over 341 364.5 Diagnostic Endoscopic Upper GI Tract Procedures + 
Biopsy, ≥ 19 years 388 
Colorectal OPD (first appointment) 143 - 
Gastroenterology OPD (first appointment) 188 - 
Ultrasound Scan with duration of less than 20 
minutes, without Contrast 40 
47.5 
 
  
Ultrasound Scan with duration of less than 20 
minutes, with Contrast 48 
Ultrasound Scan with duration of 20 minutes and 
over, without Contrast 48 
Ultrasound Scan with duration of 20 minutes and 
over, with Contrast 54 
MRI Scan of Two or Three Areas, without Contrast 
(plus reporting) 159  
175.5 MRI Scan of Two or Three Areas, with Contrast (plus 
reporting) 192 
CT Scan of Two Areas, without Contrast (plus 
reporting) 97  108.5 CT Scan of Two Areas, with Contrast (plus reporting) 120 
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3.4.1 Abstract 
Objective: To determine the diagnostic accuracy of calprotectin to diagnose IBD 
in children in whom general practitioners (GPs) suspected IBD.  
Design: Prospective observational cohort study of a new calprotectin-based 
primary care referral pathway. 
Setting: 49 GP practices and gastroenterology secondary care services at the 
Royal Devon and Exeter NHS Foundation Trust in the South-West of England, 
UK. 
Patients: 142 children aged between 4-18 years referred on the pathway 
between January 2014 and August 2017 for investigation of gastrointestinal 
symptoms were included.  
Interventions: Primary-care-driven faecal calprotectin testing. Primary and 
secondary care records over 12 months from the point of calprotectin testing 
were used as the reference standard.    
Main outcome measures: Diagnostic accuracy of calprotectin testing to detect 
IBD.  
Results: 8% (11/142) tested patients were diagnosed with IBD. Using our pre-
specified cut-off of 100 μg/g, calprotectin had a diagnostic accuracy of 93% (95% 
CI 87-97%) with a sensitivity for distinguishing IBD from non-IBD of 100% (95% 
CI 72-100%), a specificity of 92% (95% CI 86-96%), a positive predictive value of 
52% (95% CI 30-74%) and a negative predictive value of 100% (95% CI 97-
100%). Calprotectin testing had no effect on the time to diagnosis, but a negative 
test saved referrals in 39% (40/102) and was associated with fewer diagnostic 
tests in secondary care.    
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Conclusions: Calprotectin testing of children with suspected IBD in primary care 
accurately distinguishes IBD from a functional gut disorder, reduces secondary 
care referrals and associated diagnostic healthcare costs. 
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3.4.2 Background  
Most children who present to their general practitioner (GP) with gastrointestinal 
symptoms are diagnosed with a self-limiting infection or functional gut disorder 
that can be managed in primary care 266–268; a minority, however, will have 
inflammatory bowel disease (IBD).  
 
Because of the practical constraints of venepuncture, in particular in young 
children, primary care physicians often rely on presenting symptoms alone to 
formulate a differential diagnosis. The presence of ‘red-flag’ symptoms including 
weight loss, rectal bleeding, and a family history of IBD should prompt secondary 
care referral; however, these symptoms are common and have poor 
discriminative power.227,269,270  Where C-reactive protein (CRP) is available, its 
diagnostic accuracy for IBD is limited by moderate sensitivity, particularly for 
diagnosing terminal ileal Crohn’s disease and left-sided ulcerative colitis.224,225 
Faecal calprotectin is a stool biomarker that distinguishes paediatric IBD and 
other organic intestinal disease from functional gut disorders.219,271 We, like 
others, have shown that in adults with suspected IBD, calprotectin can be used 
by GPs to risk stratify patient referrals and permit timely diagnoses.240,241,272,273 
Despite the benefits of being non-invasive, there is a paucity of data exploring 
the real-world use of faecal calprotectin testing in paediatric primary care referral 
pathways.270  
 
We hypothesised that calprotectin testing would distinguish IBD from non-IBD 
with clinically useful positive and negative predictive values, save secondary care 
referrals and reduce the time to diagnosis from GP presentation.  
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3.4.2.1 Objectives 
We aimed to: 
i) compare the diagnostic accuracy of primary care calprotectin 
testing in children to distinguish IBD from non-IBD diagnoses with 
‘red-flag’ symptoms and other biomarkers of inflammation including 
CRP 
ii) define whether calprotectin testing alters primary care referral 
behaviour, reduces the time to diagnosis from presentation to GP 
and influences the use of secondary care investigations 
iii) compare the phenotype and time to diagnosis of patients referred 
on and off our primary care calprotectin pathway  
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3.4.3 Methods  
3.4.3.1 Design & clinical setting 
We designed a prospective observational cohort study to describe the diagnostic 
accuracy of calprotectin in children with suspected IBD in primary care.  
 
The Royal Devon & Exeter (RD&E) NHS Trust provides paediatric secondary 
care services to the Eastern locality of the Northern, Eastern and 
Western Devon Clinical Commissioning group and serves a local population of 
378,000 people, of whom 75,000 are under 18 years old. 
3.4.3.2 Patients 
Children aged between 4-18 years referred on the calprotectin pathway between 
January 2014 and August 2017 for investigation of gastrointestinal symptoms 
were included and followed-up for at least 12 months. Exclusion criteria were a 
previous diagnosis of IBD, suspicion of cancer and use of non-steroidal anti-
inflammatory drugs (NSAIDs) within the previous six weeks. This was a 
convenience sampling series: the use of calprotectin was not mandated in all 
patients meeting our eligibility criteria; rather, the test was used at the discretion 
of the treating GP.  
3.4.3.3 Variables and data acquisition 
We used a purpose-designed request form that captured patient demographic 
data, presenting symptoms and family history of IBD, colorectal or ovarian cancer 
at the point of calprotectin testing (Supplemental Appendix 3.4-1). General 
Practitioners (GPs) were prompted to send blood tests for full blood count (FBC), 
ferritin, C-reactive protein (CRP) and coeliac serology (tissue TransGlutaminase 
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[tTG]). Incomplete request forms were rejected by the blood sciences 
laboratory, and prompts sent to aid completion. Patients with one or more of 
rectal bleeding, unintentional weight loss, a family history of IBD, and anaemia 
(defined according to the age adjusted World Health Organization criteria274), 
were deemed to have ‘red-flag’ symptoms. GPs were also asked the following 
hypothetical referral question to assess expected referral behaviour: ‘Would you 
have referred this patient if calprotectin had been unavailable?’ [‘Yes’; ‘No’; 
‘Unsure’] 
 
Using electronic secondary care databases, we recorded health-care utilisation 
data in the year after calprotectin testing including: outpatient clinic referrals 
(paediatrics, gastroenterology, colorectal surgeons, upper gastrointestinal 
surgeons, dieticians and private clinics); diagnostic imaging (ultrasound [USS], 
computerised tomography [CT] and magnetic resonance imaging [MRI]); and 
endoscopy (colonoscopy, flexible sigmoidoscopy and gastroscopy).  
 
We compared baseline demographics, IBD phenotype according to the Paris 
classification275, presenting symptoms, emergency department presentations, 
faecal calprotectin, inflammatory biomarkers, and time to diagnosis between 
patients with IBD referred using our new pathway and those referred directly 
without calprotectin testing.     
3.4.3.4 Reference standard 
The diagnosis of IBD was made on clinical, radiological and histopathological 
findings in line with the Porto criteria. 276 This burden of investigation is impractical 
and inappropriate for the diagnosis of a functional gut disorder, particularly in 
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children. In common with previous published literature267, absence of IBD was 
defined as no endoscopic, histopathological and radiological evidence of IBD, or 
no IBD diagnosis after a 12-month period of follow-up. We mandated this period 
of follow-up to allow sufficient time for organic pathology to evolve and any 
missed cases of IBD to be correctly diagnosed. The primary care notes of children 
not referred to secondary care were reviewed to see whether there had been any 
further contact with a healthcare practitioner.  
3.4.3.5 Faecal calprotectin (index test) 
Samples were analysed in accordance with our previously described methods.272 
In short, a quantitative ELISA (Immundiagnostik, Bensheim, Germany) reported 
levels in the range 6-2100 µg/g. Results ≥ 100 µg/g were deemed positive. 
Calprotectin results and recommended actions were returned to GPs within 10 
days. Primary care management was suggested for those with a negative test, 
although GPs were encouraged to refer patients whom they felt required 
specialist review based on their clinical assessment.   
3.4.3.6 Statistical methods 
Because this study was designed as a service evaluation, a priori power 
calculations were not undertaken. Rather we decided to allow our new pathway 
to become established and then assessed its utility over three years. All analyses 
were two tailed and P-values < 0.05 were considered significant and were 
conducted in R 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria). 
We included patients with missing clinical data in analyses for which they had 
data and specified the denominator for each variable.  
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We used chi-squared analyses to compare expected and observed GP referrals 
to determine whether calprotectin influenced GP referral behaviour. We used 
Fisher’s exact tests for categorical data and Mann-Whitney U tests for continuous 
data to identify baseline clinical variables and biomarkers associated with a 
diagnosis of IBD and to identify phenotypic differences, including the time to 
diagnosis between children diagnosed with IBD referred on and off our new 
pathway.  
 
Receiver operator characteristic curves and area under the curve (AUC) 
analyses were undertaken to determine clinical validity of calprotectin as a 
continuous variable to diagnose IBD and organic intestinal disease; Youden’s 
formula was used to determine the optimal cut-off. 258 We calculated sensitivity, 
specificity, positive (PPV) and negative (NPV) predictive values at our pre-
specified cut-off and then at various calprotectin cut-off thresholds to optimise its 
use in diagnosing IBD. We used stepwise forward multivariable logistic 
regression models to compare diagnostic strategies using calprotectin and CRP 
with ‘red-flag’ symptoms.   
3.4.3.7 Ethical consideration and patient involvement 
This project was endorsed by the Local Medical Council, Devon Clinical 
Commissioning Group, primary- and secondary-care Caldicott guardians and the 
Southwest Academic Health Sciences Network (SWAHSN). Patients were not 
involved in the conception or design of this study, and in accordance with UK 
Health Research Authority guidelines, we did not require formal ethical 
approval.259   
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3.4.4 Results 
3.4.4.1 Study overview 
We report data according to the sequence of events on our pathway as outlined 
in Figure 3.4-1. The laboratory received 256 calprotectin samples from 241 
children between January 2014 and May 2016. Overall, 99 children were 
excluded from the final analysis for the following reasons: less than 12 months’ 
follow-up (n=81), age < 4years (n=6), inadequate GP data or faecal sample (n=5), 
requested in secondary care (n=5) and non-enteric diagnosis (n=2: Rett’s 
syndrome and pyelonephritis). 
 
142 patients were included in the final analysis: 49% (69/142) were female with 
a median [range] age of 15.0 [5.9-17.9] yrs. At least one ‘red-flag’ criterion was 
present in 49% (72/142) of all patients. 21% (29/136) children had a family history 
of IBD. Overall, 7% (14/142) tested patients were not referred to secondary care 
and had no further primary care record entries. For the purposes of our study they 
were coded as non-IBD after a median follow-up 1.6 years [IQR 1.3-2.1].  
  
CHAPTER 3: RESEARCH PAPER II-CALPROTECTIN IN CHILDREN 
 
 
148 
Figure 3.4-1: Flow diagram showing derivation of the cohort, faecal 
calprotectin and diagnosis of functional gut disorder 
  
Flow diagram showing derivation of the cohort, faecal calprotectin result and diagnosis 
of functional gut disorders and Inflammatory Bowel Disease (IBD). CT, computerised 
tomography; MRI, magnetic resonance imaging; NPV, negative predictive value, PPV, 
positive predictive values; GP, general practitioner; GI, gastrointestinal. Note, 13 patients 
missing data for GP expected referral behaviour. 
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their patient had calprotectin testing not been available; 32% (46/142) were 
unsure if they would have referred; and 6% (9/142) stated that they would not 
have referred (Table 3.4-1). On multivariable logistic regression, the final decision 
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= 3.2 [95% CI 1.5-7.0] for ‘yes’ vs. ‘unsure’ or ‘no’, p=0.003) and faecal 
calprotectin ≥ 100 µg/g (OR = 6.5 [95% CI 1.7-43.1, P = 0.018]). 
Table 3.4-1. Table comparing expected and observed GP behaviour by 
calprotectin result 
Key 
3.4.4.3 Diagnostic accuracy  
8% (11/142) patients were diagnosed with IBD (8 Crohn’s disease, 1 UC, 2 IBD-
U). The most frequent non-IBD (n = 131) diagnoses were: IBS/functional gut 
disorder 82%; anal fissure/haemorrhoids 4%; infective gastroenteritis 4% and 
coeliac disease 1% (Supplemental Table 3.4-1).  
Expected referral behaviour 
(pre-calprotectin test 
result)a 
Calprotectin test 
result (µg/g) 
Observed referral behaviour                                                    
(post-calprotectin test result) 
No referral made Referral made 
GP not intending to refer 
the patient if calprotectin 
testing were unavailable = 
6% (9/142) 
< 100 62% (5/8) 38% (3/8) 
≥ 100 0% (0/1) 100% (1/1) 
 GP unsure whether to refer 
the patient if calprotectin 
testing were unavailable = 
32% (46/142) 
 
< 100 54% (21/39) 46% (18/39) 
≥ 100 29% (2/7) 71% (5/7) 
GP did intend to refer the 
patient if calprotectin 
testing were unavailable = 
52% (74/142) 
< 100 30% (19/63) 70% (44/63) 
≥ 100 0% (0/11) 100% (11/11) 
Missing GP response 9% 
(13/142) 
< 100 36% (4/11) 64% (7/11) 
≥ 100  0% (0/2) 100% (2/2) 
  Calprotectin saved referral 
 Referred: not influenced by calprotectin 
 Calprotectin added referral 
 Not referred: not influenced by calprotectin 
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3.4.4.4 Clinical and inflammatory biomarkers to distinguish IBD and non-IBD 
Symptoms: Patients diagnosed with IBD more commonly reported diarrhoea 
(Bristol stool ≥ type 6) (P = 0.010), a change in stool appearance (P = 0.017) and 
change in stool frequency (P = 0.036) than patients with non-IBD (Table 3.4-2). 
At the time of GP referral, 55% (6/11) of patients diagnosed with IBD and 51% 
(66/131) of patients subsequently diagnosed with non-IBD (P = 1.0) met one or 
more of the ‘red-flag’ criteria.  
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Table 3.4-2. Comparison of clinical variables and biomarkers in patients 
diagnosed with inflammatory bowel disease and non-IBD 
Variable Nf IBD n = 11 
Non-IBD 
n = 131 P value
e 
Demographics 
Age 142 14.9 (14.2 - 15.9) 15.0 (11.8 - 16.5) 0.497 
Gender 142 45% (5/11) 49% (64/131) 1 
Family history IBD 136 20% (2/10) 21.4% (27/126) 1 
Symptoms 
Duration of symptoms (months) 139 3.0 (2.0 - 5.5) 6.0 (2.8 - 12.0) 0.08 
Abdominal pain 140 73% (8/11) 90% (116/129) 0.114 
Pain improves on defaecation 128 22% (2/9) 36% (43/119) 0.492 
Number of stools in 24 hours 137 4.0 (3.2 - 4.0) 3.0 (1.0 - 4.5) 0.226 
Diarrhoea (Bristol stool ≥ 6) 97 78% (7/9) 31.8% (28/88) 0.010 
Change in stool frequency  134 100% (11/11) 70.7% (87/123) 0.036 
Change in stool appearance 130 100% (11/11) 65.5% (78/119) 0.017 
Rectal bleeding 139 18% (2/11) 20.3% (26/128) 1 
Unintentional weight loss 140 18% (2/11) 18.6% (24/129) 1 
Nocturnal symptoms 137 45% (5/11) 26.2% (33/126) 0.178 
Blood Biomarkers: Continuous 
Haemoglobin (g/L) 119 128 (116 - 132) 136 (129 - 147) 0.006 
White Blood Cell count (x 109/L) 119 9.2 (8.0 - 10.1) 6.2 (5.0 - 7.8) <0.001 
Platelet count (x 109/L) 119 305 (250 - 380) 248 (220 - 296) 0.039 
CRP (mg/L) 111 17 (6 - 25) <1 (<1 - 2) <0.001 
Ferritin (μg/L) 65 30 (15 - 52) 38 (29 - 55) 0.38 
Albumin (g/L) 89 44 (38 - 49) 48 (47 - 51) 0.007 
B12 (ng/L) 29 628 (273 - 700) 452 (289 - 721) 0.878 
Folate (μg/L) 29 7.2 (6.0 - 10.2) 11.0 (7.6 - 12.8) 0.185 
Blood Biomarkers: Binary      
Anaemia a 119 36% (4/11) 7% (8/108) 0.014 
Raised CRP (> 5 mg/L) 111 73% (8/11) 5% (5/100) <0.001 
Raised platelets (> 400 μg/L) 119 27% (3/11) 3% (3/108) 0.010 
Low ferritin b 63 86% (6/7) 20% (11/56) 0.001 
Raised ferritin c 119 0% (0/11) 5% (5/108) 1 
Low B12 (< 180 ng/L) 29 0% (0/7) 5% (1/22) 1 
Stool Biomarker     
Faecal calprotectin (μg/g) 142 1140 (264 - 1489) 22 (10 - 48) <0.001 
Red-flag criteria d     
Red-flag criteria present  142 55% (6/11) 51% (66/129) 1.0 
% (numerator/denominator); median (interquartile range) 
IBD, inflammatory bowel disease; CRP, C-reactive protein 
a Anaemia threshold: 4-12 years < 115 g/L; males 4-18 < 130 g/L; females 4-18 < 120 g/L 
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b Low ferritin threshold:  If CRP > 5 mg/L, then ferritin threshold <100 µg/L; if CRP ≤ 5 mg/L, 
then ferritin threshold 13 µg/L for females and 30 µg/L for males 
c Raised ferritin threshold: female > 150 µg/L; male > 400 µg/L 
d Red-flag criteria include one or more of: unintentional weight loss, rectal bleeding, family 
history of IBD 
e P values represent Mann-Whitney U, chi-squared or Fisher’s exact test as appropriate 
f denominator denoted by column N 
 
Calprotectin: Calprotectin levels were significantly greater in the IBD than the 
non-IBD group (Supplemental Figure 3.4-1). Using our pre-specified cut-off of 
100 μg/g, calprotectin had a diagnostic accuracy of 93% (95% CI 87-97%) with a 
sensitivity for distinguishing IBD from non-IBD of 100% (95% CI 72-100%), a 
specificity of 92% (95% CI 86-96%), a positive predictive value of 52% (95% CI 
30-74%) and a negative predictive value of 100% (95% CI 97-100%). 
 
Increasing the threshold separating positive and negative calprotectin results 
from 50 µg/g, as recommended by the manufacturers, to 100 µg/g doubled the 
positive predictive value (PPV) of the test with no reduction in negative predictive 
value (NPV) (Supplemental Table 3.4-2). Further increases likewise increased 
the PPV but at the expense of a reduction in the NPV and a reduction in sensitivity 
due to missed IBD cases. 
 
13 patients had a false positive calprotectin, 11 of whom were referred by their 
GP to secondary care. Of the two patients not referred to secondary care, one 
(calprotectin = 125 µg/g) was given an inferred diagnosis of non-IBD after 1.9 
years’ follow-up and the other (calprotectin = 102 µg/g) a diagnosis of 
gastroenteritis by their GP. Of the 11 referred patients, 9/11 underwent imaging 
investigations (1 CT, 1 ultrasound and 9 MRI small bowel) and all 11 children 
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underwent upper and lower GI endoscopy with no other organic treatable 
diagnoses made. 
 
Calprotectin versus other biomarkers: Faecal calprotectin had a significantly 
better AUC when compared with albumin (P = 0.016), haemoglobin (P = 0.001), 
white blood cell count (P < 0.001) and platelets (P = 0.001) but not CRP 
(P = 0.144). Using Youden’s method to maximize the difference between the true 
positive and false positive rate over all possible cut-off values, the optimal cut-off 
threshold for distinguishing IBD from non-IBD was 112 µg/g (Figure 3.4-2). 
Figure 3.4-2. Receiver operating characteristic curves for faecal 
calprotectin and blood biomarkers as predictors of inflammatory bowel 
disease 
 
Receiver operating characteristic curves for faecal calprotectin and blood biomarkers as 
predictors of Inflammatory Bowel Disease (IBD) or Non-IBD. AUC, area under the curve; 
CI, confidence interval; CRP, C-reactive protein. 
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27% (3/11) of patients diagnosed with IBD had a normal CRP (≤ 5 mg/L); in all 
three cases the calprotectin was ≥ 100 µg/g (in two patients the blood and stool 
tests were performed on the same day, in the third, the calprotectin was taken 13 
days after the CRP) (Supplemental Table 3.4-3). 
3.4.4.5 Strategies for predicting an IBD diagnosis  
Red-flags alone: Using a referral strategy based on the presence of red-flag 
symptoms alone was not predictive of IBD (logistic regression with ‘red-flag’ as 
univariable: P = 0.83, AIC = 81.0). The AUC for the receiver operator curve for 
the red-flag model was 0.517.  
 
Red-flags and abnormal CRP (> 5 mg/L): Adding CRP to this model, showed 
that irrespective of the presence of red-flag symptoms, an abnormal CRP 
(> 5mg/L) increased the odds of IBD 50-fold (95% CI 11.1 to 294.4, P = 4.8x10-
6) with a signifcant increase in the ROC AUC to 0.855 (P = 0.002).  
 
Red-flags and calprotectin: We were unable to include abnormal calprotectin 
(≥ 100 µg/g) as a binary covariate as it had a perfect sensitivity for IBD. However, 
adding this biomarker as a continuous covariate (after log transformation) 
demonstrated that independently of red-flag symptoms, for every 10-fold increase 
in calprotectin, the risk of IBD increased 408-fold (95% CI 32.5 to 37564), P = 3.9 
x10-4, AUC 0.98).  
3.4.4.6 Secondary care investigations 
Patients with a negative calprotectin were referred to secondary care less 
frequently than the positive calprotectin cohort (60% [72/121] vs 91% [19/21] 
respectively, P = 0.006), they also underwent fewer endoscopic investigations 
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(14% [17/121] vs 71% [15/21] respectively, P < 0.001) and underwent less 
imaging (13% [16/121] vs 52% [11/21] respectively, P < 0.001) (Table 3.4-3) 
Table 3.4-3: Influence of faecal calprotectin on primary care referrals to 
secondary care services and secondary care investigation of referred 
patients  
Variable 
Calprotectin  
< 100 µg/g 
n = 121 
Calprotectin 
 ≥ 100 µg/g 
n = 21 
P Value 
Primary care referral of patients to secondary care  
Referred to GI services  72/121 (60%) 19/21 (90%) 0.006 
Emergency presentation 
to medical or surgical 
assessment unita 
4/121 (3%) 3/21 (14%) 0.066 
Secondary care investigation of referred patients referred  
Reviewed in outpatients 71/121 (59%) 19/21 (90%) 0.006 
Gastroenterology 11/71 (15%) 4/18 (22%) 0.676 
Paediatrics 56/71 (79%) 14/18 (78%) 0.676 
Surgeons 4/71 (6%) 0/18 (0%) 0.676 
Radiological investigations 
One or more 
radiological 
investigations 
16/121 (13%) 11/21 (52%) <0.001 
X-Ray 3/121 (2%) 4/21 (19%) 0.009 
CT 0/121 (0%) 1/21 (5%) 0.148 
MRI 7/121 (6%) 10/21 (48%) <0.001 
USS 11/121 (9%) 2/21 (10%) 1 
Endoscopic Investigations 
One or more endoscopic 
procedures 
17/121 (14%) 15/21 (71%) <0.001 
Flexible sigmoidoscopy 2/121 (2%) 2/21 (10%) 0.104 
Colonoscopy 9/121 (7%) 13/21 (62%) <0.001 
Gastroscopy 11/121 (9%) 12/21 (57%) <0.001 
CT, computerised tomography; MRI, magnetic resonance imaging; GI, gastrointestinal  
a includes GP referrals straight to medical and surgical assessment units as well as 
patients self-presenting to accident and emergency and admitted to the medical and 
surgical assessment units 
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3.4.4.7 IBD phenotype diagnosed on and off the calprotectin pathway  
Between January 2014 and May 2016, a total of 37 children were diagnosed with 
IBD, of whom 75% (26/37) were diagnosed without primary care faecal 
calprotectin testing. Of the 26 children who did not submit a primary care 
calprotectin test, 19 had a secondary care calprotectin measured prior to 
diagnosis. In all 19 instances the faecal calprotectin result was ≥100 µg/g (median 
615 µg/g, IQR 411-1930 µg/g, range 124->2100 µg/g). Patients diagnosed 
without use of a primary care calprotectin test reported more rectal bleeding (76% 
[19/26] vs. 18% [2/11], P = 0.002) but rates of unintentional weight loss (P = 
0.067) and a family history of IBD (P = 1.0) were similar. Despite the differences 
in red-flag symptoms, the IBD Montreal phenotype, number of emergency 
hospital attendances (P = 0.67), serological biomarkers, including CRP and 
faecal calprotectin were not significantly different between the two cohorts 
(Supplemental Table 3.4-4 and Supplemental Figure 3.4-2). There was no 
difference in the median [IQR] time to diagnosis between patients who underwent 
primary care calprotectin testing and those who went straight to secondary care 
(53 [32-56] days vs 79.5 [49.2-189] days respectively, P = 0.11).  
3.4.5 Discussion  
3.4.5.1 Key results & implementation 
Based on the results of our predictive modelling, stratifying paediatric referrals 
using red-flag symptoms alone is futile. Calprotectin, however, is a useful 
biomarker: the high negative predictive value allows exclusion of IBD and over 
half of patients with a raised calprotectin were subsequently diagnosed with UC 
or Crohn’s disease despite the lower pre-test probability in primary care227,277 
than in referred cohorts.271,278 Although, CRP and calprotectin both discriminated 
CHAPTER 3: RESEARCH PAPER II-CALPROTECTIN IN CHILDREN 
 
 
157 
IBD from non-IBD, calprotectin was more sensitive, detecting IBD in 3 cases 
where CRP was within the normal range (≤ 5 mg/L). Calprotectin has the added 
benefit of being non-invasive and therefore widely applicable even in young 
children in primary care, where bloodletting is not easily undertaken. In referred 
patients with a negative calprotectin, 13% underwent radiological and 14% 
endoscopic investigation. In all instances these tests were normal suggesting that 
secondary care clinicians can use this biomarker to reduce unnecessary 
investigations.  Implementation of a primary calprotectin based-pathway is likely 
to reduce the risk incurred by unnecessary endoscopic procedures, particularly 
in children that need to undergo endoscopy using a general anaesthetic.279–281 
3.4.5.2 Strengths and limitations   
The strengths of our study lay in the prospective design and meticulous follow-up 
of all primary care records of non-referred patients. We acknowledge, however, 
some important limitations. Firstly, the uptake of calprotectin testing in primary 
care was relatively poor with only approximately one third (31%, 
11/36) children diagnosed with IBD during the time-period of the study 
referred by participating practices via the pathway. We were unable to 
demonstrate a disease spectrum bias in the non-tested compared with 
calprotectin-tested patients, supporting our recommendations for faecal 
calprotectin in all primary care patients with possible IBD not meeting criteria for 
emergent referral. However, it is interesting to observe that three-quarters of 
children with IBD who did, and one-fifth of children who didn’t undergo a primary 
care calprotectin test reported rectal bleeding: this illustrates that GPs still use 
this red-flag symptom to determine direct referral and secondly the likely inherent 
limitation of conflating bloody diarrhoea and fresh rectal bleeding together as one 
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entity. Secondly, 91% (110/121) of patients with a negative calprotectin, and 29% 
(6/21) of patients with a positive calprotectin later diagnosed with non-IBD did not 
undergo a gold standard lower gastrointestinal endoscopy, leading to an 
inevitable partial verification bias that may have overestimated the accuracy 
of calprotectin. We took various measures to limit the effect of this bias, including 
using a 12-month follow-up period to allow for IBD to evolve and capturing data 
across primary and secondary care. For non-referred patients this should 
have avoided an erroneous diagnosis of functional gut disorder being assigned 
to patients who may have been diagnosed with IBD in other hospitals. Thirdly, 
despite a relatively small sample size we did detect IBD and report and no false 
negatives unlike previous studies 227,270. 
3.4.5.3 Generalisability 
It is unlikely that our proposed calprotectin cut-off is applicable in children age 0-
4 years, as normal values of faecal calprotectin are higher than children aged > 
4 years . 282–284 Despite this, calprotectin remains a useful test in the very young, 
with careful interpretation of the result. We acknowledge too that our data comes 
from a single secondary care centre in South-west England, UK. In this regard, 
nearly all of our patients were diagnosed with IBD within 100 days (median 63 
days) and calprotectin did not reduce the time to diagnosis of IBD. Contemporary 
UK data is lacking, but our time to diagnosis is shorter than previously reported 
in a UK multicentre population based study of 739 new IBD diagnoses diagnosed 
between 1998-1999, where median time to diagnosis was 5 months. [28] Whether 
our findings are applicable to other centres with less capacity is therefore 
unknown. It is likely, however, that the phenotype of paediatric IBD is similar to 
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that presenting elsewhere in the UK 285  and that calprotectin is likely to be useful 
when stratifying referrals.    
3.4.5.4 What is already known on this topic  
Distinguishing paediatric IBD from non-IBD in patients presenting to their GP for 
the first time with lower GI symptoms can be notoriously difficult. Currently GPs 
use a combination of ‘red-flag’ symptoms such as rectal bleeding, as well as 
blood biomarkers, including CRP, to guide onward specialist referral.  Faecal 
calprotectin is routinely used in the secondary care setting to rule out IBD, but 
there is a paucity of UK data exploring its real-world use in paediatric primary 
care referral pathways.  
3.4.5.5 What this study adds 
In this real-world application in children in primary care, we have shown that a 
calprotectin ≥ 100 µg/g discriminates accurately IBD from non-IBD and out-
performs ‘red-flag’ symptoms and/or CRP.  Calprotectin testing did not influence 
the time to diagnosis of IBD, but saved outpatient referrals and a negative test 
reduced secondary care investigations.  
3.4.5.6 Supplementary Methods 
New East Devon faecal calprotectin referral pathway  
We disseminated information about the new calprotectin pathway to GPs through 
a series of educational meetings. In accordance with NICE guidelines214, GPs 
were asked to use calprotectin in patients presenting with lower gastrointestinal 
symptoms whom they suspected, but were uncertain, had IBD. Purpose-
designed request forms were embedded within routine electronic primary care 
pathology requesting systems (Supplementary Appendix 5.4-1). Incomplete 
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request forms were rejected by the blood sciences laboratory and prompts sent 
to aid completion.  Test results, including defined thresholds, and recommended 
actions were returned to GPs within 10 days.  
Definition of diagnostic outcomes 
Diagnoses were recorded firstly as per the responsible clinician, and then 
grouped as either inflammatory bowel disease (IBD) or non-IBD; the latter 
encompassing all enteric conditions other than IBD which may have led to the 
initial GP presentation. Clinicians were not blinded to the index test results. The 
diagnosis of IBD was based on clinical, radiological and histopathological 
findings.256 A non-IBD diagnosis was assigned to patients based on a composite 
of lower gastrointestinal endoscopy and cross-sectional imaging with CT or MRI 
if available, and an absence of IBD after at least 12 months’ follow-up from the 
time of the index test, if not. Patients not referred to secondary care were 
followed-up by requesting diagnoses from the responsible primary care clinicians.  
Patients who were diagnosed with non-enteric diseases (e.g. urological 
diagnoses, gynaecological diagnoses, respiratory tract infections, thyroid 
disease) are reported but not included in the final analysis. 
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3.4.6 Supplement 
 
 
RESEARCH PAPER II 
SUPPLEMENT 
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Supplementary Appendix 3.4-1: Case Report Form 
 
  
Impact of FC in Primary Care:
If FC was not available would you have
referred this patient to secondary care?
Yes No Unsure
Are you planning to refer this patient to
secondary care even if FC is normal?
Yes No Unsure
Version 1.1
                                  When to use Faecal Calprotectin in Primary Care:
Suspected Inflammatory Bowel disease (IBD) in patient aged 45 or below
If you suspect a patient age !45 might have IBD then perform FC as part of your usual work up/investigations.
• Positive: FC"100 µg/g faeces, referral to Gastroenterology recommended.
• Negative: FC<50 µg/g faeces, IBD unlikely- consider primary care IBS management.
• Indeterminate: FC 50-99 µg/g faeces, if symptoms persist re-test FC. If on re-test FC "50 µg/g faeces referral to
Gastroenterology is recommended.
If FC is normal, but CRP raised without another obvious explanation, then consider referral for suspected IBD
If you remain clinically concerned about a patient despite a negative FC then there is no need to repeat the test. You may refer in the
normal way but please state in your referral letter what features are concerning you and prompting the referral.
Secondary care referral:
• Please title your referral letter “SUSPECTED IBD” and send to RD&E gastroenterology only. All patients will be seen in
gastroenterology outpatients within 3 weeks.
• For more urgent opinions please Fax 01392 402810 or call one of the gastroenterologists
    IMPORTANT  - STOOL SAMPLES MUST ARRIVE IN THE LABORATORY WITHIN 24 HOURS OF COLLECTION
Please also request:
a) FBC, Ferritin, CRP if not done in the past 6 weeks
b) TTG if not previously done
Faecal Calprotectin (FC) Request Form for Primary Care
NHS Number
/ /
Surname                                                (Block CAPITALS please) First name(s)                                     (Block CAPITALS please)
Doctor's Laboratory Code Practice Laboratory Code
Date of Birth
Sample date
Affix Label Here
M F
Gender
For EXTRA copy reports, state doctor & location
Criteria for Sample Analysis:
** Please note, samples will only be processed
when the following questions are marked "Yes" **
Yes No
Yes No
Yes No
Yes No
Do you confirm it has been >6 weeks
since any NSAID, including aspirin?
Is there a low suspicion of colorectal
cancer?
Is IBD suspected or possible?
Is patient age !45 years?
EXETER PATHOLOGY SERVICES
DEPARTMENT OF BLOOD SCIENCES
REQUESTS ENQUIRIES (01392 40)2934
Clinical Information
Duration of Symptoms (months):
24 hour stool frequency (number of times):
Stool consistency (see Bristol Stool Chart on reverse):
Alcohol (units per week):
Abdominal Pain:
Pain improves with defecation:
Change in stool frequency:
Change in stool appearance/consistency:
Rectal bleeding:
Unintentional weight loss:
Nocturnal symptoms:
Family history of IBD:
Family history of bowel or ovarian cancer:
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
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Supplementary Table 3.4-1: Summary of diagnostic frequencies in IBD and 
non-IBD patients 
IBD diagnoses (n= 11) Non-IBD diagnoses (n = 131) 
Diagnosis Frequency (%) Diagnosis  Frequency (%) 
Crohn's disease 8/11 (73%) Functional gut disorder/ Irritable bowel syndrome 107/131 (82%) 
IBD-U 2/11 (18%) Eating disorder/Chronic pain/Anxiety-related 6/131 (5%) 
Ulcerative colitis 1/11 (9%) Anal fissure/Haemorrhoids 5/131 (4%) 
 
Infective gastroenteritis 5/131 (4%) 
Symptoms resolved 5/131 (4%) 
Coeliac disease 1/131 (1%) 
Gastritis 1/131 (1%) 
Chronic appendicitis 1/131 (1%) 
CHAPTER 3: RESEARCH PAPER II-CALPROTECTIN IN CHILDREN 
 
 
164 
Supplementary Table 3.4-2: Effect of altering faecal calprotectin thresholds defining positive and negative test results on 
diagnostic performance for distinguishing IBD and non-IBD 
FC threshold 
(µg/g) Sens Sens CI Spec Spec.CI PPV PPV.CI NPV NPV.CI 
20 1.00 (0.68 - 1.00) 0.46 (0.37 - 0.55) 0.13 (0.07 - 0.23) 1.00 (0.93 - 1.00) 
50 1.00 (0.68 - 1.00) 0.76 (0.67 - 0.82) 0.26 (0.14 - 0.41) 1.00 (0.95 - 1.00) 
70 1.00 (0.68 - 1.00) 0.85 (0.77 - 0.90) 0.35 (0.20 - 0.55) 1.00 (0.96 - 1.00) 
100 1.00 (0.68 - 1.00) 0.92 (0.86 - 0.96) 0.52 (0.30 - 0.74) 1.00 (0.96 - 1.00) 
150 0.73 (0.39 - 0.93) 0.97 (0.92 - 0.99) 0.67 (0.35 - 0.89) 0.98 (0.93 - 0.99) 
200 0.73 (0.39 - 0.93) 0.97 (0.92 - 0.99) 0.67 (0.35 - 0.89) 0.98 (0.93 - 0.99) 
250 0.73 (0.39 - 0.93) 0.98 (0.94 - 1.00) 0.80 (0.44 - 0.96) 0.98 (0.93 - 0.99) 
300 0.73 (0.39 - 0.93) 0.99 (0.95 - 1.00) 0.89 (0.51 - 0.99) 0.98 (0.93 - 0.99) 
FC, faecal calprotectin; Sens, sensitivity; Spec, specificity; PPV, positive predictive value; NPV, negative predictive value; CI, confidence interval 
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Supplementary Table 3.4-3. IBD phenotype in patients diagnosed in and outside primary care calprotectin pathway 
Primary 
Care 
Calprot
ectin 
Pathwa
y 
Sex 
Age at 
diagnosis 
(years) 
IBD 
subtyp
e 
Index Lower GI 
Endoscopy Result 
Paris 
classific
ation 
CD 
Paris 
classificatio
n 
UC 
FC 
result 
(µg/g) 
CRP 
(mg/L) 
Family 
history 
IBD  
Rectal 
bleeding 
Weight 
loss 
No  F 12.1 CD Mild left-sided Crohn's disease   A1bL3B1 >2100 2 No Yes No 
No  F 13.8 CD Severe ileocolonic Crohn’s disease   A1bL3B1 >2100 133 Yes Yes Yes 
No  F 18.1 CD Mild ileocolonic inflammation   A2L3B1   1 No No No 
No  M 7.3 IBDU Mild patchy colonic inflammation  E3  >2100 
 No Yes Yes 
No  F 8.9 CD Severe ileocolonic Crohn’s disease   A1aL3B1 440 110   Yes Yes 
No  F 16.0 UC Severe recto-sigmoiditis E1    <1 No Yes Yes 
No  M 6.3 UC Moderate pan-colitis E3  >2100 27   Yes Yes 
No  M 9.8 UC Mild-moderate pan-colitis E3  >2100 <1 No Yes Yes 
No  F 14.4 IBDU Severe pan-colitis E3  544 23   Yes   
No  M 15.2 IBDU Moderate-severe left sided colitis E2    <1 No Yes No 
No  M 17.2 UC Moderate active proctitis E1    <1   Yes   
No  M 16.9 IBDU Mild patchy left-sided inflammation worse E3    <1 No No Yes 
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on right side, rectal 
sparing 
No  M 15.8 CD Moderate patchy colitis and ileitis    A1bL3B1 671 12 Yes No No 
No  M 16.9 CD Moderate ileocolonic Crohn's disease   A1bL3B1 586 12 Yes No No 
No  M 11.1 UC Moderate pan-colitis E3  1633 4 No Yes Yes 
No  F 16.2 CD Moderate ileitis   A1bL1B1 615 47 No No No 
No  M 6.3 UC Severe proctitis E1  279 <1 No Yes No 
No  M 12.6 CD Moderate Crohn's colitis    A1bL3B1 382 17 No Yes Yes 
No  M 15.1 IBDU Moderate segmental colitis E2  866 
 No Yes No 
No  F 14.3 UC Moderate pan-colitis E3    9 Yes Yes   
No  M 7.7 CD Ileocolonic Crohn’s disease   A1aL3B1   61   Yes Yes 
No  M 15.6 UC Moderate pan-colitis E3  124 5 No Yes Yes 
No  M 16.4 IBDU Moderate right-sided colitis E3  135 3       
No  F 10.2 CD Moderate right-sided pan-colitis   A1bL3B1 516 19   Yes Yes 
No  M 13.7 CD Moderate colonic Crohn's disease   A1bL2B1 125 <1 Yes No No 
No  M 15.0 IBDU Mild pan-colitis E3  1758 <1 No Yes No 
Yes F 15.6 CD Severe ileocolonic Crohn’s disease   A1bL3B1 1223 16   No No 
Yes M 17.9 UC Severe proctitis E1  119 17 No Yes No 
Yes F 14.5 CD Mild ileal Crohn’s disease   A1bL1B1 2101 6 Yes No No 
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Yes M 14.4 CD Moderate Ileocolonic Crohn's disease   A1bL3B2 548 25 No No Yes 
Yes M 13.6 CD Moderate Crohn’s colitis   A1bL2B3 2085 25 No No Yes 
Yes F 15.0 CD Moderate pan-colitis and ileitis   A1bL3B1 1373 19 No No No 
Yes M 15.7 CD Severe rectosigmoid Crohn's disease  A1bL2B1 396 65 No No No 
Yes M 16.3 IBDU Mild caecal inflammation E3  1605 5 No Yes No 
Yes F 17.9 CD Mild ileal Crohn's disease   A1bL1B1 130 98 No No No 
Yes F 14.2 IBDU 
Moderate patchy pan-
colitis and ileitis with 
rectal sparing 
E3  1140 2 Yes No No 
Yes M 13.7 CD Patchy mild Ileal Crohn's disease  A1bL1B1 132 2 No No No 
CD, Crohn’s disease; UC, ulcerative colitis; FC: Faecal calprotectin; IBDU, inflammatory bowel disease unclassified; M, male; F, female; E1, proctitis; E2, 
left sided; E3 pancolitis; L1, ileal +/- limited caecal; L2, colonic; L3 ileocolonic; B1, inflammatory; B2, stricturing; B3, penetrating
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Supplementary Table 3.4-4. Comparison of phenotype between patients 
diagnosed on and outside of primary care faecal calprotectin pathway  
Variable 
All IBD patients 
diagnosed 
2014:2017 
n = 37 
Primary care 
calprotectin 
n = 11 
Direct to 
secondary care 
n = 26 
P value 
b 
Demographic and IBD-phenotype 
Sex Female 14/37 (38%) 5/11 (45%) 9/26 (35%) 0.713 
Family history of IBD 7/29 (24.1%) 2/10 (20.0%) 5/19 (26%) 1 
IBD 
subtype 
CD 19/37 (51.4%) 8/11 (72.7%) 11/26 (42.3%) 
0.255  IBDU 9/37 (24.3%) 2/11 (18.2%) 7/26 (26.9%) 
UC 9/37 (24.3%) 1/11 (9.1%) 8/26 (30.8%) 
UC extent 
E1 4/18 (22.2%) 1/3 (33.3%) 3/15 (20.0%) 
1  E2 2/18 (11.1%) 0/3 (0.0%) 2/15 (13.3%) 
E3 12/18 (66.7%) 2/3 (66.7%) 10/15 (66.7%) 
CD  
age 
A1a 2/19 (10.5%) 0/8 (0.0%) 2/11 (18.2%) 
0.274 A1b 16/19 (84.2%) 8/8 (100.0%) 8/11 (72.7%) 
A2 1/19 (5.2%) 0/8 (0.0%) 1/11 (9.1%) 
CD location 
L1 4/19 (21.1%) 3/8 (37.5%) 1/11 (9.1%) 
0.149 L2 3/19 (15.8%) 2/8 (25.0%) 1/11 (9.1%) 
L3 12/19 (63.2%) 3/8 (37.5%) 9/11 (81.8%) 
CD 
behaviour 
B1 17/19 (89.5%) 6/8 (75.0%) 11/11 (100.0%) 
0.164 B2 1/19 (5.3%) 1/8 (12.5%) 0/11 (0.0%) 
B3 1/19 (5.3%) 1/8 (12.5%) 0/11 (0.0%) 
Emergency hospital 
presentation 8/37 (21.6%)  5/26 (19.2%) 3/11 (27.3%) 0.672 
Symptoms prior to diagnosis 
Duration symptoms 
(months) 3.5 (2.0 - 5.2) 3.0 (2.0 - 5.5) 4.0 (1.5 - 5.0) 0.691 
Abdominal pain 25/35 (71.4%) 8/11 (72.7%) 17/24 (70.8%) 1 
Change in stool 
frequency 30/35 (85.7%) 11/11 (100.0%) 19/24 (79.2%) 0.157 
Number of stools per 
day 4.0 (2.0 - 4.0) 4.0 (3.2 - 4.0) 2.5 (1.9 - 4.2) 0.434 
Bristol stool score 
 (1-7) 6.0 (5.5 - 6.0) 6.0 (6.0 - 6.0) 6.0 (5.4 - 6.0) 0.962 
Rectal bleeding 21/36 (58.3%) 2/11 (18.2%) 19/25 (76.0%) 0.002 
Unintentional weight 
loss 14/33 (42.4%) 2/11 (18.2%) 12/22 (54.5%) 0.067 
Red-flag symptomsa 29/36 (80.6%) 6/11 (54.5%) 23/25 (92.0%) 0.018 
Blood tests 
Haemoglobin (g/L) 126.0 (112.0 - 131.0) 
128.0 (115.5 - 
132.5) 
124.5 (111.0 - 
130.8) 0.666 
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White blood cell count 
(x109/L) 9.2 (7.6 - 10.2) 9.2 (8.0 - 10.1) 9.2 (7.3 - 10.9) 0.881 
Platelets (x109/L) 322.0 (251.0 - 405.0) 
305.0 (249.5 - 
380.0) 
339.0 (265.2 - 
413.8) 0.682 
CRP (mg/L) 9.0 (1.5 - 24.0) 17.0 (5.5 - 25.0) 4.5 (0.5 - 20.0) 0.116 
Raised CRP (>5mg/L) 19/35 (54.3%) 8/11 (72.7%) 11/24 (45.8%) 0.167 
Ferritin 34.0 (15.0 - 60.0) 30.0 (15.0 - 52.0) 34.5 (18.2 - 63.5) 0.649 
Albumin 44.0 (39.5 - 47.5) 44.0 (38.0 - 49.0) 44.5 (40.2 - 47.0) 0.97 
B12 628.0 (343.0 - 931.5) 
628.0 (272.5 - 
699.5) 
656.5 (446.0 - 
977.0) 0.278 
Folate 9.6 (6.7 - 14.7) 7.2 (6.0 - 10.2) 11.2 (8.8 - 17.2) 0.067 
Faecal tests 
Faecal calprotectin 643.0 (385.5 - 1726.8) 
1140.0 (264.0 - 
1489.0) 
615.0 (411.0 - 
1929.5) 0.713 
Raised calprotectin 
(≥ 100µg/g) 30/30 (100.0%)  11/11 (100.0%) 19/19 (100.0%) 1 
Time to diagnosis 
From symptom onset to 
first GP presentation 
(months) 
3.5 (2.0 - 5.2) 3.0 (2.0 - 5.5) 4.0 (1.5 - 5.0) 0.691 
From first GP 
presentation to GP 
referral (days) 
22.0 (8.8 - 60.8) 32.0 (14.0 - 32.8) 18.5 (9.2 - 76.5) 0.912 
From GP referral to 
diagnosis (days) 41.5 (20.5 - 63.0) 21.0 (15.5 - 47.5) 45.5 (38.0 - 76.8) 0.15 
Total time to diagnosis 
(days) 
63.0 (41.5 - 
101.5) 53.0 (32.0 - 56.0) 
79.5 (49.2 - 
189.0) 0.111 
% (numerator/denominator); median (interquartile range) 
IBD, inflammatory bowel disease; CRP, C-reactive protein 
a Red-flag criteria include one or more of: unintentional weight loss, rectal bleeding; family 
history of IBD 
b P values represent Mann-Whitney U for primary vs. direct  
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Supplementary Figure 3.4-1:Box plot showing difference in faecal calprotectin 
between patients with Inflammatory Bowel Disease (IBD) and Non-IBD 
 
Box plot showing difference in faecal calprotectin between patients with Inflammatory Bowel 
Disease (IBD) and non-IBD.  
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Supplementary Figure 3.4-2. Faecal calprotectin among IBD patients diagnosed 
on and off primary care calprotectin pathway 
 
Box plot showing the faecal calprotectin in Inflammatory Bowel Disease (IBD) patients 
diagnosed on and off the primary care calprotectin pathway 
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3.6.1 Abstract  
Background: Delay in the diagnosis of inflammatory bowel disease (IBD) is common 
and contemporary UK studies exploring this issue are lacking.  
Objective: To determine the factors associated with, and the consequences of, a 
prolonged time to diagnosis in IBD.  
Design: Prospective observational cohort study 
Setting: 49 GP practices and gastroenterology secondary care services at the Royal 
Devon and Exeter NHS Foundation Trust, UK. 
Patients: 304 adults with a new IBD diagnosis made between January 2014 - 
December 2017. 
Main outcome measures: Multivariable logistic regression of demographic, disease 
and biomarkers associated with a prolonged (>75th centile) time to: (a) patient 
presentation (b) GP referral (c) secondary care diagnosis. Factors associated with 
complicated disease course (hospitalisation and/or surgery and/or biologic treatment) 
in the year after diagnosis.  
Results: Of 304 eligible patients: female 48%; median [IQR, range] age-at-diagnosis 
36 [27-53, 18-91] yrs; ulcerative colitis 64%; emergent presentation 20%. Median 
[IQR] diagnosis sub-intervals: (a) patient = 2 [1-5] months; (b) GP = 0.3 [0-1] months; 
(c) secondary care = 1 [0.5-2] months. 50% of patients diagnosed within 4-months and 
11% within 2-years of symptom onset: diagnostic delay more common in Crohn’s 
disease than ulcerative colitis (P < 0.001). Patients who presented emergently (P < 
0.001) but not those with a delayed overall time to diagnosis (P = 0.35) more likely to 
have a complicated disease course in first year after diagnosis. 
Conclusion: Time to patient presentation is the biggest component of time to IBD 
diagnosis supporting the need to raise public awareness of seeking medical attention 
CHAPTER 3: RESEARCH PAPER III: DIAGNOSTIC DELAY 
 
 
 
176 
for new lower GI symptoms. Emergent presentation is common and associated with a 
complicated disease course, unlike a delayed time to diagnosis.   
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3.6.2 Introduction 
Delay in the diagnosis of inflammatory bowel disease (IBD) and in particular Crohn’s 
disease, is common. Overall, about one-third of patients report symptoms for more 
than a year before a diagnosis of IBD is made.18,230,286–288 Timely diagnosis of IBD is 
important because earlier use of biologic therapies leads to mucosal healin125,127,128, 
a reduction in hospitalisations and surgeries289,290, and improvements in quality of 
life.235  
 
Contemporary studies of the time to IBD diagnosis from the United Kingdom (UK), 
where healthcare is free at the point-of-access and general practitioners (GPs) act as 
gatekeepers to secondary care services, are lacking.286 Most patients who present to 
primary care with gastrointestinal symptoms will have a functional gut disorder and 
only a minority will have IBD.220,221,223 Distinguishing between irritable bowel syndrome 
(IBS) and IBD, even in the presence of red-flag symptoms is difficult, and misdiagnosis 
is common.251,291 Faecal calprotectin is a National Institute for Health and Care 
Excellence (NICE) endorsed biomarker that helps physicians rule out IBD, and is 
increasingly being used in primary care.214,241 However, few studies have assessed 
whether the use of calprotectin in primary care helps avoid a delay to the diagnosis of 
IBD.    
3.6.2.1 Objectives 
We aimed to define the clinical and laboratory factors associated with a delay to 
diagnosis of IBD. We hypothesised that primary care calprotectin testing would reduce 
the time to diagnosis and that diagnostic delay would be associated with a more 
complicated disease course.   
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3.6.3 Methods 
3.6.3.1 Study design and clinical setting 
We designed a prospective observational cohort study to identify factors associated 
with a prolonged time to diagnosis of IBD. The Royal Devon & Exeter (RD&E) NHS 
Foundation Trust provides secondary care services to a locality that comprises 49 GP 
practices covering a population of 378,000 people in the South West of England, UK. 
GPs refer patients with gastrointestinal symptoms to either gastroenterology or 
surgical services.292 
 
We introduced a new calprotectin-based primary care referral pathway for patients 
with suspected IBD in 2014.272 In brief, calprotectin testing was encouraged, but not 
mandated, to stratify referrals of patients reporting new gastrointestinal symptoms, to 
secondary care. We report data related to the time to diagnosis of IBD made between 
January 2014 and December 2017.  
3.6.3.2 Inclusion & exclusion criteria 
Each patient was diagnosed with IBD by their gastroenterologist using standard 
endoscopic, histological and/or radiological criteria. Patients who first presented to 
their GP with gastrointestinal symptoms after January 2014 were eligible for inclusion. 
Patients aged less than 18 years old and those diagnosed with IBD at other centres 
were excluded.  
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3.6.3.3 Primary outcome  
Time to diagnosis was defined as the time from onset of patient symptoms to diagnosis 
of IBD by endoscopy and/or imaging. We divided this into three subintervals: the time 
from symptom onset to first GP presentation; the time from first GP presentation to GP 
referral; and the time from GP referral to IBD diagnosis. Delay was defined as a time 
to diagnosis greater than the upper quartile and was calculated for each sub-interval: 
hereafter referred to as patient, primary and secondary care delays. 
3.6.3.4 Variables and data acquisition 
Identification of patients with IBD 
We searched our IBD database for new cases of IBD diagnosed after 2014. Checks 
were made, using free-text searches of both our endoscopy (Unisoft Medical Systems, 
Enfield, UK) and histology databases (Swift Integrated Healthcare Solutions DXC 
Technology Company, Virginia, US) to identify cases not registered in our database.  
Data was extracted from primary and secondary care records into a purpose designed 
electronic database in REDCap (Vanderbilt University Medical Centre, Tennessee, 
US).  
 
Patient delay variables   
We recorded demographic data (age at IBD diagnosis, sex, ethnicity, family history of 
colorectal or ovarian cancer, family history of IBD, home postcode at diagnosis and 
smoking history), presenting symptoms at the time of first GP presentation and IBD 
phenotype according to the Montreal Classification.71 Patient income deciles were 
estimated using data from the English Indices of Deprivation 2015 and patients’ 
postcodes.293 
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Primary care delay variables 
Blood (full blood count, urea and electrolytes, liver function tests, C-reactive protein 
[CRP], tissue transglutaminase, vitamin B12, folate and ferritin) and faecal biomarker 
tests (faecal calprotectin, microscopy culture and sensitivity) within 28 days of GP 
referral were captured using secondary care electronic pathology records.  
 
Secondary care delay variables  
Electronic records and patient notes were used to capture the priority category 
assigned to each referral to secondary care (routine or two-week wait) and whether 
the patient was referred by their general practitioner or self-presented to secondary 
care emergency services. In our Trust, GP referrals are vetted and triaged by 
gastroenterologists or surgeons to either outpatient clinic review or straight to 
diagnostic test. The following dates prior to diagnosis were recorded: first outpatient 
appointment, emergency hospital presentation (accident and emergency, medical 
assessment unit and/or surgical assessment unit), index endoscopy and cross-
sectional imaging (computerised tomography/magnetic resonance imaging). 
Secondary care work-force capacity was estimated through three proxy measures: 
firstly, by year of diagnosis; secondly, by ascertaining if any given patient’s IBD 
diagnosis occurred within one week either side of a national UK holiday; and thirdly, 
after developing a continuous variable (adjusted outpatient capacity), which reflected 
outpatient gastroenterology capacity between the date of referral and diagnosis (see 
methods in the Supplement).  
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Treatment and complications in the first year after diagnosis 
We captured the following data within the first year of diagnosis:  the number of and 
indication for IBD-related surgeries; IBD-related hospitalisations; and treatment (5-
aminosalicyates, corticosteroids, immunomodulatory therapies [methotrexate, 
thiopurine or ciclosporin], biologics [infliximab, adalimumab, vedolizumab and 
ustekinumab] and exclusive enteral nutrition). Patients were deemed to have 
complicated disease if they had an IBD-related hospital admission and/or IBD-related 
surgery and/or biologic therapy in the first year after their diagnosis.  
3.6.3.5 Statistical methods  
Because this study was designed as a service evaluation a priori power calculations 
were not undertaken: we decided to allow our new calprotectin pathway to become 
established and then assessed its usefulness over three years.  
 
All analyses were conducted in R 3.5.1 (R Foundation for Statistical Computing, 
Vienna, Austria). Analyses were two tailed, and p-values <0.05 were considered 
significant. We excluded patients from individual analyses where relevant data were 
missing and specified the denominator for each variable. Continuous variables are 
reported as median [interquartile range - IQR] and compared with either Mann Whitney 
U or Kruskal-Wallis tests. Categorical variables are summarised as frequencies (%) 
and compared with Fisher’s exact test. Univariable analyses were undertaken to 
identify factors associated with patient-, primary care-, and secondary care delay. We 
also sought factors associated with emergency department presentations and being 
triaged straight-to-test by secondary care specialists. We used stepwise forward and 
backwards multivariable logistic regression models, using Akaike Information Criteria 
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(AIC) scores to compare models and avoid over-fitting, to identify factors 
independently associated with delays in diagnosis. We only included significant 
univariable factors (P < 0.05) with more than 100 observations in our models. 
Continuous data were transformed to a binary categorical variable. Checks were made 
for multi-collinearity using a variance inflation factor (VIF) score of more than 10. 
Collinear variables that added least to our regression models were removed. Results 
are presented as odds ratio (OR) and 95% confidence interval (95% CI). 
3.6.3.6 Ethical consideration 
This quality improvement project was endorsed by primary and secondary care 
Caldicott guardians, the Southwest Academic Health Sciences Network (SWAHSN), 
the Local Medical Council, and the Devon Clinical Commissioning Group. Patients 
were not involved in the conception or design of this study. In accordance with UK 
Health Research Authority guidelines we did not require formal ethical approval.294 
3.6.4 Results 
We report our data according to the flow diagram in Figure 1: 514 adult patients were 
identified as diagnosed with IBD between January 2014 and December 2017. We 
excluded 87 patients because we were unable to define the onset of symptoms, 40 
patients who were not-referred from primary care, and 15 subjects where we unable 
to verify the diagnosis of IBD. Baseline demographics are shown in Supplemental 
Tables 3.5-1 and 3.5-2.  
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Figure 3.6-1. Flow diagram 
 
 
 
Missing dates, missing one or more dates required to calculate three sub-intervals; IBD, 
inflammatory bowel disease; GP, general practitioner; not confirmed IBD, patients diagnosed 
with possible or refuted diagnosis of IBD; RD&E, Royal Devon and Exeter Hospital  
3.6.4.1 Time to diagnosis  
The median time to diagnosis from onset of symptoms was 4.3 months [IQR 2.2 to 
10.7 months]. Over half (60%) of patients were diagnosed within 6 months, 79% within 
12 months and 92% within 24 months of the onset of symptoms. The greatest 
contributor to the overall delay was the time it took patients to present to their GP, with 
a median duration of 2.1 months [IQR 0.9–5.1 months]. In comparison, the median 
time to secondary care referral from the GP was 0.3 months [IQR 0.0–0.9 months] and 
the median time from GP referral to diagnosis 1.1 months [IQR 0.5–2.1 months] 
(P < 0.001). Patients with Crohn’s disease had a longer overall time to diagnosis: UC, 
514
patients identified 
with IBD diagnosed  
2014-2017
Exclusions:
• Missing dates = 87
• Age < 18 years old = 35
• GP visit prior to  01/01/2014 = 19
• Referred by secondary care = 19
• Not confirmed IBD = 15
• Known IBD prior to 2014 = 14
• Transferred care to RD&E = 13
• Private referral = 8
304 eligible 
IBD patients
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3.3 months [IQR 1.9–7.3 months], IBD-U, 3.9 months [IQR 2.0–7.2 months] and 
Crohn’s disease, 7.6 months [IQR 3.1–15.0 months]; P < 0.001) (see Table 3.5-1, 
Figure 3.5-2 and Supplemental Tables 3.5-1 and 3.5-2)  
Table 3.6-1. Time to IBD diagnosis by IBD-subtype 
Subintervals   
Crohn’s 
disease 
n = 94 
IBD-
unclassified 
n = 15 
Ulcerative 
colitis 
n = 195 
P valuea 
Patient delay: time from first 
symptoms to first GP 
presentation (months) [median,  
IQR, range] 
3, 1-7, 0-107 2, 1-5, 0-12 2, 1-4, 0-59 0.017 
Primary care delay: time 
between first GP presentation 
and GP referral (months) 
[median , IQR, range] 
0, 0-1, 0-20 0, 0-1, 0-4 0, 0-1, 0-25 0.26 
Secondary care delay: time 
between GP referral and 
secondary care diagnosis 
(months) [median , IQR, range] 
2, 1-4, 0-13 1, 1-1, 0-4 1, 1-2, 0-27 0.027 
Overall time to diagnosis: 
time from first symptoms to 
secondary care diagnosis 
(months) [median , IQR, range] 
8, 3-15, 0-112 4, 2 - 7, 0-16 3, 2-7, 0-65 <0.001 
IQR, interquartile range; IBD, inflammatory bowel disease 
a P value represents Kruskal-Wallis test  
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Figure 3.6-2. Box plot of intervals constituting time to diagnosis among all 304 
patients by IBD subtype 
CD, Crohn’s disease; UC, ulcerative colitis; IBD-U, IBD-unclassified 
3.6.4.2 Factors associated with emergent IBD diagnoses 
Approximately one-fifth (19%, 58/304) of all new IBD diagnoses from 2014-2018 were 
made following an emergency presentation to hospital: 86% (50/58) patients were 
referred to hospital by their GP whilst 14% (8/58) patients self-presented to the A&E 
department. 
 
Demographic and disease factors associated with either an emergent or a non-
emergent IBD diagnosis are presented in Supplemental Table 3.5-3. Age under 30 
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years old at IBD diagnosis (OR 2.42, 95%CI 1.35 - 4.34), duration of symptoms less 
than 6 weeks (OR 4.97, 95%CI 2.73 - 9.29), abdominal pain (OR 3.15, 95%CI 1.64 - 
6.51), unintentional weight loss (OR 4.10, 95%CI 1.89 – 8.94), anaemia (OR 7.18, 
95%CI 2.70 - 20.51), raised platelet count (OR 6.30, 95%CI 2.20 - 18.79) and raised 
white blood cell count (OR 6.00, 95%CI 1.84 – 20.64) were associated with an 
increased odds of an initial presentation of IBD as an emergency. 
 
In the final multivariable model, duration of symptoms less than 6 weeks and anaemia 
increased the odds of an emergent presentation 8-fold (OR = 8.26, 95%CI 1.77 – 
50.75) and 19-fold (OR 19.01, 95%CI 3.76 – 160.48), respectively (see Table 3.5-2).  
 
A diagnosis of IBD following an emergency hospital admission was associated with 
greater use of corticosteroids (P < 0.001), biologics (P < 0.001) and exclusive enteral 
nutrition (P < 0.001) than non-emergent diagnoses. In contrast the use of 5-ASAs was 
reduced (P < 0.001) and the use of immunomodulators was no different in those with 
an emergent rather than non-emergent diagnosis (P = 0.308). Patients with an 
emergent diagnosis experienced more IBD-related hospitalisations (P < 0.001) after 
the index presentation and surgeries (P < 0.001).   
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Figure 3.6-3. Boxplot of time to diagnosis among all IBD patients by emergent 
and non-emergent diagnosis 
Table 3.6-2. Uni- and multi-variable analysis of factors associated with an 
emergent diagnosis of IBD 
Emergent 
diagnosis of IBD 
variables a 
Univariable analysis Multivariable analyses 
P value OR OR 95%CI P value OR OR 95%CI 
Patient factors       
Aged < 30 yrs at 
IBD diagnosis  
0.003 2.42 1.35 - 4.34    
Patient symptoms       
Duration 
symptoms < 6 wks 
2.5 x10-7 4.97 2.73 - 9.29 0.012 8.26 1.77 - 50.75 
Abdominal pain 0.001 3.15 1.64 - 6.51    
Weight loss 3.4 x10-4 4.10 1.89 - 8.94    
Blood biomarkers       
Presence of 
anaemiab 
1.2 x10-4 7.18 
2.70 - 
20.51 
0.001 19.01 
3.76 - 
160.48 
Raised platelet 
count 
6.9 x10-4 6.30 
2.20 - 
18.79 
   
Raised white blood 
cell count 
0.003 6.00 
1.84 - 
20.64 
   
P < 0.001
1
6
12
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Patient
 Delay
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 Delay
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 Delay
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M
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log
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Referral Route
Emergent referral
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P < 0.001 P < 0.001
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OR, odds ratio; CI, confidence interval; IBD, inflammatory bowel disease 
 a Only factors with n >100 and P < 0.05 shown. See Supplemental Table 3.5-3 for complete UVA.  
b Anaemia threshold (World Health Organisation definition) defined as haemoglobin 
concentration < 120g/L for females and < 130g/L for males 
c Raised platelets defined as platelet count > 400 x109/L 
d Raised white blood cell count defined as > 10.6 x109/L for females and > 11.0 x109/L for males 
3.6.4.3 Factors associated with patient-delay in presentation to primary care 
The median [IQR] patient delay was 2.1 [0.9-5.1] months. Demographic and disease 
factors associated with either timely or delayed patient presentation to their GP are 
presented in Supplemental Table 3.5-4. Reporting abdominal pain (OR 2.47, 95%CI 
1.40 to 4.51), altered bowel habit to diarrhoea (OR 2.81, 95%CI 1.15 to 8.44), 
unintentional weight loss (OR 2.37, 95%CI 1.19 to 4.66), and a higher estimated higher 
household income (OR 1.20, 95%CI 1.24 to 5.34) all increased the odds of a delayed 
patient presentation (see Table 3.5-3). 
 
In the final multivariable model, the odds of a delayed patient presentation were 
increased 2-fold by the presence of abdominal pain (OR 2.11, 95%CI 1.01 to 4.64), 
1.3-fold for every increase in estimated income decile (OR 1.27, 95%CI 1.07 to 1.53), 
and 3-fold by the presence of unintentional weight loss (OR 2.57, 95%CI 1.21 to 5.50), 
and decreased 2-fold by the presence of rectal bleeding (OR 0.45, 95%CI 0.22 to 
0.91).  
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Table 3.6-3. Uni- and multi-variable analysis of factors associated with a 
prolonged time (> 5.1 months) from onset of symptoms to first GP presentation 
Patient delay 
variables a 
Univariable analysis Multivariable analyses 
P value OR OR 95% CI P value OR OR 95% CI 
Patient Factors 
Income  
decile b  0.008 1.2 1.24 - 5.34 0.008 1.27 1.07 to 1.53 
Patient Symptoms 
Rectal bleeding 0.001 0.39 0.22 - 0.67 0.025 0.45 0.22 to 0.91 
Abdominal pain 0.002 2.47 1.40 - 4.51 0.054 2.11 1.01 to 4.64 
Unintentional 
weight loss 
0.013 2.37 1.19 - 4.66 0.014 2.57 1.21 to 5.50 
Altered bowel 
habit-diarrhoea c 
0.038 2.81 1.15 - 8.44 - - - 
OR, odds ratio; CI, confidence interval; IBD, inflammatory bowel disease 
a Only factors with n >100 and P < 0.05 shown 
b Income estimated using patient postcode (see methods) 
c Reference = constipation/no change in bowel habit 
3.6.4.4 Factors associated with primary care delay  
The median [IQR] primary care delay was 0.3 [0-0.9] months. Demographic and 
disease factors associated with either timely or a delayed patient presentation to their 
GP are presented in Supplemental Table 3.5-5. Only duration of symptoms less than 
6 weeks and patient age at diagnosis were significant in both the uni- and multi-
variable analysis and therefore only the latter is described (see Table 3.5-4). In the 
multivariable analysis, for every 10-year increase in age at IBD diagnosis the odds of 
delay were reduced by approximately a third (OR 0.96, 95%CI 0.94 to 0.98). Whereas 
a shorter than 6-week symptom duration prior to GP presentation reduced the odds of 
a primary care delay by approximately 80% (equivalent to 5-fold reduction in odds) 
(OR 0.18, 95%CI 0.08 to 0.36). 
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Table 3.6-4. Primary Care Delay: Uni- and multi-variable factors associated with 
a prolonged time (> 0.9 months) from first patient presentation to GP referral 
Primary care delay 
variables a 
 
Univariable analysis Multivariable analyses 
P value OR OR 95% CI P value OR OR 95% CI 
Patient Factors       
Age at IBD diagnosis  2.8 x10-4 0.97 0.95 - 0.98 2.5 x10-4 0.96 0.94 - 0.98 
Patient Symptoms       
Duration symptoms < 6 
weeks 
9.4 x10-6 0.19 0.08 - 0.37 7.4 x10-6 0.18 0.08 - 0.36 
 
OR, odds ratio; CI, confidence interval; IBD, inflammatory bowel disease 
a Only factors with n >100 and P < 0.05 shown 
3.6.4.5 Factors associated with secondary care delay 
From the point of GP referral, 63%(191/304) of IBD patients were reviewed within 4 
weeks by a hospital specialist. The median [IQR] secondary care delay was 1.1 [0.5-
2.1] months. Demographic and disease factors associated with either timely or a 
delayed secondary care as shown in Supplemental Table 3.5-6. Male sex (OR 0.49, 
95%CI 0.28 to 0.83), family history of IBD (OR 0.23, 95%CI 0.05 to 0.66), duration of 
symptoms < 6 weeks (OR 0.21, 95%CI 0.10 to 0.42), urgent GP referral (OR 0.14, 
95%CI 0.06 to 0.30) and being triaged straight-to-test (OR 0.11, 95%CI 0.06 to 0.21) 
were associated with a reduction in the odds of a prolonged secondary care delay (see 
Table 5).  
 
In the final model, adjusted by workforce capacity, male sex (OR 0.37, 95%CI 0.13 to 
1.02), duration of patient symptoms lasting less than 6 weeks prior to first GP 
presentation (OR 0.14, 95%CI 0.03 to 0.51), urgent GP referral (OR 0.12, 95%CI 0.04 
to 0.35) and being triaged straight-to-test (OR 0.08, 95%CI 0.02 to 0.25) were 
associated with a reduction in the odds of secondary care delay. 
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Table 3.6-5. Secondary Care Delay: Univariable and multivariable factors 
associated with a prolonged time (>2.1 months) from GP referral to diagnosis 
Secondary care delay 
variables a Univariable analysis Multivariable analyses 
 P value OR OR 95%CI P value OR OR 95%CI 
Patient factors       
Male sex 0.008 0.49 0.28 - 0.83 0.058 0.37 0.13 to 1.02 
Family history IBD  0.017 0.23 0.05 - 0.66 - - - 
Patient symptoms       
Duration symptoms < 
6 weeks 
2.4 x10-5 0.21 0.10 - 0.42 0.007 0.14 0.03 to 0.51 
Change in bowel habit-
diarrhoea 
0.030 0.46 0.23 - 0.94 - - - 
Primary Care Factors       
Urgent GP referral b 1.6 x10-6 0.14 0.06 - 0.30 1.4 x10-4 0.12 0.04 - 0.35 
Secondary Care 
Factors       
Straight-to-test 1.1 x10-11 0.11 0.06 - 0.21 4.9 x10-5 0.08 0.02 - 0.25 
Workforce capacity c 0.418 1 1.00 - 1.00 0.009 1.01 1.00 - 1.01 
 
OR, odds ratio; CI, confidence interval; IBD, inflammatory bowel disease; straight-to-test, 
patients referred by primary care are triaged to go directly to undergo a diagnostic test without 
being seen an outpatient clinic first; GP, general practitioner 
a Only factors with n >100 and P < 0.05 shown 
b Reference = routine referral 
c See supplementary methods, a priori this was included in the multivariable analysis 
 
3.6.4.6 Disease course in patients with a delay in diagnosis 
The median time [IQR] to an overall IBD diagnosis was 4.3 [2.2 to 10.7] months. IBD-
related complications (surgery and hospitalisation) and therapies within the first year 
of diagnosis among patients with either timely or a delayed overall time to diagnosis 
are shown in Supplemental Table 3.5-7. Patients with a delayed time to diagnosis 
were no more likely to receive corticosteroids (P = 0.427), immunosuppressives (P = 
0.105), aminosalicylates (P = 0.101), biologics (P = 1), exclusive enteral nutrition (P = 
0.761), experience more IBD-related hospitalisations (P = 0.149) or undergo more 
surgeries (P = 0.415) than patients with a timely diagnosis.  
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In a post-hoc sensitivity analysis having removed the emergently diagnosed patients, 
there was an association with delayed diagnosis (>2 years from symptom onset) and 
higher IBD-related hospital admissions (P = 0.038) and steroid use (P = 0.043), but 
not IBD-related surgeries (P = 0.356), immunosuppressives (P = 0.117) or biologics 
(P = 0.302) in the first year after diagnosis (see Supplemental Table 3.5-8).  
3.6.4.7 Faecal calprotectin  
Primary care calprotectin was performed in 11% (53/304) of all IBD patients prior to 
their first point of contact with secondary care (see Supplemental Table 3.5-9 and 
Supplemental Figure 3.5-1). Of the 5 patients (2 male, 3 female) with a false negative 
calprotectin (< 100µg/g), 4 were diagnosed with ulcerative colitis, all of whom had 
E1:proctitis (P = 0.021), and 1 with Crohn’s disease (A2: Age <40 yrs; L1:ileal; 
B1:inflammatory); 3 had rectal bleeding and none had either a family history of IBD, 
unintentional weight loss or an elevated CRP (>5 mg/L). Neither primary- nor 
secondary-care delay were increased following a false negative calprotectin: P = 0.761 
and P = 0.429, respectively.  Nor was a positive calprotectin (≥ 100 µg/g) associated 
with a more rapid (< 25th centile) GP referral or secondary care diagnosis. 
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3.6.5 Discussion 
3.6.5.1 Key results 
In this study one-fifth of patients diagnosed with IBD presented emergently, half of 
patients were diagnosed within 4 months of symptom onset and one-tenth of patients 
suffered symptoms for more than 2 years before diagnosis. The time taken for patients 
to present to primary care was the major factor contributing to overall diagnostic delay. 
Uptake of primary care calprotectin testing was low and had no effect on time to 
diagnosis. ‘Urgent’ GP referral and directing patients straight-to-test reduced 
secondary care delay independently of temporal changes in workforce capacity. 
Patients who presented emergently and those whose diagnosis was made after 2 
years were more likely to have a complicated disease course in the year after 
diagnosis.  
3.6.5.2 Interpretation 
The overall time to diagnosis reported here is similar to recent reports from Swiss25, 
American26 and Italian27 cohorts, but longer than reports from other European 
countries5. The reasons for these differences are likely to be complex and related to 
local healthcare pathways, in particular the involvement of primary care physicians in 
the decision to refer, rather than self-referral to a gastroenterologist. We, like others, 
report a longer time to diagnosis in patients with Crohn’s disease compared with either 
ulcerative colitis or IBD-unclassified25–27; an observation possibly explained by the 
presence of rectal bleeding, which is not only reported more commonly in patients with 
ulcerative colitis but also associated with timely GP consultation. 
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The median sub-interval between symptom onset and primary care presentation was 
7-times longer than the time it took GPs to refer patients and twice as long as the time 
it took secondary care services to diagnose referred patients. We have replicated 
previous findings that rectal bleeding and lower GI symptoms are associated with a 
shorter time to presentation.26 It is unclear why we found a seemingly paradoxical 
association with increased patient delay with weight loss and abdominal pain. Perhaps 
the latter reflects the widespread public assumption, especially in younger patients 
that abdominal pain is likely to be due to a functional gut disorder.2,28 Arguably, as 
secondary care clinicians we are unable to influence patient or primary care delay.  
 
The uptake of faecal calprotectin testing, limited in clinical practice to patients under 
the age of 46 years, was low, and we were under-powered to answer whether 
calprotectin influences time to diagnosis. However, we report that referrals triaged 
straight-to-test were associated with a reduced time to diagnosis, and in common with 
previous work, that the wider use of faecal calprotectin and/or faecal 
immunohistochemical testing (FIT) to triage patients straight-to-test may reduce the 
time to diagnosis.29,30 
 
To our knowledge, we are the first adult UK study to report the frequent GP-directed 
emergent referral of suspected IBD through medical and surgical assessment units. 
This emergent cohort had a higher inflammatory burden with a more extensive and 
complicated phenotype at presentation.  Consequently, this cohort were more likely to 
experience IBD-related surgery, IBD-related hospital admission and receive treatment 
with immunosuppressive and biologic therapies in the year after diagnosis.   
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3.6.5.3 Limitations/Strengths 
Our study has several strengths: first, to our knowledge this is the largest 
contemporary adult UK study to identify factors associated with delays at each of the 
constituent stages that make-up ‘overall time to IBD diagnosis’. Second, we captured 
primary care data using GP records in order to accurately establish the date of first 
GP presentation, reducing recall bias and inaccuracies. Further work across this 
primary and secondary care interface should be encouraged and is to the advantage 
of all stakeholders, but particularly patients. Second, we adjusted our findings using a 
novel proxy for workforce capacity, a strong confounder that undermines many other 
previous similar studies.  
 
However, we also note some limitations: although we electronically interrogated 
hospital pathology records, enabling the assimilation of millions of data-points, the 
exclusion of both blood and faecal tests prior to 28 days of GP referral and also 
variables with less than 100 observations, may have limited our power to detect 
association with these parameters. Second, it is unclear whether the date of symptom 
onset reflects an underlying inflammatory or functional gut disorder36, although this 
limitation is shared by all similar studies. Third, in common with most UK primary care 
calprotectin pathways37,38, we discourage use of this biomarker in older patients who 
constituted one third of our inception cohort. However, limiting our analysis to younger 
calprotectin-eligible patients would have been to the detriment of the objectives and 
generalisability of this study.  
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3.6.5.4 Generalisability  
Whilst we accept that time to diagnosis depends on healthcare provision in a locality, 
our principle findings are likely to be generalisable to most hospitals in the UK. 
Pressures on NHS services are increasing, and we believe that observations such as 
the GP referral of one-fifth of patients as emergency admission, secondary care 
triaging of over half of newly diagnosed patients straight-to-test and our failure to 
review a third of suspected IBD referrals within the 4-week recommended timeframe 
reflect this.39,40 In this regard our performance is in line with over a quarter of UK 
gastroenterology services surveyed in the 2014 UK IBD audit.41 Even centres who met 
this target in 2014 might have struggled to meet it more recently as reflected by 2018 
NHS performance indicators.42 We note a few possible differences between our local 
secondary care service and others nationally, and, indeed internationally, which may 
aid interpretation of our findings: first, in comparison with other larger UK cities, the  
Royal Devon and Exeter Hospital serves an ethnically homogenous white population 
and the time to presentation and utilisation of healthcare services in other populations 
may differ.43 Second, in comparison with national data we report a relatively low 
endoscopy waiting time for diagnostic flexible sigmoidoscopy and colonoscopy:10 
weeks.295,296 In comparison, in April 2019,  the proportion of NHS patients waiting 
longer than 6 weeks for a diagnostic colonoscopy or flexible sigmoidoscopy was 
10.9% and 7.4%, respectively.44 Third, we report relatively high use of biologics with 
34% of Crohn’s disease and 9% of ulcerative colitis/IBD-unclassified patients receiving 
such treatment in the first year from diagnosis.  In comparison, the EPI-IBD inception 
cohort, which comprised data from 22 European countries between 2010-2015, 
reported that approximately 16% of Crohn’s and 4% of ulcerative colitis patients 
received biologic treatment in the year after diagnosis.4,34 As these therapies have 
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been shown to reduce hospitalisation and complications, other hospitals with lower 
use of such therapies may report different outcomes.  
3.6.5.5 For the future 
Diagnostic delay can be considered to have patient-, primary care- and secondary 
care- related components. Our data lend strong support to the need for raising 
awareness about the importance of seeking medical attention for new lower GI 
symptoms among members of the general public. Targeting adolescents and young 
adults seems to be particularly important given the more complicated disease in this 
cohort. Prompt patient-GP consultation is not only important for the early diagnosis of 
IBD, but more widely for the diagnosis of colorectal cancer which is rising most rapidly 
in patients aged 20-29 yrs old.45 Application of faecal biomarkers in the ‘low risk but 
not no risk’ group (NICE; NG1246) may help stratify appropriate onward GP referral.47–
49 Furthermore, more widespread early use of calprotectin and blood tests, where 
diagnostic uncertainty exists, in primary care patients not meeting acute severe IBD 
parameters may save money and aid appropriate triaging to secondary care 
services.29,50
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3.6.6.1 Faecal Calprotectin Pathway 
We introduced primary care calprotectin in January 2014 based on 2013 NICE 
(DG11)18 guidance to all 49 local and encouraged GPs to use this test in all patients 
with lower GI symptoms aged under 46 years old where they suspected, but were not 
confident in a diagnosis of IBD. Calprotectin use was therefore not mandated prior to 
GP referral.  Although we have now modified our calprotectin pathway based on recent 
data21, the following thresholds were used during the time of data collection: 
calprotectin ≥100 µg/g = positive, calprotectin 50-99 µg/g = intermediate and 
calprotectin <50 µg/g = negative. GPs were asked to send repeat stool samples from 
patients with intermediate results and second samples considered positive if 
calprotectin ≥50 μg/g. We advised referral of adult patients with a positive calprotectin 
and GP management for negative tests; although GPs were also able to refer patients 
whom they felt required specialist review based on their clinical assessment.  
3.6.6.2 Calculation of ‘workforce capacity’ variable 
Data pertaining to the weekly surplus or deficit of outpatient and endoscopy 
appointments at our centre between 2014 and 2018 were obtained. These data 
provided either a positive (reflecting a surplus of outpatient clinic and endoscopy slots 
relative to referrals for each week) or negative integer (reflecting deficit of outpatient 
clinic and endoscopy slots relative to referrals for each week).  A new variable 
representing shortage in available appointments for each patient between their time 
of referral and diagnosis was calculated from the area under a curve of appointment 
surplus / deficit. The area was approximated using the trapezium rule for numerical 
integration, with endpoints (time of referral and diagnosis) linearly interpolated using 
neighbouring points. Only area below the x axis was considered; a surplus of 
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outpatient appointments reflected by areas above this line (y>0) were deemed 
clinically irrelevant as any referral could have been instantly offered a slot, regardless 
of whether for example 1 or 10 slots were available. The area was then divided by the 
time between referral and diagnosis. The variable, called the adjusted workforce 
capacity therefore represents the average deficit each day in that time period. This is 
illustrated for a hypothetical patient in Supplementary M Fig 1 below. 
Supplementary M.Fig 1: Hypothetical workforce capacity variable assessment
 
Patient was referred on day 21 (21st January 2014) and diagnosed on day 69 (10th of March). The plot 
shows the surplus / deficit (blue) with date of referral (red) and date of diagnosis (yellow) annotated. 
The area used is shaded area in grey, and divided by the time between referral and diagnosis to give 
the ‘adjusted workforce capacity variable’ 
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Supplemental Figures 
Supplementary Table 3.6-1. Calprotectin results among all IBD patients 
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Supplemental Tables 
Supplementary Table 3.6-2. Overall cohort demographics, delay and 
complications 
Variable Level Value 
Sex Female 145/303 (47.9%) 
Ethnicity White  288/304 (94.7%) 
Age at IBD diagnosis (years)  36.3 (26.8 - 52.5) 
Family history of IBD  38/268 (14.2%) 
Family history of bowel/ovarian cancer  20/250 (8.0%) 
Income decile  6.0 (5.0 - 8.0) 
Smoking status Current smoker 45/303 (14.9%) 
IBD subtype 
CD 94/304 (30.9%) 
IBDU 15/304 (4.9%) 
UC 195/304 (64.1%) 
UC extent 
E1: proctitis 88/204 (43.1%) 
E2: left-sided 64/204 (31.4%) 
E3: total 52/204 (25.5%) 
CD location 
L1: ileal 46/95 (48.4%) 
L2: colonic 20/95 (21.1%) 
L3: ileocolonic 29/95 (30.5%) 
CD behaviour 
B1: inflammatory 74/93 (79.6%) 
B2: stricturing 10/93 (10.8%) 
B3: penetrating 9/93 (9.7%) 
Perianal CD  8/94 (8.5%) 
Patient delay (months)  2.1 (0.9 - 5.1) 
Primary care delay (months)  0.3 (0.0 - 0.9) 
Secondary care delay (months)  1.1 (0.5 - 2.1) 
Overall time to diagnosis (months)  4.3 (2.2 - 10.7) 
IBD-related hospitalisation  One or more 65/295 (22.0%) 
IBD-related surgery  One or more 4/279 (1.4%) 
Treatment in the first year after diagnosis 
Corticosteroids 159/295 (53.9%) 
Immunomodulator 83/295 (28.1%) 
Aminosalicylate 180/295 (61.0%) 
Biologic 50/295 (16.9%) 
 CD, Crohn’s disease; UC, ulcerative colitis; IBD, inflammatory bowel disease 
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Supplementary Table 3.6-3. Comparing demographics, symptoms at initial GP 
presentation, blood and stool tests, primary care factors, secondary care 
factors and complications among IBD subtypes 
Supplemental Table 3.5-3 continued…  
Variable N Level 
Crohn’s 
disease 
n = 94 
IBD-
unclassified 
n = 15 
Ulcerative 
colitis 
n = 195 
P 
value 
Demographics 
Sex  303 Female 50/94 (53.2%) 3/15 (20.0%) 92/194 (47.4%) 0.055 
Ethnicity 304 White  91/94 (96.8%) 14/15 (93.3%) 183/195 (93.8%) 0.458 
Age at IBD 
diagnosis  304 Years 
32.1 
(24.4 - 45.4) 
42.4 
(37.7 - 52.1) 
37.9 
(27.7 - 54.1) 0.053 
Family history 
of IBD 268  8/83 (9.6%) 7/14 (50.0%) 23/171 (13.5%) 0.002 
Income decile 291  7.0 (5.0 - 8.0) 7.0 (5.0 - 7.5) 6.0 (5.0 - 8.0) 0.692 
Smoking 
status 303 
Ex-
smoker 17/94 (18.1%) 5/15 (33.3%) 57/194 (29.4%) <0.001 
 Non-smoker 49/94 (52.1%) 10/15 (66.7%) 
120/194( 
61.9%) 
Smoker 28/94 (29.8%) 0/15 (0.0%) 17/194 (8.8%) 
Symptoms 
Duration 
symptoms  304 Months 3.0 (1.0 - 6.8) 2.0 (1.1 - 4.5) 2.0 (1.0 - 4.0) 0.015 
Rectal 
bleeding 298  36/90 (40.0%) 9/14 (64.3%) 
169/194 
(87.1%) <0.001 
Abdominal 
pain 300  74/93 (79.6%) 8/14 (57.1%) 95/193 (49.2%) <0.001 
Weight loss 226  29/70 (41.4%) 4/10 (40.0%) 19/146 (13.0%) <0.001 
Change 
appearance 291  65/90 (72.2%) 10/15 (66.7%) 
161/186 
(86.6%) 0.004 
Pain improves 
on 
defaecation 
69  8/27 (29.6%) 2/4 (50.0%) 10/38 (26.3%) 0.637 
Number of 
stools 24 hrs 141  4.0 (3.0 - 6.0) 
8.0 (5.5 - 
10.0) 4.0 (3.0 - 7.0) 0.077 
Change stool 
frequency 296  74/89 (83.1%) 13/15 (86.7%) 
167/192 
(87.0%) 0.677 
Nocturnal 
symptoms 163  14/49 (28.6%) 2/10 (20.0%) 19/104 (18.3%) 0.385 
Change bowel 
habit 280 diarrhoea 67/83 (80.7%) 11/13 (84.6%) 
159/184 
(86.4%) 0.458 
Blood and stool tests 
Anaemia 102 see footer 20/37 (54.1%) 0/4 (0.0%) 13/61 (21.3%) 0.001 
Raised CRP  94 > 5mg/L 29/36 (80.6%) 2/5 (40.0%) 21/53 (39.6%) <0.001 
Raised 
platelets  100 
> 400 
x109/L 12/36 (33.3%) 0/4 (0.0%) 8/60 (13.3%) 0.055 
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…continued Supplemental Table 3.5-2 
 N Level 
Crohn’s 
disease 
n = 94 
IBD-
unclassified 
n = 15 
Ulcerative 
colitis    
n = 195 
P 
value 
Raised ferritin 49 see footer 2/14 (14.3%) 1/2 (50.0%) 0/33 (0.0%) 0.012 
Low ferritin 49 see footer 1/14 (7.1%) 0/2 (0.0%) 11/33 (33.3%) 0.151 
Raised WBC 102 see footer 6/37 (16.2%) 1/4 (25.0%) 7/61 (11.5%) 0.419 
Low B12  18 < 180ng/L 1/6 (16.7%) 0/1 (0.0%) 1/11 (9.1%) 1 
Low folate  18 < 3.6µg/L 3/6 (50.0%) 0/1 (0.0%) 0/11 (0.0%) 0.043 
Low ferritin 49 see footer 1/14 (7.1%) 0/2 (0.0%) 11/33 (33.3%) 0.151 
Low albumin  74 < 30g/L 2/26 (7.7%) 1/5 (20.0%) 2/43 (4.7%) 0.306 
Primary Care Factors 
Urgent GP 
referral 148 urgent 24/46 (52.2%) 5/6 (83.3%) 48/96 (50.0%) 0.314 
Secondary Care Factors 
Secondary 
care team 
triaging GP 
referral 
244 surgeons 29/65 (44.6%) 5/12 (41.7%) 103/167 (61.7%) 0.036 
Straight-to-
test 301  45/92(48.9%) 10/15(66.7%) 123/194(63.4%) 0.055 
Time to diagnosis 
Patient delay  304  3.0 (0.9 - 6.7) 2.1 (1.0 - 4.5) 2.1 (0.9 - 3.9) 0.017 
Primary care 
delay  296  0.3 (0.0 - 1.2) 0.3 (0.0 - 0.7) 0.2 (0.0 - 0.8) 0.26 
Secondary 
care delay  296  1.6 (0.6 - 3.7) 0.7 (0.5 - 1.3) 0.9 (0.5 - 2.0) 0.027 
Overall time 
to diagnosis  304  
7.6 (3.1 - 
15.0) 3.9 (2.0 - 7.2) 3.3 (1.9 - 7.3) <0.001 
Complications 
IBD-related 
hospitalisatio
n 
295  34/93 (36.6%) 3/14 (21.4%) 28/188 (14.9%) <0.001 
IBD-related 
surgeries 293  12/92 (13.0%) 1/14 (7.1%) 5/187 (2.7%) 0.003 
Treatment in 
the first year 
after 
diagnosis 
295 
 
Steroids 68/93 (73.1%) 10/14 (71.4%) 81/188 (43.1%) <0.001 
IS 53/93 (57.0%) 5/14 (35.7%) 25/188 (13.3%) <0.001 
5ASA 8/93 (8.6%) 6/14 (42.9%) 166/188 (88.3%) <0.001 
Biologic 32/93 (34.4%) 2/14 (14.3%) 16/188 (8.5%) <0.001 
EEN 14/93 (15.1%) 0/14 (0.0%) 0/188 (0.0%) <0.001 
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Straight-to-test, patients referred by primary care are triaged to go directly to undergo a 
diagnostic test without being seen an outpatient clinic first; GP, general practitioner; WBC, 
white blood cell count; CRP, c-reactive protein IBD, inflammatory bowel disease; EEN, exclusive 
enteral nutrition; IS, immunosuppressive medication (azathioprine, mercaptopurine, 
methotrexate or ciclosporin); 5ASA, 5-aminosalicylate; Steroids, corticosteroids). Data 
displayed as % (n/N) or median (IQR); P value represents Fisher’s exact or Mann Whitney U test 
as appropriate. Anaemia threshold (WHO definition) as haemoglobin concentration < 120g/L for 
females and < 130g/L males. Raised WBC defined as > 10.6 x109/L for females and > 11.0 x109/L 
for males. Raised ferritin defined as > 150ng/mL for females and > 400ng/mL for males. Low 
ferritin defined as < 15ng/mL for females and < 30ng/mL for males. Income decile estimated 
using patient postcode (see methods) 
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Supplementary Table 3.6-4. Demographics, presenting symptoms, biomarkers 
and delay intervals among non-emergently and emergently diagnosed IBD 
patients  
Variable N Level Non-emergent n = 246 
Emergent 
n = 58 P value 
Demographics      
Sex  303 Female 118/246 (48.0%) 27/57 (47.4%) 1 
Ethnicity 304 White  232/246 (94.3%) 56/58 (96.6%) 0.745 
Age at IBD diagnosis  304 Years 38.1 (28.3 - 54.0) 30.0 (22.5 - 43.5) 0.005 
Age < 30 yrs at IBD 
diagnosis 304  72/246 (29.3%) 29/58 (50.0%) 0.003 
Family history of IBD 268  30/218 (13.8%) 8/50 (16.0%) 0.657 
Family history of 
colorectal- /ovarian 
cancer 
250  17/200 (8.5%) 3/50 (6.0%) 0.773 
Income decile 291  7.0 (5.0 - 8.0) 6.0 (5.0 - 8.0) 0.436 
Smoking status 303 Smoker 36/245 (14.7%) 9/58 (15.5%) 0.839 
Symptoms      
Duration symptoms < 
6 weeks 304  68/246 (27.6%) 38/58 (65.5%) <0.001 
Rectal bleeding 298 Yes 179/243 (73.7%) 35/55 (63.6%) 0.139 
Abdominal pain 300 Yes 132/243 (54.3%) 45/57 (78.9%) <0.001 
Weight loss 226 Yes 36/193 (18.7%) 16/33 (48.5%) <0.001 
Change appearance 291 Yes 193/238 (81.1%) 43/53 (81.1%) 1 
Pain improves on 
defaecation 69 Yes 17/63 (27.0%) 3/6 (50.0%) 0.346 
Number of stools in 24 
hours 141  4.0 (3.0 - 7.0) 5.0 (1.5 - 12.0) 0.824 
Change stool 
frequency 296 Yes 211/243 (86.8%) 43/53 (81.1%) 0.282 
Nocturnal symptoms 163 Yes 29/148 (19.6%) 6/15 (40.0%) 0.094 
Change bowel habit 280 Diarrhoea 193/226 (85.4%) 44/54 (81.5%) 0.528 
Blood and stool tests 
Anaemia 102 see footer 17/78 (21.8%) 16/24 (66.7%) <0.001 
Raised CRP  94 > 5mg/L 32/74 (43.2%) 20/20 (100.0%) <0.001 
Raised platelets  100 > 400 x10
9 
/L 9/76 (11.8%) 11/24 (45.8%) <0.001 
Raised ferritin  49 see footer 2/46 (4.3%) 1/3 (33.3%) 0.176 
Low ferritin  49 see footer 10/46 (21.7%) 2/3 (66.7%) 0.144 
Raised WBC  102 see footer 6/78 (7.7%) 8/24 (33.3%) 0.004 
Low B12  18 < 180ng/L 2/17 (11.8%) 0/1 (0.0%) 1 
Low folate  18 < 3.6µg/L 3/17 (17.6%) 0/1 (0.0%) 1 
Low albumin  74 < 30g/L 2/56 (3.6%) 3/18 (16.7%) 0.089 
Faecal calprotectin  53 µg/g 338.0 (223.0 - 1031.8) 
2100.0 (2100.0 - 
2100.0) 0.133 
Raised faecal 
calprotectin  53 > 100µg/g 47/52 (90.4%) 1/1 (100.0%) 1 
 
Supplemental Table 3.5-3 continued… 
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…continued Supplemental Table 3.5-3 
Variable N Level Non-emergent n = 246 
Emergent 
n = 58 P value 
Disease subtype 
IBD subtype  304 
CD 64/246 (26.0%) 30/58 (51.7%) 
< 0.001 IBD-U 12/246 (4.9%) 3/58 (5.2%) 
UC 170/246 (69.1%) 25/58 (43.1%) 
UC extent 204 
E1: proctitis 86/177 (48.6%) 2/27 (7.4%) 
< 0.001 E2: left-sided 49/177 (27.7%) 15/27 (55.6%) 
E3: total 42/177 (23.7%) 10/27 (37.0%) 
CD location 95 
L1: ileal 32/65 (49.2%) 14/30 (46.7%) 
0.616 L2: colonic 12/65 (18.5%) 8/30 (26.7%) 
L3: ileocolonic 21/65 (32.3%) 8/30 (26.7%) 
CD behaviour 93 
B1:inflammat
ory 54/64 (84.4%) 20/29 (69.0%) 
0.072 B2: stricturing 7/64 (10.9%) 3/29 (10.3%) 
B3: 
penetrating 3/64 (4.7%) 6/29 (20.7%) 
Perianal CD 94 Yes 7/64 (10.9%) 1/30 (3.3%) 0.429 
Year of IBD diagnosis 
Year of IBD 
diagnosis 
304 2014 58/246 (23.6%) 19/58 (32.8%) 
0.197 304 2015 82/246 (33.3%) 20/58 (34.5%) 304 2016 78/246 (31.7%) 11/58 (19.0%) 
304 2017 28/246 (11.4%) 8/58 (13.8%) 
Time sub-intervals 
Patient delay  304  3.0 (0.9 - 6.0) 0.9 (0.3 - 2.1) <0.001 
Primary care 
delay  296  0.3 (0.0 - 1.0) 0.0 (0.0 - 0.3) <0.001 
Secondary care 
delay  296  1.3 (0.7 - 2.4) 0.2 (0.0 - 0.6) <0.001 
Overall time to 
diagnosis  304  5.5 (2.8 - 11.9) 1.5 (0.8 - 3.6) <0.001 
Complications 
IBD-related 
hospitalisation 295 One or more 21/243 (8.6%) 44/52 (84.6%) <0.001 
IBD-related 
surgeries 279 One or more 6/242 (2.5%) 12/51 (23.5%) <0.001 
Treatment in the 
first year after 
diagnosis 
295 
Steroids 118/243 (48.6%) 41/52 (78.8%) <0.001 
IS 65/243 (26.7%) 18/52 (34.6%) 0.308 
5ASA 162/243 (66.7%) 18/52 (34.6%) <0.001 
Biologic 32/243 (13.2%) 18/52 (34.6%) <0.001 
EEN 239/243 (1.6%) 42/52 (19.2%) <0.001 
Complicated 
disease in the first 
year after 
diagnosisa 
304  46/246 (18.7%) 45/58 (77.6%) <0.001 
 
Data displayed as % (n/N) or median (IQR); P value represents Fisher’s exact or Mann Whitney 
U test as appropriate. IBD, inflammatory bowel disease; WBC, white blood cell count; CRP, c-
reactive protein; EEN, exclusive enteral nutrition; IS, immunosuppressive medication 
(azathioprine, mercaptopurine, methotrexate or ciclosporin); 5ASA, 5-aminosalicylate; Steroids, 
corticosteroids). Data displayed as % (n/N) or median (IQR); P value represents Fisher’s exact 
or Mann Whitney U test as appropriate. Anaemia threshold (WHO definition) as haemoglobin 
concentration < 120g/L for females and < 130g/L males. Raised WBC defined as > 10.6 x109/L for 
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females and > 11.0 x109/L for males. Raised ferritin defined as > 150ng/mL for females and > 
400ng/mL for males. Low ferritin defined as < 15ng/mL for females and < 30ng/mL for males  
a complicated disease defined as either IBD-related hospitalisation or IBD-related surgeries or 
received biologic drug treatment in the first year of diagnosis 
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Supplementary Table 3.6-5. Patient delay: Patient factors and symptoms 
associated with a prolonged time (> 5.1 months) from onset of symptoms to first 
GP presentation 
Patient Delay 
Variable N Level 
Timely patient 
presentation  
n = 230 
Delayed patient 
presentation  
n = 74 
P value 
Demographics 
 Sex  303 Male 52.8% (121/229) 50.0% (37/74) 0.690 
Ethnicity 304 White  95.2% (219/230) 93.2% (69/74) 0.551 
Age at IBD diagnosis  304 Years 37.0 (27.4 - 52.5) 34.3 (25.6 - 46.5) 0.412 
Family history of IBD 268  14.9% (30/202) 12.1% (8/66) 0.687 
Family history of bowel/ 
ovarian cancer 250  6.4% (12/187) 12.7% (8/63) 0.176 
Income decilea 291  6.0 (5.0 - 8.0) 7.0 (6.0 - 8.0) 0.009 
Income in upper quartile 
(highest earning) 291  14.2% (31/219) 22.2% (16/72) 0.138 
Smoking statusb 303 Current smoker  13.5% (31/230) 19.2% (14/73) 0.258 
 Symptoms 
Rectal bleeding 298  76.9% (173/225) 56.2% (41/73) 0.001 
Abdominal pain 300  54.0% (122/226) 74.3% (55/74) 0.003 
Unintentional weight loss 226  19.1% (33/173) 35.8% (19/53) 0.015 
Change appearance 291  80.3% (175/218) 83.6% (61/73) 0.607 
Pain improves on 
defaecation 69  31.4% (16/51) 22.2% (4/18) 0.556 
Number of stools in 24 
hours 141  4.0 (3.0 - 6.5) 6.0 (3.0 - 8.2) 0.100 
Change stool frequency 296  84.8% (189/223) 89.0% (65/73) 0.442 
Nocturnal symptoms 163  21.3% (26/122) 22.0% (9/41) 1.000 
Change in bowel habit 280 Diarrhoea 82.0% (173/211) 92.8% (64/69) 0.034 
 
Data displayed as % (n/N) or median (IQR); P value represents Fisher’s exact or Mann Whitney 
U test as appropriate. IBD, inflammatory bowel disease 
a Income decile estimated using patient postcode (see methods) 
b Reference = ex-smokers and non-smokers  
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Supplementary Table 3.6-6. Primary Care Delay: Factors associated with a 
prolonged time (> 0.9 months) from first patient presentation to GP referral 
Primary Care Delay 
Variable N Level 
Timely GP referral  
n = 222 
Delayed GP 
Referral 
n = 74 
P value 
Demographics 
Sex  295 Male 55.2% (122/221) 44.6% (33/74) 0.139 
Ethnicity 296 White ethnicity 95.5% (212/222) 93.2% (69/74) 0.540 
Age at diagnosis of IBD 296 Years 41.4 (27.4 - 55.6) 31.7 (24.7 - 37.8) < 0.001 
Family history of IBD 260  13.8% (26/189) 16.9% (12/71) 0.556 
Family history of 
bowel/ovarian cancer 242  8.8% (15/170) 6.9% (5/72) 0.800 
Income decile a 283  6.0 (5.0 - 8.0) 7.0 (5.0 - 8.0) 0.057 
Smoking status 295 Current smoker 14.9% (33/222) 15.1% (11/73) 1.000 
 Symptoms 
Duration symptoms < 6 wks 296  42.8% (95/222) 12.2% (9/74) < 0.001 
Rectal bleeding 290  74.3% (162/218) 65.3% (47/72) 0.172 
Abdominal pain 292  57.5% (126/219) 61.6% (45/73) 0.585 
Unintentional weight loss 221  23.1% (39/169) 23.1% (12/52) 1.000 
Change appearance 283  81.0% (171/211) 81.9% (59/72) 1.000 
Pain improves on 
defaecation 69  29.8% (14/47) 27.3% (6/22) 1.000 
Number of stools in 24 hours 140  4.0 (3.0 - 7.0) 5.0 (3.0 - 8.5) 0.675 
Change stool frequency 288  84.7% (182/215) 89.0% (65/73) 0.440 
Nocturnal symptoms 161  19.2% (24/125) 30.6% (11/36) 0.170 
Change bowel habit 272 Diarrhoea 84.7% (171/202) 84.3% (59/70) 1.000 
Bloods and faecal tests 
Anaemia 99 see footer 27.5% (19/69) 36.7% (11/30) 0.476 
Raised CRP  91 > 5mg/L 51.6% (32/62) 58.6% (17/29) 0.653 
Raised platelets  97 > 400 x109/L 19.1% (13/68) 20.7% (6/29) 1.000 
Raised ferritin  49 see footer 6.5% (2/31) 5.6% (1/18) 1.000 
Low ferritin  49 see footer 16.1% (5/31) 38.9% (7/18) 0.094 
Raised WBC  99 see footer 15.9% (11/69) 6.7% (2/30) 0.333 
Low B12  18 < 180ng/L 0.0% (0/12) 33.3% (2/6) 0.098 
Low folate  18 < 3.6µg/L 25.0% (3/12) 0.0% (0/6) 0.515 
Low albumin  71 < 30g/L 10.0% (5/50) 0.0% (0/21) 0.312 
Faecal calprotectin (µg/g) 53  348.0 (193.5 - 1056.0) 
343.0 (245.0 - 
1073.2) 0.986 
Raised faecal calprotectin  53 > 100µg/g 87.1% (27/31) 95.5% (21/22) 0.389 
 
Data displayed as % (n/N) or median (IQR); P value represents Fisher’s exact or Mann Whitney 
U test as appropriate. IBD, inflammatory bowel disease; WBC, white blood cell count; CRP, c-
reactive protein. Anaemia threshold (WHO definition) as haemoglobin concentration < 120g/L 
for females and < 130g/L males. Raised WBC defined as > 10.6 x109/L for females and > 11.0 
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x109/L for males. Raised ferritin defined as > 150ng/mL for females and > 400ng/mL for males. 
Low ferritin defined as < 15ng/mL for females and < 30ng/mL for males 
a Income decile estimated using patient postcode (see methods) 
 
  
CHAPTER 3: RESEARCH PAPER III: DIAGNOSTIC DELAY 
 
 
 
212 
Supplementary Table 3.6-7. Secondary Care Delay: Factors associated with a 
prolonged time (> 2.1 months) from GP referral to IBD diagnosis  
Variable N Level 
Timely 
secondary care 
diagnosis  
n = 222 
Delayed 
secondary care 
diagnosis 
n = 74 
P value 
Demographics 
Sex  295 Male 57.0% (126/221) 39.2% (29/74) 0.010 
Ethnicity 296 
White 
ethnicity 94.6% (210/222) 95.9% (71/74) 0.769 
Age at IBD diagnosis  296 Years 
38.0 (27.8 - 
53.1) 
32.1 (25.0 - 
50.8) 0.150 
Family history of IBD 260  17.9% (35/196) 4.7% (3/64) 0.008 
Family history of 
bowel/ovarian cancer 242  7.2% (13/181) 11.5% (7/61) 0.291 
Income decile 283  7.0 (5.0 - 8.0) 6.0 (5.0 - 8.0) 0.502 
Smoking status 295 
Current 
smoker 13.1% (29/221) 20.3% (15/74) 0.137 
Symptoms 
Duration symptoms 296 Months 2.0 (1.0 - 4.0) 4.0 (2.0 - 12.0) 0.001 
Duration symptoms < 6 
weeks 296  42.3% (94/222) 13.5% (10/74) 0.001 
Rectal bleeding 290  73.8% (163/221) 66.7% (46/69) 0.283 
Abdominal pain 292  57.8% (126/218) 60.8% (45/74) 0.684 
Weight loss 221  23.8% (40/168) 20.8% (11/53) 0.712 
Change appearance 283  84.1% (180/214) 72.5% (50/69) 0.050 
Pain improves on 
defaecation 69  31.2% (15/48) 23.8% (5/21) 0.580 
Number of stools in 24 
hours 140  4.0 (3.0 - 7.0) 5.0 (3.0 - 6.8) 0.924 
Change stool 
frequency 288  87.2% (190/218) 81.4% (57/70) 0.242 
Nocturnal symptoms 161  19.2% (23/120) 29.3% (12/41) 0.192 
Change bowel habit 272 Diarrhoea 87.3% (179/205) 76.1% (51/67) 0.033 
Bloods and faecal tests 
Anaemia 99 see footer 33.3% (24/72) 22.2% (6/27) 0.334 
Raised CRP  91 > 5mg/L 60.3% (41/68) 34.8% (8/23) 0.052 
Raised platelets  97 
> 400 
x109/L 23.9% (17/71) 7.7% (2/26) 0.089 
Raised ferritin  49 see footer 0.0% (0/37) 25.0% (3/12) 0.012 
Low ferritin  49 see footer 32.4% (12/37) 0.0% (0/12) 0.024 
Raised WBC  99 see footer 18.1% (13/72) 0.0% (0/27) 0.017 
Low B12  18 < 180ng/L 14.3% (2/14) 0.0% (0/4) 1.000 
Low folate  18 < 3.6µg/L 21.4% (3/14) 0.0% (0/4) 1.000 
Supplemental Table 3.5-6 continued… 
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…continued Supplemental Table 3.5-6 
Variable N Level 
Timely 
secondary care 
diagnosis  
n =222 
Delayed 
secondary care 
diagnosis 
n = 74 
P value 
Low albumin  71 < 30g/L 9.3% (5/54) 0.0% (0/17) 0.328 
Faecal calprotectin 
(µg/g) 53  
375.5 (241.5 - 
1129.8) 
328.0 (114.0 - 
435.0) 0.336 
Raised faecal 
calprotectin  53 > 100µg/g 92.5% (37/40) 84.6% (11/13) 0.586 
Primary Care Factors 
Urgent GP referral 148  66.3% (67/101) 21.3% (10/47) < 0.001 
Secondary Care Factors 
Year of IBD diagnosis  296 
2014 26.1% (58/222) 21.6% (16/74) 
0.672  
2015 33.8% (75/222) 35.1% (26/74) 
2016 29.7% (66/222) 28.4% (21/74) 
2017 10.4% (23/222) 14.9% (11/74) 
Referral triaging team c 244 Surgeons 52.8% (93/176) 64.7% (44/68) 0.114 
Straight-to-test 294  71.0% (157/221) 21.9% (16/73) < 0.001 
Diagnosis within 7 days 
of bank holidaya 296  23.0% (51/222) 20.3% (15/74) 0.747 
Workforce capacity 
variable b 293  
104.7 (30.0 - 
217.1) 
151.8 (60.5 - 
211.4) 0.202 
 
Straight-to-test, patients referred by primary care are triaged to go directly to undergo a 
diagnostic test without being seen an outpatient clinic first; GP, general practitioner; WBC, 
white blood cell count; CRP, c-reactive protein. Data displayed as % (n/N) or median (IQR); P 
value represents Fisher’s exact or Mann Whitney U test as appropriate. Anaemia threshold 
(WHO definition) as haemoglobin concentration < 120g/L for females and < 130g/L males. Raised 
WBC defined as > 10.6 x109/L for females and > 11.0 x109/L for males. Raised ferritin defined as 
> 150ng/mL for females and > 400ng/mL for males. Low ferritin defined as < 15ng/mL for females 
and < 30ng/mL for males 
a Bank holidays for England and Wales 
b See supplementary methods 
c Reference = gastroenterology 
d Income decile estimated using patient postcode (see methods) 
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Supplementary Table 3.6-8. Complications in the first year after diagnosis in 
patients with a delayed (> 10.7 months ) and timely overall time to IBD diagnosis 
Overall time to 
diagnosis N Level 
Timely diagnosis 
n = 228 
Delayed 
diagnosis 
n = 76 
P value 
Complications 
IBD-related 
hospitalisation 
295 one or more 24.2% (53/219) 15.8% (12/76) 0.149 
IBD-related 
surgeries 
293 One or more 5.5% (12/218) 8.0% (6/75) 0.415 
Treatment in the 
first year after 
diagnosis 
295 Steroids 52.5% (115/219) 57.9% (44/76) 0.427 
295 IS 25.6% (56/219) 35.5% (27/76) 0.105 
295 5ASA 63.9% (140/219) 52.6% (40/76) 0.101 
295 Biologic 16.4% (36/219) 18.4% (14/76) 0.724 
295 EEN 4.6% (10/219) 5.3% (4/76) 0.761 
Complicated 
disease course in 
first year after 
diagnosisa 
304  29.8% (68/228) 30.3% (23/76) 1.000 
 
IBD, inflammatory bowel disease; EEN, exclusive enteral nutrition; IS, immunosuppressive 
medication (azathioprine, mercaptopurine, methotrexate or ciclosporin); 5ASA, 5-
aminosalicylate; Steroids, corticosteroids) 
a composite outcome for patients who had either IBD-related hospitalisation or IBD-related 
surgeries or received biologic drug treatment in the first year of diagnosis 
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Supplementary Table 3.6-9. Complications in the first year after diagnosis in 
patients with a timely (< 1 year) and delayed (> 2 years) time to IBD diagnosis 
from symptom onset to diagnosis among ONLY NON-EMERGENTLY diagnosed 
IBD patients 
Overall time to 
diagnosis n Level 
Very timely 
diagnosis 
(< 1 yr) 
n = 185 
Markedly 
delayed 
diagnosis 
( > 2 yrs) 
n = 22 
P value 
Complications 
IBD-related 
hospitalisation 204 One or more 7.7% (14/182)  22.7% (5/22)  0.038  
IBD-related 
surgeries 199 One or more 1.6% (3/182) 4.8% (1/21)   0.356 
Treatment in the 
first year after 
diagnosis 
204 Steroids 44.5% (81/182)  68.2% (15/22)  0.043  
204 IS 23.6% (43/182)  40.9% (9/22)  0.117  
204 5ASA 71.4% (130/182)  59.1% (13/22)  0.230  
204 Biologic 11.0% (20/182)  18.2% (4/22)  0.302  
204 EEN 1.6% (3/182)  4.5% (1/22)  0.369  
Complicated 
disease course in 
first year after 
diagnosisa 
207 see footer 15.7% (29/185) 36.4% (8/22)   0.034 
 
Data displayed as % (n/N) or median (IQR). IBD, inflammatory bowel disease; EEN, exclusive 
enteral nutrition; IS, immunosuppressive medication (azathioprine, mercaptopurine, 
methotrexate or ciclosporin); 5ASA, 5-aminosalicylate; Steroids, corticosteroids) 
a composite outcome for patients who had either IBD-related hospitalisation or IBD-related 
surgeries or received biologic drug treatment in the first year of diagnosis 
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Supplementary Table 3.6-10. Demographic, patient symptom, biomarkers, time 
to diagnosis and complications in patients undergoing primary care faecal 
calprotectin prior to diagnosis of IBD  
 
 
 
Supplemental Table 3.5-10 continued … 
  
Variable n Level 
Negative 
(<100µg/g) 
Calprotectin 
n = 5 
Positive 
(≥100µg/g) 
Calprotectin 
n = 48 
P value 
Demographics      
Sex  53 Male 2 (40.0%) 26 (54.2%) 0.658 
Ethnicity 53 White ethnicity 5 (100.0%) 47 (97.9%) 1 
Age at IBD diagnosis  53  26.2 (24.1 - 30.5) 28.5 (23.4 - 33.8) 0.927 
Family history of IBD 53 Yes 0 (0.0%) 11 (22.9%) 0.571 
Family history of 
colorectal- /ovarian 
cancer 
51 Yes 1 (20.0%) 3 (6.5%) 0.347 
Income decile 53  5.0 (4.0 - 7.0) 6.5 (4.0 - 8.0) 0.281 
Smoking status 52 Smoker 0 (0.0%) 6 (12.8%) 1 
Symptoms      
Duration symptoms < 
6 wks 53 Yes 3 (60.0%) 32 (66.7%) 1 
Rectal bleeding 53 Yes 4 (80.0%) 34 (70.8%) 1 
Abdominal pain 49 Yes 0 (0.0%) 11 (25.0%) 0.574 
Weight loss 53 Yes 4 (80.0%) 43 (89.6%) 0.465 
Change appearance 26 Yes 1 (33.3%) 9 (39.1%) 1 
Pain improves on 
defaecation 36  3.0 (2.5 - 4.2) 4.0 (3.0 - 7.0) 0.42 
Number of stools in 24 
hours 53 Yes 4 (80.0%) 45 (93.8%) 0.336 
Change stool 
frequency 39 Yes 0 (0.0%) 11 (30.6%) 0.545 
Nocturnal symptoms 53 Yes 3 (60.0%) 32 (66.7%) 1 
Change bowel habit 45 diarrhoea 4 (80.0%) 40 (100.0%) 0.111 
Blood and stool tests 
Anaemia 31 see footer 0 (0.0%) 7 (24.1%) 1 
Raised CRP  30 > 5mg/L 0 (0.0%) 12 (42.9%) 0.503 
Raised platelets  31 > 400 x10^9/L 0 (0.0%) 4 (13.8%) 1 
Raised ferritin  16 see footer 0 (0.0%) 1 (6.7%) 1 
Low ferritin  16 see footer 0 (0.0%) 4 (26.7%) 1 
Raised WBC  31 see footer 0 (0.0%) 3 (10.3%) 1 
Low B12  5 < 180ng/L 1 (100.0%) 4 (100.0%) NA 
Low folate  5 < 3.6µg/L 1 (100.0%) 4 (100.0%) NA 
Low albumin  21 < 30g/L 0 (0.0%) 1 (5.3%) 1 
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…Supplemental Table 3.5-10 continued 
Straight-to-test, patients referred by primary care are triaged to go directly to undergo a 
diagnostic test without being seen an outpatient clinic first; GP, general practitioner; WBC, 
white blood cell count; CRP, c-reactive protein IBD, inflammatory bowel disease; EEN, exclusive 
enteral nutrition; IS, immunosuppressive medication (azathioprine, mercaptopurine, 
methotrexate or ciclosporin); 5ASA, 5-aminosalicylate; Steroids, corticosteroids). P value 
represents Fisher’s exact or Mann Whitney U test as appropriate. Anaemia threshold (WHO 
definition) as haemoglobin concentration < 120g/L for females and < 130g/L males. Raised WBC 
defined as > 10.6 x109/L for females and > 11.0 x109/L for males. Raised ferritin defined as > 
Variable N Level 
Negative 
Calprotectin  
n = 5 
Positive 
Calprotectin 
n = 48 
P value 
Disease subtype 
IBD subtype  53 CD 1 (20.0%) 16 (33.3%) 1 UC/IBDU 4 (80.0%) 32 (66.7%) 
UC extent 35 
E1: proctitis 4 (100.0%) 8 (25.8%) 
0.021 E2: left-sided 0 (0.0%) 17 (54.8%) 
E3: total 0 (0.0%) 6 (19.4%) 
CD location 17 
L1: ileal 1 (100.0%) 5 (31.2%) 
1 L2: colonic 0 (0.0%) 6 (37.5%) 
L3: ileocolonic 0 (0.0%) 5 (31.2%) 
CD behaviour 17 
B1:inflammator
y 1 (100.0%) 14 (87.5%) 1 B2: stricturing 0 (0.0%) 2 (12.5%) 
B3: penetrating 0 (0.0%) 0 (0.0%) 
Perianal CD 17  0 (0.0%) 2 (12.5%) 1 
Primary Care Factors 
Urgent GP referral 46  2 (40.0%) 26 (63.4%) 0.365 
Secondary Care Factors 
Secondary care team triaging 
GP referral 49 Surgeons 2 (40.0%) 8 (18.2%) 0.267 
Straight-to-test 53  1 (20.0%) 23 (47.9%) 0.362 
Time to diagnosis 
Patient delay  53 Months 0.9 (0.9 - 3.9) 3.9 (2.1 - 6.5) 0.161 
Primary care delay  53 Months 0.7 (0.5 - 0.8) 0.9 (0.5 - 2.4) 0.761 
Secondary care delay  53 Months 1.5 (1.5 - 2.9) 1.3 (0.9 - 2.0) 0.429 
Overall time to diagnosis  53 Months 3.9 (3.2 - 5.1) 7.5 (3.9 - 12.0) 0.224 
Delayed GP referral 53  1/5 (20.0%) 21 (43.8%) 0.389 
Delayed secondary care 
diagnosis 52  1 (20.0%) 14 (29.2%) 1 
Patient in first quartile of 
time to GP referral  52 
Rapid GP 
referral 0 (0.0%) 0 (0.0%) NA 
Patient in first quartile of 
time to secondary care 
diagnosis   
52 Rapid secondary care diagnosis 0 (0.0%) 2 (4.2%) 1 
Complications 
IBD-related hospitalisation 53 One or more 1 (20.0%) 4 (8.3%) 0.403 
IBD-related surgeries 53 One or more 0 (0.0%) 1 (2.1%) 1 
Treatment in the first year 
after diagnosis 
52 
 
steroids 2 (40.0%) 29 (60.4%) 0.638 
IS 1 (20.0%) 16 (33.3%) 1 
5ASA 4 (80.0%) 30 (62.5%) 0.643 
Biologic 0 (0.0%) 8 (16.7%) 1 
EEN 1 (20.0%) 2 (4.2%) 0.262 
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150ng/mL for females & > 400ng/mL for males. Low ferritin defined as < 15ng/mL for females 
and < 30ng/mL for males. Income decile estimated using patient postcode (see methods) 
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3.7 Discussion 
3.7.1  How the chapter addresses the aims and objectives of the thesis 
In the following section I will assess whether each of the objectives were successfully 
addressed by the three calprotectin studies: 
Objective 1: Assess the diagnostic accuracy of faecal calprotectin in 
distinguishing functional gut disorder from IBD in adult and paediatric patients 
in the primary care setting 
 
In adults, the positive and negative predictive values of calprotectin distinguishing IBD 
from functional gut disorder using 100µg/g cut-off were 39% and 99%, respectively; 
the diagnostic accuracy was 90%. In children, the positive and negative predictive 
values for distinguishing IBD from non-IBD using the same 100 µg/g threshold were 
52% and 100%, respectively; the diagnostic accuracy was 93%. By increasing the cut-
off threshold from 50µg/g to 100µg/g I noted an approximate doubling of the positive 
predictive value in both adults and children, with little or no decrease in negative 
predictive value. 14% (7/43) of adult, but none (0/11) of the paediatric IBD patients 
had a false negative test result at this threshold.  
 
These data suggest that faecal calprotectin is a useful biomarker to aid GPs in 
distinguishing IBD from IBS in adults, and IBD from non-IBD in children. In particular, 
the high negative predictive values (NPV) in both cohorts should empower clinicians 
to confidently exclude IBD after a negative test. It is, however, worthwhile noting that 
raising the threshold from the original NICE and manufacturer recommended limit of 
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50µg/g to 100µg/g will lead to some missed diagnoses of IBD, as I report a 14% false 
negative rate.214,238 Reassuringly for the clinician, if not the patient who experiences 
unchecked inflammatory disease, these false negative cases tend to be of milder IBD 
phenotype, where inflammatory burden is lower, and complications are less frequent. 
This observation, however, highlights the importance of GP follow-up of patients with 
negative tests to ensure that symptoms have resolved or improved with treatment; this 
is common practice in primary care and is referred to as ‘safety-netting’.297  
 
Inherent with the exploration of an optimal calprotectin threshold is the trade-off 
between sensitivity and specificity which is best illustrated by the receiver operator 
curve (ROC). ROC curves compare sensitivity versus specificity across a range of 
values for the ability to predict a dichotomous outcome, whereas the area under the 
ROC curve (AUC) is another measure of test performance.298 In adults the AUC for 
distinguishing functional gut disorder from IBD was 0.93 (95%CI 0.88-0.98). In 
children, the AUC for distinguishing IBD from non-IBD was 0.99 (95%CI 0.97-1.0). 
 
If the aim of calprotectin were solely to facilitate the early diagnosis of IBD, one might 
argue that the calprotectin cut-off threshold should be reduced from our recommended 
100µg/g so as to maximise the sensitivity of the test and thus avoid any missed cases 
of IBD. However, this would increase the number of false positive tests requiring 
referral and investigation. Currently endoscopy and gastroenterology departments 
throughout the NHS are struggling to meet the UK Department of Health targets for 
the timely investigation of patients due to the increasing demands of a growing and 
aged population.295,296,299 Reducing the FC threshold may increase the number of 
referrals and paradoxically negatively impact the diagnosis of IBD, cancer and other 
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organic pathology. An equitable balance needs to be found, and this may vary from 
centre to centre. Therefore, I advocate maximising sensitivity and specificity using 
Youden’s method, which estimated the optimal threshold to be 107µg/g and 112µg/g, 
in adults and children, respectively.  
Objective 2: To assess whether faecal calprotectin testing alters primary care 
referral behaviour 
In adults, I estimated that the calprotectin pathway saved 279 referrals over a 17-
month period: 196 referrals saved per year.  In children, 41 referrals were estimated 
to have been saved over the same period: 29 referrals saved per year.  However, I 
found that nearly half of adults (45%, 195/657) and nearly two thirds (60%, 72/121) of 
children who returned a negative calprotectin (≤ 100µg/g) were subsequently referred 
to secondary care gastroenterology services. Of these calprotectin negative referrals 
two-thirds of adults and one in seven children underwent either endoscopic or cross-
sectional radiological imaging. If the adult calprotectin pathway had been rigidly 
adhered to, or perhaps enforced, then a further 254 outpatient appointments might 
have been saved. Whilst neither study was set up as cost-effectiveness analyses, it 
was estimated that in adults the pathway resulted in savings of £160 per patient 
(£52,355 per year) to the point of diagnosis. If complete adherence were achieved, 
the estimated savings would have doubled to £326 per patient - £106,469 saved per 
year. 
 
In adults, these data clearly show that calprotectin altered GP referral behaviour, 
however, a large number of calprotectin negative patients were still referred. I believe 
that this reflects two underlying issues: in some patients, GPs are confident of a 
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diagnosis of functional gut disorder but have either exhausted treatment options or 
believe that further patient reassurance would be helpful; in other patients, GPs 
question the validity of the calprotectin result and refer regardless. This second point 
may reflect the diagnostic uncertainty created by the presence of alarm symptoms, 
which have traditionally been used by GPs to determine the urgency of referral. Such 
symptoms were present in 39% of the adult cohort. Interestingly, as noted by others, 
these alarm symptoms were also reported by 64% of adult patients later diagnosed 
with a functional gut disorder, demonstrating their modest value as a predictor of 
disease.251,300 This creates an interesting dilemma; in order to maximise the impact of 
faecal calprotectin in primary care, I advocate pathway oversight, such that test 
negative referrals are either returned to GP-led care or directed to dietetic 
therapy.241,301  This is a difficult scenario, as such a policy over-rides the clinical 
acumen of responsible primary care clinician who has deemed the patient appropriate 
for referral. Solutions to this impasse require the following: first, a good relationship 
between primary and secondary care physicians that empowers GPs to discuss 
individual patients, thus enabling investigation in exceptional cases; second, 
concomitant use of other biomarkers, as the likelihood of organic pathology is further 
diminished in the presence of  a normal haemoglobin, platelet count and CRP302; and, 
third, a refractory IBS referral pathway for patients in whom first and second line IBS 
managements have failed.  
 
In children, the effect of calprotectin on secondary care referrals was less marked; this 
is consistent with NICE guidance (DG11; 2013214) which recommends that the test is 
only used as, ‘an option to support children suspected of IBD who have already been 
referred for specialist assessment’. However, I observed that only 84% (16/19) of 
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patients with a positive- and 86% (95/1010) with a negative-calprotectin test were 
referred by their GP. This is an interesting example of how the predicted use of a 
biomarker cannot be assumed when rolled out in the real-World, and furthermore, 
reflects how GPs quickly adapt new technology into established patterns of practice. 
In paediatric patients I still advocate secondary care referral of all patients with ongoing 
symptoms regardless of the calprotectin result, and that calprotectin is used to guide 
secondary care prioritisation of clinical review and the need for endoscopic 
investigation.  
Objective 3: To ascertain whether the presence of gastrointestinal alarm 
symptoms altered the performance of the test 
In adult patients, GI alarm symptoms were reported by 39% of patients. The presence 
of these symptoms nearly doubled the PPV at lower calprotectin thresholds (50-
100µg/g) with a more modest effect above 100µg/g. For NPV the opposite was seen, 
at lower thresholds the performance of the tests was very similar in patients with and 
without alarm symptoms; however, at higher thresholds there was a notable but still 
modest increase in PPV seen patients with alarm symptoms.  
 
In paediatric patients, GI alarm symptoms were present in half of the cohort, although 
their impact on the diagnostic accuracy of calprotectin was less clear. At thresholds 
below 70µg/g the presence of alarm symptoms marginally improved the PPV of 
calprotectin when compared to the performance in patients without such symptoms. 
However, at thresholds above 70µg/g the PPV was lower in the presence rather than 
absence of alarm symptoms. This may reflect the difficulty in eliciting such symptoms 
in a paediatric population.   
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Using multivariable logistic regression, I demonstrated that calprotectin increased the 
odds of an IBD diagnosis independently of GI alarm symptoms: in paediatric patients 
(calprotectin could not be used as binary variable as it was a perfect predictor of 
disease), for every 10-fold increase in calprotectin level, the odds of IBD increased 
408-fold (95% CI 32.5 to 37564, P = 3.9 x10-4); whereas, in adult patients a positive 
calprotectin (≥100µg/g) increased the odds of IBD 54-fold (95% CI 23.2-125.2, P < 
0.001). 
 
In the adult cohort, I also looked at diagnostic strategies combining calprotectin with 
GI-alarm symptoms: in adults, the use of calprotectin or GI alarm symptoms to 
determine referral resulted in a notable fall in the PPV when compared with 
calprotectin alone (PPV 39% and 14%, respectively). Whereas, calprotectin and GI 
alarm symptoms raised the PPV when compared with calprotectin alone (PPV 39% 
and 50%, respectively) but unfortunately also reduced the sensitivity, thus missing an 
unacceptable number of IBD cases (Sens 86% and 56%, respectively).  
Objective 4: To ascertain where delays occur in the referral pathway between 
onset of symptoms through primary and secondary care to diagnosis of IBD  
In adults, half of patients were diagnosed within 4 months of symptom onset and one-
tenth of patients suffered symptoms for more than 2 years before diagnosis. The 
greatest component of the time to diagnosis was the time taken for patients to present 
to their GP with symptoms. The median sub-interval between symptom onset and 
primary care presentation was 7-times longer than the time it took GPs to refer patients 
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and twice as long as the time it took secondary care services to diagnose referred 
patients.  
 
Arguably, these data suggest that the most effective way of reducing the delay in IBD 
diagnosis is to focus on timely patient presentation. This might be achieved through 
greater public awareness of gastrointestinal symptoms particularly if severe or 
persistent.230 The recent UK news coverage of the publication by Vuik et al reporting 
the increasing incidence of colorectal cancer in young patients is a great example of 
how this can be achieved.303  
Objective 5: To explore the clinical and laboratory factors which influence time 
to diagnosis in IBD patients, and specifically whether faecal calprotectin 
reduces time to diagnosis 
In adults, the time it took patients to present to their GP (patient delay) was increased 
by the presence of abdominal pain, higher estimated household income and 
unintentional weight loss, but reduced by the presence of rectal bleeding. Ileal Crohn’s 
disease may present with isolated abdominal pain which may incorrectly be attributed 
by patients (and clinicians), as functional rather than inflammatory in aetiology. The 
factors underlying the association of patient delay and unintentional weight loss are 
more difficult to explain. I believe the most likely explanation for this observation is an 
ascertainment bias, whereby this information was elicited more frequently by clinicians 
reviewing patients with long-standing rather than shorter duration symptoms. This 
seems more plausible than a situation in which multiple patients with unintentional 
weight loss actively avoid healthcare consultation. Socioeconomic status has 
previously been linked disparities in the delivery and effectiveness of healthcare for 
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patients with IBD.304 However, a recent French study by Nahon et al failed to identify 
an association between socioeconomic status and diagnostic delay.287 Interestingly, 
we found that a higher estimated household income was associated with an increased 
time to GP presentation. However, again I feel that this result may be confounded: in 
a relatively small city such as Exeter, households with the lowest estimated income 
are geographically co-located and served by high performing GP practices. A 
combination of low waiting times for clinic appointments and highly trained GPs may 
have led to shorter delay to referral for their patients. The reduction in time to 
presentation with rectal bleeding has previously been reported several other cohorts; 
clearly such symptoms lead to health-seeking in most, if not all, patients.230,287,305,306  
 
The time-taken for GPs to refer patients with suspected IBD following a first 
consultation was very short in nearly all patients (median [IQR] = 1.1 months [0.5 - 
2.1]). I report that a shorter time to referral (primary care delay) was associated with 
increasing age at presentation and shorter duration of symptoms prior to presentation. 
These observations likely reflect the higher incidence of IBS as compared with IBD, 
longer duration symptoms being more likely to be of a benign/non-sinister aetiology 
and the poor discriminatory diagnostic performance of clinical symptoms and 
demographics for distinguishing organic from non-organic lower GI disease.16,221,291,307  
 
I also report that independent of estimated workforce capacity, a timely secondary 
care diagnosis was associated with male sex, shorter duration of symptoms, urgent 
GP referral and triage of patients straight-to-test. This last finding is particularly 
interesting and reflects a common pathway used in the NHS to speed up diagnosis 
and reduce workload by directing patients straight-to-endoscopy or imaging. This 
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initiative was originally driven by NHS England’s National Cancer Programme308 and 
has been demonstrated to shorten time to diagnosis of colorectal cancer in the 
UK.309,310  
 
Locally, primary care calprotectin testing was rolled-out to patients < 46 yrs in 2014, 
but initial uptake in the 4-years following was relatively poor: it was used in only one-
quarter of eligible adults, and one-third of children prior to IBD diagnosis between 2014 
and 2017. However, calprotectin is unnecessary in cases of acute severe colitis, who 
should instead be directed towards urgent diagnostic services or emergent care. 
Similarly, a negative calprotectin test is not a prerequisite to confirm a diagnosis of 
IBS; indeed, widespread use of the test in this way would inadvertently result in   
significantly more false positives, and thus negate many of the tests benefits. Zhang 
et al used a decision analytic model to demonstrate that the time to diagnosis for 
patients with IBD could be reduced by 40 days (95% CI 16 to 65) using calprotectin 
compared with standard practice.311 I found no such association with use of 
calprotectin and time to diagnosis in either paediatric or adult cohorts, although both 
analyses were underpowered due to low uptake of the test.  
Objective 6: To investigate whether a delayed diagnosis is associated with a 
more complicated disease course in the first year 
In adult IBD patients, I found no association between diagnostic delay and IBD-related 
hospital admission, IBD-related surgery or advanced therapeutic strategies, such as 
use of immunomodulators and biologics in the first year after diagnosis. This remained 
the case even when I compared complications in rapid- (< 12 months) and very 
delayed- (>2 years) patients. In keeping with other European data17,230,312, I report that 
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approximately 20% of our adult Crohn’s patients had stricturing (B2) and fistulating 
(B3) disease at presentation. This finding reinforces the need to better identify patients 
at risk of developing IBD and to streamline their diagnosis in order to commence early 
disease-modifying therapies. The lack of an association between time to diagnosis 
and complications is explained by the inclusion of emergently diagnosed patients; this 
cohort have a higher inflammatory burden, are more likely to experience a complicated 
disease course and yet have shorter time to diagnosis. When emergently diagnosed 
patients were removed and the analysis repeated in markedly (> 2 yrs to diagnosis) 
and rapidly diagnosed (<12 months to diagnosis) patients, I found that diagnostic delay 
was associated with both IBD-related hospitalisation and the need for corticosteroids 
in the first year after diagnosis, thus supporting my hypothesis that inclusion of the 
emergent cohort biased the original analysis towards the null. 
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3.7.2 The implications for practice  
In light of these data we have redesigned our adult primary care faecal calprotectin 
pathway for the North, East and West Devon catchment area which covers a 
population of approximately 378,000 people (see Appendix A). Advanced plans are 
also in place to extend this pathway to Torbay, which covers an additional population 
of 286,000 people. 
 
This new pathway uses a single calprotectin cut-off of 100µg/g, a direct-to-test option 
in patients with a calprotectin of ≥ 250µg/g, as over two thirds (68%) of patients with 
this level of calprotectin are later diagnosed with IBD and an 8-week GP safety-net 
review of patient symptoms. It is hoped that the time to diagnosis of IBD will be reduced 
by the widespread adoption of the test by GPs at patients’ first presentation.   
 
In patients who present with symptoms of severe colitis (> 6 bloody stools per day and 
pulse > 90 beats per minute or temperature >37.8℃) there is no need to perform 
calprotectin prior to referral.313 Such patients can be emergently directed to secondary 
care services.  
 
We have also appointed a ‘clinical lead’ to oversee the new pathway. Both Turvill et al 
and the National NHS Business Authority recommend initiation of a ‘clinician 
champion’ responsible for, ‘organising support, delivering guidance on the correct use 
of the pathway and leading educational sessions for local stakeholders’.241,314 
Additionally, I think it is also important for the clinical lead to have oversight of 
secondary care endoscopy usage: locally, in 2015-16 (1-year after primary care- and 
8-years after secondary care- calprotectin was introduced) only 20% of routine 
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referrals for diagnostic colonoscopy/flexible sigmoidoscopy in patients < 46 yrs had a 
faecal calprotectin test performed prior to their endoscopy (unpublished data).  I feel 
that the appointment of a clinical lead was probably the main determinant of the 
notable difference in the pathway adherence between the York and Exeter studies: 
90% and 60%, respectively.241,272,315 
  
The predicted cost savings from the initiation of our new pathway have been used to 
pay for a ring-fenced primary care dietician to deliver and oversee specialist 
interventions, such as the FODMAP diet, in patients who have failed first-line IBS 
therapies. The low–fermentable oligo-, di-, and monosaccharide and polyol 
(FODMAP) diet is a two-phased intervention, with strict reduction of all slowly 
absorbed or indigestible short-chain carbohydrates (i.e. FODMAPs) followed by 
reintroduction of specific FODMAPs according to tolerance. In one case series 
evaluating this dietary intervention, 63% of patients reported satisfactory control of 
their IBS after specialist dietetic input with 74% reporting improved quality of life.301 
This provides GPs with an extremely effective second-line option for the treatment of 
refractory IBS and helps to provide equality of services for both patients with IBS and 
IBD.  
 
In 2017, NICE issued guidance (DG30; 2017) supporting use of a new faecal occult 
blood test (FOBT), called the faecal immunohistochemical test (FIT), to replace the 
older and less sensitive guaiac assay.316 This guidance recommended that FIT is used 
to aid referral decisions in patients with lower GI symptoms that did not meet 2-week 
wait criteria. In 2019, the qFIT project was rolled out across Southwest England by the 
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Cancer Alliance: GPs were asked to consider its use in the following ‘low risk but not 
no risk’ patients:317  
• ≥ 50 years old with unexplained abdominal pain or weight loss 
• 50 to 60 years old with changes in bowel habit or iron-deficiency anaemia 
• ≥ 60-year-old with anaemia without iron deficiency 
 
The qFIT age cut-off dovetails nicely with our own Devon calprotectin pathway, such 
that calprotectin and FIT may be used in patients under- and older- than 50 yrs old, 
respectively. FIT performs very similarly to calprotectin in distinguishing IBD from IBS 
and is reportedly cheaper and superior to faecal calprotectin for detecting cancer and 
high risk adenoma.247,264,318 Only time will tell it replaces calprotectin entirely in the 
future. 
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Chapter 4 
4  The role of pharmacogenomics in the delivery of 
precision medicine: avoiding adverse drug 
reactions in IBD  
4.1 Background to the chapter 
This work was published as a book chapter in Biomarkers in Inflammatory 
Bowel Diseases, N. S. Ding, P. De Cruz (eds.) Springer (2019). This particular 
chapter was written by Walker G and edited by Ahmad T.  
4.1.1 Clinical significance of ADRs in IBD  
An adverse drug reaction (ADR) is defined as an appreciably harmful or unpleasant 
reaction resulting from the use of a medicinal product; adverse effects usually predict 
hazard from future administration and warrant prevention, or specific treatment, or 
alteration of the dosage regimen, or withdrawal of the product.319 ADRs result in 
morbidity and mortality as well as placing a significant financial burden on health-care 
resources. In Europe (EU) and North America, they are responsible for between 3.5-
6.5% of all hospital admissions320–322, with a further 10% of ADRs occurring during the 
subsequent hospital stay.320 ADRs are thought to contribute to the deaths of 
approximately 197,000 EU, and 159,000 US citizens annually, which places ADRs as 
one of the top 10 causes of death.2,4,6 It is estimated that EU countries spend 15-20% 
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of their healthcare budgets dealing with the consequences of ADRs and in the UK 
alone this exceeds £500 million per year. 4,6 
4.1.2 Types of ADRs 
Traditionally ADRs have been classified as Type A and Type B. Type A reactions (80% 
of ADRs) are predictable through the known pharmacological mode of action of the 
drug and are often a consequence of an exaggerated on-target effect. They have a 
strong dose relationship such that a dose reduction will usually lead to resolution of 
sequelae (e.g. oral iron and gastrointestinal side effects). Type B reactions (20% of 
ADRs) are off-target interactions, often associated with a high mortality and require 
drug cessation. These ADRs were previously thought to be idiopathic and independent 
of drug dose, however, recent studies have shown that they actually have a complex 
dose relationship324, and many are predictable through knowledge of the underlying 
immunological and genetic aetiology (e.g. thiopurine-induced pancreatitis325). They 
are often referred to as ‘allergic’ or ‘hypersensitivity’ reactions because they involve 
complex interactions of multiple components of the host’s adaptive immune system 
including IgE antibodies, drug-specific T-cells and immune complexes.326–328 Indeed, 
the same drug may activate many different arms of the immune system via different 
pathways.196 A common theme to many hypersensitivity ADRs is the activation of T-
lymphocytes, which occurs in some cases exclusively in patients with a specific human 
leukocyte antigen (HLA) type. Candidate gene studies as well as hypothesis-free 
genome wide association studies (GWAS), have shown a number of HLA associations 
with Type B ADRs, for example, abacavir hypersensitivity [HLA-B*57:01]329, 
carbamazepine hypersensitivity in Caucasians and Japanese [HLA-A*31:01]330,331 
and carbamazepine-induced Stevens-Johnson syndrome in Han Chinese [HLA-
B*15:02]332. However, these studies have shown that the carriage of specific HLA 
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genotype is often not sufficient, nor indeed necessary, to cause an ADR in patients 
exposed to a particular drug. This suggests that other factors such as regulatory T-
cells (T-reg), the cytokine milieu and danger signals caused by tissue damage also 
may also contribute to the development of ADRs.333 
4.1.3 Pharmacogenetic biomarkers of ADRs 
Predictive biomarkers allow the identification of individuals who are more likely to 
respond to a particular therapy.  This response could be a symptomatic benefit, 
improved survival, or an ADR. Predictive biomarkers of ADRs may direct drug-
avoidance, dose-reduction or enhanced monitoring in at risk individuals. 
Pharmacogenetic biomarkers are particularly attractive for the purpose of predicting 
ADRs as they are present at diagnosis and are unaffected by disease phenotype, 
disease activity and other drug therapies. Pharmacogenetic biomarker discovery has 
been made possible by the increasing availability of reliable, cheap high throughput 
genotyping and sequencing platforms. This has led to a rapid expansion in the number 
of publications reporting pharmacogenetic associations, although very few have 
reached clinical practice. The first step towards implementation is independent 
replication and many claimed biomarkers have fallen at this first hurdle. In this review 
we highlight the most promising examples of pharmacogenetic associations for drugs 
used in patients with inflammatory bowel disease (IBD). 
4.1.4 Biomarker discovery 
The essential requirements of an ADR pharmacogenetic biomarker discovery study 
include strict phenotype definitions, a robust assessment of causality and an adequate 
sample size. Rare idiosyncratic drug reactions are notoriously difficult to characterise 
due to the small number of cases available to individual researchers. Therefore, 
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nationwide and global collaboration is essential to build cohorts of sufficient size for 
hypothesis-free genome wide pharmacogenetic studies. Recent efforts of the UK IBD 
pharmacogenetics network334, the international IBD genetics consortium335 and the 
serious adverse events consortium (iSAEC)336 have demonstrated that collaboration 
can successfully deliver sufficient patient numbers to adequately power such studies. 
Strict phenotype definitions allow the inclusion of a homogenous population and work 
by the Phenotype Standardisation Project337 has been instrumental in the effort to 
address this issue. In clinical practice it is often difficult to be certain that an ADR has 
been caused by the drug of interest.  Adjudication is an essential part of ADR 
pharmacogenetic studies; this process maximises the likelihood that symptoms 
experienced by recruited patients are due to the drug rather than other unrelated 
causes.  Case adjudication is typically carried out by an independent panel of clinicians 
using a validated adjudication pathway e.g. the Liverpool Causality Pathway (see 
Figure 4.4-1).338 High quality cases demonstrate a clear temporal relationship with 
drug administration, no other identifiable risk factors for the ADR, including the 
concomitant use of other drugs recognised as causing a similar ADR, and resolution 
of the ADR on drug withdrawal. A positive rechallenge with a second ADR developing 
after re-exposure to the same drug provides even stronger evidence of causality. 
Cases which successfully pass through this adjudication process are sent for 
genotyping using hypothesis-free array and/or exome sequencing or whole genome 
sequencing methodologies. Replication of positive findings in an independent cohort 
is crucial. Particular attention should be paid to minimising population stratification in 
the analysis of data, especially when cases and controls are recruited from populations 
of differing ethnic backgrounds. This confounding factor could lead researchers to 
assume an association with an ADR is present, when in fact this variant is simply more 
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commonly found in patients of one particular ethnicity who are over or under 
represented in either cases or controls.  
Figure 4.1-1: Causality assessment tool 
 
Adapted version of the Liverpool Adverse Drug Reaction Causality Assessment Tool used in 
the adjudication process. Adapted from Gallagher et al. (Gallagher, R.M. et al. Development and 
inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool. PLoS 
One, e28096, 2011). 338 
4.1.5 Overview of gene-drug adverse drug reaction biomarkers in IBD 
4.1.5.1 Adverse reactions to thiopurine drugs, azathioprine and mercaptopurine 
The thiopurines (mercaptopurine and its prodrug azathioprine) are commonly used in 
patients with IBD to maintain corticosteroid-free remission, prevent postoperative 
recurrence and reduce the risk of immunogenicity associated with biologic therapy.  
59% of CD and 33% of UC patients receive thiopurine therapy within the first 5 years 
of diagnosis.339 Despite this widespread use, up to 40-50% of European IBD patients 
have to discontinue therapy, most commonly (~15%) because of the development of 
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one or more ADRs.340,341 Thiopurine-induced ADRs include: pancreatitis (4-7% 
prevalence)342,343; liver injury (3-10%)343–345; myelosuppression (7%)346; GI side 
effects (1-6%)347,348 and a flu-like hypersensitivity reaction (8-12%).24,31  Over recent 
years there has been significant progress in our understanding of thiopurine 
metabolism (reviewed in González-Lama and Gisbert, 2015351) and the mechanisms 
underlying ADRs.   
4.1.5.2 Thiopurine-induced myelosuppression (TIM) 
TIM may occur at any time during thiopurine treatment and whilst most patients are 
asymptomatic, serious opportunistic infections may occur, especially if neutrophils fall 
≤ 1.0x109/L, with an estimated mortality of 1%.340,341 In the 1980’s, Weinshilboum and 
others recognised that TPMT activity in white Europeans followed an autosomal co-
dominant mode of inheritance with a trimodal distribution.352,353 Approximately 89% of 
individuals possess high TPMT activity levels, 11% intermediate activity and 0.3% low 
activity.354  This phenotypic observation correlates with genetic variation in 
the thiopurine S methyltransferase (TPMT) gene, with variant alleles resulting in 
decreased TPMT enzyme activity and higher production of the active 6 thioguanine 
nucleotides (6TGNs), which predispose patients to bone marrow suppression.352,353  
Pre-treatment phenotyping (usually measurement of TPMT activity in red blood cells) 
or genotyping of TPMT is recommended by the European Medicine Agency (EMA)355 
and U.S Food and Drug Administration (FDA)356 and routinely carried out prior to 
initiation of treatment to identify patients at risk of over-production of 6TGNs and 
therefore TIM: in those with reduced TPMT activity, thiopurines are used in reduced 
dose or avoided altogether.357 However, TPMT variants are only found in 25% of TIM 
cases in European populations, suggesting the presence of other genetic and 
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environmental determinants.357,358 In contrast, variant TPMT haplotypes are rare in 
East Asian patients; a population where TIM is particularly prevalent.359–361  Recently, 
Yang et al identified a common variant in NUDT15 associated with myelosuppression 
in East Asians.362 The exact mechanism of action of NUDT15 is still being elucidated, 
however, it is thought to catalyse the hydrolysis of nucleoside triphosphates. Patients 
with defective NUDT15 variants therefore have excessive levels of thiopurine active 
metabolites (thioguanosine triphosphate [TGTP] and DNA-incorporated thioguanine 
[DNA-TG]) and increased host toxicity.363  
4.1.5.3 Thiopurine-induced pancreatitis (TIP):  
Thiopurine-induced pancreatitis is a well-recognised, idiosyncratic, dose-independent 
ADR with an incidence of approximately 4-7% in patients with IBD.342,343  This ADR 
most commonly occurs within the first month after commencement of therapy, and re-
challenge with either AZA or MP usually leads to recurrence of symptoms. Most 
episodes of acute pancreatitis are mild and resolve after the discontinuation of the 
drug, although more severe cases can occur (with local and systemic complications 
of pancreatitis, including death).364 The pathogenesis of thiopurine-induced 
pancreatitis is unknown. We previously reported the first large scale clinical and 
genetic analyses of thiopurine-induced pancreatitis and identified an association with 
a common variant (rs2647087) in the Class II HLA region which tags HLA-
DRB1*07:01.325 In our study we estimated that the odds of developing pancreatitis 
amongst variant carriers was increased 2.5 times for heterozygous and 5 times for 
homozygote patients.  This finding has recently been replicated in a cohort of 373 
azathioprine exposed patients from Canada.365 In this cohort, which included 13 
patients with a history of azathioprine pancreatitis, the risk was highly predictable and 
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genotype dependent: 0.5% for wild type (A/A), 4.3% (OR = 4, 95% CI 1-36, P = 0.044) 
for heterozygous (A/C), and 14.6% (OR = 16, 95% CI 4-145, P = 0.0001) for 
homozygous variant (C/C) patients. Data from our UK study suggests that for every 
1000 patients tested, 77 risk allele homozygotes will be identified, and these 
individuals will have a 17% risk of pancreatitis. If azathioprine/mercaptoprine are 
subsequently avoided in all homozygote risk allele individuals (and we believe most 
clinicians would consider this reasonable), this equates to an overall number needed 
to genotype of 76 patients to prevent one case of pancreatitis.  
4.1.5.4 Thiopurine-induced liver injury (TILI):  
TILI most commonly leads to an asymptomatic hepatocellular liver injury characterised 
by elevated transaminases (alanine aminotransferase [ALT] and aspartate 
aminotransferase [AST]) within the first 12 weeks of treatment, or soon after dose 
escalation.366 This hepatocellular liver injury generally resolves after dose reduction or 
drug cessation.343,367 Less commonly, approximately 1 in 1000 treated patients, 
thiopurines cause a cholestatic liver injury in association with symptoms of jaundice, 
fatigue and itching.367 This ADR often is typically seen between 2-12 months after 
starting treatment and resolves after drug cessation, although some persistent cases 
have been described.367  Finally, after long-term therapy thiopurines rarely lead to 
chronic liver injury  with symptoms and signs of portal hypertension. Histologically such 
cases demonstrate nodular regenerative hyperplasia, sinusoidal dilatation, central 
congestion and injury to sinusoidal endothelial cells suggestive of veno-occlusive 
disease.367–369  
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The enzyme, thiopurine S-methyltransferase (TPMT) inactivates thiopurines to 
methylated metabolites, reducing the production of the active 6-thioguanine 
nucleotides (6TGN). High TPMT enzyme activity may result in a greater 6-
methylmercapopurine (6MMP) production, which has been associated with liver 
toxicity.370,371 In such cases of thiopurine hypermethylation, the use of adjunctive 
allopurinol (a xanthine oxidase inhibitor) has proven effective in shunting thiopurine 
metabolites towards active 6TGN’s without increasing 6MMP levels.372 However, TILI 
may still occur in the absence of elevated 6MMP and 6TGN levels.373 To date, there 
have been no hypothesis-free genome wide association (GWAS) approaches 
employed to investigate the genetic basis of drug-induced liver injury. However, data 
from our study of over 200 patients with thiopurine induced-liver injury using GWAS 
and whole exome sequencing methodologies will be published shortly.  
4.1.5.5 Thiopurine-induced hypersensitivity reactions (THR):  
Thiopurine hypersensitivity reactions are dose independent and occur in 8-12% of 
patients treated with azathioprine and mercaptopurine.342,349,350  Most hypersensitivity 
reactions are mild, presenting with a flu-like illness within the first four weeks of therapy 
and resolve rapidly on drug withdrawal. Symptoms and signs of mild hypersensitivity 
reactions are poorly defined in the literature but include fever, myalgia, arthralgia, 
headache and fatigue often leading to drug cessation. These symptoms can be 
associated with an acute inflammatory response, supported by a rise in serum markers 
e.g. CRP, mimicking active IBD. The mechanism of thiopurine hypersensitivity is 
unknown. It has been proposed that the imidazole component of azathioprine may be 
responsible by binding to endogenous proteins resulting in hapten formation and 
immune activation. This might explain why a small proportion of patients who develop 
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flu-like illness in response to azathioprine therapy are subsequently able to tolerate 
mercaptopurine.374 However, this theory must be challenged as there is no evidence 
to suggest that the syndrome is more common with azathioprine than mercaptopurine 
and a number of patients experience identical reactions to mercaptopurine 
rechallenge. This hypersensitivity syndrome does not appear to be associated with 
TMPT genotype and is not dose related, suggesting an idiosyncratic mechanism.375 
An association with flu-like hypersensitivity to thiopurines and an exonic variant in 
ITPA has been described in a case-control candidate gene study, however, this finding 
has not been replicated.376  Our preliminary data from a genome-wide association 
study suggests the presence of a genetic determinant in the class II HLA region. 
Further work is underway to replicate this finding prior to publication. 
4.1.5.6 Mesalazine-induced nephrotoxicity 
5-Aminosalicylates (5-ASAs) are the most frequently prescribed class of drug to 
induce and maintain remission in patients with mild to moderately active ulcerative 
colitis. The use of these agents in maintenance therapy over decade’s means that 
long-term toxicity is an important consideration. Mesalazine-induced nephrotoxicity is 
rare (incidence of approximately at 0.17 cases per 100 patients per year377) but the 
consequences may be serious including the development of end stage renal failure 
and the need for renal replacement therapy. As a consequence, regular monitoring of 
renal function for the duration of mesalazine treatment is advised by European Crohn’s 
and Colitis Organisation (ECCO), British National Formulary (BNF) and American 
Gastroenterology Society (AGA).111,112,378 Data from our previous work has shown that 
5-ASA-induced nephrotoxicity may present at any age and is characterised 
histologically by chronic tubulointerstitial nephritis.379 In our case control study, median 
CHAPTER 4: BIOMARKERS OF ADVERSE DRUG REACTIONS 
 
 
243 
time to renal injury was three years, following which only 30% of our cohort fully 
recovered renal function, with 10% requiring permanent renal replacement therapy. A 
genome wide association demonstrated association within the HLA region although 
this failed to reach genome wide significance (OR = 2, 95%CI 2–3, P = 1×10−7). 
Limiting the association analyses to the biopsy positive cases significantly 
strengthened the HLA association signal despite the smaller number of cases, with an 
odds ratio 3.1, and a genome-wide significant P-value (P = 4x10-9). The high 
frequency of this single nucleotide polymorphism (SNP) and the low frequency of the 
adverse event limits its clinical utility and we therefore cannot recommend its use in 
guiding treatment choice or monitoring intervals. 
4.1.5.7 Sulphasalazine-induced agranulocytosis 
Sulphasalzine consists of a sulphonamide antibiotic (sulphapyridine) linked via an azo 
bond to 5-aminosalicylic acid (5-ASA). It is rarely used in IBD, aside for maintenance 
treatment of UC patients suffering from IBD associated arthropathy, having largely 
been replaced by 5-ASAs which have a comparatively better side effect profile. 
Sulphasalazine reaches the colon mostly unchanged and is split by gut bacteria at the 
azo linkage, releasing 5-ASA and sulphapyridine.380 Whilst the systemic absorption of 
5-ASA is limited,  a positive correlation exists between serum sulphapyridine 
concentration and both therapeutic efficacy and toxicity.380 The more severe adverse 
drug reactions include, agranulocytosis, liver injury, Stevens-Johnson syndrome 
(SJS) and Toxic Epidermal Necrolysis (TEN). Plasma levels of sulphapyridine are 
influenced by common polymorphisms in genes that encode N-acetyl transferase 2 
(NAT2) and ATP-binding cassette protein G2 (ABCG2).381 Allelic variation at the NAT2 
gene locus determines whether individuals are fast or slow acetylators382 with fast 
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acetylators having lower plasma concentrations.380,383  Prevalence of the slow 
acetylator phenotype shows marked ethnic variation: 40-70% Caucasians and African-
Americans, 10-20% Japanese, >80% Egyptians and certain Jewish populations.384–
386 However, to date, studies involving low patient numbers have mostly failed to detect 
a relationship between NAT2 acetylator status and drug toxicity381,387 and pre-
treatment genotyping of NAT2 or phenotyping of acetylator status is not carried out in 
clinical practice. 
4.1.5.8 Allopurinol-induced severe cutaneous adverse reactions (SCAR) 
Allopurinol a commonly prescribed medication for gout and hyperuricemia, and is 
increasingly used alongside thiopurines in order to reduce thiopurine toxicity or 
increase efficacy in hypermethylators.388,389 Up to 0.4% of patients treated with 
allopurinol suffer severe cutaneous adverse reaction (SCAR) with a mortality rate up 
to 25% including drug reaction with eosinophilia and systemic symptoms (DRESS), 
SJS, or TEN.390 Allopurinol induced SCAR is strongly associated with HLA-B*58:01 
carriage (OR = 165 when compared to allopurinol-tolerant controls).391 This allele is 
rare in Europeans with a 1% carriage rate, but common in Asians, including the Han-
Chinese in whom the PPV of this association is 2% and NPV 100%.392 The clinical 
utility of pre-treatment genetic testing for HLA-B*5801 has been demonstrated in a 
non-randomised trial design using historical data as control.393 Given the high negative 
predictive value of the allele, especially in patients of Asian descent (>99%), the 
clinical and pharmacogenetics implementation consortium (CPIC) states that HLA-
B*58:01 testing could significantly reduce the incidence and risk for allopurinol-
associated SCAR. 394 
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4.1.5.9 Methotrexate-induced mucositis, hepatotoxicity and haematological toxicity 
Methotrexate is a commonly used immunosuppressive agent used in the maintenance 
treatment of IBD. Therapy is frequently limited by side effects including mucositis, 
hepatotoxicity and haematological toxicity. In a meta-analysis of 14 paediatric 
oncology candidate gene studies of ADRs methylenetetrahydrofolate reductase 
(MTHFR) gene polymorphisms were associated with hepatotoxicity and 
haematological toxicity  and mucositis.362 These authors concluded that ‘in children 
with malignancy, genotyping of the MTHFR C677T polymorphism is expected to be a 
useful tool in reducing toxicity and improving outcome in personalised MTX therapy.362 
This is not currently advocated by CPIC (evidence level C/D).395 
4.1.5.10 Calcineurin-induced hypertension and nephrotoxicity 
The calcineurin inhibitors include: ciclosporin, which is used as rescue therapy in acute 
severe ulcerative colitis; and  tacrolimus, which is used to induce and maintain 
remission in patients with ulcerative colitis refractory to systemic corticosteroids.396 
Dosing of ciclosporin and tacrolimus is routinely directed by therapeutic drug level 
monitoring because of their narrow therapeutic index and significant inter-individual 
variability in blood concentrations. The calcineurin inhibitors are metabolised by 
CYP3A5 and genetic variation in this gene contributes to the pharmacokinetic 
variability of these drugs and the risk of developing hypertension.397,398 Data from the 
solid organ and stem cell transplantation literature suggests that CYP3A5 genotype 
based dosing of tacrolimus may allow target tacrolimus levels to be achieved earlier, 
although whether this translates to improved efficacy and reduced toxicity is not 
known.399 Using this algorithm CYP3A5 extensive (*1/*1) or intermediate (*1/*-) 
metabolisers are started with 1.5-2 times the standard dose. To date 
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CYP3A5 genotype directed dosing of calcineurin inhibitors has not be studied in 
patients with IBD.  
4.1.5.11 Anti-TNF induced skin reactions 
The use of anti-tumour necrosis factor (anti-TNF) drugs are associated with the 
development of paradoxical inflammatory skin eruptions in up to 30% of treated 
patients across all disease indications.400,401 Skin manifestations may present after 
many years of anti-TNF treatment and include palmoplantar pustulosis, psoriasis, 
psoriasiform eczema, eczema and xerosis.400 Smoking and obesity have been 
identified as risk factors particularly of palmoplantar psoriasis but these clinical factors 
are not currently used to stratify patients.402–405 Initial treatment of skin lesions includes 
the use of topical steroids in mild-moderate cases (<5% of skin affected), but 10-40% 
of patients fail to respond necessitating anti-TNF drug withdrawal.400,403 Switching to 
an alternative anti-TNF drug does not lead to resolution of skin lesions suggesting a 
class effect for this ADR.403 In contrast, switching out-of-class to ustekinumab (an 
antibody directed against the p40 subunit of IL-12 and IL-23, approved for use in 
psoriasis and Crohn’s disease) has been shown to be effective in the treatment of anti-
TNF induced skin lesions refractory to topical steroids.404,406 Severe skin lesions cause 
patients with inflammatory bowel disease to discontinue anti-TNF therapy. The 
mechanism of anti-TNF induced skin lesions is not well understood but recent data 
suggests that the skin lesions are characterised by infiltration of interferon-γ 
expressing Th1 lymphocytes and IL-17A/IL-22 expressing Th17 cells, with the severity 
of skin lesions correlating with the density of Th17 cell infiltrates.402 It is speculated 
that the Fc region of anti-TNF antibodies bind to Fc-gamma CD64 (Fc-gamma receptor 
I (FcγRI)) and CD16/32 (Fc-gamma receptor III/II (FcγRIII/II)) on monocytes and 
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macrophages triggering secretion of IL-23 which drives Th17 production of IL-17 and 
IL-22 and the development of skin lesions.407 A preliminary small candidate gene study 
has reported association with the rare IL23R variant rs11209026 (p.Arg381Gln) and 
severe anti-TNF induced psoriasiform skin lesions suggesting it might be possible to 
identify patients at risk of adverse skin reactions prior to treatment.402 
4.1.6 Clinical implementation and future clinical use of pharmacogenetic 
biomarkers of ADRs 
The clinical implementation of a genetic association into a pre-treatment test has 
traditionally demanded a randomised controlled trial (RCT) to assess its clinical utility 
and cost-effectiveness. However, these studies are costly, require large sample sizes 
and often fail to deliver consistent actionable results.408 To hold pharmacogenetic 
studies up to the same standards designed to assess drug efficacy may be 
inappropriate and delay translation of research from bench-to-bedside; although 
clearly an appropriate balance is needed.  The greater availability and falling costs of 
whole genome sequencing, (currently less than US$ 1,500)409,410, means that the 
question is increasingly not whether to genotype but how best to utilise existing 
sequence data, perhaps generated at diagnosis or even at birth. 
 
As our knowledge of gene-drug interactions increases this information needs to be 
curated, reviewed and translated into actionable prescribing guidelines for clinicians 
who lack knowledge and confidence of pharmacogenetic testing. This crucial work is 
being supported by bodies such as Clinical Pharmacogenetics Implementation 
Consortium (CPIC)395 and Pharmacogenetics and Pharmacogenomics 
KnowledgeBase (PharmGKB).411  There is a need to integrate genetic data into 
electronic patient systems to help physicians choose and deliver the right drug at the 
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right dose first time for individual patients. A number of genomic prescribing systems 
are being developed by academic institutions. These typically employ a web-based 
portal which displays interactive, patient-specific, pharmacogenomic results in the 
form of a patient-tailored synopsis including prescribing recommendations and 
suggested alternative medications. Finally, the turnaround time for these tests needs 
to be short so that clinicians are able to receive actionable results in a time-frame 
which doesn’t delay the instigation of treatments in the acutely unwell patient.  
  
249 
4.2 The objective(s) of the chapter 
The thiopurines are the commonest immunosuppressive drugs used in the 
maintenance treatment of IBD, although up to one-third of patients have to stop 
treatment due to drug side-effects, including thiopurine-induced myelosuppression 
(TIM).412,413 Pre-emptive dose adjustments based on TPMT genotype, and drug 
avoidance in homozygotes have reduced thiopurine-induced adverse effects without 
compromising desired immunosuppressive therapeutic effects. Whilst this strategy is 
fairly commonplace, it only identifies one-quarter of European patients that suffer 
TIM.357,414 Recently, retrospective studies in East Asian patients have uncovered 
association between variants in nudix (nucleoside diphosphate linked moiety X)-type 
motif 15 (NUDT15) and TIM, although their relevance in European patients in 
unknown.362,363,415 
 
Therefore, in this chapter I set the following objectives:  
 
• Objective 7: To investigate the association between novel genetic variants 
and thiopurine-induced myelosuppression in European patients with IBD 
 
• Objective 8: If genetic variants are present, to explore if the frequency of 
these variants were enriched in those patients with early drug reactions (≤ 8 
weeks from start of maximum dose) 
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It is crucial that this TIM cohort is accurately phenotyped in order to describe the 
morbidity associated with each adverse drug reaction and to uncover any genotype-
phenotype associations.   
 
• Objective 9: explore the clinical phenotype and morbidity related to carriage 
of a TIM associated genetic variant(s) 
 
Finally, I aim to explore the clinical validity of any novel genetic variants; that is, the 
performance of the test including sensitivity, specificity as well as positive and negative 
predictive values in light of disease prevalence. This may aid translation of any positive 
findings into clinical practice.  
 
• Objective 10: To ascertain the clinical validity (e.g. sensitivity, specificity, 
negative and positive predictive values) of genetic testing to identify patients at 
risk of TIM
  
251 
 
4.3 Research Paper IV 
 
 
RESEARCH PAPER IV 
 
‘Association of Genetic Variants in NUDT15 With 
Thiopurine-Induced Myelosuppression in Patients with 
Inflammatory Bowel Disease.’  
 
PUBLISHED: JAMA, (2019) 321(8), p. 773. doi: 
10.1001/jama.2019.0709. 
 
 
Walker, G. J., Harrison, J. W., Heap, G. A et al 
 
  
CHAPTER 4: RESEARCH PAPER IV:THIOPURINE-INDUCED 
MYELOSUPPRESSION 
 
 
 
252 
CHAPTER 4: RESEARCH PAPER IV:THIOPURINE-INDUCED 
MYELOSUPPRESSION 
 
 
 
253 
4.3.1 Key Points 
Question: What genetic variants are associated with thiopurine-induced 
myelosuppression among patients of European ancestry with inflammatory bowel 
disease? 
Findings: In this case-control study that used whole exome sequence data from 961 
thiopurine-exposed patients of European ancestry with inflammatory bowel disease, 
three coding NUDT15 variants, including a 6bp in-frame deletion (odds ratio 38.2), 
were identified that were associated with thiopurine-induced myelosuppression. 
Meaning: Among patients of European ancestry with inflammatory bowel disease, 
variants in NUDT15 were associated with increased risk of thiopurine-induced 
myelosuppression.
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4.3.2 Abstract 
Importance: Thiopurines are commonly prescribed immunosuppressants but their 
use may be limited by myelosuppression. TPMT pharmacogenetic testing identifies 
only 25% at-risk patients of European ancestry. In East Asians, NUDT15 variants are 
associated with thiopurine-induced myelosuppression (TIM). 
Objective: To identify genetic variants associated with thiopurine-induced 
myelosuppression in patients of European ancestry with inflammatory bowel disease 
(IBD). 
Design, Setting, and Participants: Case-control study of 491 patients affected by 
TIM and 679 thiopurine-tolerant unaffected patients who were recruited from 89 
international sites between March 2012 and November 2015. Affected patients were 
verified by an independent panel of clinicians. Genome-wide (GWAS) and exome-
wide association studies (EWAS) of patients of European ancestry were conducted. 
The replication cohort comprised 73 affected and 840 unaffected patients.  
Exposure: Genetic variants associated with TIM.  
Main Outcome and Measures: Thiopurine-induced myelosuppression was defined 
as a  decline in absolute white blood cell count to ≤ 2.5×109/L or decline in absolute 
neutrophil cell count to ≤ 1.0×109/L leading to thiopurine drug dose reduction or 
withdrawal. 
Results: Among 1077 patients (398 affected and 679 unaffected patients) in the final 
analysis (median age at IBD diagnosis 31.0 years [IQR 21.2 to 44.1], 540 [50%] 
women, 602 [56%] Crohn’s disease), 919 patients (311 affected and 608 unaffected 
patients) were included in the GWAS and 961 patients (328 affected and 633 
unaffected patients) in the EWAS analyses. The GWAS confirmed association of 
TPMT (chromosome 6, rs11969064) with thiopurine-induced myelosuppression 
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(30.5% [95/311] affected patients versus 16.4% [100/608] unaffected patients; odds 
ratio [OR] 2.3, 95% CI 1.7 to 3.1; P = 5.2×10-9). The EWAS demonstrated an 
association with an in-frame deletion in NUDT15 (chromosome 13, rs746071566) and 
thiopurine-induced myelosuppression (5.8% [19/328] affected patients versus 0.2% 
[1/633] unaffected patients; OR 38.2, 95% CI 5.1 to 286.1; P = 1.3 × 10-8) which was 
replicated in a different cohort (2.7% [2/73] affected versus 0.2% [2/840] unaffected 
patients; OR 11.8, 95% CI 1.6 to 85.0; P = .03). Carriage of any of three coding 
NUDT15 variants, including the in-frame deletion, was associated with an increased 
risk (OR 27.3, 95% CI 9.3 to 116.7; P = 1.1×10-7) of thiopurine-induced 
myelosuppression, independent of TPMT genotype and thiopurine dose. 
Conclusions and Relevance: Among patients of European ancestry with 
inflammatory bowel disease, variants in NUDT15 were associated with increased risk 
of thiopurine-induced myelosuppression. These findings suggest that NUDT15 
genotyping may be considered prior to initiation of thiopurine therapy; however, further 
study including additional validation in independent cohorts is required.  
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4.3.3 Introduction 
The thiopurines (mercaptopurine and its prodrug azathioprine) are the most commonly 
used immunosuppressive drugs in the management of patients with inflammatory 
bowel disease [IBD]. However, approximately15% of patients develop adverse drug 
reactions that necessitate drug withdrawal.342,346 Thiopurine-induced 
myelosuppression (TIM) has a cumulative incidence of 7% and usually occurs within 
a few weeks of starting the drug.346 Most patients are asymptomatic, but serious 
opportunistic infection may occur and there is an estimated mortality of 1%.346 
 
The enzyme, thiopurine S-methyltransferase (TPMT) converts thiopurines to 
methylated metabolites, reducing the production of the active 6-thioguanine 
nucleotides.370 Genetic variation in the TPMT gene [RefSeqGene NG_012137.2] can 
result in decreased TPMT enzyme activity and higher production of 6-thioguanine 
nucleotides, predisposing patients to bone marrow suppression.346,358,370 Pre-
treatment testing of TPMT is recommended by the US Food and Drug Administration 
(FDA) to identify patients at risk of TIM356. Among patients with reduced TPMT 
activity, the drug may be avoided or the dose reduced.357 However, TPMT variants are 
only found in 25% of TIM affected patients of European ancestry, suggesting the 
presence of other genetic and environmental determinants.357,414 Recently, studies in 
patients of East Asian ancestry362,415 and other populations416–420 have identified 
variants in nudix hydrolase 15 (NUDT15; RefSeqGene NG_047021.1) as risk factors 
for TIM. Although a novel NUDT15 variant (rs746071566, p.Gly17_Val18del) was 
described by Moriyama et al (2017)416 in a single paediatric patient with TIM of 
European ancestry, the association of NUDT15 genetic variation with TIM in this 
population has not been fully evaluated.  
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The primary objective of this study was to investigate the association between genetic 
variants and TIM in patients of European ancestry with IBD. It was hypothesised that 
the frequency of these variants would be increased among TIM affected patients and 
enriched in those with early TIM (≤ 8 weeks from start of maximum dose).346 
 
4.3.4 Methods 
4.3.4.1 Study Design and Setting  
The protocol was approved by the National Research Ethics Committee (11/SW/0222, 
Exeter pharmacogenetic PRED4 program and STB1, Exeter IBD Genetics cohort, 
England). All participants provided informed written consent. A retrospective case-
control study of the association of genetic variants with TIM was designed as part of 
the Exeter pharmacogenetic PRED4 program, which aims to investigate the genetic 
basis of serious adverse drug reactions to drugs commonly used in gastroenterology 
(www.ibdresearch.co.uk).325,379 Both genome-wide (GWAS) and exome-wide 
association (EWAS) platforms were used to investigate common and rare genetic 
variation, respectively.  
4.3.4.2 Study Populations and Case Definition  
Thiopurine-induced myelosuppression cases (affected patients) were recruited from 
82 UK and 7 international sites between March 2012 and November 2015 and not 
followed up after their initial research visit. They were identified through: opportunistic 
clinical encounters; systematic searches of electronic records; recall via the Medicines 
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and Healthcare Products Regulatory Agency (MHRA) Yellow Card Scheme; and by 
direct advertising to patients.  
 
Inclusion criteria included all of the following: diagnosis of IBD; history of thiopurine 
exposure in the seven days prior to onset of TIM; decline in absolute white blood cell 
count to ≤ 2.5×109/L or decline in absolute neutrophil cell count to ≤ 1.0×109/L; treating 
physician concluded that the thiopurine was the likely cause of myelosuppression and 
the dose was reduced or the drug withdrawn. 
 
Investigators at each site completed a custom-designed case report form (eAppendix 
4.3-1 in the Supplement), that captured the following data: patient demographics 
(age, weight, height, ethnicity and smoking history); adverse drug reaction data 
(thiopurine, thiopurine dose, drug start date, drug stop date, full blood count 
parameters before, during and after drug exposure and full blood count normal range 
reference values) and IBD phenotype. Each patient was diagnosed with IBD by their 
gastroenterologist using endoscopic, histological and/or radiological data and 
phenotyped using the Montreal classification. This classifies ulcerative colitis extent 
as: limited to the rectum (E1), distal to the splenic flexure (E2) or proximal to the splenic 
flexure (E3). For Crohn’s disease, patients are categorised by age (years) at disease 
onset (A1: < 17 years, A2: 17 to 40 years or A3: >40 years); location of disease (L1: 
ileal, L2: colonic or L3: ileocolonic) and disease behaviour (B1: non-stricturing and 
non-penetrating, B2: stricturing or B3: penetrating). 
 
Consistent with previous published pharmacogenetics studies,325,379 all recruited 
affected patients were reviewed independently by at least four gastroenterologists and 
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assigned an adjudication category (eAppendices 4.3-2 to 4.3-4, eFigure 4.3-1 and 
eMethods in the Supplement).338 Only patients assigned as definitely or probably 
affected by TIM were included in the discovery and replication analyses. 
 
Thiopurine-exposed controls without TIM (unaffected patients) were identified from the 
Exeter IBD Genetics (IBDGEN) cohort recruited at the Royal Devon & Exeter Hospital, 
UK (additional details appear in the eMethods in the Supplement). In the final 
analysis, only patients with an absolute white blood cell count ≥ 3.0×109/L and an 
absolute neutrophil cell count ≥ 1.5×109/L for the duration of their treatment with a 
thiopurine were included in the final analyses.  
 
The replication cohort met the identical inclusion criteria and included nonoverlapping 
patients from the same central study site (Royal Devon and Exeter Hospital) and 
patients from 4 new sites (Saint-Antoine Hospital in France, University Medical Centre 
Groningen in the Netherlands, Cedars-Sinai Medical Centre in the United States, and 
Massachusetts General Hospital in the United States). Patients at these new sites 
were identified from searches of pre-existing genetics cohorts in April 2017. These 
sites had started recruitment in 2005 (Massachusetts General Hospital and Cedars-
Sinai Medical Centre), 2011 (University Medical centre Groningen), and 2013 (Saint-
Antoine Hospital). 
4.3.4.3 Genetic Analysis  
Details of the genetic data generation and quality control prior to the GWAS and EWAS 
analyses appear in the eMethods in the Supplement. For the  GWAS, 245,185 variants 
were genotyped using the Illumina Infinium G4L Genome-Wide Association Study 
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(GWAS) array (Illumina, San Diego, CA, USA). Patients were excluded if they had 
variants with a call rate of less that 98%, had variants with a minor allele frequency of 
less than 1% or had variants with a Hardy Weinberg equilibrium (HWE) of P < 1×10-6 
in the unaffected patients. Principal component analysis was carried out using 
Genome-wide Complex Trait Analysis v1.24421 with data from the 1000 Genomes 
project.422 Only data from patients clustering with non-Finnish Europeans (NFE) were 
included. This process minimised the potential confounding effects of population 
stratification, which might have resulted in association of variants with TIM when in 
fact the association was with a specific ethnicity, which was by chance over- or under- 
represented among affected patients compared with unaffected patients.   
 
We excluded patients of Finnish ancestry due to their unique genetic background, 
which has occurred as a consequence of the geographical and cultural isolation of this 
population leading to enrichment of some disease-causing gene variants and losses 
of others. Other quality control measures included a sex-mismatch check (a method 
which used X chromosome homozygosity rates to determine sex and identify patients 
for whom the sex recorded in the case report form/phenotype database did not match 
the predicted sex based on genetic data)  and relatedness-checking”(in which sample 
and pedigree integrity were both simultaneously examined by reconciling genomic 
data with self-reported relationships between patients).  
 
After pre-phasing with Eagle2423, imputation with PBWT424 was performed into the 
1000 Genomes Project Phase 3422 reference panel using the Wellcome Trust Sanger 
Imputation Service. Only single nucleotide polymorphisms (SNPs) with a post-
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imputation info score of < 0.85 or minor allele frequency < 0.01 were included. After 
all quality control measures, 6,272,335 variants remained.  
 
For the EWAS, exonic regions were sequenced using the Illumina HiSeq platform 
(150bp paired reads) and reads mapped to the human genome reference sequence 
(GRCh37) using BWA-MEM.425 Each sample was sequenced to an average depth of 
34×, with ∼99% of the targeted regions covered by ≥1×, ∼92% covered by ≥10× and ∼70% covered by ≥25×. Variants with a Hardy Weinberg equilibrium (HWE) P < 1×10-
6 were excluded as were any variants with a genotyping success rate of < 0.98, a read 
depth of < 10× or with a genotype skew P < 5×10-9 (binomial test). For the post quality 
control EWAS quantile–quantile plot (eFigure 4.3-2 in the Supplement). 
4.3.4.4 Statistical Analysis 
Phenotype comparisons: Continuous data were summarised using medians and 
interquartile ranges and compared using Mann-Whitney U tests. The estimate of the 
median of the difference between affected and unaffected patients and its confidence 
interval were also calculated, as implemented in R 3.5.1 (R Foundation for Statistical 
Computing, Vienna, Austria). Categorical data were summarised as the number and 
percentage and compared using Fisher’s exact tests. 
 
Primary analyses: Associations for both the GWAS and EWAS were determined using 
the Fisher exact test implemented in PLINK 1.9. Manhattan plots were generated 
using R to display negative log10 P values at each SNP. A genome-wide significance 
threshold of P < 5×10-8 was deemed significant. Gene burden testing using PLINK-seq 
0.10 and Sequence Kernel Association Tests (SKAT)426 were used to evaluate if an 
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association existed between sets of rare variants across individual candidate genes 
associated with affected patients. Technical validation of variants was carried out 
using Sanger sequencing (see eMethods in Supplement). For the replication cohort, 
case adjudication, genotype data generation, genetic quality control and analyses 
were undertaken using the same platforms and methods as the discovery cohort. 
Replicated variants with a Fisher exact P value < .05 were considered significant. 
 
Exploratory analyses: Having found an association with a variant and TIM, the final 
dataset was examined for any other non-monomorphic variants within this gene 
annotated as ‘missense’ or ‘loss of function’ in the Genome Aggregation Database 
(gnomAD).427 Further missense variants were evaluated using in silico PROtein 
Variation Effect ANalyzer (PROVEAN).428 As the functional significance of this 
modelling is uncertain, only replicated NUDT15 variants and those previously 
described in other thiopurine-induced myelosuppression cohorts362,415 were used in 
subsequent genotype-phenotype, multivariable logistic regression, and clinical 
usefulness analyses.  
 
Combinations of TPMT variants on the same chromosome have been reported as 
haplotypes; these were reconstructed using Eagle2423 and matched to the Clinical 
Pharmacogenetics Implementation Consortium (CPIC) definitions.429 Categorical 
TPMT enzyme activity (i.e. absent; low; normal; high) was measured in red blood cells 
using radiometric high-performance liquid chromatography (HPLC) as part of routine 
clinical practice. The relationship between TPMT haplotypes and enzyme activity was 
determined.  
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Genotype-phenotype interactions were explored using Mann-Whitney U and the 
Fisher exact tests. All statistical tests were two-sided, and a P < .05 was considered 
significant. No adjustment of the P-value was made for multiple comparisons of 
phenotype data. Weight-adjusted dose (mg/kg) was calculated using the following 
formula: [mercaptopurine dose (mg)∙2.08 / weight (kg)], or for azathioprine: 
[azathioprine dose (mg) / weight (kg)]. 
 
A multivariable logistic regression analysis was undertaken to assess the independent 
associations of NUDT15, TPMT, and weight adjusted thiopurine dose with risk of 
myelosuppression. Time to TIM (stratified by genotype) was analysed using Mann-
Whitney U statistics.  
 
The potential for clinical usefulness (sensitivity, specificity, negative and positive 
predictive value) of genotyping for variants associated with TIM was estimated 
according to adapted methods by Tonk et al430 and de Graaff et al431 (see eMethods 
in Supplement). These estimates assumed the following: an overall risk of TIM of 
7%346; either avoidance of drug (reducing risk of TIM to zero) or target dose reduction 
in those people carrying deleterious variants (reducing risk of TIM to that seen in 
patients with the reference haplotype/genotype); the non-Finnish European population 
variant carrier frequency from gnomAD427 and the odds ratio of TIM for the variant in 
multivariable logistic regression analysis. Confidence intervals for the number needed 
to genotype were estimated using 10,000 bootstraps of the case-control cohort and 
randomly generated estimates of the population NUDT15 and TPMT variant carriage 
and TIM rates based on sampling from binomial distributions. For TPMT, detailed 
methods can be found in eMethods in the Supplement.   
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The prevalence of NUDT15 variants in patients of other ancestry was explored using 
all adjudicated affected patients and population data from gnomAD.427  
4.3.5 Results 
4.3.5.1 Study Overview 
Participant flow through the study is shown in Figure 4.3-1. 491 patients with IBD and 
TIM (affected patients) were recruited from 82 UK and 7 international sites between 
March 2012 and November 2015. One UK centre recruited 843 thiopurine-exposed 
patients with IBD and no history of myelosuppression (unaffected patients). Following 
the adjudication process, 1077 patients (398 affected and 679 unaffected patients) 
entered the final analysis.  
 
After assessment using the genetic quality control measures, 70 affected patients 
were excluded (68 for ethnicity, 1 for relatedness, and 1 for sex mismatch) and 46 
unaffected patients were excluded (31 for ethnicity, 13 for relatedness, and 2 for sex 
mismatch). In addition, for the GWAS analysis, 17 affected patients were excluded (10 
due to failure of quality control genotyping and 7 to failure of genotyping) and 25 
unaffected patients were excluded (23 due to failure of quality control genotyping and 
2 to failure of genotyping). Thus, 919 patients (311 affected and 608 unaffected 
patients) were included in the GWAS and 961 patients (328 affected and 633 un- 
affected patients) were included in the EWAS analysis. Replication was conducted in 
73 affected and 840 unaffected patients recruited from 5 international sites. 
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Figure 4.3-1. Flow diagram and study overview 
 
 
TIM, Thiopurine-induced myelosuppression; EWAS, Exome Wide Association Study; GWAS, 
Genome Wide Association Study. Genetic quality control terms: “Sex mismatch”- discrepancy 
between genetically determined sex and phenotype data; “Relatedness”- exclusion of patients 
too closely related to each other; “Ethnicity”-exclusion of patients not of non-Finnish 
European ancestry based on principal component analysis.  
4.3.5.2 Phenotype Comparisons 
There were no differences in sex when comparing affected and unaffected patients 
(female 53.0% [211/398] vs 48.5% [329/679], respectively, P = .17; Table 4.3-1). 
There were no differences when comparing affected and unaffected patients by type 
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of IBD diagnosis: Crohn disease (57.8% [230/398] vs 54.8% [372/679], respectively), 
ulcerative colitis (39.7% [158/398] vs 44.0% [299/679]), and IBD-unclassified (2.5% 
[10/398] vs 1.2% [8/679], P = .12). 
Table 4.3-1. IBD and drug exposure phenotype in adjudication affected patients 
and unaffected patients prior to genomic quality control 
Characteristic Affected patients n = 398 a 
Unaffected patients 
n = 679 a 
Sex   
Female 211 (53.0%) 329 (48.5%) 
Male 187 (47.0%) 350 (51.5%) 
Diagnosis   
Crohn’s disease 230 (57.8%) 372 (54.8%) 
IBD-Unclassified 10 (2.5%) 8 (1.2%) 
ulcerative colitis 158 (39.7%) 299 (44.0%) 
Age at inflammatory bowel disease 
diagnosis (years) 30.1 (19.3 to 43.1) 31.6 (22.2 to 44.7) 
Estimate of difference [95% Confidence 
Interval] 2.3 [0.4 to 4.2] 
Montreal Crohn’s disease classification b    
Age at diagnosis c   
A1: < 17y 52 (22.7%) 23 (7.7%) 
A2: 17-40y 122 (53.3%) 235 (78.3%) 
A3: > 40y 55 (24.0%) 42 (14.0%) 
Location c   
L1: ileal 57 (24.9%) 132 (44.0%) 
L2: colonic 74 (32.3%) 79 (26.3%) 
L3: ileocolonic 98 (42.8%) 89 (29.7%) 
Behaviour d   
B1: non-stricturing and non-penetrating 123 (57.7%) 175 (58.9%) 
B2: stricturing 62 (29.1%) 82 (27.6%) 
B3: penetrating 28 (13.1%) 40 (13.5%) 
Montreal ulcerative colitis /Inflammatory 
Bowel Disease-Unclassified extent e   
E1: limited to the rectum 15 (9.4%) 14 (6.0%) 
E2: distal to the splenic flexure 73 (45.6%) 112 (47.9%) 
E3: proximal to the splenic flexure 72 (45.0%) 108 (46.2%) 
Weight-adjusted thiopurine dose (mg/kg) f 2.07 (1.69 to 2.45) 1.84 (1.48 to 2.19) 
Estimate of difference [95% Confidence 
Interval] -0.24 [-0.32 to -0.17] 
a values represent: n (%) or median [interquartile range] 
b Montreal Classification System from Silverberg MS, Satsangi J, Ahmad T, et al. Toward an 
integrated clinical, molecular and serological classification of inflammatory bowel disease: 
report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Canadian 
Journal of Gastroenterology 2005;19 Suppl A(5):5A-36A. 
c Denominator for affected patients = 229 and for unaffected patients = 300 
d Denominator for affected patients = 213 and for unaffected patients = 297 
e Denominator for affected patients = 160 and for unaffected patients = 234 
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f weight adjusted dose represents the maximum azathioprine equivalent dose prior to 
thiopurine-induced myelosuppression and adjusted for weight (mg/kg): [(mercaptopurine dose 
(mg) x 2.08) / weight (kg)] or [azathioprine dose (mg) / weight (kg)] 
 
There were no differences in behaviour of IBD when comparing affected and 
unaffected patients using the Montreal classification of IBD: B1 (non-stricturing and 
non-penetrating, 57.7% [123/213] vs 58.9% [175/297], respectively), B2 (stricturing, 
29.1% [62/213] vs 27.6% [82/297]), and B3 (penetrating, 13.1% [28/213] vs 13.5% 
[40/297], P = .94). There were no differences in the extent of ulcerative colitis and IBD- 
unclassified when comparing affected and unaffected patients using the Montreal 
Classification system: E1 (limited to the rectum, 9.4% [15/160] vs 6.0% [14/234], 
respectively), E2 (distal to the splenic flexure, 45.6% [73/160] vs 47.9% [112/ 234]), 
and E3 (proximal to the splenic flexure, 45.0% [72/160] vs 46.2% [108/234], P = .46). 
In contrast, affected patients were younger at the time of IBD diagnosis (median, 30.1 
years [IQR, 19.3-43.1 years]) com- pared with unaffected patients (median, 31.6 years 
[IQR, 22.2-44.7 years], P = .02) and received a higher weight- adjusted thiopurine 
dose (median, 2.07 mg/kg [IQR, 1.69- 2.45 mg/kg] vs 1.84 mg/kg [IQR, 1.48-2.19 
mg/kg], respectively, P < .001). In addition, affected patients with Crohn disease were 
more likely to have colonic or ileo-colonic dis- ease than unaffected patients (L1 [ileal]: 
24.9% [57/229] vs 44.0% [132/300], respectively; L2 [colonic]: 32.3% [74/229] vs 
26.3% [79/300], and L3 [ileocolonic]: 42.8% [98/229] vs 29.7% [89/300], P < .001). 
 
Among the 398 affected patients, 143 (36%) episodes of TIM occurred within 8 weeks 
of therapy with the maximum dose of thiopurine (eTable 4.3-1 in the Supplement). 
The median time from commencement of thiopurine to TIM was 28.3 weeks (IQR, 9.0-
81.1 weeks) and the median time from maximum dose of thiopurine to TIM was 14.7 
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weeks (IQR, 5.9-37.9 weeks). Phenotype data for the replication cohort appear in 
eTable 4.3-2 in the Supplement. 
4.3.6 Primary Analyses 
4.3.6.1 GWAS 
Data from 311 affected and 608 unaffected patients (eTable 4.3-3 in the Supplement) 
were included in the GWAS discovery cohort. The association of TIM with TPMT 
(rs11969064) was confirmed (30.5% [95/311] affected patients versus 16.4% 
[100/608] unaffected patients; odds ratio [OR] 2.3, 95% CI 1.7 to 3.1; P = 5.2×10-9) 
(eFigure 4.3-3 in the Supplement). This association was enriched in early (≤ 8 weeks 
of starting maximum thiopurine dose) affected patients (OR 4.0, 95% CI 2.8 to 5.8; 
P = 1.8×10-15 in early and OR 1.6, 95% CI 1.1 to 2.2; P = .01 in late TIM) (eFigure 4.3-
4 in the Supplement). No other genetic associations with TIM exceeded the a priori 
threshold for statistical significance. 
4.3.6.2 EWAS 
Data from 328 affected and 633 unaffected patients were included in the EWAS 
discovery cohort (eTable 4.3-4 in the Supplement). The EWAS, performed to 
investigate the role of rare coding variants, revealed a TIM association with a 6bp in-
frame deletion at position 48611918 of chromosome 13 in exon 1 of NUDT15 
(rs746071566, p.Gly17_Val18del; 5.8% [19/328] of affected patients versus 0.2% 
[1/633] unaffected patients; OR 38.2, 95% CI 5.1 to 286.1; P = 1.3×10-8) (Figure 4.3-
2). The odds ratio for affected patients with early-onset TIM versus unaffected patients 
was 74.2 (95% CI 9.6 to 573.5; P = 8.2×10-10) and late-onset TIM was 20.9 (95% CI 
2.6 to 170.1, P = 4.2×10-4); affected patients with early-onset TIM were significantly 
CHAPTER 4: RESEARCH PAPER IV:THIOPURINE-INDUCED 
MYELOSUPPRESSION 
 
 
 
270 
enriched for the variant (OR 3.6, 95% CI 1.4 to 9.2, P = .005) (eTable 4.3-5 in the 
Supplement).  
Figure 4.3-2. Manhattan plot for the discovery exome-wide association study 
analysis in 328 affected and 633 unaffected patients  
 
 
Each coloured dot represents a single variant within each respective chromosome. The 
negative log10 P value represents a Fisher’s exact analysis between affected and unaffected 
patients. Red dotted horizontal line indicates genome-wide significance at Fisher’s exact P = 
5.0×10-8. Gene names correspond to the gene in closest proximity to the variant with the 
lowest P value at each locus if within 50kbp. 
 
The association of the p.Gly17_Val18del variant and TIM was confirmed in the 
replication analysis: 2.7% (2/73) of affected patients versus 0.2% (2/840) thiopurine-
exposed unaffected patients with IBD (OR 11.8; 95% CI 1.6 to 85.0; P = .03). A 
duplication at this multi-allelic site within NUDT15 (rs746071566, p.Gly17_Val18dup – 
also annotated as p.Val18_Val19insGlyVal) was also noted but did not meet genome 
wide significance (1.5% [5/328] of affected patients versus 0.3% [2/633] unaffected 
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patients; OR 5.2, 95% CI 1.0 to 26.6; P = .04) (Table 4.3-2). The only variant outside 
of NUDT15 significantly associated with TIM in the exome sequencing data was 
rs1800460 in TPMT (OR 3.0, 95% CI 2.0 to 4.3; P = 2.0×10-8). Gene burden testing 
did not identify any novel associations beyond TPMT and NUDT15 (eTable 4.3-6 in 
the Supplement). 
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Table 4.3-2. Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with 
inflammatory bowel disease using data from the Exome Wide Association Study (EWAS) 
NUDT15 Identifiers Thiopurine-Induced Myelosuppression Affected Patients (n = 328) 
Thiopurine-Tolerant 
Unaffected Patients (n = 633) Odds Ratio 
(95% 
Confidence 
Interval) 
P value b 
Position rsID Protein Sequence Variant Allele 
Reference 
Allele 
Variant 
Heterozyg
ote 
(n) 
Reference 
Homozygo
te  
(n) 
Minor Allele 
Frequency 
Affected 
Individualsa 
Variant 
Heterozyg
ote 
(n) 
Reference 
Homozygo
te 
 (n) 
Minor Allele 
Frequency 
Unaffected 
Individualsa 
48611918 
c  
rs7460715
66 p.Gly17_Val18del A AGGAGTC 19 304 0.029 1 630 7.9×10-4 
38.2 
(5.1 to 
286.1) 
1.3×10-8 
48619855 rs116855232 p.Arg139Cys T C 8 320 0.012 0 633 0 NA 1.8×10
-4 
48611918 
c  
rs7460715
66 
p.Gly17_Val18dup
d 
AGGAGT
C 
GGAGTC 
AGGAGTC 5 304 0.008 2 630 0.002 
5.2 
(1.0 to 
26.6) 
.04 
48611979 rs768057637 p.Lys33Glu G A 1 327 0.002 0 633 0 NA .34 
48615121 13:48615121 p.Val75Gly G T 1 327 0.002 0 633 0 NA .34 
48611961 rs777311140 p.Cys28GlyfsTer28 CGCGG C 0 328 0 1 632 7.9×10
-4 NA >.99 
48611883 13:48611883 p.Met1? C A 0 328 0 1 632 7.9×10
-4 NA >.99 
Position, chromosome 13 position; rsID, single nucleotide polymorphism identification number, or chromosome: position if no rsID available; NA, 
not applicable 
a Minor Allele Frequency (MAF) = [number of variant alleles in population/(2*number of participants)] noting that no affected patients or unaffected 
patients were homozygote for NUDT15 variant alleles  
b P values calculated using Fisher’s exact test. A genome-wide significance threshold of P < 5×10-8 was considered significant. 
c This site is multi-allelic and both of these variants occur at the same chromosome position (48611918): 19 patients were heterozygous for 
p.Gly17_Val18del, 5 affected patients were heterozygous for p.Gly17_Val18dup and 304 affected patients were homozygous reference = 328 
patients in total 
d previously annotated as p.Val18_Val19insGlyVal 
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4.3.6.3 Exploratory Analyses  
NUDT15 sequence data were next examined for the presence of all coding variants, 
either previously associated with TIM362,415,416, or identified in gnomAD427 and 
predicted as deleterious in PROVEAN428 (Table 4.3-2 and eFigure 4.3-5 in the 
Supplement). However, four (p.Lys33Glu, p.Val75Gly, p.Cys28GlyfsTer28 and 
p.Met1?) of the seven NUDT15 variants were each only found in a single individual. 
Therefore, only variants either meeting genome-wide association in this analysis 
(p.Gly17_Val18del) or previously associated with TIM in other analyses (p.Arg139Cys 
and p.Gly17_Val18dup) were included for subsequent exploratory analyses.  
 
Overall, 9.5% (31/328) of the non-Finnish European TIM discovery cohort carry any of 
the three NUDT15 coding variants, compared with 0.5% (3/633) of unaffected patients 
(OR 20.9, 95% CI 6.4 to 68.6; P = 1.5×10-12). The association with these NUDT15 
variants was enriched in early versus late TIM affected patients (OR 3.3, 95% CI 1.6 
to 6.9, P < .001). 
 
75% (717/961) of the study patients had TPMT activity levels available for analysis: all 
ten patients with ‘absent’, and 73% (80/109) with ‘low’ TPMT activity carried variant 
TPMT haplotypes (eFigure 4.3-6 and eTables 4.3-7 to 4.3-9 in the Supplement). 
Overall, 4.9% (16/328) of affected patients and 0.2% (1/633) of unaffected patients 
had two TIM-associated TPMT variant haplotypes. 
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4.3.6.4 Genotype-Phenotype Analyses 
Among all affected patients in the EWAS analysis, the median time to TIM was 15 
weeks (IQR 6 to 41) with 34% (111/328) experiencing early myelosuppression. Of 
note, 18% (59/328) presented with an opportunistic infection, 23% (77/328) were 
admitted to hospital with a median length of stay of 6 days (IQR 2 to 9) and 9% 
(31/328) required granulocyte colony stimulating factor (GCSF) rescue therapy. 
 
The median time to TIM was shorter in affected patients who carried NUDT15 variants 
compared with affected patients without risk variants (7.7 weeks [IQR, 5.7-20.0 weeks] 
vs 20.0 weeks [IQR, 7.6-48.3 weeks], respectively; P = .009) and in those who carried 
double TPMT variants (6.1 weeks [IQR, 4.2-7.6 weeks] vs 20.0 weeks [IQR, 7.6-48.3 
weeks], respectively; P = .002). 
 
The median time to TIM was shortest in patients with both TPMT and NUDT15 variants 
compared with affected patients without risk variants (2.5 weeks [IQR, 1.5-4.1 weeks] 
vs 20.0 weeks [IQR, 7.6-48.3 weeks], respectively, P < .001; Figure 4.3-3 and 
eFigure 4.3-6 in the Supplement). No difference in time to TIM was seen in patients 
carrying one variant TPMT haplotype and affected patients without risk variants (13.9 
weeks [IQR 5.9 to 40.4] versus 20.0 weeks [IQR 7.6 to 48.3], respectively, P = .14). 
 
Patients with NUDT15 and/or TPMT variants developed lower median neutrophil 
counts than non-variant carrier affected patients (0.8 ×109/L [IQR 0.4 to 1.1] versus 
1.0 ×109/L [IQR 0.7 to 1.2], respectively; P < .001), were more likely to be admitted to 
hospital (40% [39/97] versus 17% [38/231], respectively; P < .001) and were more 
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likely to receive GCSF rescue therapy (20% [19/97] versus 5.2% [12/231], 
respectively; P < .001) (eTables 4.3-10 to 4.3-11 in the Supplement).  
Figure 4.3-3. Boxplot for time to thiopurine-induced myelosuppression (TIM) 
among affected patients defined by NUDT15 and TPMT genotype 
 
ref, reference genotype/haplotype; var, variant; TIM, thiopurine-induced myelosuppression; 
IQR, inter-quartile range. Data points are each represented by a dot; the lower and upper 
boundaries of the box correspond to the first and third quartiles; the line within the box 
represents the median; the upper whisker extends from the upper boundary of the box to the 
largest value no further than 1.5 * inter-quartile range (IQR). The lower whisker extends from 
the lower boundary of the box to the lowest value, at most no further than 1.5 * inter-quartile 
range (IQR).Time to thiopurine-induced myelosuppression (weeks) calculated using the 
following formula: [Time to TIM (weeks) = date of meeting entry criteria for TIM - start date of 
highest dose prior to TIM]. Median and interquartile ranges provided to facilitate interpretation 
of time to TIM (weeks). One TIM case carried two NUDT15 variants (rs746071566 
[p.Gly17_Val18dup] and rs116855232 [p.Arg139Cys])-it was unknown if this represented a 
compound heterozygote or a heterozygote (*2 NUDT15 haplotype). For the purposes of 
analysis, this patient was grouped with NUDT15 heterozygotes and annotated as NUDT15var/*. 
One TIM case was TPMT var/var and NUDT15 var/ref; for the purposes of analysis, this patient was 
grouped with five others who carried single NUDT15 and TPMT variants (TPMT var/ref & NUDT15 
var/ref). Compared to leftmost group, P values (Mann Whitney-U test) for the time difference were 
.14, .009, .002 and < .001, respectively.  
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The success of thiopurine re-challenge according to genotype was then explored: 51% 
(167/328) of affected patients were re-challenged and 57% (95/167) were able to 
tolerate a lower dose (median successful rechallenge dose = 1.2 mg/kg [IQR 0.9 to 
1.5]). Neither weight-adjusted dose, type of thiopurine drug, patient age, TPMT 
genotype, nor NUDT15 genotype were associated with subsequent tolerance after re-
challenge (eTable 4.3-12 in the Supplement). 
4.3.6.5 Multivariable Logistic Regression 
In a multivariable logistic regression model, the odds of thiopurine-induced 
myelosuppression among those with variants in NUDT15 (OR 27.3, 95% CI 9.3 to 
116.7; P = 1.1×10-7) and TPMT (OR 2.2, 95% CI 1.4 to 3.3; P = 3.5×10-4 in 
heterozygotes; OR 53.4, 95% CI 10.4 to 980.1; P = 1.5×10-4 in homozygotes) were 
independent of thiopurine weight adjusted dose (OR 2.2, 95% CI 1.8 to 2.8; 
P = 5.3×10-11) (Table 4.3-3). 
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Table 4.3-3. Association with TPMT and NUDT15 variants on clinical phenotype: 
multivariate logistic regression model of genetic and dose related factors 
associated with thiopurine-induced myelosuppression (n = 919 a) 
Variable 
Odds Ratio 
(95% Confidence Interval) 
P value d 
Weight adjusted thiopurine dose c 
 For every 1mg/kg increase in azathioprine 
equivalent dose 
2.2 (1.8 to 2.8) 5.3×10-11 
NUDT15 genotype   
   NUDT15 ref/ref Reference  
   NUDT15 var/* b 27.3 (9.3 to 116.7) 1.1×10-7 
TPMT haplotype   
   TPMT ref/ref Reference  
   TPMT ref/var 2.2 (1.4 to 3.3) 3.5×10-4 
   TPMT var/var 53.4 (10.4 to 980.1) 1.5 ×10-4 
 
Ref, reference haplotype or genotype; var, variant haplotype or genotype 
a 42 observations were missing (n = 919) 
b Carriage of 1 or more of 3 NUDT15 variants: rs746071566 [p.Gly17_Val18del], rs746071566 
[p.Gly17_Val18dup], and rs116855232 [p.Arg139Cys]. One patient with TIM possessed 2 
NUDT15 variants (rs746071566 [p.Gly17_Val18dup] and rs116855232 [p.Arg139Cys]); however, 
it was not possible to ascertain if this represented a compound heterozygote or 2 variants on 
the same strand 
(*2 NUDT15 haplotype). For the purpose of the analysis, this case was considered as a single 
NUDT15 variant carrier (NUDT15 var/*). 
c weight-adjusted thiopurine dose represents the maximum azathioprine equivalent dose prior 
to thiopurine-induced myelosuppression adjusted for weight (mg/kg) 
d represents P value from logistic regression with all three variables included. P < .05 deemed 
clinically significant.  
4.3.6.6 Clinical Usefulness  
For NUDT15, the estimated number of patients needed to genotype to prevent 1 
patient from developing TIM was 95 patients (95% CI, 62-143 patients). For every 
10000 patients genotyped, 164 would test positive for a NUDT15 variant, and of these 
patients, 105 would have developed TIM if they had not received an alternative 
treatment (positive predictive value, 64% [95% CI, 43%-100%]; eMethods in 
Supplement). Genotyping 10000 patients for NUDT15 would prevent 105 cases of 
TIM, which is 95 patients genotyped for every case pre- vented. The number needed 
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to genotype assumed a cumulative incidence of TIM of 7% (95% CI 6% to 8%) taken 
from a meta-analysis of 8302 patients346, drug avoidance strategy in NUDT15 variant 
carriers, a population carriage frequency of 1.6% (95% CI 1.5% to 1.8%) and odds 
ratios derived from bootstrapping our affected and unaffected population (sampling 
with replacement to estimate the variability of the odds ratio). If a dose reduction 
strategy were used in NUDT15 variant carriers instead, thus reducing risk of TIM to 
that of patients with the reference genotype (absolute risk 6%, 95% CI 5% to 7%), the 
number needed to genotype was 105 (95% CI 65 to 168).  
 
For TPMT the estimated number needed to genotype was 123 (95% CI 75 to 235). 
For every 10000 patients genotyped, 996 would test positive for a TPMT variant and 
need to receive an alternative therapy to prevent TIM in 81 patients (95% CI, 43-133 
patients). Genotyping 10000 patients for TPMT would prevent 81 cases of TIM, which 
is 123 genotyped for every case prevented. This assumed the following for patients 
carrying two TPMT variant haplotypes: drug avoidance, a population carrier frequency 
of 0.26%432 (95% CI 0.19% to 0.34%) and an odds ratio of 53.4 (95% CI 10.4 to 980.1); 
and for patients carrying one TPMT haplotype: dose reduction, a population carrier 
frequency of 9.7% (95% CI 8.4% to 11.0%) and an odds ratio of 2.2 (95% CI 1.4 to 
3.3) 
 
In the wider cohort of 398 adjudicated affected patients, including patients of non-
European ancestry excluded from GWAS and EWAS analyses, carriage of NUDT15 
variants was more frequent than in patients of non-Finnish European ancestry (South 
Asian 100% [4/4] versus non-Finnish European 9% [31/328], P = 1.1×10-4 ; East Asian 
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56% [23/41] versus non-Finnish European 9% [31/328], P = 2.0×10-11) (eTable 4.3-13 
in the Supplement). 
 
Estimates of the rate of carrying one or more NUDT15 risk alleles in general population 
using gnomAD reference database ranged from 0.7% in people of African ancestry to 
29.2% in people of East Asian ancestry (eTable 4.3-14 in the Supplement). 
4.3.7 Discussion 
An association between an NUDT15 variant (p.Gly17_Val18del) and TIM has been 
identified and replicated in independent non-Finnish European ancestry cohorts. In 
total, three NUDT15 coding variants, including p.Gly17_Val18del, were identified and 
collectively associated with TIM independent of TPMT genotype and thiopurine dose. 
Patients with NUDT15 and/or TPMT variants had a faster onset, more severe 
myelosuppression, and had a greater need for GCSF rescue therapy.  
 
 This is the first study, to our knowledge, to describe association of an NUDT15 variant 
with TIM in patients of European ancestry at genome-wide significance. This extends 
previous work by Moriyama et al who first described this p.Gly17_Val18del variant in 
two paediatric patients with acute lymphoblastic leukaemia and thiopurine-induced 
myelosuppression; one of whom was of European, and the second, of African 
ancestry.416  
 
The p.Arg139Cys variant has previously been associated with TIM in an admixed 
North American IBD cohort study where the minor allele frequency reported was 2.7% 
in affected and 0.3% in unaffected patients (OR 9.50; P = 4.6×10−4).362 In contrast, 
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prior to this study the p.Gly17_Val18dup variant had only been reported in cohorts of 
East Asian ancestry, to our knowledge.415  
 
NUDT15 is hypothesised to hydrolyse nucleoside triphosphate active metabolites (6-
thio-dGTP, 6-thio-GTP, and dGTP) thus preventing their incorporation into DNA where 
they would otherwise lead to futile mismatch repair and apoptosis.362,415,433 Functional 
experiments confirm that NUDT15 variants result in lower enzymatic activity leading 
to higher levels of thiopurine active metabolites and a greater risk of 
myelosuppression.362,415,416,433 The p.Gly17_Val18dup variant reduces NUDT15 
activity to approximately 15% of normal activity whilst p.Gly17_Val18del and 
p.Arg139Cys are nearly void of enzyme activity, suggesting that patients with these 
variants may be particularly sensitive to thiopurines.415,416  
 
Given the widespread use of the thiopurines, these findings may have ramifications 
beyond the management of IBD in patients of European ancestry. Indeed, while 
NUDT15 variants were first associated with TIM in East Asian patients with IBD362 this 
phenomenon has now been demonstrated in oncology and other immune mediated 
diseases363,434 as well as other populations.362,416–420 For population stratification 
reasons, patients of non-European ancestry were excluded from the genetic analyses 
of this study. However, it is interesting to note the high frequencies of NUDT15 variants 
and absence of TPMT variants in these other ethnic groups: in populations of East 
Asian ancestry the frequency of variant NUDT15 haplotypes is 29.2% in comparison 
to Latin American, South Asian and non-Finnish European populations where the 
frequency of variant carriers is 20.7%, 13.4% and 1.6%, respectively.427  
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As expected, in the wider cohort of adjudicated affected patients, patients of non-
European descent demonstrated a higher carriage frequency of NUDT15 variants and 
a lower carriage frequency of TPMT variants. If replicated in additional studies, these 
findings suggest that NUDT15 testing may be considered prior to thiopurine therapy 
irrespective of the ethnic background of the patient. 
 
The positive predictive value of NUDT15 genotyping estimated in this study together 
with the recent development of alternative, but more expensive, therapies, suggests 
potential clinical utility of pre-treatment testing and drug avoidance in genetically at 
risk patients. Recommendations regarding pre-treatment NUDT15 genotyping are 
under review by the Clinical Pharmacogenetics Implementation Consortium (CPIC) 
based on data from East Asians.429 Our data suggest that pre-treatment sequencing 
of the NUDT15 gene, including the p.Gly17_Val18del deletion, may also be 
considered in patients of European ancestry. However, this will not obviate the 
requirement for regular blood test monitoring for the duration of treatment in patients 
deemed at low risk of TIM.  
 
The estimated number needed to genotype for NUDT15 is 95, similar to the number 
needed to genotype reported here and by others435 for TPMT (123 and 100, 
respectively). However, further validation studies including a cost effectiveness 
analysis should be conducted prior to implementation of pre-treatment NUDT15 
genotyping.   
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4.3.7.1 Limitations 
This study has several limitations. First, inclusion was restricted to patients with IBD 
of non-Finnish European ancestry. Further research is required to evaluate the 
association of these variants with TIM in other ancestries and disease groups.  
 
Second, the replication cohort was not exclusively recruited from independent sites, 
as the central site recruited affected and unaffected patients to the discovery cohort 
and then additional patients to the replication cohorts.  
 
Third, in keeping with all case-control studies, the data are likely to be susceptible to 
recall bias, with greater recruitment of more severe affected patients. We estimate that 
our affected patients represent 5% of the total eligible IBD patients with an episode of 
TIM. This is based on a UK IBD prevalence of 388/100,000436, a thiopurine exposure 
rate of 31%437, and a 7% rate of TIM.346 This recall bias might explain the IBD 
phenotype differences observed between cases and controls and over-estimate the 
risk associated with NUDT15 variants and TIM.  
 
Fourth, 4.9% (16/328) of affected and 0.2% (1/633) of unaffected patients had two of 
the known TIM-associated TPMT variant haplotypes, despite the recommended 
practice of pre-treatment measurement of TPMT activity and thiopurine avoidance in 
TPMT-deficient patients. These patients arguably should not have received treatment 
with a thiopurine, regardless of the presence of NUDT15 variants.  
 
Fifth, the proposed mitigation strategy of drug avoidance rather than dose reduction in 
patients with NUDT15 coding variants may be over-cautious. Previous studies in 
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patients of East Asian ancestry have shown that even patients with two low function 
NUDT15 alleles may successfully tolerate a 90% thiopurine dose reduction.415,433,434 
Likewise, in NUDT15 knockout mice models, accumulation of thiopurine metabolites 
was noted to be in an MP-dose related fashion, suggesting that dose reduction might 
be an effective strategy.433 However, as discussed above, not all variants affect 
NUDT15 enzymatic function to the same extent and the magnitude of the deleterious 
effect of individual variants may differ across ethnic groups.43 Furthermore, it is 
unknown whether such a marked dose reduction would compromise the therapeutic 
effect of thiopurines in IBD. In our study of patients of non-Finnish European ancestry, 
almost 50% of patients with a single variant did not tolerate a thiopurine re-challenge 
at a lower dose. These arguments may justify the use of alternative, more expensive 
therapies in this small group of patients at high risk of TIM. However, further data are 
needed to explore whether dose reduction with enhanced monitoring or drug 
avoidance is the safer, cheaper and more clinically effective strategy.  
4.3.7.2 Conclusions 
Among patients of European ancestry with inflammatory bowel disease, variants in 
NUDT15 were associated with increased risk of thiopurine-induced myelosuppression. 
These findings suggest that NUDT15 genotyping may be considered prior to initiation 
of thiopurine therapy; however, further study including additional validation in 
independent cohorts is required.  
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eFigure 4.3-1. Adjudication assessment tool 
 
 
 
Adapted version of the Liverpool Adverse Drug Reaction Causality Assessment Tool used in 
the adjudication process. Adapted from Gallagher et al. (Gallagher, R.M. et al. Development 
and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool. 
PLoS One, e28096, 2011).338
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eFigure 4.3-2. Quantile-Quantile plot demonstrating genomic inflation factor in 
328 affected and 633 unaffected individuals used in the primary ExWAS 
discovery cohort  
 
 
Genomic inflation factor (λGC) and quantile–quantile (Q–Q) plots are used to compare the 
genome-wide distribution of the test statistic with the expected null distribution. The Q–Q plot 
is a useful visual tool to mark deviations of the observed distribution from the expected null 
distribution. Inflated ( λGC >1.0) values or residual deviations in the Q–Q plot may point to 
undetected sample duplications, unknown familial relationships, a poorly calibrated test 
statistic, systematic technical bias or gross population stratification.438  
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eFigure 4.3-3. A Manhattan plot showing genome wide associations (GWA) 
between single-nucleotide polymorphisms (SNPs) and thiopurine-induced 
myelosuppression after 1000 Genomes imputation using 311 affected and 608 
unaffected individuals  
 
 
Each dot represents a –log10 P value calculated by Fisher’s exact test for the allele frequency 
in 311 thiopurine-induced myelosuppression affected individuals with inflammatory bowel 
disease and 608 thiopurine-exposed unaffected individuals with inflammatory bowel disease. 
The red dotted horizontal line represents at P = 5.0×10-8 represents the genome wide 
significance level. The gene name corresponds to the gene in closest proximity to the variant 
with the lowest P value at each locus. 
  
TPMT 
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eFigure 4.3-4. A Manhattan plot showing genome wide associations (GWA) 
between single-nucleotide polymorphisms (SNPs) and early (≤ 8 weeks of 
starting maximum thiopurine dose) thiopurine-induced myelosuppression after 
1000 Genomes imputation using 107 affected and 608 unaffected individuals 
 
 
Each dot represents a –log10 P value calculated by Fisher exact test for the allele frequency in 
107 early thiopurine-induced myelosuppression affected individuals with inflammatory bowel 
disease and 608 thiopurine-exposed unaffected individuals with inflammatory bowel disease. 
The red dotted horizontal line represents at P = 5.0×10-8 represents the genome wide 
significance level. Gene name corresponds to the gene in closest proximity to the variant with 
the lowest P value at each locus. 
 
TPMT 
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eFigure 4.3-5. Gene map illustrating location (labelled A to F) of 7 deleterious coding NUDT15 variants on chromosome 13 
found among 964 exome sequenced thiopurine-exposed patients: 328 affected and 633 unaffected individuals  
 
 
 
 
 
 
rsID; Single Nucleotide Polymorphism database (dbSNP) ID; Location, chromosome 13 position; gnomAD, Genome Aggregation Database 
(http://gnomad.broadinstitute.org/); Position, chromosome  
13 position; rsID, single nucleotide polymorphism identification number (dbSNP), or chromosome and position if no rsID available  
 
NUDT15 identifiers 
NUDT15 risk allele 
frequencies reported in 
this study b 
Estimates of NUDT15 risk allele frequencies in general population 
using gnomAD reference database 
rsID Location 
Reference 
allele/Variant 
allele 
Annotati
on 
Position 
on Gene 
Map 
Protein 
Sequence 
Risk Allele 
Frequency 
Affected 
Individuals 
Risk Allele 
Frequency  
Unaffected 
Individuals 
Carriage Rate of 
Risk Allele in Non-
Finnish Europeans  
% (95% CI) 
Risk Allele Count 
in Non-Finnish 
Europeans 
(95% CI) 
Total Allele 
Number in 
Non-Finnish 
Europeans 
Homozygote 
Risk Allele 
Count in Non-
Finnish 
Europeans 
rs746071566 48611918 AGGAGTC /A in-frame deletion B
a p.Gly17_Val18del 0.029 7.9×10
-4  0.43 (0.37 - 0.49) 216 (188-246) 101458 0 
rs116855232 48619855 C/T missense F p.Arg139Cys 0.012 0 0.71 (0.64 - 0.77) 448 (405-488) 126510 2 
rs554405994 48611918 
AGGAGTC / 
AGGAGTC 
GGAGTC 
in-frame 
insertion B
a p.Gly17_Val18dup 0.008 0.002 0.52 (0.46 - 0.59) 264 (233-297) 101458 0 
 rs768057637 48611979 A/G missense D p.Lys33Glu 0.002 0 0.010 (0.002 - 0.020) 5 (1-10) 101230 0 
13:48615121 48615121 T/G missense E p.Val75Gly 0.002 0 0.005 (0.000 - 0.012) 3 (0-7) 112164 0 
 rs777311140 48611961 C/CGCGG frame-shift C 
p.Cys28GlyfsT
er28 0 7.9×10
-4 0.041 (0.025 - 0.059) 23 (14-33) 111744 0 
13:48611883 48611883 A/C start lost A p.Met1? 0 7.9×10-4 0.003 (0.000 - 0.009) 1 (0-3) 70518 0 
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a This site is multi-allelic and both of these variants occur at the same chromosome position (48611918): 19 affected individuals were 
heterozygous for rs746071566, 5 affected individuals were heterozygous for rs554405994 and 304 affected individuals were homozygous reference 
= 328 individuals in total  
b Risk Allele Frequency (RAF) = [number of variant alleles in population/(2*number of participants)] noting that no affected or unaffected 
individuals were homozygote for NUDT15 variant alleles 
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eFigure 4.3-6. Relationship between TPMT diplotype and TPMT phenotype-
enzyme activity among 328 thiopurine-induced myelosuppression affected 
individuals and 633 thiopurine-exposed unaffected individuals 
 
 
Patients with missing TPMT phenotype data excluded. Numbers of patients with respective 
diplotype reported to the right of bars. Ref, reference genotype; var, variant genotype.  
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eFigure 4.3-7. Estimated cumulative incidence of thiopurine-induced 
myelosuppression among patients with NUDT15 and/or TPMT variants 
 
 
 
Time = number of weeks after starting maximum dose of thiopurine. Case control exome 
sequenced dataset of variant frequencies adjusted by duplicating control cohort to match the 
non-thiopurine-induced myelosuppression frequency (93%) that would be expected in the 
general inflammatory bowel disease population (7% cumulative incidence of thiopurine-
induced myelosuppression reported by Gisbert JP, Gomollón F. Thiopurine-Induced 
Myelotoxicity in patients with Inflammatory Bowel Disease: A Review. Am J Gastroenterol. 
2008;103(7):1783-1800).346 
  
TPMTvar/* NUDT15var/ref
TPMTvar/var NUDT15ref/ref
TPMTref/ref NUDT15var/*
TPMTvar/ref NUDT15ref/ref
TPMTref/ref NUDT15ref/ref
1.00
0.75
0.50
0.25
0.00
0 26 52 78 104
Time (weeks)
C
um
ul
at
iv
e 
pr
op
or
tio
n 
de
ve
lo
pi
ng
 m
ye
lo
su
pp
re
ss
io
n
CHAPTER 4: RESEARCH PAPER IV:THIOPURINE-INDUCED 
MYELOSUPPRESSION 
 
293 
 
eTable 4.3-1. Number of thiopurine-induced myelosuppression affected 
individuals and thiopurine-exposed unaffected individuals among all patients 
used in the final analyses subdivided by early (≤ 8 weeks) and late onset 
myelosuppression 
 
Experiment 
Early thiopurine 
induced 
myelosuppression 
affected individuals a 
(≤ 8 weeks) 
n (%) 
Late thiopurine 
induced 
myelosuppression 
affected individuals b 
(> 8 weeks) 
n (%) 
Thiopurine-
exposed 
unaffected 
individuals  
N 
Adjudicated patients 
c  143 (36%) 255 (65%) 679 
Imputed GWAS 107 (34%) 204 (66%) 608 
ExWAS 111 (34%) 217 (66%) 633 
 
GWAS, Genome Wide Association Study; ExWAS, Exome Wide Association Study 
a Early thiopurine induced myelosuppression defined as ≤ 8 weeks from maximum dose of 
thiopurine to thiopurine-induced myelosuppression 
b Late thiopurine induced myelosuppression defined as > 8 weeks from maximum dose of 
thiopurine to thiopurine-induced myelosuppression 
c Includes patients of all ethnicities prior to selection of Non-Finnish Europeans (NFE) for 
GWAS and ExWAS analyses 
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eTable 4.3-2. IBD and drug exposure phenotype in adjudication affected and unaffected 
individuals in the replication cohort (after quality control) 
a values represent: n (%) or median [interquartile range] 
b P value represents Fisher’s exact or Mann-Whitney U test as appropriate with P < .05 deemed statistically 
significant   
c Montreal Classification System from Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated 
clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of 
the 2005 Montreal World Congress of Gastroenterology. Canadian Journal of Gastroenterology 2005;19 Suppl 
A(5):5A-36A. 
d Denominator for affected individuals = 44 and for unaffected individuals = 399 
e Denominator for affected individuals = 46 and for unaffected individuals = 536 
f Denominator for affected individuals = 44 and for unaffected individuals = 525 
g Denominator for affected individuals = 29 and for unaffected individuals = 298 
 
 
 
Characteristic 
Thiopurine-induced 
myelosuppression affected 
individuals n = 73  a 
Thiopurine-exposed 
unaffected individuals 
n = 840  a 
P value b 
Centre    
Cedars Sinai 1 (1.4%) 302 (36.0%) 
<.001 
Additional UK cases 32 (43.8%) 0 (0.0%) 
Massachusetts General Hospital 4 (5.5%) 68 (8.1%) 
Paris 16 (21.9%) 282 (33.6%) 
University Medical Centre Groningen 20 (27.4%) 188 (22.4%) 
Sex    
Female 49 (67.1%) 449 (53.5%) .03 Male 24 (32.9%) 391 (46.5%) 
Diagnosis    
Crohn's disease 43 (58.9%) 541 (64.4%) 
.05 IBD-unclassified (IBD-U) 6 (8.2%) 23 (2.7%) 
ulcerative colitis (UC) 24 (32.9%) 276 (32.9%) 
Age at IBD diagnosis (years) 26.0 [18.9 to 43.0] 23.0 [17.0 to 31.0] .004 
Montreal Crohn's age at diagnosis  c, d    
A1: <17 yrs 5 (11.4%) 104 (26.1%) 
<.001 A2: 17 to 40 yrs 19 (43.2%) 248 (62.2%) 
A3: >40 yrs 20 (45.5%) 47 (11.8%) 
Montreal Crohn's location  c, e    
L1: ileal 10 (21.7%) 116 (21.6%) 
>.99 L2: colonic 11 (23.9%) 126 (23.5%) 
L3: ileocolonic 25 (54.3%) 294 (54.9%) 
Montreal Crohn's behaviour  c, f    
B1: non-stricturing and non-penetrating 14/44 (31.8%) 186/525 (35.4%) 
.49 B2: stricturing 15/44 (34.1%) 134/525 (25.5%) 
B3: penetrating 15/44 (34.1%) 205/525 (39.0%) 
Montreal ulcerative colitis extent c, g    
E1: limited to the rectum 1 (3.4%) 12 (4.0%) 
.63 E2: distal to the splenic flexure 11 (37.9%) 89 (29.9%) 
E3: proximal to the splenic flexure 17 (58.6%) 197 (66.1%) 
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eTable 4.3-3. Inflammatory bowel disease and drug exposure phenotype in affected and 
unaffected individuals used in Genome Wide Association Study (GWAS) 
a values represent: n (%) or median [interquartile range]  
b P value represents Fisher’s exact or Mann-Whitney U test as appropriate with P < .05 deemed statistically 
significant  
 c Montreal Classification System from Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated 
clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of 
the 2005 Montreal World Congress of Gastroenterology. Canadian Journal of Gastroenterology 2005;19 Suppl 
A(5):5A-36A. 
d Denominator for affected individuals = 181 and for unaffected individuals = 267 
e Denominator for affected individuals = 182 and for unaffected individuals = 267 
f Denominator for affected individuals = 168 and for unaffected individuals = 265 
g Denominator for affected individuals = 121 and for unaffected individuals = 208 
Characteristic 
Thiopurine-induced 
myelosuppression 
affected individuals 
n = 311 a 
Thiopurine-exposed 
unaffected individuals                
n = 608 a 
P  value b 
Sex    
Female 174 (55.9%) 296 (48.7%) 
.04 
Male 137 (44.1%) 312 (51.3%) 
Diagnosis    
Crohn’s disease (CD) 182 (58.5%) 333 (54.8%) 
.009  IBD-unclassified (IBD-U) 8 (2.6%) 3 (0.5%) 
Ulcerative colitis (UC) 121 (38.9%) 272 (44.7%) 
Age at IBD diagnosis (yrs) 31.3 (21.3 to 46.1) 31.5 (22.2 to 44.7) 
.59 
Estimate of difference [95% Confidence Interval] 0.6 [-1.5 to 2.7]  
Montreal Crohn’s disease classification c    
Age at diagnosis d    
A1: <17 yrs 36 (19.9%) 17 (6.4%) <.001 
 A2: 17-40 yrs 97 (53.6%) 210 (78.7%) A3: >40 yrs 48 (26.5%) 40 (15.0%) 
Location e    
L1: ileal 44 (24.2%) 116 (43.4%) 
<.001 L2: colonic 63 (34.6%) 74 (27.7%) 
L3: ileocolonic 75 (41.2%) 77 (28.8%) 
Behaviour f    
B1: non-stricturing and non-penetrating  99 (58.9%) 157 (59.2%) 
.69 B2: stricturing 51 (30.4%) 73 (27.5%) 
B3: penetrating 18 (10.7%) 35 (13.2%) 
Montreal ulcerative colitis /inflammatory bowel disease-
unclassified extent c    
E1: limited to the rectum 13 (10.7%) 14 (6.7%) 
.38 E2: distal to the splenic flexure 53 (43.8%) 101 (48.6%) 
E3: proximal to the splenic flexure 55 (45.5%) 93 (44.7%) 
Weight-adjusted thiopurine dose (mg/kg) h 2.07 (1.69 to 2.44) 1.84 (1.48 to 2.20) 
<.001 
Estimate of difference [95% Confidence Interval] -0.23 (-0.32 to -0.15) 
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h weight adjusted dose represents the maximum azathioprine equivalent dose prior to thiopurine-induced 
myelosuppression and adjusted for weight (mg/kg): [(mercaptopurine dose (mg) x 2.08) / weight (kg)] or 
[azathioprine dose (mg) / weight (kg)] 
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eTable 4.3-4. Inflammatory bowel disease and drug exposure phenotype in affected and 
unaffected individuals used in Exome Wide Association Study (ExWAS) 
a values represent: n (%) or median [interquartile range]  
b P value represents Fisher’s exact or Mann-Whitney U test as appropriate with P < .05 deemed statistically 
significant  
c Montreal Classification System from Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated 
clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of 
the 2005 Montreal World Congress of Gastroenterology. Canadian Journal of Gastroenterology 2005;19 Suppl 
A(5):5A-36A. 
d Denominator for affected individuals = 192 and for unaffected individuals = 282 
e Denominator for affected individuals = 193 and for unaffected individuals = 282 
f Denominator for affected individuals = 178 and for unaffected individuals = 280 
g Denominator for affected individuals = 127 and for unaffected individuals = 214 
h weight adjusted dose represents the maximum azathioprine equivalent dose prior to TIM and adjusted for 
weight (mg/kg): [(mercaptopurine dose (mg) x 2.08) / weight (kg)] or [azathioprine dose (mg) / weight (kg) 
 
Characteristic 
Thiopurine-induced 
myelosuppression 
affected individuals 
n = 328 a 
Thiopurine-exposed 
unaffected individuals                
n = 633 a 
P value b 
Sex    
Female 181 (55.2%) 310 (49.0%) .08 Male 147 (44.8%) 323 (51.0%) 
Diagnosis    
Crohn’s disease (CD) 193 (58.8%) 350 (55.3%) 
.01 IBD-unclassified (IBD-U) 8 (2.4%) 3 (0.5%) 
Ulcerative colitis (UC) 127 (38.7%) 280 (44.2%) 
Age at IBD diagnosis (yrs) 31.4 [21.0 to 45.7] 32.0 [22.3 to 45.4] 0.36  Estimate of difference [95% Confidence Interval] 1.0 [-1.1 to 3.1] 
Montreal Crohn’s disease classification c    
Age at diagnosis d    
A1: <17 yrs 40/ (20.8%) 18 (6.4%) 
<.001 A2: 17-40 yrs 101 (52.6%) 223 (79.1%) 
A3: >40 yrs 51 (26.6%) 41 (14.5%) 
Location e    
L1: ileal 51 (26.4%) 125 (44.3%) 
<.001 L2: colonic 64 (33.2%) 76 (27.0%) 
L3: ileocolonic 78 (40.4%) 81 (28.7%) 
Behaviour f    
B1: non-stricturing and non-penetrating  104 (58.4%) 164 (58.6%) 
.48 B2: stricturing 56 (31.5%) 78 (27.9%) 
B3: penetrating 18 (10.1%) 38 (13.6%) 
Montreal ulcerative colitis /inflammatory bowel disease-
unclassified extent c    
E1: limited to the rectum 14 (11.0%) 14 (6.5%) 
.32 E2: distal to the splenic flexure 57 (44.9%) 105 (49.1%) 
E3: proximal to the splenic flexure 56 (44.1%) 9 (44.4%) 
Weight-adjusted thiopurine dose (mg/kg) h 2.07 (1.69 to 2.44) 1.84 (1.47 to 2.20) <.001 Estimate of difference [95% Confidence Interval] -0.23 [-0.31 to -0.15] 
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eTable 4.3-5. Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with 
inflammatory bowel disease using data from the Exome Wide Association Study (ExWAS) stratified by time to 
myelosuppression 
 
NUDT15 identifiers 
Early (≤ 8 weeks) thiopurine-induced 
myelosuppression affected individuals b 
(n = 111) 
Late (> 8 weeks) thiopurine-induced 
myelosuppression affected individuals b 
 (n = 217) 
Thiopurine-
tolerant unaffected 
individuals            
(n = 633) 
Position 
Referenc
e (Ref)  
allele 
Variant 
(Var) 
allele 
Amino acid 
change 
Var 
hom 
 (n) 
Var    
het  
(n) 
Ref    
hom 
(n) 
Odds 
Ratio 
(95% CI) 
P valuea 
Var 
hom 
(n) 
Var  
het 
(n) 
Ref 
hom 
(n) 
Odds 
Ratio 
(95% CI) 
P valuea 
Var 
hom 
(n) 
Var 
het 
(n) 
Ref 
hom 
(n) 
4861191
8c 
AGGAGT
C A 
p.Gly17_Val18
del 0 12 96 
74.2 (9.6 to 
573.5) 8.2×10
-10 0 7 208 20.9 (2.6 to170.1) 4.2×10
-4 0 1 630 
4861985
5 C T p.Arg139Cys 0 4 107 NA 4.8×10
-4 0 4 213 NA 0.004 0 0 633 
4861191
8c 
AGGAGT
C 
AGGA
GTC 
GGAG
TC 
p.Gly17_Val18
dupd 0 3 96 
9.7 (1.6 to 
58.5) 0.02 0 2 208 
5.1(1.0 to 
26.6) 0.26 0 2 630 
 
 
Position, chromosome position; het, heterozygote; hom, homozygote; var, variant; ref, reference; NA, not applicable; CI, Confidence Interval. 
a P values calculated using Fisher’s exact test between early (≤ 8 weeks from maximum thiopurine dose to thiopurine-induced myelosuppression) 
TIM affected vs. thiopurine-exposed unaffected individuals and late (> 8 weeks from maximum dose thiopurine to thiopurine-induced 
myelosuppression) TIM affected vs. thiopurine-exposed unaffected individuals. P < 5.0×10-8 deemed statistically significant 
b Time to myelosuppression (weeks) = [date of maximum thiopurine dose] – [date of meeting inclusion criteria]   
c This site is multi-allelic and both of these variants occur at the same chromosome position (48611918): 19 individuals were heterozygous for 
rs746071566 (p.Gly17_Val18del), 5 TIM affected individuals were heterozygous for rs554405994 (p.Gly17_Val18dup) and 304 TIM affected 
individuals were homozygous reference (328 individuals in total) 
d p.Gly17_Val18dup previously also annotated as p.Val18_Val19insGlyVal 
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eTable 4.3-6. Genes associated with thiopurine-induced myelosuppression on 
gene burden testing in discovery and replication cohorts 
 
Gene 
NCBI 
RefSeq 
identifier 
Chromosome 
number 
Number of 
variants 
identified 
Discovery 
cohort P value a 
Replication 
cohort P value a 
TPMT NM_018283 6 19 variants 2.1×10-7 1.6×10-5 
NUDT15 NM_000367 13 64 variants 3.0×10-10 5.1×10-5 
CDC37 NM_007065 19 14 variants 5.5×10-8 .51 
 
NCBI, National Center for Biotechnology Information 
a SKAT P value provided with P < 5.0×10-8 deemed statistically significant 
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eTable 4.3-7. TPMT haplotypes among entire dataset of 328 thiopurine-induced myelosuppression affected individuals and 
633 thiopurine-exposed unaffected individuals 
Haplotypes 
TPMT enzyme 
activity 
assigned in 
this study  
TPMT enzyme activity status assigned by CPICa 
and/or LOVDb 
dbSNP rsID and 
chromosome 
position 
Nucleotide 
change in 
TPMTc 
Amino acid 
change 
*1 Normal Functional/normal activity/wild-type  rs2842934 allele Ad Wild type 474Td Not applicable 
*2 Non-functional CPIC: Non-functional, variant, or mutant/no activity LOVD: Variant affects function rs1800462 238G>C Ala80Pro 
*3A Non-functional CPIC: Non-functional, variant, or mutant/no activity  LOVD: Effect not classified 
rs1800460 
rs1142345 
460G>A 
719A>G 
Ala154Thr 
Tyr240Cys 
*3C Non-functional CPIC: Non-functional, variant, or mutant/no activity LOVD: Variant affects function rs1142345 719A>G Tyr240Cys 
*4 Non-functional CPIC: Non-functional, variant, or mutant/no activity LOVD: Effect not classified rs1800584  626-1G>A Unknown 
*8 Non-functional CPIC: Probable reduced-function/decreased activity LOVD: Effect unknown rs56161402 644G>A Arg215His 
*9 Non-functional CPIC: Uncertain Function LVID: Effect unknown rs151149760 356A>C Lys119Thr 
*12 Non-functional CPIC: Uncertain Function LOVD: Effect not classified rs200220210 374C>T Ser125Leu 
*21 Non-functional CPIC: Uncertain Function LOVD: Effect not classified rs200591577 205C>G Leu69Val 
*37 Non-functional CPIC: Uncertain Function LOVD: Effect not classified rs398122996 648T>A Cys216Ter 
*40 Non-functional CPIC: Uncertain Function LOVD: Not listed rs139392616 677G>A Arg226Gln 
 
a CPIC, Clinical Pharmacogenetics Implementation Consortium (https://cpicpgx.org/). Function listed by curator. 
b LOVD, Leiden Open (source) Variation Database (https://databases.lovd.nl/shared/transcripts/TPMT) 
c Nucleotide changes in the TPMT gene (given on the negative chromosomal strand, NCBI reference sequence NM_000367.2) are numbered such 
that the A in the ATG is + 1.  
d dbSNP reports G>A at this position: however, the TPMT nomenclature committee has defined wildtype as having allele A at this position 
(positive chromosomal strand) and the *1S allele as having allele G at this position (positive chromosomal strand) 
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eTable 4.3-8. TPMT phenotype-enzyme activity among 328 thiopurine-induced 
myelosuppression affected individuals and 633 thiopurine-exposed unaffected 
individuals 
 
TPMT phenotype / 
enzyme activity 
level a 
Affected individuals   
(n)% 
Unaffected individuals 
(n)% P value
 b 
absent 10 (3%) 0 (0%) 
<.001 
low 39 (12%) 70 (11%) 
normal 171 (52%) 427 (68%) 
high 7 (2%) 3 (1%) 
not tested 101 (31%) 133 (21%) 
Grand Total 328 633  
 
a manufacturer of assay as well as processing laboratory for quantitative TPMT enzyme 
activity levels differ among participants, therefore, only ordinal data reported.  
b P < .05 deemed statistically significant   
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eTable 4.3-9. TPMT diplotype and TPMT phenotype-enzyme activity among 328 thiopurine-induced myelosuppression 
affected individuals and 633 thiopurine-exposed unaffected individuals 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Ref, reference genotype; var, variant genotype.  
a manufacturer of assay as well as processing laboratory for quantitative TPMT enzyme activity levels differ among participants, therefore, only 
ordinal rather than quantitative data reported.  
 
TPMT diplotype 
Frequency of TPMT phenotype / enzyme activity level a 
Grand Total TPMT genotype 
‘absent’ ‘low’ ‘normal’ ‘high’ test not done 
*2/*3A 2 1 0 0 0 3 
Double variant 
(TPMT var/var) 
 
*3A/*21 1 0 0 0 0 1 
*3A/*3A 3 2 0 0 5 10 
*3A/*3C 1 0 0 0 1 2 
*3A/*9 1 0 0 0 0 1 
*1/*12 0 0 1 0 0 1 
Single variant 
(TPMT ref/var) 
*1/*2 0 5 0 0 6 11 
*1/*21 0 0 1 0 0 1 
*1/*37 0 0 0 0 1 1 
*1/*3A 2 59 6 0 25 92 
*1/*3C 0 12 0 0 3 15 
*1/*4 0 1 0 0 0 1 
*1/*40 0 0 1 0 0 1 
*1/*8 0 0 2 0 0 2 
*1/*1 0 29 587 10 193 819 
Reference  
genotype 
(TPMT ref/ref) 
Grand Total 10 109 598 10 234 961  
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eTable 4.3-10. Clinical phenotype among 328 thiopurine-induced 
myelosuppression affected individuals according to NUDT15 and TPMT 
genotype 
 
Fisher’s exact and Mann-Whitney U tests used as appropriate. P < .05 deemed statistically 
significant    
a Weight adjusted dose represents the maximum azathioprine equivalent dose prior to TIM and 
adjusted for weight (mg/kg): [(mercaptopurine dose (mg) x 2.08) / weight (kg)] or [azathioprine 
dose (mg) / weight (kg)] 
b An unsuccessful drug rechallenge was defined as a second exposure to a thiopurine at the 
same or lower dose which was then subsequently withdrawn due to any adverse event, or, a 
second fall in absolute white blood cell count to ≤ 3.0 x109/L 
c Time to TIM (weeks) = [date of meeting entry criteria for TIM - start date of highest dose prior 
to TIM] 
Phenotype variable 
Thiopurine induced 
myelosuppression (TIM) 
affected individuals with 
reference genotype for 
both TPMT and NUDT15 
(n = 231) 
Thiopurine induced 
myelosuppression 
affected individuals 
with TPMT and/or 
NUDT15 variants 
(n = 97) 
P value 
Thiopurine / n (%)    
.29 
 
  Azathioprine (AZA) 157 (68.0%) 72 (74.2%) 
  Mercaptopurine (MP) 74 (32.0%) 25 (25.8%) 
Weight adjusted thiopurine dosea    
  Median [IQR] / (mg/kg) 2.1 [1.7 to 2.5] 1.9 [1.6 to 2.2] .002 
Time to TIMc    
  Median [IQR] / (weeks) 20.0 [7.6 to 48.3] 7.9 [4.7 to 25.0] <.001 
  ≤ 8 weeks / n (%) 62 (26.8%) 49 (50.5%) <.001 
Lowest white cell count    
  Median [IQR] / (×109/L) 2.2 [1.9 to 2.4] 1.9 [1.3 to 2.3] <.001 
Lowest neutrophil count    
  Median [IQR] / (×109/L) 1.0 [0.7 to 1.2] 0.8 [0.4 to 1.1] <.001 
Infective complication of TIM    
  Yes / n (%) 38 (16.5%) 21 (21.6%) .27 
Hospital admission required    
  Yes / n (%) 38 (16.5%) 39 (40.2%) <.001 
Granulocyte simulating factor 
(GCSF) required    
  Yes / n (%) 12 (5.2%) 19 (19.8%) <.001 
Successfully rechallenged at lower 
thiopurine dose    
  Yes / n (%) 77 (61.1%) 18 (43.9%) .07 
Weight adjusted dose successful 
rechallengesa,b    
 Median dose [IQR] / (mg/kg) 1.2 [0.9 to 1.6] 1.2 [0.9 to 1.3] .43 
Weight adjusted dose 
unsuccessful rechallengesa,b    
  Median dose [IQR] / (mg/kg) 0.8 [0.6 to 1.5] 1.1 [0.9 to 1.2] .86 
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eTable 4.3-11. Clinical phenotype among 328 thiopurine-induced myelosuppression affected individuals according to 
NUDT15 and TPMT genotype 
eTable 4.3-11 continued… 
 
 
 
 
 
Phenotype variable 
TPMT ref/ref 
NUDT15 ref/ref 
(n = 231) 
TPMT var/ref 
NUDT15 ref/ref 
(n = 51) 
TPMT ref/ref 
NUDT15 var/* 
(n = 25) a 
TPMT var/var 
NUDT15 ref/ref 
(n = 15) 
TPMT var/* 
NUDT15 var/ref   
(n = 6) e 
P value d 
Thiopurine responsible for  
thiopurine-induced 
myelosuppression (TIM) / n (%) 
      
  Azathioprine (AZA) 157 (68.0%) 37 (72.5%) 16 (64.0%) 14 (93.3%) 5 (83.3%) .24   Mercaptopurine (MP) 74 (32.0%) 14 (27.5%) 9 (36.0%) 1 (6.7%) 1 (16.7%) 
Weight adjusted thiopurine 
dose b       
  Median [IQR] / (mg/kg) 2.1 [1.7 to 2.5] 2.0 [1.7 to 2.3] 1.9 [1.6 to 2.3] 1.7 [1.4 to 2.0] 2.0 [1.4 to 2.1] .004 
Time to TIM c       
  Median [IQR] / (weeks) 20.0 [7.6 to 48.3] 13.9 [5.9 to 40.4] 7.7 [5.7 to 20.0] 6.1 [4.2 to 7.6] 2.5 [1.5 to 4.1] <.001 
  ≤ 8 weeks / n (%) 62 (26.8%) 18 (35.3%) 13 (52.0%) 12 (80.0%) 6 (100.0%) <.001 
Lowest white cell count       
  Median [IQR] / (×109/L) 2.2 [1.9 to 2.4] 2.1 [1.5 to 2.3] 2.1 [1.6 to 2.4] 1.1 [0.9 to 1.4] 2.1 [1.8 to 2.2] <.001 
Lowest neutrophil count       
  Median [IQR] / (×109/L) 1.0 [0.7 to 1.2] 1.0 [0.6 to 1.2] 0.8 [0.5 to 1.0] 0.2 [0.1 to 0.4] 0.3 [0.2 to 0.8] <.001 
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…eTable 4.3-11. continued 
 
TIM, thiopurine-induced myelosuppression. Values represent: n (%) or median [IQR]. The following were used to define variant subgroups of 
among TIM affected individuals:  
TPMT ref/ref & NUDT15 ref/ref: TPMT reference and NUDT15 reference genotype  
TPMT var/ref & NUDT15 ref/ref: TPMT heterozygote variant and NUDT15 reference genotype 
TPMT ref/ref & NUDT15 var/*/: TPMT reference and NUDT15 heterozygote variant genotype 
TPMT var/var & NUDT15 ref/ref: TPMT homozygote variant and NUDT15 reference genotype 
TPMT var/* & NUDT15 var/ref: TPMT heterozygote or homozygote variant and NUDT15 heterozygote variant genotype 
 a one TIM case possessed two NUDT15 variants (rs554405994 [p.Gly17_Val18dup] and rs116855232 [p.Arg139Cys]). It was not possible to 
ascertain if this represented a compound heterozygote or two variants on the same strand (*2 NUDT15 haplotype). For the purposes of the 
analysis, this case was considered as a single NUDT15 variant carrier (NUDT15 var/*) 
b weight adjusted dose represents maximum azathioprine equivalent dose prior to TIM and adjusted for weight (mg/kg): [(mercaptopurine dose 
(mg) x 2.08) / weight (kg)] or [azathioprine dose (mg) / weight (kg)] 
Phenotype variable 
TPMT ref/ref 
NUDT15 ref/ref 
(n = 231) 
TPMT var/ref 
NUDT15 ref/ref 
(n = 51) 
TPMT ref/ref 
NUDT15 var/* 
(n = 25) a 
TPMT var/var 
NUDT15 ref/ref 
(n = 15) 
TPMT var/* 
NUDT15 var/ref   
(n = 6) e 
P value 
d 
Infective complication of  
thiopurine induced 
myelosuppression (TIM) 
      
  Yes / n (%) 38 (16.5%) 9 (17.6%) 5 (20.0%) 5 (33.3%) 2 (33.3%) .34 
Hospital admission required       
  Yes / n (%) 38 (16.5%) 18 (35.3%) 6 (24.0%) 13 (86.7%) 2 (33.3%) <.001 
Granulocyte simulating factor 
(GCSF) required f       
  Yes / n (%) 12 (5.2%) 7 (14.0%) 4 (16.0%) 7 (46.7%) 1 (16.7%) <.001 
Successfully rechallenged at 
lower thiopurine dose g       
  Yes / n (%) 77 (61.1%) 12 (50.0%) 5 (38.5%) 0 (0.0%) 1 (50.0%) .17 
Weight adjusted dose 
successful rechallenges b,c       
  Median dose [IQR] / (mg/kg) 1.2 [0.9 to 1.6] 1.0 [0.9 to 1.2] 1.2 [1.0 to 1.3] NA 1.5 [1.5 to 1.5] .65 
Weight adjusted dose 
unsuccessful rechallenges b,c        
  Median dose [IQR] / (mg/kg) 0.8 [0.6 to 1.5] 1.1 [1.1 to 1.2] 0.9 [0.8 to 1.5] NA NA .95 
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c an unsuccessful drug rechallenge was defined as a second exposure to a thiopurine at the same or lower dose which was then subsequently 
withdrawn due to any adverse event, or, a second fall in absolute white blood cell count to ≤ 3.0 x109/L 
d Fisher’s exact and Kruskal-Wallis tests were used for comparison among all groups. P values < .05 deemed statistically significant  
e one TIM case was TPMT var/var and NUDT15 var/ref in order that this patient was neither lost or analyzed alone, they were grouped with five 
patients who were TPMT var/ref and NUDT15 var/ref 
f from leftmost group denominators = 230, 50, 25, 16, 6 
g from leftmost group denominators = 126, 24, 13, 2, 2 
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eTable 4.3-12. Comparison of phenotype among thiopurine-induced 
myelosuppression affected individuals with successful and unsuccessful 
rechallenge with a thiopurine 
values represent: n (%) or median [interquartile range]. ref/ref, reference genotype; ref/var, 
heterozygote genotype; var/var, homozygote variant genotype 
 a weight adjusted dose represents the maximum azathioprine equivalent dose prior to 
thiopurine-induced myelosuppression and adjusted for weight (mg/kg): [(mercaptopurine dose 
(mg) x 2.08) / weight (kg)] or [azathioprine dose (mg) / weight (kg)] 
b P values reflect Fisher’s exact or Mann-Whitney U test as appropriate. P < .05 deemed 
statistically significant 
c an unsuccessful drug rechallenge was defined as a second exposure to a thiopurine at the 
same or lower dose which was then subsequently withdrawn due to any adverse event, or, a 
second fall in absolute white blood cell count to ≤ 3.0 x109/L  
Variable Level 
Successful 
thiopurine 
rechallenge 
n = 95 
Unsuccessful 
thiopurine 
rechallenge c 
n = 72 
P value b 
Age at inflammatory bowel 
disease diagnosis  Years 29.8 [18.7 to 43.1] 31.0 [19.0 to 45.3] .77 
Age at time of index 
myelosuppression Years 36.8 [24.2 to 52.2] 38.8 [25.4 to 52.0] .77 
Sex Female 47 (49.5%) 39 (54.2%) .64 
Disease type 
Crohn's disease 59 (62.1%) 39 (54.2%) 
.53 IBD-unclassified 2 (2.1%) 2 (2.8%) 
ulcerative colitis 34 (35.8%) 31 (43.1%) 
TPMT haplotype 
TPMT ref/ref 82 (86.3%) 57 (79.2%) 
.18 TPMT ref/var 13 (13.7%) 13 (18.1%) 
TPMT var/var 0 (0.0%) 2 (2.8%) 
NUDT15 haplotype NUDT15 ref/var 6 (6.3%) 9 (12.5%) .18 
Thiopurine used in 
rechallenge azathioprine 52 (59.8%) 38 (70.4%) .21 
Weight adjusted 
azathioprine equivalent 
thiopurine dose of 
rechallenge a 
mg/kg 1.2 [0.9 to 1.5] 1.0 [0.6 to 1.5] .21 
CHAPTER 4: RESEARCH PAPER IV:THIOPURINE-INDUCED 
MYELOSUPPRESSION 
 
308 
 
eTable 4.3-13. TPMT and NUDT15 variants in thiopurine-induced 
myelosuppression affected individuals of non-European and European ancestry 
(n = 373) 
Gene 
Variant 
position/  
rsID/  
protein sequence 
Genotype/
Haplotype 
East Asian 
(n=4) 
South Asian 
(n=41) 
Non-Finnish 
European 
(n=328) 
NUDT15 
48611918/  
rs746071566 
p.Gly17_Val18del 
ref/var 0 (0.0%) 0 (0.0%) 19 (5.8%) 
48611918/  
rs554405994 
p.Gly17_Val18dup 
ref/var 1 (25.0%) 2 (4.9%) 5 (1.5%) 
48619855/ 
rs116855232/  
p.Arg139Cys 
ref/var 2 (50.0%) 16 (39.0%) 8 (2.4%) 
var/var 2 (50.0%) 6 (14.6%) 0 (0.0%) 
Any of the above NUDT15 coding 
variants 4 (100.0%) 23 (56.1%) 31 (10.1%)  
TPMT 
var a /var a 0 (0.0%) 0 (0.0%) 16 (4.9%) 
ref b /var a 1 (25.0%) 1 (2.4%) 56 (17.1%) 
ref b /ref  b 3 (75.0%) 40 (97.6%) 256 (78.0%) 
 
Variant position, chromosome position; rsID, single nucleotide polymorphism identification 
number; ref, reference haplotype/genotype; var, variant haplotype/genotype 
a Variant TPMT haplotypes include: *2, *3A, *3C, *4, *8, *9, *12, *21, *37, *40 
b Reference TPMT haplotype include: *1 
CHAPTER 4: RESEARCH PAPER IV:THIOPURINE-INDUCED MYELOSUPPRESSION 
 
309 
 
eTable 4.3-14. Genotype frequencies of NUDT15 variants in the gnomADa populations (n = 373) 
rsid genotype African (n=11164) 
Ashkenazi 
Jewish 
(n=4548) 
East Asian 
(n=7925) 
European 
(Finnish) 
(n=10812) 
European 
(Non-
Finnish) 
(n=50729) 
Latino 
(n=14791) 
South Asian 
(n=13166) 
Other 
(n=3179) 
48611918/  
rs746071566 
p.Gly17_Val18del 
ref/var 0.0% 0.0% 0.0% 0.1% 0.4% 0.1% 0.1% 0.0% 
var/var 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
48611918/  
rs554405994 
p.Gly17_Val18dup 
ref/var 0.4% 0.1% 11.3% 2.5% 0.5% 9.6% 0.3% 1.9% 
var/var 0.0% 0.0% 0.3% 0.0% 0.0% 0.3% 0.0% 0.0% 
48619855/ 
rs116855232/  
p.Arg139Cys 
ref/var 0.2% 0.8% 18.6% 4.4% 0.7% 11.5% 12.4% 3.6% 
var/var 0.0% 0.0% 1.2% 0.1% 0.0% 0.4% 0.6% 0.1% 
Any of the above 
NUDT15 coding 
variants 
 0.7% 0.9% 29.2% 6.9% 1.6% 20.7% 13.4% 5.6% 
 
ref, reference haplotype/genotype; var, variant haplotype/genotype  
Frequency of carrying one or more variants calculated using the minor allele frequencies for each genomic position and calculating the probability 
of carrying no minor alleles. 
a gnomAD, Genome Aggregation Database (http://gnomad.broadinstitute.org/)
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eAppendix 4.3-1. Participants of adjudication meetings  
 
Name Institution 
Gareth J Walker Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK 
Graham A Heap Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK 
Chris Calvert Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK 
Andy T Cole Gastroenterology and Hepatology , Royal Derby Hospital, Derby Teaching Hospitals NHS Foundation Trust, Derby, UK 
Tom J Creed Gastroenterology and Hepatology, University Hospitals Bristol, University Hospitals Bristol NHS Foundation Trust, Bristol, UK 
Tawfique K Daneshmend Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK 
Anjan Dhar Department of Gastroenterology, Bishop Auckland General Hospital, County Durham and Darlington NHS Foundation Trust, Darlington, UK 
Suranga Dharmasiri Department of Gastroenterology, Southampton General Hospital, University Hospital Southampton NHS Foundation Trust, Southampton, UK 
Daniel R Gaya Department of Gastroenterology, Glasgow Royal Infirmary, NHS Greater Glasgow and Clyde, Glasgow, UK 
John N Gordon Gastroenterology & Hepatology Services, Royal Hampshire County Hospital, Hampshire Hospitals NHS Foundation Trust, Winchester, UK 
Emma Greig Department of Gastroenterology, Musgrove Park Hospital, Taunton and Somerset NHS Hospitals, Taunton, UK 
Ailsa L Hart Department of Gastroenterology, St Mark's Hospital, London North West Healthcare NHS Trust, Harrow, UK 
Neel M Heerasing Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK 
Peter Hendy Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK 
Peter M Irving Department of Gastroenterology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK 
Stephen J  Lewis Department of Gastroenterology, Plymouth Hospitals NHS Trust , Plymouth, UK 
James Lindsay Department of Gastroenterology, The Royal London Hospital, Barts Health NHS Trust, London, UK 
John C Mansfield Department of Gastroenterology, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK 
Charles DR Murray Department of Gastroenterology, Royal Free Hospital, Royal Free London NHS Foundation Trust, London, UK 
Timothy R Orchard Faculty of Medicine, Imperial College Healthcare NHS Trust , London, UK 
Richard CG Pollok Department of Gastroenterology, St George's Healthcare NHS Trust, Tooting, UK 
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Subramaniam 
Ramakrishnan Gastrointestinal and Liver services, Warrington and Halton Hospitals NHS Foundation Trust , Warrington, UK 
David S Rampton Department of Gastroenterology, The Royal London Hospital, Barts Health NHS Trust, London, UK 
Richard K Russell Department of Paediatric Gastroenterology , Royal Hospital for Children, NHS Greater Glasgow and Clyde, Glasgow, UK  CONT…. 
Shaji Sebastian Gastroenterology and Hepatology, Hull and East Yorkshire Hospitals NHS Trust , Hull, UK 
Abhey Singh Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK 
Anthony Todd Department of Haematology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK 
Mark Tremelling Department of Gastroenterology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK 
James R Goodhand Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK 
Nicholas A Kennedy Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK 
Tariq Ahmad Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK 
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eAppendix 4.3-2. Rules for adjudication of thiopurine-induced 
myelosuppression affected individuals 
 
1. A positive rechallenge requires a fall in total white cell count or neutrophil count on repeated 
administration of the same or lower dose. If a rechallenge of a lower dose is tolerated then the 
patient is classified as a probable, not definite. 
2. If a rechallenge is tolerated at the same or a higher dose the patient is unlikely irrespective of 
the time frame of administration.  
3. If there have been multiple (greater than 2) rechallenges and some have been tolerated at an 
equivalent mg/kg but others have not, then the patient is classified as unlikely. 
4. The role of other leukopenia causing drugs can usually be dismissed in affected individuals which 
meet the definite criteria for thiopurine induced myelosuppression. 
5. Any co-administration of a drug known to cause leukopenia renders the case a possible, 
irrespective of the temporal relationship unless they continued to take the drug at the same dose. 
6. Other confounding leukopenia causing drugs can be excluded as a cause if stopped more than 3 
months before the episode of leukopenia.  
7. Inclusion criteria are absolute (white cell count ≤ 2.5 × 109/L and/or reduction in neutrophil count 
to ≤ 1.0 × 109/L) 
8. Infliximab is not a cause of leukopenia and there is insufficient evidence to suggest an interaction 
with azathioprine. Equally 5ASA drugs have insufficient evidence for an interaction with 
azathioprine. 
9. If we do not have a recorded stop date for thiopurines, we can seek clarification if necessary, but 
the major criteria require its use within the last 7 days prior to leucopoenia. 
10. Concurrent administration of allopurinol categorizes the patient as possible as a result of shunting 
the metabolic pathway towards 6-TGN and thus increasing the risk of myelosuppression. 
CHAPTER 4: RESEARCH PAPER IV:THIOPURINE-INDUCED 
MYELOSUPPRESSION 
 
313 
 
eAppendix 4.3-3. Drugs deemed to cause leukopenia for adjudication process 
 
1. Allopurinol 
2. Anti-thyroid drugs (thionamides – Methimazole, Carbimazole, Propylthiouracil) 
3. Anti-inflammatory drugs (Sulfasalazine, Nonsteroidal anti-inflammatory drugs [NSAIDs], 
Penicillamine) 
4. Psychotropic drugs (Clozapine, Phenothiazines, Tricyclic and tetracyclic antidepressant) 
5. Gastrointestinal drugs (Sulfasalazine, Histamine H2- receptor antagonists) 
6. Cardiovascular drugs (Antiarrhythmic agents (tocainide, procainamide, flecainide), ACE inhibitors 
(enalapril, captopril), Propranolol, Dipyridamole, Digoxin) 
7. Dermatologic drugs (Dapsone, Isotretinoin) 
8. Antibacterial drugs (Macrolides including minocycline, Trimethoprim-sulfamethoxazole, 
Chloramphenicol, Sulfonamides, Vancomycin, Cephalosporin) 
9. Antimalarial drugs 
10. Antifungal agents (Amphotericin B, Flucytosine) 
11. Anticonvulsants (Carbamazepine, Phenytoin, Ethosuximide, Valproate, lamotrigine) 
12. Diuretics (Thiazides, Acetazolamide, Frusemide, Spironolactone) 
13. Chlorpropamide 
14. Bupropion 
15. Immunosuppressive drugs
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eAppendix 4.3-4. Case Report Form 
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eAppendix 4.3-5. IBD Pharmacogenetics Study Group Members 
 
Name Institution City Country 
Prof Peter Bampton 
Flinders Medical Centre, 
Flinders University of South 
Australia 
Adelaide Australia 
Prof Jane Andrews Royal Adelaide Hospital Adelaide Australia 
Assoc Prof Graham 
Radford-Smith 
Royal Brisbane & Women’s 
Hospital Brisbane Australia 
Dr Kavitha 
Subramaniam Canberra Hospital Canberra Australia 
Dr Susan Connor Liverpool Hospital, New South Wales Liverpool Australia 
Prof Timothy H Florin Mater Research Institute – University of Queensland South Brisbane Australia 
Dr Marianne 
Mortimore 
Mater Research Institute – 
University of Queensland South Brisbane Australia 
Dr Sally Bell St Vincent’s Hospital Sydney Australia 
Dr Alissa Walsh St Vincent’s Hospital Sydney Australia 
Prof Ian C Lawrance Fremantle Hospital, Fremantle 
Western 
Australia Australia 
Dr Richard N Fedorak University of Alberta Edmonton Canada 
Dr Richard N Fedorak University of Alberta Edmonton Canada 
Dr Mark Silverberg Mount Sinai Hospital Toronto Canada 
Prof Vibeke Andersen Regional Hospital Viborg Viborg Denmark 
Prof Laurent 
Beaugerie 
Saint-Antoine Hospital and 
Sorbonne Universite Paris France 
Dr Philippe Seksik Saint-Antoine Hospital and Sorbonne Universite Paris France 
Prof Harry Sokol Saint-Antoine Hospital and Sorbonne Universite Paris France 
Dr Andre Franke Christian-Albrechts-University of Kiel Kiel Germany 
Dr Stefan Schreiber Christian-Albrechts-University of Kiel Kiel Germany 
Dr Sebastian Zeissig University Medical Center Schleswig-Hostein Kiel Germany 
Prof Epameinondas 
Tsianos 
University Hospital of 
Ioannina Ioannina Greece 
Dr Konstantinos H 
Katsanos University of Ioannina Ioannina Greece 
Dr Amir Karban Rambam Health Care Campus Haifa Israel 
Dr Raffi Lev-Tzion Shaare Zedek Medical Centre Jerusalem Israel 
Dr Vito Annese Azienda Ospedaliero Universitaria Careggi Florence Italy 
Dr Vito Annese Azienda Ospedaliero Universitaria Careggi Florence Italy 
Dr Giacomo Sturniolo Univerita di Padova Padova Italy 
Dr Renata D'Inca University Hospital of Padova Padua Italy 
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Dr Pierre Ellul Mater Dei Hospital Msida Malta 
Dr Eleonora AM 
Festen 
University Medical Center 
Groningen Groningen Netherlands 
Dr Michiel D Voskuil University Medical Center Groningen Groningen Netherlands 
Prof Rinse K Weersma University Medical Center Groningen Groningen Netherlands 
Assoc Prof Michael 
Schultz Dunedin Hospital Dunedin New Zealand 
Dr Gillian Watermeyer Groote Schuur Hospital Cape Town South Africa 
Assoc Prof Jonas 
Halfvarson Örebro University Örebro Sweden 
Dr Mauro D'Amato Karolinska Institute Stockholm Sweden 
Dr Malcolm Smith Aberdeen Royal Infirmary Aberdeen UK 
Dr Karen Yearsley Nevill Hall Hospital Abergavenny UK 
Dr Vinod Patel 
Tameside and Glossop 
Integrated Care NHS 
Foundation Trust 
Ashton-under-
Lyne UK 
Dr Dipak Roy 
Tameside and Glossop 
Integrated Care NHS 
Foundation Trust 
Ashton-under-
Lyne UK 
Dr Sue Cullen Stoke Mandeville Hospital Aylesbury UK 
Dr David Gorard Stoke Mandeville Hospital Aylesbury UK 
Dr Elaine Spalding University Hospital Crosshouse 
Ayrshire & 
Arran UK 
Dr Steve Mann 
Barnet & Chase Farm 
Hospitals, Royal Free London 
NHS Foundation Trust 
Barnet UK 
Dr Alex Moran Northern Devon Healthcare Trust Barnstaple UK 
Dr Zia Mazhar 
Basildon and Thurrock 
University Hospitals NHS 
Foundation Trust 
Basildon UK 
Dr Matthew Brown Basingstoke and North Hampshire Hospital Basingstoke UK 
Dr Rebecca Saich Basingstoke and North Hampshire Hospital Basingstoke UK 
Dr Ben Colleypriest Royal United Hospitals Bath NHS Foundation Trust Bath UK 
Dr Jonathan Quinlan Royal United Hospitals Bath NHS Foundation Trust Bath UK 
Dr Rafeeq Muhammed Birmingham Children's Hospital Birmingham UK 
Dr Naveen Sharma Birmingham Heartlands Hospital Birmingham UK 
Dr Mark Thomas Heart of England NHS Foundation Trust Birmingham UK 
Dr Tariq Iqbal Queen Elizabeth Hospital Birmingham UK 
Dr Rachel Cooney Sandwell Hospital Birmingham UK 
Dr David Grimes Royal Blackburn Hospital Blackburn UK 
Dr Salil Singh Bolton NHS Foundation Trust Bolton UK 
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Dr Sean Weaver Royal Bournemouth General Hospital Bournemouth UK 
Dr Cathryn Preston Bradford Royal Infirmary Bradford UK 
Dr Alan Ireland Royal Sussex County Hospital Brighton UK 
Dr Melissa Smith Royal Sussex County Hospital Brighton UK 
Dr James Kennedy Southmead Hospital, North Bristol NHS Trust Bristol UK 
Dr Melanie Lockett Southmead Hospital, North Bristol NHS Trust Bristol UK 
Dr Dharam Basude 
University Hospitals Bristol, 
University Hospitals Bristol 
NHS Foundation Trust 
Bristol UK 
Dr Tom J Creed 
University Hospitals Bristol, 
University Hospitals Bristol 
NHS Foundation Trust 
Bristol UK 
Dr Miles Parkes 
Addenbrooke's Hospital, 
Cambridge University 
Hospitals NHS Foundation 
Trust 
Cambridge UK 
Dr Franco Torrente 
Addenbrooke's Hospital, 
Cambridge University 
Hospitals NHS Foundation 
Trust 
Cambridge UK 
Dr Michael Delaney Kent & Canterbury Hospital Canterbury UK 
Dr John Green University Hospital Llandough Cardiff UK 
Dr Barney Hawthorne University Hospital of Wales Cardiff UK 
Dr Theresa Barnes Countess of Chester Hospital Chester UK 
Dr Andy Milestone Countess of Chester Hospital Chester UK 
Dr David Elphick Chesterfield Royal Hospital NHS Foundation Trust Chesterfield UK 
Dr Acuth Shenoy Colchester Hospital University NHS Foundation Trust Colchester UK 
Dr Anjan Dhar 
Bishop Auckland General 
Hospital, County Durham and 
Darlington NHS Foundation 
Trust 
Darlington UK 
Dr Andy T Cole Royal Derby Hospital Derby UK 
Dr Kathleen Holding Royal Derby Hospital Derby UK 
Dr Andy T Cole 
Royal Derby Hospital, Derby 
Teaching Hospitals NHS 
Foundation Trust 
Derby UK 
Dr James Shutt Dorset County Hospital NHS Foundation Trust Dorchester UK 
Dr Jo Taylor Dorset County Hospital NHS Foundation Trust Dorchester UK 
Dr Shanika Silva Russells Hall Hospital Dudley UK 
Dr Sheldon Cooper The Dudley Group NHS Foundation Trust Dudley UK 
Dr Shanika deSilva The Dudley Group NHS Foundation Trust Dudley UK 
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Dr Craig Mowat Ninewells Hospital, NHS Tayside Dundee UK 
Dr Sam Panthakalam Eastbourne District General Hospital Eastbourne UK 
Dr Charlie W Lees Western General Hospital, NHS Lothian Edinburgh UK 
Prof Jack Satsangi Western General Hospital, NHS Lothian Edinburgh UK 
Dr Pritash Patel Epsom & St. Helier University Hospital NHS Trust Epsom UK 
Dr Deb Ghosh Princess Alexandra Hospital Essex UK 
Dr Rosemary Philiips Princess Alexandra Hospital Essex UK 
Dr Rosemary Philips Princess Alexandra Hospital Essex UK 
Dr Tariq Ahmad 
Royal Devon and Exeter 
Hospital NHS Foundation 
Trust 
Exeter UK 
Dr Chris Calvert 
Royal Devon and Exeter 
Hospital NHS Foundation 
Trust 
Exeter UK 
Dr Neil Chanchlani 
Royal Devon and Exeter 
Hospital NHS Foundation 
Trust 
Exeter UK 
Dr Helen Clarke 
Royal Devon and Exeter 
Hospital NHS Foundation 
Trust 
Exeter UK 
Dr Richard D'Souza 
Royal Devon and Exeter 
Hospital NHS Foundation 
Trust 
Exeter UK 
Dr Tawfique K 
Daneshmend 
Royal Devon and Exeter 
Hospital NHS Foundation 
Trust 
Exeter UK 
Dr Naomi Edney 
Royal Devon and Exeter 
Hospital NHS Foundation 
Trust 
Exeter UK 
Dr James R Goodhand 
Royal Devon and Exeter 
Hospital NHS Foundation 
Trust 
Exeter UK 
Dr James Goodhands 
Royal Devon and Exeter 
Hospital NHS Foundation 
Trust 
Exeter UK 
Dr James Hart 
Royal Devon and Exeter 
Hospital NHS Foundation 
Trust 
Exeter UK 
Dr Graham A Heap 
Royal Devon and Exeter 
Hospital NHS Foundation 
Trust 
Exeter UK 
Dr Neel M Heerasing 
Royal Devon and Exeter 
Hospital NHS Foundation 
Trust 
Exeter UK 
Dr Neel M Heerasing 
Royal Devon and Exeter 
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eAppendix 4.3-6. The International Serious Adverse Events Scientific 
Management Committee Members  
 
Full Name  
 
Matt Nelson, PhD, GSK 
Sally John, PhD, Pfizer 
Jeffrey F Waring, PhD, Abbott 
Scott Patterson, PhD, Amgen 
Bryan J. Barratt, PhD, Astra-Zeneca 
Joe Walker, PhD, Daiichi Sankyo 
Peter Shaw, PhD, Merck 
Steve Lewitzky, PhD, Novartis 
Michael Dunn, PhD 
Gareth J Walker 
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eMethods in the Supplement 
Identification of thiopurine-exposed unaffected individuals 
Thiopurine-exposed patients with IBD were identified as unaffected individuals from 
the Exeter IBDGEN cohort (IBDGEN CLRN 9073). This cohort includes approximately 
85% of patients under the care of the IBD team at The Royal Devon & Exeter (RD&E) 
NHS Trust; a specialist referral centre for IBD in the South West of England. In order 
to appropriately identify thiopurine-exposed unaffected individuals, the start and stop 
dates as well as the doses of thiopurines were extracted from paper and electronic 
medical records. Full blood count results were interrogated to identify the lowest 
absolute white blood cell count and absolute neutrophil count during the period of 
thiopurine therapy. Only patients with an absolute white blood cell count ≥ 3.0×109/L 
and absolute neutrophil count ≥ 1.5×109/L throughout their time on a thiopurine were 
included in the final control cohort.  
Adjudication of thiopurine-induced myelosuppression affected individuals 
Adjudication of all thiopurine-induced myelosuppression (TIM) affected individuals 
was undertaken using a series of expert panels to rigorously assess cases using a 
modified version of the validated Liverpool Adverse Drug Reaction Causality 
Assessment Tool (eFigure 4.3-1 and eAppendix 4.3-2 in the Supplement): 
“probable” TIM affected individuals must have demonstrated a clear temporal 
relationship with thiopurine and no other identifiable risk factors for TIM, including the 
concomitant use of other drugs recognised as causing myelosuppression (eAppendix 
4.3-3 in the Supplement). In addition to these criteria, “definite” TIM affected 
individuals also developed a second episode of TIM after thiopurine rechallenge. The 
collective results from each panel member were collated and the panel discussed 
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discrepant cases before a final adjudication decision was reached. Only “definite” and 
“probable” TIM affected individuals were included in the final analyses.  
Extraction of DNA 
Two 6 mL EDTA blood samples (BD Vacutainer, USA) were taken from each 
participant in the discovery cohort and DNA was extracted using the Qiagen Autopure 
LS with Puregene chemistry (Qiagen NV, Venlo, Netherlands).  
Genetic Data Sources and Measurement 
GWAS: 245,185 variants were genotyped using the Illumina Infinium G4L Genome-
Wide Association Study (GWAS) array (Illumina, San Diego, CA, USA) genotype calls 
were made using Birdsuite439 at the Broad Institute, Boston, USA. We excluded 
individuals and variants with a call rate < 98% or minor allele frequency (MAF) < 1%. 
We also excluded individuals where the sex determined from the genetic data 
disagreed with the phenotype. The genotyping had been performed in two batches. 
On initial review of principal component analysis, there was a batch effect evident and 
so we removed any variants with an uncorrected P value of < .05 for association with 
batch on a chi-squared allelic test. Variants with Hardy Weinberg equilibrium (HWE) 
P < 1×10-6 in the unaffected individuals were excluded from further analysis. The 
relatedness of all samples was assessed from the GWAS data using KING 1.9440 and 
for any pairs of samples whose scores suggested that they were third degree relatives 
or closer (kinship coefficient > 0.0442) one of the pair was excluded. Principal 
component analysis was carried out using Genome-wide Complex Trait Analysis 
(GCTA) v1.24421 with data from the 1000 Genomes project.422 Only individuals 
clustering with the non-Finnish European (NFE) individuals from the 1000 Genomes 
project were included. An overview of the numbers and reasons for individuals being 
excluded are displayed in Figure 4.3-1. We imputed the GWAS data into the 
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Haplotype Reference Consortium panel using EAGLE2 and PBWT (Positional 
Burrows-Wheeler Transform) and the Wellcome Trust Sanger imputation 
service.423,424,441 We excluded SNPs with a post-imputation info score of < 0.85 or MAF 
< 0.01. Post QC, we had 6,272,335 variants.  
 
ExWAS: Whole exome sequencing was performed in two batches. Exonic sequences 
were enriched using the Illumina Nextera prep kit and hybrid capture (Illumina Rapid 
Capture Enrichment - 37Mb target) and sequenced using the Illumina HiSeq platform 
(150bp paired reads). We processed exome sequencing reads in accordance with the 
Broad Institute best practice guidelines. Reads were mapped to the human genome 
reference sequence (GRCh37) using BWA-MEM. Each sample was sequenced to an 
average depth of 34×, with ∼99% of the targeted regions covered by ≥ 1×, ∼92% 
covered by ≥ 10× and ∼70% covered by ≥ 25×. The Genome Analysis Toolkit v26442 
was used to call alleles at variant sites and the Variant Quality Score Recalibration 
(VQSR) pipeline was used to assess the quality of variant calls and only those passing 
quality control were included in the analyses. Variants with a Hardy Weinberg 
equilibrium (HWE) P < 1×10-6 were excluded as were any variants with a genotyping 
success rate of < 0.98. Additionally, we excluded any variants with a read depth of 
< 10x or with a genotype skew P < 5×10-9 (binomial test). To eliminate a possible batch 
effect, we compared allele frequencies in TIM affected individuals processed in the 
two batches and excluded variants that demonstrated an association with batch (P < 
.05). We also checked for an association between the novel variant and the first five 
principal components to ensure that this was not due to residual population 
stratification. The post genotype quality control QQ plot is shown in eFigure 4.3-2 in 
the Supplement. 
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Sanger sequencing 
Exon 1 and the intron/exon boundary of NUDT15 was amplified by PCR using M13-
tailed primers (ctctcgctttgatttcggcg and cacctcacagacgaactccc). The resulting 
amplicon was sequenced on an ABI 3730 Capillary sequencer (Applied Biosystems, 
CA, USA) using standard methods. Sequencing products were compared to the 
published sequence (NM_018283.2) using Mutation Surveyor Software v5.0.1 
(SoftGenetics, PA, USA).  
Gene Burden Test 
We performed a collapsed variant association test using PLINK-seq 0.10443 and 
Sequence Kernel Association Test (SKAT) as a SNP-set level test to evaluate if an 
association existed between sets of rare variants among TIM affected individuals and 
thiopurine-exposed IBD unaffected individuals. SKAT aggregates individual score test 
statistics of SNPs in a SNP set and efficiently computes SNP-set level P-values, e.g. 
a gene or a region level P-value, while adjusting for covariates, such as principal 
components to account for population stratification. 
Genotype-Phenotype Calculations 
We calculated the maximum azathioprine equivalent dose prior to TIM and adjusted 
this for weight according to the following formula:    
• Weight adjusted thiopurine dose (mg/kg) = [mercaptopurine dose (mg)∙2.08 / 
weight (kg)] OR [azathioprine dose (mg) / weight (kg)] 
• Time to TIM was calculated using the following formula: 
Time TIM (weeks) = [date first met TIM criteria - 
date commenced maximum dose]  
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Clinical Usefulness Estimates: NUDT15 
Although we report data from an observational case-control study, estimates for 
clinical usefulness are made according to adapted methods based on Tonk et al430 
and de Graaff et al.431  For these estimates we assumed an overall risk of TIM of 7% 
(cumulative incidence),346 avoidance of drug in individuals carrying NUDT15 variants, 
overall population NUDT15 coding variant carrier frequency of 1.6% (95% CI carriage 
frequency 1.5%-1.8%)427 and used the unadjusted odds ratio taken from our 
multivariable logistic regression model for NUDT15 variant carriers (OR = 27.3). In 
brief, we formed a 2×2 contingency table (Table A below), and used the following 
rearrangement of the odds ratio (OR) formula to derive a, b, c and d from p, q:	#$ =
	&' ()*  
Noting also that:  + = , − ., c = / − ., 0 = 1 − (, − .) − (/ − .) − . .
= (, + /)(#$ − 1) + 1 − 5,6(#$ − 1)6 + 2,(−/ ∙ #$6 + / + #$ − 1) + (/(#$ − 1) + 1)62(#$ − 1)  
Table A: 2x2 contingency tables  
 
Thiopurine-induced myelosuppression (TIM) 
Adverse Event Total 
Affected Unaffected 
Presence 
of one or 
more  
NUDT15 
variants 
Positive (G1) a b p 
Negative (G0) c d (1-p) 
Total q (1-q) 1 
 
 
Thiopurine-induced myelosuppression (TIM) 
Adverse Event Total 
Affected Unaffected 
Presence 
of one or 
more  
NUDT15 
variants 
Positive (G1) 0.0105 0.0060 0.0164 
Negative (G0) 0.0595 0.9240 0.9836 
Total 0.0700 0.9300 1.0000 
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Table B: Clinical validity estimates for TIM in patients with one or more of three 
deleterious coding variants in NUDT15  
 
Term Definition Formula 
Estimates for 
patients with 
one or more 
NUDT15 
variants 
Carriage 
frequency (CF) 
Population carriage frequency of three 
NUDT15 variants (p.Gly17_Val18del, 
p.Arg139Cys, p.Gly17_Val18dup) from 
gnomAD427  
p 0.0164 
Sensitivity 
(Sens) 
Probability that the genetic variants are 
present in those with TIM a/q 0.15 
Specificity 
(Spec) 
Probability that the genetic variants are 
absent in those without TIM 
d(1 − q) 0.99 
Positive 
Predictive 
Value (PPV) 
Probability of TIM when the genetic 
variants are present a/p 0.64 
Negative 
Predictive 
Value (NPV) 
Probability of no TIM when the genetic 
variants are absent 
d(1 − p) 0.94 
Relative Risk 
(RR) 
Ratio of the probability of TIM if variants 
present, and probability of TIM if 
variants absent 
a/(a + b)c/(c + d) 10.53 
Absolute Risk 
Difference 
(ARD) (also 
known as 
attributable 
risk) 
Difference in the probability of TIM if 
variants are present and the probability of 
TIM if variants are absent 
@(@AB) - C(CAD) 0.58 
Population 
attributable 
fraction (PAF) 
Proportion of TIM that would be 
eliminated from the population if patients 
with variants were not exposed to 
thiopurine treatment 
p(RR − 1)(1 + p(RR − 1)) 0.14 
Number 
needed to 
receive 
alternative 
treatment: 
Drug avoid 
Number of patients with variants who 
need alternative treatment to prevent one 
patient from having TIM (drug 
avoidance strategy)  
1PPV 1.57 
Number 
needed to 
receive 
alternative 
treatment: 
Dose reduce  
Number of patients with variants who 
need alternative treatment to prevent one 
patient from having TIM (dose reduction 
strategy)  
1ARD 1.73 
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Number 
needed to harm 
(NNH) 
Number of patients who need receive a 
thiopurine to see one case of TIM 1/q 14.29 
Number 
needed to 
genotype 
(NNG): Drug 
avoid 
Number of patients that have to be 
genotyped to prevent one patient from 
having TIM: drug avoidance strategy in 
both heterozygotes and homozygotes 
reduces risk of TIM to zero  
1/a ≡ (1/CF)Sens   95.4 
Number 
needed to 
genotype 
(NNG): Dose 
reduce 
Number of patients that have to be 
genotyped to prevent one patient from 
having TIM: dose reduction strategy 
reduces risk of TIM in heterozygotes to 
that of wild-type affected individuals and 
avoidance of drug in homozygotes 
1(ARD ∙ p) 105.4 
 
Clinical Usefulness Estimations: TPMT 
To calculate similar clinical usefulness estimates for TPMT, we assumed the following: 
a population prevalence for homozygotes352 (G2) , = 0.0033 (1/300); a mitigation 
strategy of drug avoidance in homozygotes and dose reduction in heterozygotes; odds 
ratios (OR’s) informed by our multivariable logistic regression model for TPMT variant 
carriers (OR = 2.2 and OR = 53.4 in TPMT heterozygotes and homozygotes, 
respectively). We used an iterative process to calculate one cell in the 3x2 table below 
and derived the remaining five cells from this.  
Table C: 3x2 contingency tables 
 
Thiopurine-induced myelosuppression (TIM) 
Adverse Event Total 
Affected Unaffected 
TPMT 
variant 
status 
Positive 
Homozygote 
(G2) 
a b , 
Positive 
Heterozygote 
(G1) 
c d 2(5,)-2	, 
Negative 
(G0) e f (1-5,)2 
Total q 1-q 1 Note	that	, = population	prevalence	of	[\][	homozygotes = 1/300 
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Thiopurine-induced myelosuppression (TIM) 
Adverse Event Total 
Affected Unaffected 
TPMT 
variant 
status 
Positive 
Homozygote 
(G2) 
0.0020 0.0006 0.0026 
Positive 
Heterozygote 
(G1) 
0.0121 0.0849 0.0970 
Negative 
(G0) 0.0558 0.8446 0.9004 
Total 0.0700 0.9300 1 
  Figures given to 4 decimal places. Exact figures used to calculate clinical validity estimates below 
 
Table D: Clinical validity estimates for TIM in patients with variants in TPMT  
Term Definition Formula 
Estimates for 
patients with one or 
more TPMT 
variants 
Absolute risk in 
wild-type/ 
variants absent 
(ARG0)  
Absolute risk of TIM in 
patients with wild-type/ absent 
variants genotype (ARG0) 
d(d + e) 0.06 
Absolute risk in 
heterozygotes 
(ARG1)  
Absolute risk of TIM in 
patients with heterozygote 
genotype (ARG1) 
f(f + 0) 0.12 
Absolute risk in 
homozygotes 
(ARG2)  
Absolute risk of TIM in 
patients with heterozygote 
genotype (ARG2) 
.(. + +) ≡ 	., 0.78 
Relative Risk in 
heterozygotes 
(RRG1)  
Ratio of the probability of TIM 
in heterozygotes (ARG1), and 
probability of TIM in patients 
with wild-type genotype (ARG0) 
f/(f + 0)d/(d + e) 2.01 
Relative Risk in 
homozygotes  
(RRG2)  
Ratio of the probability of TIM 
in homozygotes (ARG2), and 
probability of TIM in patients 
with wild-type genotype (ARG0) 
./(. + +)d/(d + e) 12.56 
Attributable risk 
G1 (=absolute 
risk 
difference)(ARDG
1) 
Difference in the probability of 
TIM if heterozygote (ARG1) 
and probability of TIM in 
patients with wild-type 
genotype (ARG0) 
d(d + e) − f(f + 0) 
 
0.06 
Attributable risk 
G2 (=absolute 
risk 
difference)(ARDG
2) 
Difference in the probability of 
TIM if homozygote (ARG2) and 
probability of TIM in patients 
with wild-type genotype (ARG0) 
d(d + e) − .(. + +) 
 
0.72 
Population 
attributable 
fraction (PAF) 
Proportion of TIM that would 
be eliminated from the 
population if patients with 
variant were not exposed to 
thiopurine treatment 
(/ − [ARG0])/  0.11 
Number needed 
to genotype: 
Drug avoidance 
Number of patients that have 
to be genotyped to prevent 
one patient from having TIM: 
1(. + f) 
 
70.7 
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heterozygotes 
(and drug 
avoidance in 
homozygotes 
drug avoidance strategy in 
both heterozygotes (G1) and 
homozygotes (G2) 
Number needed 
to genotype: 
Dose reduction in 
heterozygotes 
(and drug 
avoidance in 
homozygotes)  
Number of patients that have 
to be genotyped to prevent 
one patient from having TIM: 
dose reduction strategy 
reduces risk of TIM in 
heterozygotes to that of wild-
type affected individuals (G0) 
and avoidance of drug in 
homozygotes (G2) 
 See	formula	below	 for	NNG	[dose	reduction] 123.0 
 
NNG[dose	reduction] = 1(ARG2 ∙ p) + k(ARG1 − ARG0) ∙ 2l5, − ,mn 
Estimation of confidence intervals around population carrier frequencies and number 
needed to genotype calculations 
 
To provide a confidence interval for the number needed to genotype point estimate 
requires three inputs: 
 
1. Odds ratio of thiopurine-induced myelosuppression for those carrying genetic 
variant versus patients with reference genotype (taken from the multivariable 
model in the manuscript)  
 
2. Population probability of carrying one or more NUDT15 variants (a dominant 
model was used as it is noted that with a low minor allele frequency (MAF), 
compound heterozygotes and homozygotes are rare, and no estimate for the 
effect size in those individuals was available) 
 
3. Population probability of thiopurine-induced myelosuppression 
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To generate confidence intervals for the external estimates for the minor allele 
frequency or carriage frequency, 10,000 bootstrapped replicates of our own 
genotype/phenotype data were generated. For each one, the probability of thiopurine-
induced myelosuppression was also randomly simulated using a binomial distribution 
centered on the best published estimate of 0.07 and a sample size of 8302 (from meta-
analysis by Gisbert JP and Gomollón F. Thiopurine-induced myelotoxicity in patients 
with inflammatory bowel disease: A Review. American Journal of Gastroenterology. 
2008).346 For the genetic data, the minor allele frequency was again simulated for each 
of our three variants using a binomial distribution and the population size of 101458 or 
126510 alleles in gnomAD. Overall rate of carrying one or more relevant NUDT15 
variants = 1 - ((1 - MAF1 – MAF2)2 × (1 - MAF3)2). For TPMT, the minor allele frequency 
was calculated using data in a large British cohort.432 
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The final estimates are:  
Variable Point estimate 2.5%tile 97.5%tile 
Probability of TIM in all thiopurine-exposed IBD patients 0.070 0.064 0.076 
Probability of carrying ≥1 TIM-associated NUDT15 variants in 
non-Finnish Europeans 0.016 0.015 0.018 
Odds ratio for ≥1 TIM-associated NUDT15 variants of TIM 27.3 10.9 33805857.1 
Positive predictive value of ≥1 TIM-associated NUDT15 variants 
for TIM 63.7% 42.7% 100.0% 
Number needed to genotype for NUDT15 (avoidance strategy) 95 62 143 
Number needed to genotype for NUDT15 (dose reduction 
strategy) 105 65 168 
Minor allele frequency of combined TPMT loss of function 
haplotypes 0.051 0.044 0.058 
Odds ratio for 1 TPMT loss of function haplotype for TIM 2.16 1.40 3.29 
Odds ratio for 2 TPMT loss of function haplotypes for TIM 53.4 14.6 54566558.2 
Positive predictive value for 1 TPMT loss of function haplotype 
for TIM 12.5% 8.8% 16.8% 
Positive predictive value for 2 TPMT loss of function haplotypes 
for TIM 77.9% 49.5% 100.0% 
Number needed to genotype for TPMT (avoidance strategy) 71 52 98 
Number needed to genotype for TPMT (dose reduction strategy 
for 1 loss of function haplotype, avoidance for 2) 123 75 235 
 
Note that occasionally the bootstrapping resulted in a very large odds ratio as one may 
end up with combinations that have probabilities of TIM of 1; however, the NNG is 
robust to this. 
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4.4 Discussion 
4.4.1 How the chapter addresses the aims and objectives of the thesis 
Objective 7: To investigate the association between novel genetic variants and 
thiopurine-induced myelosuppression in European patients with IBD 
First, in a genome-wide association study, I confirmed the known association with 
thiopurine methyltransferase (TPMT) and thiopurine-induced myelosuppression (TIM) 
in European IBD patients: a variant TPMT single nucleotide polymorphism 
(rs11969064) was found in 31% (95/311) of affected patients compared with 16% 
(100/608) of unaffected patients (OR 2.3 [95% CI, 1.7 to 3.1], P = 5.2 ×10−9). No other 
genetic associations with TIM exceeded the a priori threshold for statistical 
significance.  
 
TPMT activity is inherited as a monogenic, autosomal co-dominant trait, and its 
association and importance in thiopurine metabolism and toxicity has long been 
established.352 TPMT catabolizes mercaptopurine to an inactive 
methylmercaptopurine base, leaving less parent drug available for eventual anabolism 
to active thioguanine nucleotides (TGNs).429,444 The thioguanine nucleotides are 
responsible for the immunosuppressive action of thiopurines and inhibit de novo 
purine synthesis.445 Individuals with one loss-of-function allele (heterozygotes) are at 
slight increased risk, whilst those with two loss-of-function alleles (homozygotes) are 
at profound increased risk of myelosuppression unless dosing is reduced accordingly. 
Pre-treatment testing of TPMT is recommended to identify patients at risk of TIM.446  
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Second, using whole-exome sequence data, which facilitates the detection of rare 
variants, I also identified an association with a 6-base-pair in-frame deletion 
(p.Gly17_Val18del) in nudix (nucleoside  diphosphate  linked  moiety  X)-type motif 15 
(NUDT15). This association was then replicated in an independent cohort of European 
IBD patients. In total I found three coding NUDT15 variants in our data-set 
(p.Gly17_Val18del, p.Gly17_Val18dup and p.Arg139Cys) that were present in 9.5% 
of cases and 0.5% of controls (OR 20.9 [95% CI, 6.4 to 68.6], P = 1.5 × 10−12).  
 
The protein encoded by NUDT15 is thought to hydrolyse and inactivate one of the 
thioguanine nucleotide (TGN) active metabolites called thioguanine triphosphate, 
which when incorporated into DNA leads to futile mismatch repair and apoptosis.447 
Therefore, patients with variants that reduce NUDT15 activity accumulate higher 
levels of certain active TGNs that are thought to lead to myelosuppression.  However, 
current clinical assays for TGNs do not distinguish tri- from di- from mono-phosphates, 
and therefore TGN levels cannot be used to identify low NUDT15 activity.446 Recent 
evidence suggests that thioguanine incorporated into red blood cell DNA may be an 
indicator of NUDT15 status in patients receiving thiopurines, but this assay is not 
widely available and further work is needed prior to clinical use. 415 
 
The frequency of TPMT variants is lower in East Asian as compared with European 
populations (~3% versus ~10%), however, the incidence of TIM in Asians is 
considerably higher.360,362,448,449 Studies in Asian patients have recently identified 
variants in NUDT15 as risk factors for TIM.362,418,450,451 My study is the first to report 
association between NUDT15 variants and TIM at the genome-wide significance level 
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and suggests that these variants are also clinically relevant in Europeans 
populations.416  
Objective 8: If genetic variants are present, to explore if the frequency of these 
variants were enriched in those patients with early drug reactions (≤ 8 weeks from start 
of maximum dose) 
As hypothesised, the association between the p.Gly17_Val18del variant and TIM was 
enriched in cases occurring within 8 weeks of first commencing the maximum dose of 
thiopurine. In a meta-analysis of over 8000 patients, Gisbert and Gomollón reported 
that TIM occurred as soon as 12 days but up to 27 years after commencing 
treatment.346 In another study by Lewis et al looking at the timing of myelosuppression 
among 1997 new thiopurine users, the authors found that the median time from onset 
of therapy to first documentation of severe leukopenia was 25 days (range, 15–53 
days).452 This is much faster than in my study where the median time to TIM was 28 
weeks (IQR, 9–81weeks) and the median time from maximum dose of thiopurine to 
TIM was 15 weeks (IQR, 6–38 weeks). Our definitions of myelosuppression were 
similar and therefore these differences likely reflect the use of pre-treatment TPMT 
testing, which was excluded in the Lewis et al study, but used in two-thirds of the 
patients recruited to mine. Lewis et al also reported that the majority of TIM events 
occurred within the first 8 weeks of starting treatment: during this period, the incidence 
of severe leukopenia per 100 person-months was 0.16 in comparison to 0.01 after 
week 26.452 The authors suggested that stable mild leucopenia was likely attributable 
to changes in drug adherence or body weight, whereas rapid onset severe leucopenia 
was probably a consequence of either drug interaction or infection.452  
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Whilst TPMT (Chromosome 6) and NUDT15 (Chromosome 13) are inherited 
separately, the likelihood of an individual being an intermediate metabolizer for both 
genes depends upon the population frequencies of the variant alleles. Hitherto, it was 
unclear what effect this compound intermediate genotype would have. In my study I 
found that the median time to TIM was shortest in patients with both TPMT and 
NUDT15 variants compared with affected patients without risk variants. Whereas, no 
difference in time to TIM was seen in patients carrying one variant TPMT haplotype 
compared with affected patients without risk variants.  
 
In the multivariable logistic regression, I demonstrated that weight-adjusted dose, and 
NUDT15 and TPMT genotypes were independently associated with TIM and that there 
was no significant interaction between NUDT15 and TPMT in the model.  
 
Together these data endorse the current practice of short interval blood monitoring in 
the early stages of thiopurine treatment when the risk of myelotoxicity is greatest, 
however, the occurrence of late toxicity, even in patients with genetic variants means 
that long-term blood monitoring is still required.   
Objective 9: the clinical phenotype and morbidity related to carriage of a TIM 
associated genetic variant(s) 
In the genotype-phenotype analysis, I found that patients carrying NUDT15 and/or 
TPMT variants experienced a more profound myelosuppressive episode than affected 
patients without these variants with lower neutrophil counts, higher rates of 
hospitalisation and use of rescue granulocyte colony–stimulating factor (GCSF) 
therapy. However, my study design precluded more definitive conclusions being 
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drawn on the genotype-phenotype interaction which would require a prospective 
cohort design.  
 
Importantly for the consideration of future prescribing in European patients, I found 
that neither weight-adjusted dose, type of thiopurine, patient age, TPMT genotype, nor 
NUDT15 genotype were associated with subsequent thiopurine tolerance after drug 
rechallenge.  
 
The UK IBD pharmacogenetics group have deemed that a drug-avoidance strategy is 
the most appropriate for European patients, whereas the latest 2018 CPIC guidelines, 
written prior to our publication, recommend a 30–80% mercaptopurine dose reduction 
in intermediate NUDT15 metabolisers and only drug-avoidance for non-malignant 
treatment indications in poor NUDT15 metabolisers. 446  
Objective 10: To ascertain the clinical validity (e.g. sensitivity, specificity, negative 
and positive predictive values) of genetic testing to identify patients at risk of TIM  
Although I report data from an observational case-control study, which by design have 
a different proportion of cases than in the true population of interest, one can still make 
estimates of clinical utility according to adapted methods based on Tonk et al430 and 
de Graaff et al431. Tonk et al stated that the clinical validity of a pharmacogenetic test 
is determined not only by the strength of the association between the genetic variant 
and the adverse event, but also, by the frequencies of the genetic variant and the 
adverse event; therefore, a strong association is essential but not a sufficient condition 
to ensure good clinical validity.  
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The clinical validity then in turn influences the clinical utility of the test, which in my 
study is the ability of NUDT15 genotyping to prevent TIM through the use of mitigating 
strategies including dose reduction or drug avoidance. Therefore, an assessment of 
clinical utility of  NUDT15 testing needs to go beyond the strength of the association 
alone.  
 
In order to aid translation of pharmacogenetic testing I calculated clinical validity 
estimates for NUDT15 in accordance with CPIC guidelines.395 Accordingly,  I used the 
genetic variant frequency for the total population (p) from the gnomAD reference 
database453 (1.6%, 95% CI, 1.5%-1.8%) and the cumulative incidence for TIM (7%, 
95% CI, 6%-8%) based on a meta- analysis of 8302 patients by Gisbert et al346 to 
enable completion of cells a to d in the 2x2 contingency table (see Figures 4-1 and 4-
2).  
Figure 4.4-1. Blank 2x2 contingency table 
 
Adverse Event 
Total 
Affected Unaffected 
Presence of 
one or more 
NUDT15 
variant 
Positive (G1) a b p 
Negative (G0) c d (1-p) 
Total q (1-q) 1 
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Figure 4.4-2. Completed 2x2 contingency table 
 
Adverse Event 
Total 
Affected Unaffected 
Presence of 
one or more 
NUDT15 
variant 
Positive (G1) 1.05 0.60 1.64 
Negative (G0) 5.95 92.40 98.36 
Total 7.00 93.00 1.00 
These tables can be constructed using empirical data or using hypothetical data calculated from 
summary statistics and association measures, such as odds ratios derived from observational 
studies with a case–control design in combination with the frequencies of the genetic variant 
and the adverse event. The following formulae can be used to derive cells a to d in accordance 
with methods by Tonk et al 430 
p = variant frequency (taken from reference database-gnomAD)  
q = adverse event frequency (taken from meta-analysis by Gisbert el al) 
a =  (((p×OR+(1-p)+q×(OR-1))-√(((-p×OR-(1-p)-q×(OR-1))^2-4×(OR-1)×p×q×OR) )))/(2×(OR-1) ) 
b = p-a 
c = q-a 
d = 1-a-b-c 
 
For NUDT15, the estimated number of patients needed to genotype (NNG) to prevent 
one patient from developing TIM was 95 patients (95% CI, 62-143 patients). That is, 
for every 10,000 patients genotyped, 164 would test positive for a NUDT15 variant, 
and of these patients, 105 would have developed TIM if they had not received an 
alternative treatment (PPV = 64%). Genotyping 10,000 patients for NUDT15 would 
therefore prevent 105 cases of TIM, which is 95 patients genotyped for every case 
prevented. Finally, I estimated that introduction NUDT15 testing would reduce TIM by 
14% (population attributable fraction). Even if one uses a dose-reduction rather than 
drug-avoidance strategy the NNG only increases marginally to 105.  
 
My clinical validity estimates for NUDT15 are similar to those previously reported by 
others for TPMT435 (NNG = 100), and therefore support the extension of NUDT15 pre-
treatment genetic testing to European patients.  
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4.4.2 The Implications for future practice 
Whilst NUDT15 variants have previously been shown to be important in patients of 
East Asian362,418,450, South Asian451 and South American419 ancestry who suffer TIM, 
this is the first time that a genetic association has been described in a large European 
cohort at the genome-wide significance level. In order to bridge the gap from ‘bench-
to-bedside’ and translate this discovery into clinical practice several factors need to be 
considered. 
 
Traditionally, a prospective randomised-control trial (RCT) is next required to assess 
the clinical utility and cost-effectiveness of a drug or biomarker. However, it would be 
ethically unacceptable to randomize patients with and without TPMT and NUDT15 
variants to receive thiopurines given the risks of myelosuppression and potentially fatal 
consequences.346 An alternative methodology utilizes a ‘historic-cohort study’ design, 
where historical data relating to disease outcome and costs of current best practice 
are compared with prospective data captured after the introduction of 
pharmacogenetic testing. This study design focuses recruitment on just one arm of 
the study, thus maximising the power to detect outcome differences in patients with 
rare variants. It is worth noting in the case of NUDT15, one would need to recruit an 
estimated 10000 IBD patients to find 164 variant carriers.  
 
Experts have argued that to hold biomarkers to the same level of evidence as required 
for a new drug unjustifiably slows progress in the field of precision medicine.408 
Advocates of this argument might cite the widespread successful implementation of 
pre-abacavir treatment HLA-B*5701 testing as an example of a pharmacogenetic test 
that was adopted without RCT data.329  
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The next decision to be made prior to rolling-out NUDT15 testing, is whether to 
recommend a dose-reduction or drug-avoidance strategy. The Clinical 
Pharmacogenetics Implementation Consortium (CPIC) have recently released their 
guidance for thiopurine-dosing based on TPMT and NUDT15 genetics in 2018.446 The 
publication of these recommendations, predated our own publication and were largely 
based on data in patients of Asian ancestry with Acute Lymphoblastic Leukaemia. The 
CPIC authors have recommended a 30-80% mercaptopurine dose-reduction in 
‘intermediate’ heterozygote NUDT15 metabolizers; whilst NUDT15 homozygotes with 
‘poor’ functional enzyme activity may tolerate a 10-fold dose reduction.446 Whether to 
risk myelosuppression in this latter group is dependent on the indication for thiopurine 
treatment; a risk justified perhaps in patients with malignant disease. In IBD we 
propose a drug-avoidance strategy for patients with NUDT15 variants as two-thirds of 
European patients carrying one of three NUDT15 variants developed TIM, and 
rechallenge with a thiopurine was rarely successful even at a lower dose. The 
consequences of our drug-avoidance strategy are more profound for the large number 
of South Asians living in the UK; 14% of whom carry an NUDT15 variant (see Appendix 
B). However, in contrast to even a few years ago, there are now a growing number of 
safe and arguably more effective alternative IBD therapies.454–456 Furthermore, I feel 
that it would introduce unnecessary complexity to offer different advice to patients of 
different ethnicities, not least because self-reported ethnicity is notoriously unreliable. 
 
Following consultation at the Personalised Medicine NHS review board in 2018 no 
further prospective studies were deemed necessary prior to rolling out NUDT15 
genotyping to the UK and this service will shortly be rolled-out to the NHS, starting in 
Exeter.  
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Chapter 5 
5 Conclusion 
Individual patient variability may explain why despite a growing number of 
therapeutic options in the treatment of inflammatory bowel disease (IBD) many 
patients still suffer disabling disease. Precision medicine aims to address this 
dilemma by improving the timing and delivery of healthcare for each patient by 
targeting treatment according to the application of biomarkers. I focused on two 
key components of precision IBD medicine: accelerating the time to diagnosis 
through biomarker application and the use of pharmacogenetics to facilitate safe 
drug prescribing.  
 
I found that faecal calprotectin was a clinically useful biomarker that helped 
General Practitioners (GPs) identify IBD in young adults and children. In adults, 
raising the cut-off threshold used to distinguish positive from negative calprotectin 
tests from 50µg/g to 100µg/g doubled the positive predictive value with a 
negligible loss in negative predictive value. However, there was a 14% false 
negative rate which requires GPs to safety-net calprotectin negative patients. 
Among paediatric IBD patients, there were no false negative calprotectin tests 
and this test was superior to both symptoms and CRP in distinguishing IBD from 
non-IBD. This makes it an attractive non-invasive alternative method to 
conventional bloods tests for the targeted assessment of paediatric patients. In 
adults over the first three years following introduction of the test to primary care, 
I estimated that calprotectin saved 200 referrals- and £52,000 -per year. 
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However, further significant savings are achievable if primary and secondary care 
physicians take greater confidence in this test.  
 
The median time to diagnosis in adults and children was 4 and 2 months, 
respectively; the greatest component of which in both cohorts was the time it took 
patients to present to their GP. A positive primary care calprotectin was neither 
associated with a reduction in the time to GP referral nor the time to secondary 
care diagnosis. However, uptake in adults and children was low and only used 
prior to a new IBD diagnosis in approximately one-quarter of patients. In adults, 
one-fifth of patients were diagnosed with IBD following an emergent presentation, 
which was associated with a higher inflammatory burden, more severe and 
extensive disease and a greater need for hospitalisation and biologic treatment 
in the first year after diagnosis as compared with non-emergent IBD diagnoses. 
Conversely, a delayed diagnosis was not associated with a complicated disease 
course.   
 
Using agnostic genome-wide and exome-wide methodologies to explore 
thiopurine-induced myelosuppression. I discovered a novel association with a 
variant in NUDT15 and reported that patients with TPMT and/or NUDT15 variants 
experience a quicker and more severe myelosuppressive phenotype. Thiopurine 
dose-reduction was not associated with subsequent rechallenge success and 
therefore a drug-avoidance rather than dose-reduction strategy in patients 
carrying NUDT15 variants should be encouraged. The clinical validity estimate 
for the number needed to genotype is similar to that of TPMT, which is already 
commonly measured prior to initiating thiopurine treatment and supports 
extension of pre-treatment testing to NUDT15. 
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The actionable findings reported in this thesis have led to changes in clinical 
practice locally and nationally and will help deliver precision medicine in the field 
of IBD. The primary care calprotectin study has demonstrated how a faecal 
biomarker can help prioritise outpatient referrals and deliver cost-savings, leading 
to the adoption of our clinical pathway across several UK sites.  Our new revised 
pathway has now been rolled-out locally and uses a single calprotectin cut-off of 
100µg/g, an 8-week GP safety-net review of patient symptoms, a direct-to-test 
option in patients with a calprotectin of ≥ 250µg/g, and a ring-fenced dietician who 
offers specialist dietetic advice for patients with functional gut disorders. Further 
work is needed to promote both a greater public awareness of the need for 
patients to seek medical help with persistent or worrisome new lower GI 
symptoms and to encourage greater use of calprotectin among primary care 
physicians. Furthermore, we also need to evaluate whether use of calprotectin 
actually delivers on our predicted savings with a measurable reduction in 
endoscopy referrals and increase in diagnostic yield. Locally, faecal 
immunohistochemical testing (qFIT) has been introduced for patients greater 
than 50 years old with new lower GI symptoms not meeting two-week wait 
criteria. We are in the process of working with the qFIT steering group in order to 
ensure that GPs have a clear coherent strategy for testing and referring patients 
of all ages.  
 
The identification of NUDT15 variants as determinants of thiopurine-induced 
myelosuppression in European individuals has led to the rapid development of 
an NHS clinical service from the Exeter molecular genetics laboratory and in due 
course adoption of the test to the National Genomic Test Directory. In time further 
work is needed to evaluate the impact of this pharmacogenetic test on disease-
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related outcomes and treatment costs.  Prospective data collection after 
commencing the NUDT15 testing service will hopefully enable identification of 
further NUDT15 variants
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Irritable Bowel Syndrome (IBS) 
Diagnosis and Management for adults 
under the age of 50 
Irritable bowel syndrome can be difficult to diagnose, and it is important to reach the correct 
diagnosis while striking the right balance between too few and too many investigations. 
This IBS pathway aims to provide a patient focused and cost effective diagnostic and management 
pathway for people with irritable bowel syndrome.  
The objectives are: 
• Support healthcare professionals to make a positive diagnosis of IBS and to manage patients 
in primary care, if no red flag indicators are present and investigations are normal. A positive 
diagnosis will help to reduce unnecessary anxiety in people with symptoms of irritable bowel 
syndrome and to start effective treatment. 
• Where there is diagnostic uncertainty in diagnosing IBS versus inflammatory bowel disease 
(IBD), to support healthcare professionals in diagnosis with use of faecal calprotectin, 
reducing avoidable invasive endoscopic procedures  
• Provide earlier access to specialist dietetic support and improve patient experience 
Key Messages 
Scope 
This guidance refers to: 
• Patients aged 18-49 years who present with lower gastrointestinal symptoms in whom you 
suspect IBS or IBD 
Out of scope  
This guidance does not cover: 
• Patients under the age of 18 or over the age of 50 (for patients ≥ 50 years old please see 
local FIT testing guidelines) 
• Patients where colorectal cancer is suspected (see red flags) 
• Patients in whom there is diagnostic certainty of an IBS diagnosis 
Assessment 
Signs and Symptoms 
Consider IBS when the patient presents with: 
• Abdominal pain 
• Bloating 
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• Change of bowel habit 
This is usually accompanied by at least two of the following: 
• Related to defecation 
• Associated with a change in bowel habit 
• Associated with a change in stool form (appearance)  
Common additional symptoms include abdominal bloating and distension. 
Other features such as lethargy, nausea, depression/anxiety, fibromyalgia, backache & bladder 
symptoms are common in people with IBS, and may be used to support the diagnosis. 
 
History and Examination 
Based on the history, IBS can be divided into: 
• IBS with diarrhoea (IBS-D) = loose (mushy) or watery stools for ≥25% of bowel movements 
and hard or lumpy stool for ≤25% of bowel movements. 
• IBS with constipation (IBS-C) = hard or lumpy stools for ≥25% of bowel movements and loose 
(mushy) or watery stools for ≤25% of bowel movements. 
• Mixed IBS (IBS-M) = hard or lumpy stools for ≤25% of bowel movements and loose (mushy) 
or watery stools for ≤25% of bowel movements. 
• Unspecified IBS: insufficient abnormality of stool consistency to meet criteria for IBS-C, IBS-
D, or IBS-M 
The classification of IBS patients into sub-groups is useful for clinical practice, but it is common for 
IBS patients to switch from one subtype to another over time. More than 75% of IBS patients change 
to either of the other 2 subtypes at least once over a 1-year period. 
 
Differential Diagnoses 
Differential diagnoses may include: 
• Inflammatory Bowel Disease (IBD) 
• Coeliac disease 
• Chronic pancreatitis or pancreatic insufficiency (perform faecal elastase) 
• Bile acid malabsorption (common following cholecystectomy) 
• Malignancy 
• Infection 
Red Flags 
Please see the suspected cancer NICE guidelines NG12 and the latest local DG30 guidelines for faecal 
immunochemical testing (FIT)in patients ≥50 years.  Patients meeting these criteria should be 
referred via the lower GI 2ww pathway: 
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Referral 
IBS is a condition to be primarily managed in the community. In patients with symptoms of IBS and 
that have not responded to simple lifestyle, dietary and pharmacological therapy as recommended 
by NICE consider referral to the Specialist IBS Dietetic services. 
See: 
• IBS Investigation flow chart ***LINK*** 
• IBS Management  ***LINK TO MANAGEMENT PAGE ON FORMULARY*** 
Referrals should only go on to secondary care gastroenterology with a negative faecal calprotectin 
(<100 µg/g) if there remains a significant doubt of the diagnosis of IBS and in severe refractory cases 
that have not responded to specialist IBS dietary changes and first- and second-line medical 
treatment.  Note referrals to Gastroenterology that have not been managed as per this guideline will 
be rejected. 
 
Referral Instructions 
Pathway 1: Specialist Dietician pathway 
e-Referral Service Selection 
Specialty: Dietetics 
Clinic Type: Gastroenterology 
Service: DRSS-Eastern-Dietetic-Devon CCG -15N 
 
Pathway 2: Suspected IBD for luminal Gastroenterology (to be seen within 2 weeks) 
In an unwell patient with acute abdominal pain or significant bloody diarrhoea and possible 
IBD, due not let primary care investigations delay appropriate urgent assessment, please 
contact the on-call Consultant Gastroenterologist or use the electronic advice and guidance 
service. 
 
Pathway 3: Gastroenterology refractory IBS pathway  
e-Referral Service Selection 
Specialty: GI & Liver 
Clinic Type: Lower GI (medical) excl IBD 
Service: DRSS-Eastern-GI & Liver (Medicine & Surgery)-Devon CCG -15N 
***Please highlight on the referral form that the referral is in relation to 
refractory IBS*** 
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Investigations 
 
***LINK TO FLOWCHART*** 
In adults 18-49 years old, with symptoms suggestive of IBS please organise:   
• Full Blood Count (FBC) 
• Coeliac serology   - please do not repeat if previous performed in last 3 years 
• C-reactive Protein (CRP)   
• If diarrhoea, Stool for culture and sensitivity 
A positive diagnosis of IBS always helps management: patients without ‘red flags’ and with normal 
tests should be managed in primary care. Please see IBS management flowchart. 
Diagnostic uncertainty between IBS and IBD 
 
If the above bloods tests are normal but you still suspect IBD please organise:  
•  Stool faecal calprotectin – sampling from the first bowel movement of the day when the 
patient is most symptomatic is recommended. This may increase the diagnostic yield. 
• Please ensure off NSAID and PPIs for 2 weeks prior to testing 
IBS symptoms and signs versus IBD 
IBS Symptoms IBD- Ulcerative colitis IBD- Crohns disease 
Abdominal Pain Blood mixed in stool Abdominal Pain 
Bloating Diarrhoea including nocturnal Weight loss 
Change in bowel habit - 
Typically alternating 
Urgency/incontinence Diarrhoea 
Other features: mood, 
backache, bladder symptoms 
Family history IBD Family history of IBD 
Fibromyalgia, headaches Erythema nodosum, uveitis Erythema nodosum, uveitis 
 
About the Calprotectin stool test 
• Calprotectin is a protein released into the gastrointestinal tract when it is inflamed, such as 
in inflammatory bowel disease (IBD; Crohn's disease and ulcerative colitis) it is stable 
protein, so can be detected in the stool by laboratory assay. 
• Elevated levels of faecal calprotectin are found in IBD. 
• By contrast, in functional disorders of the gastrointestinal tract, such as the irritable bowel 
syndrome (IBS) faecal calprotectin levels are normal. 
• Clinically, it can be difficult to be able to distinguish IBS from IBD based on symptoms, signs 
and blood tests.  Here, faecal calprotectin can be used as a biomarker to support your 
assessment. 
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•  No biomarker test is 100% accurate but this IBS care pathway has been shown to be 
effective and safe in supporting your clinical decision making. (J. Turvill et al, Frontline 
Gastroenterology, 2017) 
What do the results mean? 
• Faecal calprotectin <100 µg/g - IBS is 98% likely 
If all blood tests and faecal calprotectin are less than 100 µg/g – reassure and manage as IBS – unless 
there remains a significant clinical doubt as to the diagnosis.  
• Faecal calprotectin 100-250 µg/g -IBD is 12% likely 
This result is equivocal and the Calprotectin should be repeated in 2 weeks. If the repeat result 
remains ≥100 µg/g, then refer urgently to gastroenterology highlighting suspected IBD.  
In an unwell patient with acute abdominal pain or significant bloody diarrhoea and possible IBD, 
due not let primary care investigations delay appropriate urgent assessment, please contact the 
on call Consultant Gastroenterologist or use the electronic advice and guidance service, otherwise: 
Before repeating please exclude: 
o Non-steroidal anti-inflammatory drugs (NSAID) ingestion within the last 2 weeks 
o GI Infection (repeat stool culture) 
 
• Faecal calprotectin >250 µg/g IBD is 46% likely 
In an unwell patient with acute abdominal pain or significant bloody diarrhoea and possible IBD, 
due not let primary care investigations delay appropriate urgent assessment, please contact the 
on-call Consultant Gastroenterologist or use the electronic advice and guidance service, otherwise: 
More than 250 µg/g – refer urgently to gastroenterology highlighting suspected IBD.  Please ensure 
a stool sample is sent to rule out infection as a possible cause of the symptoms. 
 
Management 
 
For management guidance please see the ‘Symptom management’ guidance under the Irritable 
Bowel Syndrome information in the Formulary section of the Formulary & Referral website here. 
***PLEASE NOTE:  The recommendations in the management guidance are currently under review, 
with possible changes to come*** 
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Appendix B: Frequenciesa of NUDT15 alleles in major race/ethnic groupsb,f 
 
Table adapted from CPIC guidelines. The allele frequency table was made by searching the PubMed® database (no start date to 1/2018). Allele frequencies 
reported in the gnomAD browser (http://gnomad.broadinstitute.org/ - exomes and genomes) and ensembl (grch37.ensembl.org - exomes or genomes) were 
also included. 
a Average frequencies based on the reported frequencies in one or multiple studies.  
b Worldwide race/ethnic designations are based on the Human Genome Diversity Project- CEPH). 
NUDT15 
Allelec 
Effect on protein 
(NP_060753.1) 
CPIC Assigned Allele 
Functional Status  
African Allele 
Frequency 
Caucasian (European 
+ North American) 
Allele Frequency 
East Asian 
Allele 
Frequency 
South/ Central 
Asian Allele 
Frequency 
Americas Allele 
Frequency 
*1d NA Normal 0.997 0.993 0.879 0.930 0.936 
*2 p.Gly17_Val18dup
e 
and R139C Normal function 0.000 0.000 0.035 0.000 0.037 
*3 R139C No function 0.001 0.002 0.061 0.067 0.008 
*4 R139H No function 0.000 0.000 0.001 0.000 0.018 
*5 V18I Uncertain function 0.000 0.000 0.011 0.000 0.000 
*6 p.Gly17_Val18dupe Uncertain Function 0.002 0.003 0.013 0.002 0.002 
*7 R34T Uncertain Function 0.000 0.000 0.001 0.000 0.000 
*8 K35E Uncertain Function n/a n/a n/a n/a n/a 
*9 G17_V18del Uncertain Function 0.000 0.002 0.000 0.000 0.000 
Total variant carrier allele frequency (i.e. *2 to*9) 0.003 0.007 0.121 0.070 0.064 
Percentage of population that are either heterozygote or 
homozygote for alleles *2 to*9 0.6% 1.4%  22.7% 13.5% 12.3% 
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c See allele definition table (https://www.pharmgkb.org/page/nudt15RefMaterials) for allele definitions 
d Because NUDT15*1 is not genotyped directly, all alleles that are negative for a sequence variation are defaulted to a NUDT15*1 assignment. The inferred frequency for 
NUDT15*1 is calculated as: 1 - (sum of averaged variant allele frequencies). 
e p.Gly17_Val18dup is synonymous with V18_V19insGV 
f insufficient data in Middle eastern, Occeanian and American African American to estimate allele frequencies in these ethnicities.  
g carriage frequencies were estimated using the equation describing Hardy Weinberg equilibrium (genotype frequency = p2 + 2pq + q2) based on reported allele frequencies. i.e. 
percentage of population that are either heterozygote or homozygote for variant = [1-p2]*100 = [1-(*1 allele frequency2)]*100 
 
 406 
 
 
 
 
THE END 
